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Abstract 
 
Cornexistin and hydroxycornexistin were both isolated from the fungus Paecilomyces 
variotii. They were found to possess significant herbicidal activity, which triggered the 
interest of agrochemicals companies. Their structures consist of a nine-membered 
carbocyclic ring fused to a cyclic anhydride with various oxygen functionalities 
decorating the nine-membered core. 
 
Previously, the synthesis of (±)-5-epi-hydroxycornexistin was successfully achieved in 
the group, using a Stille-coupling reaction between a chloride and stannane fragments, 
followed by a key ring-closing metathesis reaction to form the core of the nine-
membered ring. However, the desired stereochemistry on the C-5 centre could not be 
installed despite the use of a variety of methods.  
 
A new strategy, involving an intramolecular Nozaki-Hiyama-Kishi reaction was 
investigated, leading to the formation of an advanced intermediate for the synthesis of 
hydroxycornexistin. The reaction proved efficient and X-ray crystallography was used to 
confirm the desired formation of the natural C-5 configuration of cornexistins. The 
stereoselectivity of the reaction was considered and alternative methods to improve the 
diastereoisomeric ratio were attempted.  
 
The asymmetric synthesis of hydroxycornexistin was studied, using an advanced model 
substrate and an efficient strategy for the asymmetric syntheses of both Stille-coupling 
partners was performed. The synthesis of the chloride fragment involved a cross-
metathesis reaction and a [3,3]-sigmatropic rearrangement reaction as main steps of 
the reaction sequence. Using a chiral auxiliary, the stannane fragment was obtained 
with excellent enantiomeric excess. Finally, the sequence leading to the synthesis of 
the NHK precursor was accomplished. 
 
 
 
 III 
Declaration 
 
I declare that the substance of this thesis has not been submitted, nor is concurrently 
being submitted in candidature for any other degree. I also declare that the work 
embodied in this thesis is the results of my own investigations. Where work of other 
investigators has been used, this has been fully acknowledged in the text. 
 
 
 
 
 
 
Anthony Aimon 
 
 
 
 
 
Prof. J. Stephen Clark 
 
  
 IV 
Acknowledgements 
 
Firstly, I would like to thank my supervisor, Prof. J. Stephen Clark, for all his 
support over the past three years, and for giving me the opportunity to work on such a 
fascinating project. I appreciated having the freedom to conduct the project in the way 
I wanted, but also the precious help he provided me when needed. I would also like to 
thank EPSRC and WestCHEM for funding. 
 
Secondly, I would like to thank everyone that took part in the proof-reading of 
this thesis: Andy, Paloma, Helen, Michael, Filo and Alistair. I could not have done it 
without you. I am also grateful to Dr Louis Farrugia for X-ray crystallography, Dr David 
Adam for NMR spectroscopy, Jim Tweedie and Harry Jackson for their efficiency and 
availability regarding the mass spectrometry, and all members of the technical staff. I 
would especially like to thank the exceptional stores team, Ted Easdon and Shawn 
Maidwell, for their friendliness and efficiency in dealing with all sorts of every day 
issues. 
 
I would now like to thank all the past and present members of the Clark group, 
who made the Henderson Lab such a unique place to work. Although too numerous to 
mention, I would first like to thank the post-docs Thomas, Euan and Alistair for all their 
advice, and wish Alistair all the best in his undoubtedly successful academic career. 
Next, the ‘oldies’: Raphi, Bora, Serena, Alex and Fredounet who made my integration to 
both the lab and Glasgow so easy. The ‘in-betweeners’ Ralphy, Derek, Emelie, madame 
Mimily, Flavino, Guang, Paloma and Andy with whom I had the pleasure to spend my 
whole PhD experience. I will always remember the great times spent in and out of the 
lab from the Friday pubs, the endless ‘philosophical’ talks with Flav and Andy, Emilie’s 
Hen-do or the fabulous dinners made by Paloma, to the epic adventure in the North 
with Raphi and Flav. Special thanks to Flav, I will always be greatful that you rescued 
me on a dark, cold, windy and rainy evening near Strathblane. 
 
The current group members equally deserve a special mention, Laetitia, super 
buddy Dory who somehow managed to always cheer me up and has been tremendously 
helpful and supportive over the past months, perfect Michi, always ready for 
indoor/outdoor sports (true story), smarty Filo, and generous & funny Chao. Good luck 
to the newbies Verena, Ian, Ludo and Tintin. Last of the Clarky Cats, I would like to 
thank the final year undergraduate students especially Louise, Kate and this year’s 
remarkably enthusiastic students Gayle, Joanna and Sam. 
 V 
To all the people I met during my time in Glasgow, I would like to thank you for 
what has been such an enjoyable three years of my life. In a non exhaustive list, it goes 
to golden boy Michael, Toni, Iron-girl Jo, Raphael and Sylvain from the Raphael lab. To 
Malcolm of course; all-time best beer-brewer, my long-time flatmate Hannah, and to 
Nath; amongst everything we did together, it has always been a pleasure to not only 
walk, but also run up and down the hills. 
 
Last but not least, I am most thankful to my family, especially my brother and 
my parents, for their invaluable support and patience.  
  
 VI 
Abbreviations 
 
Ac — acetyl 
9-BBN — 9-bora-bicyclo[3,3,1]norane 
aq. — aqueous 
Ar — aryl 
BINAP — 2,2'-bis(diphenylphosphino)-
1,1'-binaphthyl 
Bn — benzyl 
bp. — boiling point 
brsm — based on recovered starting 
material 
Bu — butyl 
Bz — benzoyl 
cat. — catalytic 
CBS — Corey-Bakshi-Shibata 
CI — chemical ionisation 
conc. — concentrated 
cod — cyclooctadiene 
COSY — correlation spectroscopy 
Cp — cyclopentadienyl 
Cp* — pentamethylcyclopentadienyl 
m-CPBA — meta-chloroperoxybenzoic 
acid 
CSA — 10-camphorsulfonic acid 
Cy — cyclohexyl 
dba — di(benzylidene)acetone 
DBN — 1,5-diazabicyclo[4.3.0]non-5-ene 
DBU — 1,8-diazabicyclo[5,4,0]undec-7-
ene 
DCC — dicyclohexylcarbodiimide 
1,2-DCE — 1,2-dichloroethane 
DEAD — diethyl azodicarboxylate 
DIAD — diisopropyl azodicarboxylate 
DEPT — distorsionless enhancement by 
polarisation transfer 
DDQ — 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone 
DHP — dihydropyran 
DIBAL-H — diisobutylaluminium hydride 
DIPEA — diisopropylethylamine 
DIPT — diisopropyl tartrate 
DME — dimethoxyethane 
DMAP — 4-dimethylaminopyridine 
DMDO — dimethyldioxirane 
DMF — N,N-dimethylformamide 
DMP — Dess-Martin periodinane 
DMS — dimethyl sulfide 
DMSO — dimethylsulfoxide 
dppp — 1,3-
bis(diphenylphosphino)propane 
dr — diastereomeric ratio 
EDCI — 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide 
ee — enantiomeric excess 
EI — electron ionisation 
Enz — enzyme 
ESI — electrospray ionisation 
Et — ethyl 
Eq. — equation 
equiv — equivalent 
FAB — fast atom bombardment 
h — hour 
hυ — irradiation with light 
HMDS — hexamethyldisilazane 
HPLC — high performance liquid 
chromatography 
HRMS — high resolution mass 
spectrometry 
Hz — hertz 
i — iso 
 VII 
IR — infrared spectroscopy 
IUPAC — international union of pure and 
applied chemistry 
L — ligand 
LRMS — low resolution mass 
spectrometry 
LD — lethal dose 
LDA — lithium diisopropyl amide 
m — meta 
Me — methyl 
Mes — mesityl 
MOM — methoxy methyl 
mp. — melting point 
Ms — mesyl (methanesulfonyl) 
MS — molecular sieves 
MTPA — α-methoxy-α-
trifluoromethylphenylacetic acid 
n — normal 
NBS — N-bromosuccinimide 
NHK — Nozaki-Hiyama-Kishi 
NIS — N-iodosuccinimide 
NMO — N-methylmorpholine-N-oxide 
NMR — nuclear magnetic resonance 
o — ortho 
p — para 
P, PG — protecting group 
PCC — pyridinium chlorochromate 
PE — petroleum ether 
Ph — phenyl 
PMB — para-methoxybenzyl 
PMPTCA — para-methoxybenzyl 
trichloroacetamidate 
PMP — para-methoxyphenyl 
ppm — parts per million 
PPTS — pyridinium para-
toluenesulfonate 
Pr — propyl 
Pv — pivaloyl 
quant. — quantitative 
RCM — ring-closing metathesis 
Red-Al — sodium bis(2-
methoxyethoxy)aluminium hydride 
Rf — retention factor in chromatography 
rr — regioisomeric ratio 
rt — room temperature 
s — sec 
t — tert 
TAS-F — tris(dimethylamino)sulfonium 
difluorotrimethylsilicate 
TBAF — tetra-n-butylammonium fluoride 
TBAI — tetra-n-butylammonium iodide 
TBAT — tetra-n-butylammonium 
triphenyldifluorosilicate 
TBME — methyl tert-butylether 
TBS — tert-butylsilyl 
TBDPS — tert-butyldiphenylsilyl 
TCA — trichloroacetamidate 
Tf — triflyl (trifluoromethanesulfonyl) 
TFA — trifluoroacetic acid 
THF — tetrahydrofuran 
THP — tetrahydropyran 
TIPS — triisopropylsilyl 
TMEDA —N,N,N',N'-
tetramethylethylenediamine 
TMS — trimethylsilyl 
TPAP — tetra-n-propylammonium 
perruthenate 
p-TSA — para-toluenesulfonic acid 
Ts — tosyl 
X — halogen 
 
 
 VIII 
Table of Contents 
 
Abstract ............................................................................... II 
Declaration ........................................................................... III 
Acknowledgements ................................................................. IV 
Abbreviations ........................................................................ VI 
Part I: Introduction ................................................................. 1 
1.1 The cornexistins — activity and isolation ..................................... 1 
1.2 The nonadride family ............................................................ 3 
1.2.1 Structure and activity of the nonadrides .......................... 3 
1.2.2 Biosynthesis of the nonadrides ...................................... 7 
Biosynthesis of glauconic, glaucanic and byssochlamic acids ........................ 7 
Biosynthesis of the CP-molecules ....................................................... 11 
Biosynthesis of the other nonadrides ................................................... 12 
1.3 Previous endeavours towards the cornexistins ............................. 15 
1.3.1 Preliminary studies of the reactivity of cornexistins ........... 15 
1.3.2 Semi-synthesis of cornexistin analogues .......................... 16 
1.3.3 Previous work towards the total synthesis by Taylor and Dow Agrosciences
 ................................................................................. 17 
Observation of the retro-aldol cleavage ............................................... 17 
Intramolecular aldol reaction strategy ................................................. 18 
Synthesis of the two fragments ......................................................... 19 
Intermolecular aldol reaction ........................................................... 20 
Second strategy: a Diels-Alder approach ............................................... 21 
1.4 Previous work toward the synthesis of cornexistins by the Clark group 25 
1.4.1 Original synthetic analysis of hydroxycornexistin ............... 25 
Tandem ring-opening, ring-closing, ring-closing metathesis approach ............ 27 
Ring-closing metathesis approach ....................................................... 29 
1.4.2 Second strategy and synthesis of 5-epi-hydroxycornexistin ... 30 
Revised retrosynthetic analysis of hydroxycornexistin ............................... 30 
Preparation of the Stille coupling precursors ......................................... 31 
Stille coupling and ring-closing metathesis reactions ................................ 32 
Selectivity of the Upjohn dihydroxylation reaction .................................. 33 
Reduction of the α,β-unsaturated lactone ............................................. 33 
Completion of the synthesis of 5-epi-hydroxycornexistin ........................... 35 
1.4.3 Asymmetric approaches to the Stille coupling fragments ..... 37 
Asymmetric synthesis of the stannane fragment ..................................... 37 
Asymmetric synthesis of the chloride fragment ...................................... 40 
 IX 
1.4.4 Attempts to install the natural C-5 configuration .............. 42 
Dihydroxylation reaction ................................................................. 42 
Mitsunobu inversion reaction and other alternatives ................................ 43 
1.5 The Nozaki-Hiyama-Kishi reaction ........................................... 46 
1.5.1 Organochromium chemistry — pioneering studies .............. 46 
1.5.2 NHK — mechanistic studies ......................................... 49 
Stoichiometric reactions ................................................................. 49 
Catalytic effect of nickel on chromium-mediated coupling reactions of alkenyl 
halide or triflate with aldehydes ........................................................ 49 
Chromium-catalysed NHK ................................................................ 50 
1.5.3 NHK — enantioselective reactions ................................. 52 
Oxazoline-based enantioselective NHK................................................. 53 
1.5.4 Application of the NHK reaction in total synthesis ............. 58 
1.6 New strategy for the synthesis of hydroxycornexistin ..................... 60 
Part II: Results and discussion ................................................... 61 
2.1 New retrosynthetic analysis ................................................... 61 
2.2 An approach using racemic material to the Nozaki-Hiyama-Kishi cyclisation 62 
2.2.1 C-1 — C-5 Chloride fragment synthesis ........................... 62 
2.2.2 Synthesis of the stannane fragment ............................... 64 
Formation of the triflate ................................................................. 64 
Conversion of the triflate to the stannane ............................................ 65 
Attempted Suzuki coupling .............................................................. 66 
2.2.3 Stille coupling and efforts towards the Nozaki-Hiyama-Kishi reaction 67 
Stille cross-coupling ....................................................................... 67 
Conversion of the terminal alkyne to vinyl halide using direct methods .......... 68 
Conversion of the terminal alkyne into a vinyl halide through metal-catalysed 
silylation reaction ......................................................................... 71 
Successful conversion of the terminal alkyne to vinyl halide using tin chemistry 72 
2.2.4 Nozaki-Hiyama-Kishi cyclisation ................................... 77 
First approach of the NHK cyclisation .................................................. 77 
Second approach of the NHK reaction .................................................. 79 
Oxidation — reduction sequence ........................................................ 81 
2.2.5 Approach using racemic material — key elements .............. 82 
2.3 An approach to the enantioselective synthesis of hydroxycornexistin .. 84 
2.3.1 Chloride fragment synthesis ........................................ 84 
Study of the asymmetric approaches for the chloride fragment ................... 84 
New strategy for the chloride fragments synthesis ................................... 88 
Asymmetric synthesis of allylic alcohol 314 ........................................... 89 
Cross-metathesis reaction using allylic alcohol (+)-314 .............................. 91 
Alternative cross-coupling reaction ..................................................... 93 
Modified Ireland-Claisen rearrangement and synthesis of the chloride fragment 95 
 X 
2.3.2 Asymmetric synthesis of the stannane fragment ...............100 
Sharpless dihydroxylation approach ................................................... 100 
Synthesis of the chiral proline derivative ............................................. 102 
Condensation of the proline derivative ............................................... 103 
Completion of the stannane fragment ................................................ 105 
2.3.3 Efforts toward the Nozaki-Hiyama-Kishi cyclisation ...........107 
Strategy overview ........................................................................ 107 
Stille coupling and epimerisation issue ............................................... 108 
Modification of the post-coupling strategy ........................................... 109 
Reduction of the unsaturated lactone and protection of the diol ................ 111 
Conversion of the terminal alkyne to vinyl halide ................................... 113 
Conversion of the terminal alkyne to vinyl iodide using palladium-catalysed 
stannylation reactions ................................................................... 114 
2.4 Summary and Future work ................................................... 117 
2.4.1 Improvements to the syntheses of the chloride and stannane fragments
 ................................................................................118 
Asymmetric allylic alcohol synthesis .................................................. 118 
Asymmetric stannane synthesis ........................................................ 119 
2.4.2 Coupled fragments and future work .............................120 
Improvement of the reduction—protection sequence ............................... 120 
Diastereoselectivity of the NHK ........................................................ 120 
Completion of the total synthesis of hydroxycornexistin ........................... 122 
Alternative to the NHK cyclisation ..................................................... 123 
Part III: Experimental part ...................................................... 124 
References ......................................................................... 204 
Appendices ..................................................................... 224 (i) 
 1 
Part I: Introduction 
 
1.1 The cornexistins — activity and isolation 
 
Cornexistin (1) was originally isolated in 1987 from a culture of the fungus Paecilomyces 
variotii Bainier (strain SANK 21086) by researchers Sankyo Co. during a screen of new 
microbial products possessing herbicidal activity (Figure 1.1).1 The fungus had previously 
been isolated in 1982 from a sample of deer faeces collected in Canada. A few years 
later in 1995, the company DowElanco (now Dow Agrosciences) reported the isolation of 
hydroxycornexistin (2), from the same strain of P. variotii.2 
 
 
Figure 1.1 
 
The structures of the cornexistins were elucidated using NMR spectroscopy and by X-ray 
crystallography, but absolute configuration was not established. Cornexistin (1) 
possesses a nine-membered carbocycle fused to a cyclic anhydride. The nine-membered 
ring also features an exocyclic alkene, a ketone, a propyl chain and two hydroxyl groups 
on the - and β’-positions in relation to the ketone. The core of hydroxycornexistin (2) 
presents similar features, the only difference being the presence of a hydroxyl methyl 
group on the exocyclic alkene rather than a methyl group. 
 
At the time of their isolation, both compounds were tested for post-emergence 
herbicidal activity, and found to exhibit significant herbicidal activity against grasses 
and broadleaf weeds that are problematic in maize production (Table 1.1).1,2 Even at 
low concentration, hydroxycornexistin was particularly active against broadleaf weeds, 
while both compounds left maize (Zea mays) largely unaffected. The toxicity of 
cornexistin was found to be low, with a LD50 value greater than 1 mg·g
—1 when 
administered orally to mice.1b  Cornexistin also exhibited no antimicrobial activity 
against a variety of micro-organisms.1b Consequently, these two phytotoxins triggered 
considerable interests from agrochemical companies. 
 2 
  cornexistin (ppm)  hydroxycornexistin (ppm) 
Test species 31.25 15.63 7.81  31.25 15.63 7.81 
Crops          
  Zea mays 30 20 0  20 0 0 
  Triticum aestevium 85 0 0  40 20 35 
        
Broadleaf weeds          
  Xanthium strumarium 20 10 0  100 80 80 
  Chenopodium album 30 30 30  90 80 20 
  Ipomoea hederaceae 0 0 0  85 0 0 
  Amaranthus sp. 0 0 0  80 60 0 
  Abutilon theophrasti 30 60 0  70 40 40 
  Polygonum convolvulus 90 40 20  100 100 40 
        
Grass weeds          
  Echinochloa crus-galli 95 80 0  40 40 0 
  Setaria faberi 20 20 20  70 0 0 
  Sorghum bicolor 30 0 0  0 0 0 
  Avena sativa 100 0 0  45 25 30 
  Digitaria sanguinalis 20 20 0  80 20 20 
 
Table 1.12b - Herbicidal activity of cornexistin and hydroxycornexistin. The activity was assessed 
visually 2 weeks after treatment on a scale of 0-100 where 100 represents complete death and 0 
represents no effect. 
 
The molecular mode of action of the two phytotoxins was unknown. It was suggested 
that they might be pro-herbicides, inhibiting an aspartate amino transferase isoenzyme 
in their active form.3 In 2012, Dayan and Zaccaro reported that cornexistin (1) has an 
effect on the photosynthesis of leaves, which maybe a secondary response to its ability 
to disrupt the plasma membrane.4 Despite these advances, more than 20 years after the 
isolation of cornexistins, the exact mode of action remains unclear.  
 
The cornexistins, each containing a nine-membered carbocycle, are just two of the 
numerous natural products belonging to the nonadride family. Several of these, 
possessing intricate structures and varied biological activities are described below. 
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1.2 The nonadride family 
 
1.2.1 Structure and activity of the nonadrides 
 
The term ‘nonadride’ was introduced by Barton and Sutherland in the mid 1960s in 
reference to the bisanhydrides glauconic acid (3), glaucanic acid (4) and byssochlamic 
acid (5), since their biosyntheses appeared to be derived from two C9-units (Figure 
1.2).5  This was generally accepted and has since been extended to cover any related 
natural products containing a nine-membered carbocycle fused to at least one maleic 
anhydride unit. Cornexistins are rather unusual members of the nonadride family of 
compounds because they possess just a single anhydride unit, while to date, all the 
other ones bear two. The first of the nonadrides to be discovered were glauconic acid 
(3) and glaucanic acid (4) which were both isolated by Wijkman in 1931 from the fungus 
Penicillium glaucum (reclassified later as Penicillium purpurogenum).6,7 This was 
followed by the isolation of byssochlamic acid (5) in 1933 from the fungus byssochlamys 
fulva.8 The structures and absolute configurations of these three natural products were 
elucidated chemically and confirmed by X-ray crystallography.5,6,9 For each of them, the 
nine-membered carbocycle is substituted with simple alkyl side chains, with an 
additional hydroxyl group in the case of glauconic acid (3). 
 
 
Figure 1.2 
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Subsequently, two toxic metabolites — rubratoxin A (6) and B (7) — were isolated from 
the fungus Penicillium rubrum (Figure 1.3).10 The relative configurations of both 
structures were determined by Moss et al. in 1969, and adjusted one year later by Büchi 
and co-workers.11,12 Both species possess more elaborate side chains on either side of 
the nine membered ring. Rubratoxin B (7) does exhibit some phytotoxic activity, but 
this activity is much weaker than in the case of the cornexistins.1 
 
 
Figure 1.3 
 
Scytalidin (8, Figure 1.3), isolated in 1972 from the fungus Scytalidium sp., was found 
to be a relatively active anti-fungal agent, with low phytotoxic activity.13,14 
Deoxyscytalidin (9) was isolated later during a chemosystematic study.15 Heveadride 
(10, Figure 1.4) was discovered at the same time as scytalidin and was isolated from the 
fungus Helminthosporium heveae.16 Homoheveadride (11) is to date the only naturally 
occurring nonadride extracted from a lichen (Cladonia polycarpoides).17 More recently, 
the group of Hosoe isolated two new derivatives, dihydro- and deoxo- epiheveadride (13 
and 14 respectively).18 Oxidation of dihydroepiheveadride (13) to give epiheveadride 
(12) and subsequent X-ray crystallographic studies allowed the absolute configuration of 
the heveadride family to be deduced.18a In 2010, the six epiheveadrides were isolated 
from the same aquatic fungus Wicklowia aquatica.19 This family exhibits anti-fungal 
activities, with the most effective one, dihydroepiheveadride (13), showing activity 
against some human pathogens.  
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Figure 1.4 
 
The last and most structurally complex members of the nonadride family of natural 
products isolated to date are the fungal metabolites CP-225,917 and CP-225,114, also 
known as phomoidrides A (18) and B (19) (Figure 1.5). Both were isolated from an 
unidentified fungus by workers at Pfizer in 1997.20 They aroused considerable interests 
in the pharmaceutical industries due to their inhibitory activity on the enzymes 
squalene synthase and Ras farnesyl transferase. Inhibitors of these enzymes have been 
found to possess cholesterol-lowering and anti-cancer properties.20a,21 
Structurally, the nine-membered carbocycle of the phomoidrides is embedded within a 
bicyclo[4.3.1]deca-1,6-diene framework. The only structural difference between the 
two CP-molecules is that in phomoidride B (19), a γ-lactone forms part of a γ-lactone 
acetal whereas in phomoidride A, the acetal unit is hydrolysed, to form a γ-lactone 
hemi-acetal. 
 
 
Figure 1.5 
 
Due to their unique and challenging structures, phomoidrides A (18) and B (19) have 
been, and still are, an inspiration for many research groups interested in the total 
synthesis and structure elucidation of natural products, resulting in the development of 
new methodologies and synthetic strategies.22 
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When isolating phomoidrides A (18) and B (19), Kaneko and co-workers deduced the 
overall structure and relative configuration based purely on NMR spectroscopic data.20b 
The group of Nicolaou was the first to accomplish the total syntheses of (±)-18 and 
(±)-19 in 1999, only two years after their isolation. The key step in the synthesis 
involved a Lewis acid mediated intramolecular Diels-Alder reaction.23 Focusing next on 
the asymmetric syntheses of phomoidride A (18) and B (19), Nicolaou and co-workers 
obtained the advanced intermediate (+)-20 one year later (Scheme 1.1). Coupling of 
natural phomoidride B (19) with indoline in the presence of EDCI furnished (−)-20, 
which was found to be exactly identical to (+)-20, except for opposite optical 
rotation.24 Accordingly, the absolute configuration of phomoidride B (−)-19, and hence 
that of phomoidride A (+)-18 could be assigned. 
 
 
Scheme 1.1 
 
During their syntheses of phomoidrides, the group of Danishefsky encountered 
epimerisation issues at the C-7 centre of their synthetic material, by comparison with 
samples obtained from the natural source.25 Further investigations led to the 
identification of variable amounts of 7-epi-19 in samples obtained from various 
fermentation broths of the unidentified fungus (Figure 1.6). This was confirmed by 
Sulikowski’s group in 2001, which showed the natural co-production of 7-epi-18 
(phomoidride C) as well as 7-epi-19 (phomoidride D) by fermentation. Results from pH 
and fermentation time studies suggested that phomoidride B (18) was the first-formed 
metabolite and the source of the remaining three phomoidrides (A, C and D).26 
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Figure 1.6 
 
1.2.2 Biosynthesis of the nonadrides 
 
Biosynthesis of glauconic, glaucanic and byssochlamic acids 
 
When the nonadride family was discovered, a lot of effort was focused on the 
elucidation of the biosynthesis of these natural products, with special attention given to 
glauconic acid (3), glaucanic acid (4) and byssochlamic acid (5). Along with the 
confirmation of the structures, Sutherland and co-workers proposed that the three acids 
were formed by dimerisation of the nine-carbon anhydride 24 (Scheme 1.2).5a Head to 
head dimerisation of 24 would first lead to glaucanic acid (4), which would then 
undergo oxidation to afford glauconic acid (3). On the other hand, head to tail 
dimerisation of 24 would lead to the formation of byssochlamic acid (5). It was 
predicted that the anhydride unit 24 could be derived from the citric acid derivative 
23, formed by condensation of n-hexanoic acid 21 and oxaloacetic acid 22.27 
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Scheme 1.2 
 
Impressive results were obtained by means of carbon-14 labelling methods. Feeding 14C-
labeled acetic acid or pyruvic acid to the fungus Penicillium purpurogenum gave 
glauconic acid (3).27,28 Oxaloacetic acid 22 can be synthesised in living organisms from 
acetic or pyruvic acid,29 and so the hypothesis that oxaloacetic acid 22 was a precursor 
to the formation of glauconic acid (3) was confirmed. The same method was employed 
for anhydride 24 previously synthesised, with the similar in vivo formation of glaucanic 
and glauconic acids (4) and (3), leaving little doubt that anhydride 24 was the nine-
carbon dimerisation precursor in the synthesis of both acids.30,31  
 
The group of Sutherland also presented a possible mechanism for this dimerisation 
reaction, consisting of an electrocyclic addition of diene 24 with the anion derived from 
it (Scheme 1.3). Accordingly, diene 24 was treated with sodium hydride in DMF or 
triethylamine. Unfortunately, only small amounts of dimerised product were isolated, 
corresponding to 12-epi-glaucanic acid instead of (4). The formation of byssochlamic 
acid (5) was also attempted by reaction of the diene 26 and the anion 25 under various 
conditions, but without success.30,31  
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Scheme 1.3 
 
Intrigued by these results, Baldwin and co-workers further investigated the dimerisation 
reaction leading to the formation of glaucanic acid (4). Using diene 27, bearing an 
additional methyl group in the alkyl chain compared to that of 24, three different 
products were obtained; 29 (with the same relative configuration than 12-epi-glaucanic 
acid), a spiro compound 30 and a seven-membered carbocycle 31 (Scheme 1.4).32 This 
result suggested that the formation of the two by-products were formed as a 
consequence of a stepwise mechanism. Michael addition reaction would form the 
anionic intermediate 28; the nonadride 29 would be obtained through pathway (i) and 
the other products 30 and 31 through the nucleophilic attack of the anion on two 
different electrophilic sites (pathway (ii) or (iii)). 
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Scheme 1.4 – Reagents & conditions: a) MgCl2, Et3N, DMSO, rt [9% 29, 6% 30, <2% 31]. 
 
Interestingly, Baldwin et al. also synthesised the model substrate 32 in an attempt to 
mimic the way an enzyme might combine the two anhydrides (Scheme 1.5).33 Treated 
with DBU in a mixture of THF and DMSO, bis-anhydride 32 formed two cyclised 
products, 33 and 34, in a 3:2 ratio. The major product 33 bears a cis-C3—C12 ring 
junction and an anti-relationship with the methyl group on C-6, analogously to glaucanic 
acid, whereas 34 has an anti-C3—C12 ring junction corresponding to 12-epi-glaucanic 
acid. It was proposed that the first Michael addition was forming the six-membered ring, 
followed by the nine-membered ring formation. 
  
 
Scheme 1.5 – Reagents & conditions: a) DBU, THF—DMSO, rt [14%; 33:34, 3:2]. 
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Biosynthesis of the CP-molecules 
 
Following the approach pioneered by Sutherland and co-workers for the biosyntheses of 
acids (3), (4) and (5), the group of Sulikowski extended the dimerisation hypothesis to 
the biosynthesis of the more complex phomoidrides (18) and (19).34 They proposed a 
biosynthetic pathway based on the dimerisation of the 16-carbon unit 35 to form the 
nine-membered carbocycle 36. Subsequent decarboxylation followed by oxidation 
would lead to phomoidride A (18), which could be converted to phomoidride B (19) by 
dehydration thereafter (Scheme 1.6). 
 
 
Scheme 1.6 
 
Analogously, they proposed that the 16-carbon anhydride 35 would be formed by 
condensation of oxaloacetic acid 22 and the unsaturated fatty acid 38 (Scheme 1.7). 
Using carbon-13 labelling, the group of Sulikowski fed [2,3-13C2]-succinic acid 36 to the 
fungus responsible for the formation of the phomoidrides.35 In agreement with previous 
work done by Sutherland and co-workers for the biosynthesis of glauconic acid (3), 13C 
incorporation to the phomoidrides was observed, at C-12, C-13, C-14 and C-28. Feeding 
the fungus with [1,4-13C2]-succinic acid 31 provided 
13C incorporation at C-27, C-29 and 
C-30, confirming that succinic acid was indeed a precursor involved in the biosynthesis. 
The same method was employed for the unsaturated fatty acid 38. Studies in which 
13C-labelled acetic acid was used were inconclusive, therefore they used the acetic acid 
derivative [2-13C]-N,S-diacetyl cysteamine. Incorporation of labelled material into the 
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side chains of phomoidride B (19) was successful, supporting the proposed synthesis of 
the fatty acid chains 38 from acetic acid. 
 
 
Scheme 1.7 
 
These results looked promising and only the proposed 16C—16C dimerisation theory 
remained to be validated. Sulikowski and co-workers synthesised deuterated anhydride 
39, and fed it to the fungus (Scheme 1.8). When product 40 was isolated, deuterium  
incorporation was observed at both C-7 and C-19 positions, strongly supporting the 
dimerisation step theory.36 
 
 
Scheme 1.8 
 
 
Biosynthesis of the other nonadrides 
 
As much as the studies of the biosyntheses of glauconic acid (3) or CP-molecules (18 
and 19) were successful, far less literature has been published regarding the other 
nonadrides. Feeding 13C- and 14C-labeled proposed biosynthetical precursors to the 
fungus often showed mixed results, as reported by Cox and Holcker37 and the group of 
Tamm,38 working on the biosyntheses of glauconic acid (3) and rubratoxins (6 and 7), 
respectively. Sulikowski and co-workers suggested that the two main steps of the 
biosynthesis in the CP-molecules — polyketide-oxaloacetic acid condensation and 
subsequent decarboxylative dimerisation of the resulting anhydride — could occur in 
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most nonadride biosyntheses (Scheme 1.9).39 The diversity of the nonadrides would be 
the result of variations in the polyketide structure, oxidations and regio- and stereo-
chemistry of the dimerisation reaction. 
 
 
Scheme 1.9 
 
Glauconic acid and CP-molecules are natural products perfectly suited for direct 
dimerisation of the precursors. However, most of the other nonadrides are less 
symmetrical, increasing the difficulty of potential precursors syntheses. Furthermore, 
although head-to-head dimerisation has been observed, the head-to-tail coupling 
proposed for the synthesis of byssochlamic acid (5), scytalidin (8) and rubratoxin B (7) 
has never been achieved. 
 
Following Sulikowski’s approach, the biosynthesis of cornexistins could be seen as a 
process in which condensation of oxaloacetic acid with a triketide is followed by 
subsequent head-to-tail dimerisation of the intermediate anhydride (Scheme 1.10). 
Decarboxylation and oxidation steps would then give cornexistin (1) and an additional 
oxidation step would lead to the formation of hydroxycornexistin (2). However, because 
the core of the cornexistins are the least symmetrical of all nonadrides, with only one 
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anhydride unit, formation of the nine-membered ring by direct coupling of two 
anhydride units seems unlikely. 
 
 
Scheme 1.10 
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1.3 Previous endeavours towards the cornexistins 
 
 
The selective herbicidal activity of the cornexistins triggered considerable interest from 
the agrochemical industry, especially Sankyo Co.,1 Dow Agrosciences,2,40 and Syngenta.41 
However, the high degree of acid and base sensitivity of both natural products prevents 
their development into commercial herbicides.40 The development of more stable 
analogues, which retain the same level of phytoxicity than cornexistins, was the 
ambition of these companies. In spite of their significant potential as lead compounds 
for new post-emergence weed control agents, the cornexistins have been the subject of 
relatively few synthetic studies. Aside from our work, only Taylor and co-workers have 
attempted the total synthesis of cornexistins. This section describes the research 
activities regarding the cornexistins. 
 
1.3.1 Preliminary studies of the reactivity of cornexistins 
 
The sensitivity of cornexistins is almost certainly due to the highly reactive cyclic 
anhydride unit. Consequently, researchers at Dow Agrosciences investigated reversible 
protection of the cyclic anhydride as a bis-ester (Scheme 1.11).40 
 
 
Scheme 1.11 – Reagents & conditions: a) H2SO4 (cat.), EtOH, reflux. 
 
Treatment of cornexistin under acidic conditions resulted in a retro-aldol cleavage, 
forming lactone 49 as the major product. The same product was observed using basic 
conditions. Investigations of neutral conditions revealed that the use of trimethylsilyl-
diazomethane in a mixture of THF—MeOH afforded complete conversion of (1) to bis-
methylester 50 (Scheme 1.12). The classic conditions required for the deprotection of 
the methyl esters were unfortunately too harsh, resulting in retro-aldol cleavage once 
again. However, substituting methanol for benzyl alcohol as the co-solvent during the 
protection reaction furnished a mixture of mono-methyl esters 51 and 52 in a 1.5:1 
ratio, which could be cleanly debenzylated by phase-transfer hydrogenolysis, without 
hydrogenation of the exocyclic alkene. Hence, this protection—deprotection sequence 
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of the reactive cyclic anhydride moiety could be useful in the synthesis of cornexistin 
analogues. 
 
 
Scheme 1.12 – Reagents & conditions: a) TMSCHN2, THF—MeOH (1:1), rt [70-75% 50]; 
b) TMSCHN2, THF—BnOH (1:1), rt [61%, 51—52 (1.5:1)]; c) 51 and 52, Pd/C (10 mol%), 
cyclohexene, EtOH, reflux [68%]. 
 
1.3.2 Semi-synthesis of cornexistin analogues 
 
Researchers at Sankyo synthesised numerous analogues of cornexistin, simply by 
modification of the main functional groups (Figure 1.7).42,41 Mono- and bis-protection of 
the two hydroxyl groups of cornexistin gave analogues 53. Compounds 54 were the 
result of bis-methyl ester protection of the cyclic anhydride. Reactions of 53 and 54 
with various amines formed amides 55, which could be converted into the 
corresponding maleimide derivatives 56 by reaction with a carbodiimide. 
 
 
Figure 1.7 
 
When tested in-vivo, most compounds showed excellent post-emergence herbicidal 
activity, killing between 70 and 100% of the grasses and broadleaf plants examined. 
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However the level of application, 1000 ppm, represented an impressively large amount 
of each compounds, and no further results concerning these cornexistin analogues were 
reported. 
 
1.3.3 Previous work towards the total synthesis by Taylor and Dow 
Agrosciences 
 
Observation of the retro-aldol cleavage 
 
As mentioned previously, researchers at Dow Agrosciences discovered that treatment of 
cornexistin with a catalytic amount of sulphuric acid in ethanol promotes a retro-aldol 
reaction and leads to formation of lactone 49. Interestingly, when boron trifluoride was 
used as the catalyst, the cornexistin isomer 57 was isolated, with isomerisation of the 
exocyclic ethylidene (Scheme 1.13).43 
 
 
Scheme 1.13 
 
To explain this isomerisation reaction, a mechanism was proposed where a Lewis acid-
assisted retro-aldol cleavage would allow the formation of intermediate 58 (Scheme 
1.14). Isomerisation of the ethylidene moiety would be possible via tautomerisation of 
the conjugated aldehyde. Subsequent aldol reaction would close the nine-membered 
ring, affording 57. This unexpected result inspired the researchers at Dow Agrosciences, 
in collaboration with the research group of Richard E. Taylor, to develop a strategy 
based on a final intramolecular aldol reaction for the total synthesis of cornexistin. 
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Scheme 1.14 
 
Intramolecular aldol reaction strategy 
 
The strategy was based on construction of the unsaturated aldehyde 60 as the precursor 
required for the intramolecular aldol reaction (Scheme 1.15). The methyl ketone in 60 
would be masked as a styrene unit, and the unsaturated aldehyde as a protected allylic 
alcohol. The cyclic anhydride moiety would be derived from an enol triflate, via 
palladium-catalysed carbonylation, leading to intermediate 61.44 The enol triflate 
precursor 62 would be obtained through an intermolecular aldol reaction between ester 
63 and aldehyde 64. 
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Scheme 1.15 
 
Synthesis of the two fragments 
 
Starting from 2-methylene-1,3-propanediol 65, mono-silyl protection of the diol using 
TBDPS chloride afforded 66 (Scheme 1.16). Using a Johnson-Claisen rearrangement,45 
the desired ester 67 was obtained in 86% yield, by reaction of alcohol 66 with trimethyl 
orthoacetate.  
  
 
Scheme 1.16 – Reagents & conditions: a) TBDPSCl, n-BuLi, THF, −78 ºC to reflux [94%]; trimethyl 
orthoacetate, propanoic acid (cat.), toluene, reflux [86%]. 
 
For the second fragment, the Evans’ auxiliary 6846 was acylated using valeryl chloride 
to furnish 69 (Scheme 1.17). The aldol reaction between 69, via the Z-enolate, and α-
methyl-trans-cinnamaldehyde 70 afforded the desired syn-aldol product 71. Initially, 
alcohol 71 was protected as a silyl-ether, but because of problems encountered at a 
later stage in the synthesis, the alcohol was protected as a MOM-ether. Removal of the 
oxazolidinone with lithium borohydride followed by Swern oxidation of the resulting 
alcohol afforded aldehyde 72 in good yield. 
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Scheme 1.17 – Reagents & conditions: a) n-BuLi, valeryl chloride, THF, −78 ºC [85%]; b) 70, n-
Bu2BOTf, Et3N, CH2Cl2, −78 ºC to 0 ºC [60%]; c) MOMCl, i-Pr2NEt, CH2Cl2, rt [79%]; d) LiBH4, THF, 
0 ºC to rt  [75%] e) (COCl)2, DMSO, CH2Cl2, −78 ºC then Et3N, −78 ºC to rt [71%]. 
 
Intermolecular aldol reaction 
 
After much effort, deprotonation of ester 67 using LDA and subsequent nucleophilic 
attack of the resulting enolate on aldehyde 72 was successful, using three equivalent of 
ester 67 (Scheme 1.18). The mixture of diastereoisomers obtained was oxidised using 
Swern conditions, allowing the formation of the desired β-ketoester 73 in 85% yield over 
two steps. 
 
 
Scheme 1.18 – Reagents & conditions: a) LDA, THF, −78 ºC; b) (COCl)2, DMSO, CH2Cl2, −78 ºC 
then Et3N, −78 ºC to rt [85% (2 steps)]. 
 
Unfortunately, attempts to form the vinyl triflate 74 using KHMDS and the Comins 
reagent 7547 failed, with only recovery of the starting material (Scheme 1.19). The 
formation of the methyl ketone leading to precursor required for the intramolecular 
aldol reaction was also investigated. Under ozonolysis conditions, the two alkene units 
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reacted, providing the undesired triketone 76. Sharpless dihydroxylation and 
epoxidation reactions also proved unsuccessful. The desired precursor 60 (cf. Scheme 
1.15), required for the intramolecular aldol reaction could not be prepared, and so this 
first strategy was discontinued. 
  
 
Scheme 1.19 – Reagents & conditions: a) KHMDS, 75, THF, −78 ºC [starting material]; b) O3, 
PPh3, CH2Cl2. 
 
Second strategy: a Diels-Alder approach 
 
In 2007, Taylor and co-workers published an approach towards the synthesis of the 
cornexistin core through a Diels-Alder cycloaddition/oxidative cleavage strategy.48 Their 
retrosynthetic analysis was based on the inherent symmetry of functionality within the 
nine-membered ring system (Scheme 1.20). By bisecting the molecule horizontally, each 
substituent was mirrored across the ring, except for the propyl chain and the ethylidene 
unit. That led them to the structure 77, where chemoselective oxidative cleavage 
would expose a nine-membered cyclic diketone. The cyclohexa-1,4-diene 77 could be 
derived from a Diels-Alder reaction of dienophile 79 and diene 78. 
 
 
Scheme 1.20 
 
The synthesis of the cyclopentadiene began with aldehyde 80, previously obtained from 
TBS monoprotection of 1,3-propandiol and TEMPO oxidation (Scheme 1.21). Nucleophilic 
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attack of the lithiated pentyne on aldehyde 80 gave alcohol 81 in 91% yield. The 
resulting alcohol was protected as a PMB-ether, the TBS group removed using TBAF. The 
exposed alcohol was then oxidised using Swern conditions to provide aldehyde 82. The 
aldehyde was immediately reacted with lithiated TMS-acetylene to give a separable 
mixture of the syn- and anti-diastereoisomers. The anti-diasteroisomer could be 
converted to the desired alcohol syn-83 via Mitsunobu reaction. Desilylation of the 
terminal alkyne was carried out using TBAF and the propargylic alcohol was protected as 
a TBS-ether to give 84. Finally, the diyne was subjected to Trost reductive cyclisation 
conditions to provide cyclopentadiene 78 in excellent yield (98%).49 
 
 
Scheme 1.21 – Reagents & conditions: a) pent-1-yne, n-BuLi, −78 ºC to 0 ºC [91%]; b) PMBBr, 
NaH, n-Bu4NI (cat.), THF, −10 ºC to 0 ºC; c) n-Bu4NF, THF, rt; d) (COCl)2, DMSO, CH2Cl2, −78 ºC 
then Et3N, −78 ºC to rt [70% (3 steps)]; e) (trimethylsilyl)acetylene, n-BuLi, THF, −78 ºC to 0 ºC 
[46% syn-78, 26% anti-78]; f) n-Bu4NF, THF, rt [quant.]; g) TBSCl, imidazole, DMF, rt [75% 
(2 steps)]; g) Pd2(dba)3·CHCl3 (2.5 mol%), P(o-PhMe)3 (10 mol%), AcOH, Et3SiH, benzene, rt [98%]. 
 
Diene 78 was then reacted with dimethyl acetylenedicarboxylate to provide the Diels-
Alder cyclohexadiene 77 in 50% yield (Scheme 1.22). The anti relationship between the 
propyl chain and 4-methoxybenzyl ether was determined by X-ray analysis, confirming 
that the facial selectivity of the cycloaddition reaction was controlled by steric 
influences. Oxidative cleavage of the internal alkene using ozone revealed the diketone 
and further chemoselective methylenation using Tebbe’s reagent and an excess of 
pyridine gave the desired alkene 85 in 45% yield over the two steps. 
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Scheme 1.22 – Reagents & conditions: a) hydroquinone (cat.), toluene, reflux [50%]; b) O3, 
Sudan III dye, CH2Cl2—MeOH (2:1), −78 ºC; c) TiCp2CH2ClAlMe3, pyridine, THF, −15 ºC to −22 ºC 
[45% (2 steps)]. 
 
The ketone was reduced using sodium borohydride to give the corresponding alcohol in 
an excellent yield and as a single diastereoisomer (Scheme 1.23). Subsequent 
acetylation of the resulting alcohol furnished acetate 86. Although all attempts to grow 
suitable crystals for X-ray crystallography failed, NMR analysis of the acetate 86 
revealed a strong NOE between the hydrogens in C-4 and C-5, and the multiplicity of the 
C-5 proton suggested  a 4,5-cis-5,6-trans relationship. For the functionalisation of the 
1,1-disubstituted alkene, the use of a silicon-tethered diene ring-closing metathesis 
(RCM) reaction was considered. Silyl group exchange provided allyl silane 88, 
unfortunately, the ring-closing metathesis reaction using Grubbs II 90 as catalyst 
provided only dimeric by-products. 
  
 
Scheme 1.23 – Reagents & conditions: a) NaBH4, MeOH, 0 ºC [98%]; b) Ac2O, pyridine, DMAP 
(cat.), rt [70%]; c) n-Bu4NF, THF, rt [87%]; d) allyldimethylsilyl chloride, Et3N, CH2Cl2, rt [50%]; 
e) Grubbs II 90 (cat.), CH2Cl2, reflux. 
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Supposing that the conformation of the molecule was inappropriate for the RCM 
reaction, inversion of the alcohol stereocentre on C-8 was attempted (Scheme 1.24). 
While Mistunobu inversion resulted in elimination, Dess-Martin oxidation of 87 followed 
by simple reduction using sodium borohydride provided alcohol 91, the C-8 epimer of 
87, in a good yield and as a 4:1 ratio of isomers. Silyl protection gave the desired 
silicon-tethered diene 92 which was subjected to RCM reaction conditions using Grubbs 
II 90 as catalyst. This time the trisubstituted alkene 93 was obtained in quantitative 
yield. 
 
 
Scheme 1.24 – Reagents & conditions: a) DMP, CH2Cl2, rt; b) NaBH4, MeOH, 0 ºC [60% (2 steps), 
dr 4:1]; c) allyldimethylsilyl chloride, Et3N, CH2Cl2, rt [50%]; d) Grubbs II 90 (cat.), CH2Cl2, reflux 
[quant.]; e) KF, H2O2, KHCO3, THF—MeOH (1:1), rt [quant.]. 
 
Manipulation of the siloxacycle 93 could provide both cornexistins. Protodesilylation of 
83 to form the exo-cyclic ethylidene was unsuccessful, but Fleming-Tamao oxidation 
reaction gave diol 94 in quantitative yield.50 To date, further elaboration of diol 94 to 
give hydroxycornexistin has not been reported. 
 
Aside from the two approaches attempted by the group of Taylor and Dow Agrosciences, 
the only other published research targeting the total synthesis of the cornexistins is by 
the Clark group.51 A review of the past endeavours within the group to synthesise the 
cornexistins will now follow. 
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1.4 Previous work toward the synthesis of cornexistins by 
the Clark group 
 
1.4.1 Original synthetic analysis of hydroxycornexistin 
 
The initial approach envisioned by the Clark group was based on the formation of the 
nine-membered carbocycle by RCM reaction. It is believed that at the time a 
functionalised nine-membered carbocycle had never been formed in this way. This was 
a challenge as a medium carbocyclic system, containing from eight to eleven carbons, 
combines poor flexibility in comparison to a straight-chain alkane, and important 
transannular interactions — Prelog strain52 — between the substituents of the ring. As a 
result they are extremely difficult to synthesise. Thus, synthesis of the core of the 
cornexistins using RCM would highlight the growing use of the reaction for the formation 
of medium rings, in addition to its widespread use for the assembly of small and large 
rings. 
 
Concentrating on hydroxycornexistin (2), a first retrosynthetic analysis was conceived. 
Due to the chemically sensitive nature of the cyclic anhydride, it was decided that it 
should be formed as late in the synthesis as possible and a furan was chosen to act as a 
latent form (Scheme 1.25). This strategy had previously been used with success in the 
total synthesis of the CP-molecules by the group of Danishefsky.25,53 Synthesis of the 
exocyclic alkene with the desired (Z)-alkene geometry was anticipated as a potential 
problem, which could be avoided by connecting the two hydroxyl group in the form of a 
α,β-unsaturated lactone. Further conversion of the ketone carbonyl group into a 
hydroxyl group would reveal lactone 95 as key late stage intermediate. Alkene 96 could 
be obtained by retrosynthetic dehydration of 95, and after disconnecting the ring 
through the alkene, two options could be possible. A simple retrosynthetic RCM would 
afford diene 97, which could be formed by palladium-catalysed coupling of the 
unsaturated lactone 98 and the furan 99. On the other hand, a more ambitious 
metathesis disconnection would reveal triene 100, obtained by palladium-catalysed 
coupling of cyclopentene 101 and furan 102. 
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Scheme 1.25 
 
In the latter synthetic approach, the conversion of the triene 100 into the nine-
membered carbocycle 104 represents a tandem ring-opening, ring-closing, ring-closing 
metathesis sequence (Scheme 1.26). Initial ring-opening, ring-closing sequence would 
generate the alkylidene 103. A subsequent ring-closing metathesis reaction would 
provide the desired nine-membered carbocycle 104. 
 
 
Scheme 1.26 
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Tandem ring-opening, ring-closing, ring-closing metathesis 
approach 
 
The more ambitious tandem approach was explored first, and the two fragments were 
prepared. The chloride fragment 109 was prepared in six steps, starting from propargyl 
alcohol (Scheme 1.27). Protection of the hydroxyl group as a TBS-ether followed by 
alkyne acylation using butyric anhydride afforded ketone 106. Heating ketone 106 and 
4-phenyl-1,3-oxazole at 200 ºC resulted in a Diels-Alder cycloaddition reaction, and 
immediate retrocycloaddition to give the furan. Ketone methylenation using Nysted 
reagent 107 furnished the 1,1-disubstituted alkene 108. Finally, removal of the TBS 
group and conversion of the resulting alcohol to the chloride afforded the furan 
fragment 109. 
 
Scheme 1.27 – Reagents & conditions: a) TBSCl, imidazole, DMAP, CH2Cl2, reflux; b) n-BuLi, 
(n-PrCO)2O, THF, −78 ºC [55%, 2 steps]; c) 4-phenyl-1,3-oxazole, 200 ºC [76%]; d) Nysted reagent 
107, TiCl4, THF, rt [81%]; e) n-Bu4NF, THF, rt [93%], f) MsCl, 2,4,6-collidine, LiCl, CH2Cl2, 0 ºC to 
rt [81%]. 
 
The synthesis of the second fragment began with the asymmetric desymmetrisation of 
diacetate 110 (Scheme 1.28). Using electric eel acetylcholine esterase, the selective 
hydrolysis of one of the two acetate groups provided the alcohol (93% ee by HPLC), 
which was re-protected to give the TBS-ether 111. Hydrolysis of the remaining acetate 
group followed by oxidation of the resulting alcohol in the presence of PCC afforded 
enone 112. The vinyl bromide was obtained in good yield using bromine, and 
subsequent stereoselective Luche reduction of the enone gave alcohol 113. Allylation of 
the alcohol followed by lithium-halogen exchange on the bromide, and subsequent 
trapping with tributyltin hydride produced the stannane 114.  
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Scheme 1.28 – Reagents & conditions: a) electric eel acetylcholine esterase, NaN3, pH 7 buffer, 
rt [69%, 93% ee]; b) TBSCl, imidazole, DMAP, CH2Cl2, rt [93%]; c) K2CO3, MeOH, rt [94%]; d) PCC, 
CH2Cl2, rt [73%];, e) (i) Br2, CH2Cl2, 0 ºC; (ii) Et3N, CH2Cl2, 0 ºC [92%]; f) NaBH4, CeCl3·7H2O, 
MeOH, −78 ºC; g) allyl bromide, NaH, THF, rt [63% (2 steps)]; h) s-BuLi, Bu3SnCl,
54 THF, −78 ºC to 
rt [68%]. 
 
The coupling of chloride 109 and stannane 114 was accomplished by a palladium-
catalysed Stille cross-coupling reaction, providing the metathesis precursor in modest 
yield without optimisation (Scheme 1.29).55 Unfortunately, using Grubbs I or Grubbs II 
catalysts under various conditions, the desired trisubstituted alkene 116 could not be 
obtained from the precursor 115. Instead, only dimerisation of the allylic ether was 
observed.  
 
 
Scheme 1.29 – Reagents & conditions: a) Pd(PPh3)4 (5 mol%), toluene, reflux [33%]; b) 90 or 117 
as catalysts, various conditions. 
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Ring-closing metathesis approach 
 
Given the failure of the challenging tandem metathesis sequence, the alternative RCM-
based approach was considered (Scheme 1.25). A simple model was conceived in order 
to quickly estimate the feasibility of the key RCM reaction, starting from TBS-protected 
7-octyn-1-ol 118 (Scheme 1.30). Reaction of butanal with the lithium acetylide derived 
from alkyne 118 and immediate oxidation of the resulting alcohol using TPAP afforded 
ketone 119. The oxazole cycloaddition—retrocycloaddition sequence followed by ketone 
methylenation delivered furan 120. The protecting group was then removed and the 
resulting alcohol oxidised using Swern conditions. Wittig methylenation of the aldehyde 
delivered RCM precursor 121.   
 
 
Scheme 1.30 – Reagents & conditions: a) n-BuLi, n-PrCHO, THF, −78 ºC; b) TPAP, NMO, CH2Cl2, rt 
[66% (2 steps)]; c) 4-phenyl-1,3-oxazole, 200 ºC [70%]; d) Nysted reagent, TiCl4, THF, 0 ºC to rt 
[89%]; e) n-Bu4NF, THF, rt [99%]; f) (COCl)2, DMSO, CH2Cl2, −78 ºC then Et3N, −78 ºC to rt [91%]; 
g) PPh3=CH2, THF, rt [85%]; h) 90 or 117, CH2Cl2, rt or reflux. 
 
Unfortunately, all attempts to effect ring closure by RCM failed to deliver the nine-
membered ring 122. This unsuccessful attempt was attributed to the flexibility of the 
alkyl chain, and to difficulties in forming a conjugated trisubstituted alkene during the 
metathesis reaction. This led to a revision of the synthetic strategy. 
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1.4.2 Second strategy and synthesis of 5-epi-hydroxycornexistin 
 
Revised retrosynthetic analysis of hydroxycornexistin 
 
The problem with the previous strategy was the disconnection of a trisubstituted 
alkene, which proved difficult to obtain by RCM in the forward synthesis. Making the key 
disconnection of the nine-membered ring at a different position could potentially solve 
the problem. In the revised retrosynthetic analysis, the 1,2-syn-diol 95 could be 
recognised as the product resulting from the dihydroxylation of an alkene, which would 
lead to cyclononene 123 (Scheme 1.31). This time, disconnection of the carbocycle at 
this double bond would reveal diene 124, containing two terminal olefins. Next, 
disconnection at one of the two C—C bonds linking the two rings would give the chloride 
125 and the stannane 126, precursors of the Stille coupling product. 
 
 
 
 
Scheme 1.31 
  
 31 
Preparation of the Stille coupling precursors 
 
The synthesis of the chloride fragment (±)-125 was achieved in nine steps (Scheme 
1.32). Lithium aluminium hydride reduction of the diester 127 to the corresponding diol 
followed by selective mono-oxidation with manganese dioxide gave the aldehyde. The 
remaining alcohol was protected as a TBS-ether, delivering aldehyde 128 in 73% yield 
over three steps. Wittig reaction of the aldehyde with methyl-
(triphenylphosphoranylidene)acetate furnished the α,β-unsaturated ester 129. 
Reduction of the ester using lithium aluminium hydride and treatment of the resulting 
alcohol with diethyl chlorophosphate afforded allylic phosphate 130. The propyl chain 
was installed by copper-catalysed SN2’ displacement of the allylic phosphate with 
n-propylmagnesium bromide, allowing the formation of alkene 131. The TBS-ether was 
cleaved and finally, the alcohol was converted to the corresponding chloride via the 
mesylate gave chloride (±)-125. 
 
 
Scheme 1.32 – Reagents & conditions: a) LiAlH4, THF, −78 ºC to rt; b) MnO2, CH2Cl2, rt; c) TBSCl, 
imidazole, DMAP, CH2Cl2, rt [74% (3 steps)]; d) Ph3P=CHCO2Me, THF, rt [99%]; e) LiAlH4, THF, 
−78 ºC to −30 ºC [98%]; f) (EtO)2P(O)Cl, pyridine, DMAP, CH2Cl2, 0 ºC to rt; g) n-PrMgCl, CuCN 
(10 mol%), LiCl (30 mol%), THF, Et2O, −78 ºC to rt [64% (2 steps)]; h) n-Bu4NF, THF, 0 ºC; i) MsCl, 
2,4,6-collidine, LiCl, DMF, 0 ºC to rt [79% (2 steps)]. 
 
The coupling partner (±)-126 was prepared as shown in Scheme 1.33. Condensation of 
tetronic acid 131 with pyrrolidine gave compound 132. The vinylogous carbamate was 
then deprotonated using tert-butyllithium and treatment of the resulting anion with 
allyl bromide afforded the alkylated lactone 133. Acid-catalysed hydrolysis afforded 
134 which was converted into the corresponding triflate (±)-135. Finally, a palladium-
catalysed reaction with hexa-n-butylditin furnished the desired stannane (±)-126 in 
reasonable yield.56 
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Scheme 1.33 – Reagents & conditions: a) pyrrolidine, heat, reduced pressure; b) t-BuLi, allyl 
bromide, THF, −78 ºC to rt [76% (2 steps)]; c) aq. HCl (0.2 M), 60 ºC [85%]; d) Tf2O, i-Pr2NEt, 
CH2Cl2, −78 ºC [89%]; e) Sn2Bu6, Pd(PPh3)4 (3 mol%), LiCl, THF, 60 ºC [54%]. 
 
Stille coupling and ring-closing metathesis reactions 
 
Following the preparation of both coupling partners, the precursor of the key RCM 
reaction was obtained by Stille coupling (Scheme 1.34). Treatment of a mixture of the 
chloride (±)-125 and the stannane (±)-126 with Pd2(dba)3 and triphenylarsine in THF 
provided coupled products 124 as an inseparable 1:1 mixture of diastereoisomers. The 
mixture of dienes 124 were subjected to the RCM reaction conditions using the Grubbs I 
metathesis catalyst 117, to afford the desired tricyclic products 123 in 77% yield and as 
a 3:2 mixture of diastereoisomers. The diastereoisomers were separable and X-ray 
crystallographic analysis of both isomers syn-123 and anti-123 revealed that the major 
diastereoisomer was syn-123. At the time, the formation of a nine-membered 
carbocycle using a RCM reaction was unprecedented. 
 
 
Scheme 1.34 – Reagents & conditions: a) Pd2(dba)3 (2 mol%), AsPh3 (8 mol%), THF, 60 ºC [87%, 
dr 1:1]; b) Grubbs I 117 (20 mol%), CH2Cl2, reflux [81%, dr 3:2 (syn-123—anti-123)]. 
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Selectivity of the Upjohn dihydroxylation reaction  
 
The diastereoisomer anti-123 was found to possess the relative configuration found in 
the cornexistins, therefore the elaboration of this compound was attempted (Scheme 
1.35). Dihydroxylation of the alkene anti-123 using Upjohn conditions was sluggish, but 
the single diastereoisomer 136 was obtained in consistent yields.57 To determine the 
stereochemical outcome of the dihydroxylation reaction, the mono-p-nitrobenzoate 137 
was prepared. X-ray analysis confirmed the conclusions made on the basis of preliminary 
NMR studies in that the dihydroxylation had delivered diol 136 with the opposite 
configuration on C-5 to that found in hydroxycornexistin (2). This was a surprise because 
the X-ray structure of ester anti-123 clearly showed that the most accessible face in 
the structure was not the one where the dihydroxylation had occurred. However, 
enough material had been prepared to complete the synthesis of 5-epi-
hydroxycornexistin, and it was thought that the configuration at C-5 could be inverted 
at a later stage. 
 
 
Scheme 1.35 – Reagents & conditions: a) OsO4 (10 mol%), NMO, acetone, H2O, rt [50-55% (55-70% 
based on recovered starting material)]; b) p-O2NC6H4C(O)Cl, DMAP, pyridine, CH2Cl2 , 0 ºC to rt 
[67%]. 
 
Reduction of the α,β-unsaturated lactone 
 
During preliminary studies, diol 136 was converted into the acetonide 138 
(Scheme 1.36). From a literature precedent, it was known that the reduction of the 
α,β-unsaturated ester using lithium aluminium hydride can result in the formation of a 
furan.58 Various reducing agents including sodium borohydride, lithium borohydride, 
lithium aluminium hydride were employed for the reduction of 138 without success. 
Eventually, the reduction was achieved using a two-step, one-pot procedure. Lactone 
138 was reduced to the corresponding lactol using DIBAL-H, and in situ addition of 
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lithium aluminium hydride to the reaction mixture afforded diol 139 in a good 74% 
yield. 
 
 
Scheme 1.36 – Reagents & conditions: a) 2,2-dimethoxypropane, PPTS, CH2Cl2, rt [quant.]; 
b) DIBAL-H, THF, −78 ºC, then LiAlH4, THF, −78 ºC to 0 ºC [74%]. 
 
For a strategic point of view, diol 136 was converted into the PMP-acetals 140 instead 
of the acetonide 139 (Scheme 1.37). Unfortunately, treatment of the lactones 140 with 
DIBAL-H afforded an isomeric mixture of the bis-furans 141. 
 
 
Scheme 1.37 – Reagents & conditions: a) p-MeOC6H4CH(OMe)2, CSA, MS (4 Å), CH2Cl2, 0 ºC to rt 
[93%, dr ~1:1]; b) DIBAL-H, THF, −78 ºC [53%]. 
 
The alternative found involved the reduction of the lactones 140 using LiAlH4 in the 
presence of TMEDA (Scheme 1.38). Double TBS or PMB protection of the resulting diols 
afforded acetals 142 and 143 respectively, in good yield. 
 
 
Scheme 1.38 – Reagents & conditions: a) LiAlH4, TMEDA, Et2O, 0 ºC; b) TBSOTf, pyridine, CH2Cl2, 
−78 ºC to rt [142, 74% (2 steps)]; c) PMBCl, NaH, n-Bu4NI, DMF, 0 ºC to rt [143, 49% (2 steps)]. 
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Completion of the synthesis of 5-epi-hydroxycornexistin 
 
Focusing first on the TBS-ethers 142, a five-step sequence led to the synthesis of the 
advanced intermediate 144 (Scheme 1.39). The very last step of the synthesis, a double 
TBS-ether cleavage reaction, failed to deliver the final product 145. Presumably, the 
sensitivity of the cyclic anhydride unit to the deprotection conditions employed 
accounted for this unfortunate failure. 
 
 
Scheme 1.39 
 
A similar sequence was used for the PMB-ethers 143 (Scheme 1.40). Reductive opening 
of the mixture of cyclic acetals with DIBAL-H produced regioisomers 146 and 147 in 62% 
yield (1.3:1 mixture). Despite the lack of regioselectivity, the two alcohols could be 
separated, and the desired regioisomer 146 used to complete the synthesis. 
 
 
Scheme 1.40 – Reagents & conditions: a) DIBAL-H, CH2Cl2, toluene, −78 ºC to rt [33% 146, 29% 
147 (81% based on recovered starting material)]. 
 
Alcohol 146 was oxidised to the corresponding ketone 148 using TPAP (Scheme 1.41).59 
The reaction with singlet oxygen afforded a complex mixture of products that was 
directly treated with TPAP to deliver the unstable cyclic anhydride 149. The final 
removal of the two PMB groups was thus performed as quickly as possible with DDQ to 
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reveal (±)-5-epi-hydroxycornexistin 145, after extensive work-up and reverse HPLC 
purification. The modest overall yield of 10% obtained for the final three steps was 
unavoidable, given the instability of the cyclic anhydride on silica gel and the 
difficulties of purifying a triol, especially after a PMB-ether cleavage reaction using 
DDQ. Despite this challenging final sequence, the synthesis of (±)-5-epi-
hydroxycornexistin 145 was successfully achieved, in a total of 25 synthetic steps, with 
a longest linear sequence of 20 steps.51b 
 
 
Scheme 1.41 – Reagents & conditions: a) TPAP, NMO, MS (4 Å), CH2Cl2, rt [80%]; b) O2, hυ, rose 
Bengal, i-Pr2NEt, CH2Cl2, −78 ºC to rt; c) TPAP, NMO, MS (4 Å), CH2Cl2, rt; d) DDQ, CH2Cl2, H2O, rt 
[10% (3 steps)]. 
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1.4.3 Asymmetric approaches to the Stille coupling fragments 
 
In addition to the synthesis (±)-5-epi-hydroxycornexistin, the enantiopure synthesis of 
the two Stille coupling precursors was studied.41,60 The chloride fragment proved 
difficult to synthesise enantioselectively whereas more success was obtained for the 
formation of the stannane fragment. 
 
Asymmetric synthesis of the stannane fragment 
During the synthesis of stannane (±)-126, the allyl group had been introduced by 
deprotonation of the pyrrolidine enamine 132, prepared from tetronic acid (Scheme 
1.33). The same procedure could be applied with a pyrrolidine derivative possessing a 
chiral centre, only this time the chiral auxiliary would potentially control the 
stereochemical outcome of the γ-alkylation reaction. The first chiral auxiliary chosen 
was the C-2 symmetrical trans-2,5-dimethylpyrrolidine (Scheme 1.42). Following the 
synthetic pathway developed by Schlessinger and co-workers, benzyl carbamate 150 
was obtained in six steps starting from L-alanine.61 Carbamate 150 was converted into 
dimethylpyrrolidine 151 via treatment with trimethylsilyl iodide.62 Conjugate addition 
of the amine 151 to TBS-protected methyl 4-hydroxy-2-butynoate, followed by removal 
of the TBS group using TBAF afforded the lactone 153. Upon deprotonation with 
tert-butyllithium and subsequent treatment of the enolate of 153 with allyl bromide, 
the alkylated product 154 was obtained in 81% yield. Only one diastereoisomer could be 
detected by 1H NMR. Surprisingly, the hydrolysis of the auxiliary under acidic conditions 
was largely unsuccessful, and only a small amount of the tetronic acid derivative 155 
could be converted to enol triflate (R)-135 by treatment with triflic anhydride. Other 
acidic conditions were explored but without success, and careful analysis of the 
literature revealed that the hydrolysis of trans-2,5-dimethylpyrrolidine was actually 
unprecedented. Although this chiral auxiliary, due to its C-2 symmetry, would have 
been the most suited for the stereoselective introduction of the allyl group, a different 
auxiliary, which could be removed under hydrolysis conditions, was investigated. 
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Scheme 1.42 – Reagents & conditions: a) TMSCl, NaI, MeCN, 0 ºC to rt; b) TBSOCH2CCCO2Me, 
Et2O, t-BuOH, 60 ºC; c) n-Bu4NF, THF, rt [44% (3 steps)]; d) t-BuLi, allyl bromide, THF, −78 ºC to 
rt [81%]; e) aq. HCl (0.2 M), 60 ºC; f) Tf2O, i-Pr2NEt, CH2Cl2, −78 ºC [<5% (2 steps)]. 
 
Following the procedure developed by Enders, the chiral proline derivative 157 was 
prepared in three steps starting from ester 156 (Scheme 1.43).63 Double Grignard 
addition to the ester 156, followed by methylation of the resulting alcohol and 
hydrogenolysis of the benzyl group afforded auxiliary 157 in good yield. Carbamate 158 
was prepared by conjugate addition of the amine 157 to the TBS-protected methyl 4-
hydroxy-2-butynoate, followed by removal of the TBS group with TBAF. This time the 
alkylation reaction provided the allylated product 159 as the major product, with a 
good level of diastereoselectivity (5:1). Further hydrolysis and conversion of the 
tetronic acid derivative into the corresponding triflate delivered (S)-135 in a modest 
yield of 48% and with 65% ee. Although the enantiopurity of the triflate obtained was 
not as good as when it was prepared using dimethylpyrrolidine, the hydrolysis of the 
carbamate was more efficient with this substrate. 
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Scheme 1.43 – Reagents & conditions: a) MeMgBr, Et2O, rt [91%]; b) MeI, NaH, THF, reflux [84%]; 
c) H2, Pd(OH)2, EtOH, EtOAc [90%]; d) TBSOCH2CCCO2Me, Et2O, t-BuOH, 60 ºC; e) n-Bu4NF, THF, 
rt [54% (3 steps)]; f) t-BuLi, allyl bromide, THF, −78 ºC to rt [86%, dr 5:1]; g) aq. HCl (0.5 M), 
60 ºC; h) Tf2O, i-Pr2NEt, CH2Cl2, −78 ºC [48% (2 steps), 65% ee]. 
 
In ordered to evaluate the effect of the bulk of the auxiliary on the diastereoselectivity 
of the alkylation step, a modification of the auxiliary was attempted (Scheme 1.44). 
Carbamate 160 was prepared analogously to the previously described synthesis, the 
only modification being the introduction of two phenyl groups instead of the methyl 
ones during the Grignard reaction. As expected, a greater level of diastereocontrol was 
achieved during the alkylation step. The diastereoisomeric ratio was 8:1 in favour of the 
allylated product 161, and the diastereoisomers could be separated by flash column 
chromatography. Consequently, after hydrolysis of the auxiliary and triflate formation, 
the enantiopurity of the compound (S)-135 was excellent (95% ee as determined by 
chiral HPLC). The hydrolysis step of the auxiliary accounted for the overall low yield 
obtained for the two steps, but the enantiopurity of the triflate obtained was very 
promising. This pathway seemed to offer a very good method for the asymmetric 
synthesis of stannane fragment (S)-126. 
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Scheme 1.44 – Reagents & conditions: a) t-BuLi, allyl bromide, THF, −78 ºC to rt [79%, dr 8:1]; 
b) aq. HCl (0.5 M), 60 ºC; c) Tf2O, i-Pr2NEt, CH2Cl2, −78 ºC [28% (2 steps), 95% ee]. 
 
Asymmetric synthesis of the chloride fragment 
 
Less success was met when trying to synthesise the chloride fragment in an enantiopure 
fashion.60,41 The sequence allowing the formation of the chloride fragment involved 
a copper-catalysed SN2’ displacement reaction of the allylic phosphate 130 with 
n-propylmagnesium bromide (Scheme 1.32). An asymmetric version of this reaction had 
been reported by Hoveyda in 2001, using dialkylzinc compounds and pyridinyl peptide 
ligands such as 162 (Scheme 1.45).64 The possibility of adapting this methodology to 
allylic phosphate 130 was investigated by the Clark group, but unfortunately was 
completely unsuccessful. 
  
 
Scheme 1.45 – Reagents & conditions: a) 162 (10 mol%), CuCN (10 mol%), Pr2Zn, THF, −78 ºC. 
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The second approach investigated was inspired by the work of List and MacMillan, who 
almost simultaneously developed the enantioselective reduction of α,β-unsaturated 
aldehydes via organocatalysis.65,66 The required substrate 164 was prepared in five 
steps, starting from readily available aldehyde 128 (Scheme 1.46). Grignard addition 
followed by the oxidation of the resulting alcohol using manganese dioxide afforded 
ketone 163. A Wadsworth-Horner-Emmons reaction afforded an E, Z mixture of α,β-
unsaturated esters that was reduced using DIBAL-H to give a mixture of alcohols. 
Manganese dioxide oxidation furnished the α,β-unsaturated aldehydes 164.  
 
Scheme 1.46 – Reagents & conditions: a) n-PrMgCl, THF, −78 ºC to rt; b) MnO2, CH2Cl2, rt [80% 
(2 steps)]; c) (EtO)2P(O)CH2CO2Me, NaH, THF, reflux [88%; E:Z, 1:0.9]; d) DIBAL-H, THF, −78 ºC to 
rt [85%]; e) MnO2, CH2Cl2, rt [77%]. 
 
The organocatalytic hydride reduction was attempted using Hantzsch ester 166 as 
hydride source and the trichloroacetamide ammonium salt of 167 (Scheme 1.47). 
Unfortunately, most of the starting material was recovered after the reaction, with the 
desired aldehyde (R)-165 obtained in approximatively 20% yield, suggesting that there 
had been no catalytic turnover. Alternative salts of the organocatalyst 167 and solvents 
were screened but without success.  
 
 
Scheme 1.47 – Reagents & conditions: a) 167·TCA (20 mol%), 166, dioxane, 0 ºC to rt [ca 20%]. 
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1.4.4 Attempts to install the natural C-5 configuration 
 
A tremendous effort was undertaken to introduce the desired natural configuration at 
the C-5 stereocentre of hydroxycornexistin (2). Unfortunately, all the alternative 
methods investigated were unsuccessful, as shown in the following section.41 
 
Dihydroxylation reaction 
 
As previously mentioned (cf. Section 1.4.2), Upjohn dihydroxylation of alkene anti-123 
gave a single diastereoisomer 136, bearing the wrong configuration at the C-5 
stereocentre (Scheme 1.48). Alternative dihydroxylation methods using TMEDA or 
quinuclidine as additives gave similar results, and epoxidation reactions using DMDO or 
m-CPBA led to the decomposition of the starting material. Surprisingly, when the 
diastereoisomeric alkene syn-123 was subjected to the same reaction conditions, the 
starting material was recovered along with decomposition products, showing that in this 
case, the double bond was inaccessible to osmium tetroxide (Scheme 1.48). 
 
 
Scheme 1.48 – Reagents & conditions: a) OsO4 (10 mol%), NMO, acetone, H2O, rt. 
 
It was thought that the α,β-unsaturated lactone moiety was affecting the conformation 
of the nine-membered ring system and possibly impeding the dihydroxylation reaction. 
Accordingly, three model substrates were prepared from syn- and anti-123 and 
subjected to two different dihydroxylation conditions (Table 1.2). Along with Upjohn 
dihydroxylation conditions, the substrates 169, 170 and 171 were treated with a 
stoichiometric amount of osmium tetroxide in the presence of quinuclidine, an 
approach that was inspired by the work of Donohoe and co-workers for the directed 
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dihydroxylation of allylic alcohols.67 In all cases, most of the starting material (169, 170 
or 171) was recovered following attempted dihydroxylation under Upjohn conditions, 
while the second method resulted in a complex mixture of products with no evidence of 
diol formation. 
 
dihydroxylation 
precursors 
 
dihydroxylation  
conditions 
OsO4 (10 mol%), NMO, acetone, H2O, rt 
OsO4, quinuclidine, CH2Cl2, 0 ºC 
 
Table 1.2 
 
Mitsunobu inversion reaction and other alternatives 
 
The second approach involved inversion of configuration at C-5 via Mitsunobu reaction 
of the secondary alcohol, to afford 173 from 172 (Scheme 1.49).68  
 
 
Scheme 1.49 – Reagents & conditions: a) p-NO2C6H4CO2H, DEAD, PPh3, THF, 0 ºC to rt. 
 
Diol 136 was subjected to Mitsunobu reaction conditions (Figure 1.8). Unfortunately, no 
reaction occurred with either of the two hydroxyl groups, which suggested that both the 
C-5 and C-6 hydroxyl groups were particularly sterically hindered. With mono-acetate 
174, the same result was obtained. Even without the α,β-unsaturated lactone, only 
starting material was recovered when diol 175 was subjected to the inversion reaction 
conditions.  
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Figure 1.8  
 
The third approach that was investigated involved selective reduction of the C-5 centre. 
It was hoped that at least one set of conditions for the reduction of ketone 176 would 
provide the alcohol 177 with the desired configuration at C-5 (Scheme 1.50). 
  
 
Scheme 1.50 
 
Five model substrates were prepared and subjected to various reducing reagents (178 
to 182, Figure 1.9).41 Using NaBH4, Me4NBH(OAc)3, DIBAL-H, Al(Oi-Pr)3 or Zn(BH4)2 under 
a range of solvents and temperatures, the alcohol bearing the undesired configuration 
at C-5 was invariably obtained after the reduction reaction. In the case of ketone 182, 
it was hoped that the presence of the allylic alcohol might direct the reducing agent on 
the α-face of the nine-membered ring. The reduction reaction was attempted using 
sodium triacetoxyborohydride, but only starting material was recovered.  
 
 
Figure 1.9  
 
Lastly, epimerisation of the C-5 stereocentre of 148 and 183 was attempted (Scheme 
1.51). A variety of bases were used to epimerise the C-5 position of ketones 148 and 
183 but unfortunately, these reactions failed to deliver any of the desired isomeric 
compounds 184 and 185.  
 45 
 
Scheme 1.51 – epimerisation reagents employed: DBU, DBN, imidazole, K2CO3, KOt-Bu, n-Bu4NF, 
p-TSA, HCl. 
 
These results led to a simple observation: after the RCM reaction and formation of anti-
123, the desired C-5 configuration of hydroxycornexistin (2) is extremely difficult to 
introduce because of the conformation of the nine-membered ring (Scheme 1.52). As 
much as the RCM reaction had been useful for the formation of the core of cornexistins, 
an alternative method for ring closure had to be found to introduce the correct 
configuration at the C-5 centre. In a retrosynthetic approach, the ketone on C-6, 
formerly derived from a hydroxyl group, could also be accessed from a 1,1-disubstituted 
alkene. Using the same C—C bond disconnection, the allylic alcohol 186 could be the 
result of the intramolecular nucleophilic addition of an alkenylmetallic species to an 
aldehyde. Knowing that chromium(II) readily inserts into alkenyl halides, the precursor 
to allylic alcohol 186 could therefore be vinyl halide 187. This led to a new strategy 
with an intramolecular Nozaki-Hiyama-Kishi reaction as key ring-closing step of the 
synthesis. It was hoped that closure of the nine-membered ring using this reaction 
would offer a better chance to form the natural C-5 configuration of cornexistins. 
 
 
Scheme 1.52 
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The Nozaki-Hiyama-Kishi reaction is a powerful tool for advanced organic synthesis and 
has been applied successfully in many total syntheses. The main features of this 
reaction will be described in the following chapter.  
 
1.5 The Nozaki-Hiyama-Kishi reaction 
 
1.5.1 Organochromium chemistry — pioneering studies 
 
The first studies of organochromium chemistry started in 1914 with the report from 
Bennett and Turner of a reaction between phenylmagnesium bromide and chromic 
chloride (CrCl3(H2O)x) affording phenylbenzene in excellent yield according to the 
following equation:69  
 
Eq. 1.1 – 2CrCl3 + 2C6H5MgBr → C6H5C6H5 + 2CrCl2 + MgCl2 + MgBr2 
 
Four years later, a first communication from Hein was published, dealing with the 
isolation of the first organochromium compound: ‘pentaphenylchromium bromide’ by 
transmetalation of phenyl Grignard reagents with CrCl3.
70 Hein and co-workers 
subsequently reported an impressive series of results related to the formation of 
‘polyphenylchromium’ compounds.69a At that time, those compounds were surprising 
and the mechanism for the formation of these species was unknown because of the 
limited analytical methods and the lack of theoretical understanding of chemical bonds. 
What was found in the 1950’s was that Hein had in fact been the first to form 
bis(benzene)chromium species (or η6 sandwich complexes of biphenyl and benzene with 
Cr). Zeiss and Tsutsui, Hafner and Fisher were the main actors of this fascinating tale 
leading to the elucidation of Hein’s compounds, and brilliantly summarised by Seyferth 
in 2002.71 
In 1957, Anet and Leblanc were the first to prepare aqueous solutions of benzyl 
chromium species, by reaction of Cr(II) with benzyl chloride.72 Kinetic and spectroscopic 
studies allowed Kochi and Davies to formulate the mechanism of the oxidative addition 
of Cr(II) into the C—X bond of benzyl chloride as a two—step sequence including the 
generation of benzyl radicals as intermediates in the reaction (Eq. 1.2 and 1.3).73 The 
first rate-determining step forms the benzyl radical using one equivalent of Cr(II) and 
another equivalent of Cr(II) is needed for the second step; the rapid coupling of the free 
radical and generation of the benzylchromium ion.  
 
 47 
Eq. 1.2 – C6H5CH2—X + Cr(II)aq → C6H5CH2· + Cr(III)X
2+
aq 
Eq. 1.3 – C6H5CH2· + Cr(II)aq → C6H5CH2Cr(III)X
2+
aq  
 
The reactivity of benzylchromium and related reagents was studied by Kochi et al., and 
over the years the chromium(II) salts were mostly recognised as reducing reagents for 
organic halides.74 Realising that the preparation of chromium(II) salts in water was to 
some extent limiting the potential use of Cr(II) in organometallic chemistry, Hiyama and 
Nozaki reported in 1977 the preparation of CrCl2 by reduction of CrCl3 with lithium 
aluminium hydride in THF.75 This was a major breakthrough because it allowed the use 
of chromium(II) in aprotic media, making it available for C—C bond forming reactions. In 
the following publications they demonstrated that Cr(II) readily inserts into allyl-, 
alkenyl-, alkynyl-, propargyl- and aryl halides to form organochromium(III) nucleophiles 
that could react with a wide range of carbonyl electrophiles.76 
Another interesting characteristic of the preliminary screening made by Hiyama et al. 
was the isolation of a single diastereoisomer 191 obtained from the chromium mediated 
reaction of crotyl bromide 188 with benzaldehyde 189 (Scheme 1.53).75b The anti- 
configuration of the resulting product 184 was subsequently determined by Heathcock 
and co-workers and it was assumed that a chair-like transition state 190 accounted for 
the stereoselectivity of the reaction.77 Starting from either E- or Z- crotyl bromide 
resulted in the same product formation, suggesting that the rapid equilibrium between 
E- and Z- allylchromium(III) species was in favour of the E-configuration.78 
 
 
Scheme 1.53 
 
Finally, independently and almost simultaneously, in 1986 the group of Takai and 
Nozaki, and the group of Kishi discovered that the addition of a catalytic amount of 
nickel(II) chloride promoted more consistently the Grignard-type reaction between 
alkenyl halides or triflates and aldehydes.79 Nickel catalysis was then extended to a 
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variety of chromium-mediated coupling reactions and the now called Nozaki-Hiyama-
Kishi (NHK) reaction became a powerful method of C—C bond formation where classical 
Wittig or aldol approaches were unsuccessful. It combines many unique and important 
features: 
 
i) pronounced chemoselectivity of the organochromium(III) reagents for 
aldehydes, even in the presence of ketones; 
ii) a wide range of substrates including allyl, propargyl, alkenyl, alkynyl, aryl 
halides, alkenyl triflates, sulfonates and phosphates are suitable 
precursors for the formation of the organochromium(III) intermediates; 
iii) compatibility with an array of functional groups in both reactions 
partners; 
iv) low basicity of organochromium(III) reagents; 
v) alkenyl halides react with complete retention of their double bond 
geometry. 
 
These advantages render the NHK reaction particularly well suited for application in 
total synthesis. Chromium-induced inter- or intramolecular carbon—carbon bond 
formations have been used as key steps in the synthesis of many complex targets. One 
of the most famous examples features in the total syntheses of the complex polycyclic 
ethers halicondrin B and norhalicondrin B, achieved by Kishi and co-workers in 1992. 
The NHK reaction is used three times in the first generation synthesis of these targets 
(Figure 1.10).80  
 
 
Figure 1.10 
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1.5.2 NHK — mechanistic studies 
Stoichiometric reactions 
 
With the absence of a catalyst, the oxidative addition of Cr(II) into a C—X bond proceeds 
as two consecutive single electron transfer (SET) events (Eq. 1.4 and 1.5).72a The first 
SET allows the formation of the radical species (Eq. 1.4) and the second provides the 
organochromium(III) complex (Eq. 1.5). 
 
Eq. 1.4 – R—X + Cr(II)Cl2 → [R—X]
·−
 + Cr(III)Cl2
+
 → R· + Cr(III)Cl2X 
Eq. 1.5 – R· + Cr(II)Cl2 → R
− 
+ Cr(III)Cl2
+
 → RCr(III)Cl2  
 
Overall, the nucleophilic addition of the organochromium(III) nucleophile 195 to 
carbonyl 196 can be formally depicted as shown in Scheme 1.54. The product formed is 
the chromium alkoxide 197. In stoichiometric reactions, the high stability of the 
resulting O—Cr(III) bond is an advantage because it acts as a thermodynamic sink driving 
the reaction to completion. This bond is hydrolysed during acidic work-up to form the 
alcohol 198. 
 
 
Scheme 1.54 
 
Catalytic effect of nickel on chromium-mediated coupling 
reactions of alkenyl halide or triflate with aldehydes 
 
As previously mentioned, the catalytic effect of nickel in chromium-mediated coupling 
reactions was discovered by Takai and Kishi, both disconcerted by the dramatic effect 
that the batch of CrCl2 had on the success of the reaction, especially starting from less 
reactive alkenyl halides or triflates. Careful analysis of the commercial sources of 
chromium dichloride revealed that nickel was the major contaminant, and that the 
addition of sub-stoichiometric nickel dichloride to the reaction improved the 
consistency of the outcome.79 The catalytic cycle of the reaction was proposed by Takai 
(Scheme 1.55).79a NiCl2 is first reduced to nickel(0) with two equivalents of CrCl2. Next, 
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oxidative addition of the alkenyl species 199 with Ni(0) affords complex 200.81 
Transmetalation between a chromium(III) salt and the nickel complex 200 allows for the 
formation of the alkenylchromium(III) reagents 201, which upon reaction with an 
aldehyde 202 and subsequent hydrolysis produces alcohol 203. The nickel source and 
the amount of nickel used in the reaction were found to be crucial for the success of 
the reaction. Indeed Takai pointed out that using nickel with donor ligands like 
NiCl2(PPh3)2 was accelerating the formation of the undesired dimer 204, whereas Kishi 
had encountered the same issue using a NiCl2 content in CrCl2 of greater than 0.1 to 1% 
in weight.79,82 Pd(II) acetate was also found to have the same catalytic effect on the 
reaction, but this additive was markedly less studied.72a,79b  
 
 
Scheme 1.55 
 
Chromium-catalysed NHK 
 
The major drawback of the NHK reaction using two equivalents or more of chromium in 
the reaction is the amount of toxic chromium and nickel salts generated. To circumvent 
this problem, the group of Fürstner developed the first chromium-catalysed process 
(Scheme 1.56).83 The key feature of this catalytic cycle is that the chromium alkoxide 
207 is silylated using trimethylsilyl chloride, which releases the chromium salt from the 
organic product. Thus, the liberated chromium(III) salt, upon reduction to Cr(II) with 
manganese powder, can take part in the reaction again. Apart from rendering the 
process catalytic in chromium, this methodology offers two advantages. First, 
manganese powder is cheap, non-toxic and does not react on its own with the organic 
compounds in the reaction.72a Secondly, it makes it possible to start the reaction with a 
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sub-stoichiometric amount of CrCl3 which unlike CrCl2, is cheap and insensitive to 
oxygen and moisture. It appeared to be applicable for most halides with the exception 
of alkenyl- and aryl halides where a co-catalytic amount of NiCl2 was required. 
Samarium, iron and other sources were later used for the regeneration of the active 
Cr(II) species.72a,84  
 
 
Scheme 1.56 
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1.5.3 NHK — enantioselective reactions 
 
Given the importance of the NHK reaction, an efficient enantioselective version to 
control the absolute stereochemical outcome for a range of processes would definitely 
broaden the scope of this reaction, and would be useful for total synthesis. However, 
due to difficulties such as ligand coordination and specificity, combined with the 
tendency of chromium(II) to form dimers or clusters with polydentate ligands, relatively 
few reports of an enantioselective variant have been reported. The first successful 
enantioselective versions relied on over stoichiometric amounts of chiral ligands. For 
example, Kishi reported the application of the chiral bipyridine ligand 209 (Figure 1.11) 
in the allylation and alkenylation of benzaldehyde and obtained enantioselectivities of 
28-74% ee.85 Kibayashi’s N-benzoylpropinol ligand 210 gave enantioselectivities of up to 
98% ee for the reaction of allyl bromide with a range of aldehydes.86 In 1999, the group 
of Cozzi was the first to report a successful enantioselective NHK reaction using a 
catalytic amount of a chiral chromium complex (10 mol%).87 Using chiral Salen ligand 
211, 89% ee was obtained for the chromium-mediated allylation of various aldehydes. 
Berkessel et al. later modified the Salen ligand 211 to 212, which was then employed 
successfully with vinyl halides or triflates for the enantioselective synthesis of allylic 
alcohols.88  
 
 
Figure 1.11 
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Oxazoline-based enantioselective NHK 
 
The use of oxazoline-based ligands for asymmetric induction in metal-mediated 
reactions has already been investigated by several research groups,86,89 but Kishi and co-
workers managed to obtain the best results when using them in asymmetric NHK 
reactions. In connection with their efforts to improve the synthesis of halicondrin B 
(Figure 1.10), they investigated the asymmetric chromium-mediated addition of alkenyl 
iodides with aldehydes, and found that oxazoline 213 was efficient in delivering 
asymmetric induction during the reaction.90 Remarkably, X-ray analysis of a single 
crystal of the Cr(III)/sulphonamide ligand complex 214 revealed that the ligand 213 was 
tridentate, allowing an almost perfect octahedral structure to be attained in the 
chromium complex (Figure 1.12). 
 
 
Figure 1.12 
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The diastereoselectivity of the NHK reaction when forming the C14—C38 fragment of 
halicondrin B was 3.5:1. With the addition of the sulphonamide 213 to the reaction, a 
massive improvement in the selectivity was observed (20:1), demonstrating the 
usefulness of this ligand for total synthesis (Scheme 1.57). 
 
Scheme 1.57 – Reagents & conditions: a) NaH, 213 (3 equiv), CrCl3 (3 equiv), (Bn)(n-Bu)3NCl, 
(1 equiv), 215 (1 equiv), 216 (2 equiv), NiCl2 (1 equiv), THF, rt then t-BuOK, t-BuOH, −15 ºC 
[55%, dr 20:1(3.5:1 without 213)]. 
 
In the following paper the group of Kishi pursued their investigations and, using the pre-
formed chromium(III)/ligand complex 214, performed the asymmetric chromium-
mediated addition of alkenyl iodides to aldehydes in a catalytic process.91 This 
methodology was applied twice during the construction of the C14—C26 fragment of 
halicondrin B (Scheme 1.58). Using the antipode of 214 (10 mol%), and either NiCl2 
(40 mol%) or Ni(cod)2 (5 mol%), the coupling of vinyl iodide 218 to the aldehyde 219 
furnished the desired product 220. Following Fürstner’s work, manganese was used as 
the reducing agent for the chromium(III) species and TMSCl was employed as the 
dissociating agent for the chromium alkoxide. It was also found that addition of 
(Bn)(n-Bu)3NCl or Et3N·HCl, and LiCl enhanced the coupling efficiency. Subsequent TMS-
silyl ether removal and SN2 reaction using PPTS and pyridine gave the cyclised product 
in a good diastereoisomeric ratio (6:1 when the reaction was conducted in THF). The 
benzoyl group was then cleaved using potassium carbonate and methanol to afford the 
tetrahydrofuran 220. After DMP oxidation, the coupling of the resulting aldehyde with 
221 was more complex. In 1989, Takai and co-workers achieved the coupling of alkyl 
halides with aldehydes, in the presence of CrCl2 and a catalytic amount of vitamin B12 
or cobalt phthalocyanine. With this work in mind, the asymmetric Co/Cr-mediated 
reaction was attempted.92 After a screening to identify the optimum reaction 
conditions, the selective activation of the alkyl iodide over the vinyl iodide in 221 and 
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subsequent Cr/Co-catalysed coupling with the aldehyde provided the desired product 
222 in 73% yield and with a high level of diastereoselectivity (5.3:1). 
 
 
Scheme 1.58 – Reagents & conditions: a) (1) 218 (1 equiv), 219 (2 equiv), the antipode of 214 
(10 mol%), NiCl2 (40 mol%) or Ni(cod)2 (3 × 1 mol%), Mn (2 equiv), TMSCl (2 equiv), (Bn)(n-Bu)3NCl 
(20 mol%), LiCl (2 equiv), THF, rt; (2) PPTS, pyridine, i-PrOH, rt [dr 6.0:1]; (3) K2CO3, MeOH, rt 
[70—80% (3 steps)]; b) (1) DMP, CH2Cl2, rt [90%]; (2) the aldehyde (1 equiv), 221 (2 equiv), 214 
(50 mol%), Co-phthalocyanine (10 mol%), Mn (2 equiv), TMSCl (2 equiv), Et3N·HCl (20 mol%), LiCl 
(2 equiv), DME, rt; (3) oxalic acid (aq.), THF, rt [73% (2 steps), dr 5.3:1]. 
 
This was still not good enough for Kishi’s group, who realised that the nickel ligands 
were playing a central role in the reaction. Subsequent screening of the ligands 
revealed that using 2,9-dimethylphenanthroline·NiCl2 223 complex allowed a decrease 
in the loading of the nickel catalyst to 2 mol% (Figure 1.13).93 This was important 
because it had already been shown that the more nickel(II)-catalyst was introduced in 
the reaction, the higher the chances of forming homo-coupling side products (Scheme 
1.55). It was next envisaged that a bimetallic ligand for both nickel and chromium 
would improve the asymmetric NHK reaction, by placing the two metals in close 
proximity.94 The transmetalation step would be faster, preventing the intermediate 
alkenyl nickel halide to form any homo-coupling side products. Consequently, instead of 
the usual excess of alkenyl iodide required (1.5 to 2 equivalents), the equimolar 
amounts of coupling partners could be used. This led to the synthesis of ligand 224, 
where the left-hand site would complex the chromium and phenanthroline unit would 
complex the nickel (Figure 1.13).  
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Figure 1.13 
 
Promising results were obtained using the ligand 224 in model studies. Ultimately, the 
formation of two C—C bonds during the synthesis of the C14—C35 fragments of 
halicondrin/E7389 was successfully achieved (Scheme 1.59). Only 3 mol% of the Cr/Ni-
catalyst was used for the coupling of 225 and 226 with only 1.2 equivalent of the vinyl 
iodide 226. Manganese was again used as the reducing agent but Cp2ZrCl2 was preferred 
instead of TMSCl as the dissociating agent. The coupled product was obtained in 
excellent yield and with high selectivity (91% yield and dr 19:1). Cyclisation with TBDPS-
ether cleavage using triethylsilane and TMS triflate gave the corresponding alcohol and 
this was then oxidised to form aldehyde 227. Similar coupling conditions afforded the 
desired product from aldehyde 227 and vinyl iodide 228 in 91% yield and with 19:1 
selectivity. Subsequent SN2 displacement of the chlorine substituent with the alkoxide 
generated using potassium hydride and 18-crown-6 afforded the C14—C35 fragment of 
halicondrin/E7389 229. 
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Scheme 1.59 – Reagents & conditions: a) (1) proton sponge (3 mol%), 224·NiCl2 (3 mol%), CrCl2 
(3 mol%), 225 (1 equiv), 226 (1.2 equiv), LiCl (5 equiv), Mn (2 equiv), Cp2ZrCl2 (1.2 equiv), 
MeCN, rt [86%, dr 19:1]; (2) Et3SiH, TMSOTf, CH2Cl2, −78 ºC to 0 ºC [95%]; (3) oxidation step; 
b) (1) proton sponge (2 mol%), the antipode of 224·NiCl2 (2 mol%), CrCl2 (2 mol%), 227 (1 equiv), 
228 (1.1 equiv), LiCl (0.5 equiv), Mn (2 equiv), Cp2ZrCl2 (1.2 equiv), MeCN, rt [91%, dr 19:1]; (2) 
KH, 18-crown-6, toluene, −20 ºC [88%]. 
 
Starting from stoichiometric Cr-mediated coupling, Kishi has enhanced the NHK reaction 
in both asymmetric and catalytic aspects, always keeping in mind the goal of developing 
methodology suitable for more complex targets that can be encountered in total 
synthesis. In their most recent paper concerning Ni/Cr-mediated coupling reactions, 
Kishi and co-workers have developed an air-stable hetero-bimetallic catalyst, which 
opens the way to asymmetric, catalytic NHK reactions without the use of a glove box.95  
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1.5.4 Application of the NHK reaction in total synthesis 
 
The NHK reaction has been applied many times in total synthesis. As shown previously, 
intermolecular NHK reactions have been extensively used by Kishi and co-workers. They 
also reported a catalytic Ni/Cr-mediated macrocyclisation reaction for the synthesis of 
the halicondrins,96 but generally the classic CrCl2/NiCl2 couple with addition of a greater 
than stoichiometric amount of chromium is employed for intramolecular NHK reactions. 
In 2009, the group of Overman published the enantioselective total syntheses of 
briarellin E and F involving a key intramolecular NHK reaction to form the nine-
membered ring of the tricyclic structure (Scheme 1.60).97 The late-stage intermediate 
230 containing the desired aldehyde and proximal vinyl iodide functionalities was 
reacted under the NHK conditions to deliver briarellin E (231) in 79% yield, as a single 
isomer. Briarellin F (232) was subsequently obtained by simple DMP oxidation of 
briarellin E (231). It should be noted that 100 equivalents of CrCl2 were used for the 
reaction, although at this stage of the synthesis, the scale of the reaction minimised the 
amount of toxic waste generated. 
 
 
Scheme 1.60 – Reagents & conditions: a) CrCl2—NiCl2 (100:1 equiv), DMSO—DMS (100:1), rt [79%]; 
b) DMP, CH2Cl2, rt [79%]. 
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The same year Takao et al. achieved the asymmetric synthesis of pestalotiopsin A, also 
containing a nine-membered ring (Scheme 1.61).98 An excellent yield of 92% was 
obtained for the intramolecular NHK reaction of 233, with formation of the single 
diastereoisomer 234. This success allowed them to complete the first synthesis of 
(−)-pestalotiopsin A (235), followed by the synthesis of the natural (+)-pestalotiopsin A 
using the same strategy. 
 
 
Scheme 1.61 – Reagents & conditions: a) NiCl2 (0.06 equiv), CrCl2 (7.6 equiv), DMSO, rt [92%]. 
 
These examples emphasize that the intramolecular NHK reaction with intermediate 
sized ring systems can be achieved efficiently, which is promising for the new strategy 
that we want to develop for the synthesis of cornexistins. 
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1.6 New strategy for the synthesis of hydroxycornexistin 
 
 
The synthesis of 5-epi-hydroxycornexistin (145) was achieved using a RCM metathesis 
reaction as ring-closing step. Because the correct C-5 stereochemistry could not be 
installed, an alternative strategy was needed. The Nozaki-Hiyama-Kishi reaction has 
proven to be a powerful method for the formation of ring systems of various sizes in 
many total syntheses. The primary objective was the synthesis of the potential NHK 
reaction precursor in the most efficient manner. Modifications of the previous synthesis 
of 5-epi-hydroxycornexistin (145) were needed although the main disconnections 
remained. The feasibility of the new ring-closing step was to be evaluated as well as the 
stereoselectivity of the reaction. Providing the formation of the required C-5 
configuration for the synthesis of cornexistins, the NHK reaction was expected to be the 
method leading to the first synthesis of hydroxycornexistin (2). Finally, the 
enantioenriched approach during the two Stille-coupling fragments was to be further 
investigated, for the potential highly enantioselective synthesis of hydroxycornexistin 
(2). 
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Part II: Results and discussion 
 
2.1 New retrosynthetic analysis 
 
The aim of the project was the synthesis of cornexistins using an intramolecular NHK 
reaction as key step of the strategy. Concentrating on hydroxycornexistin (2) the new 
strategy was built upon previous work. The cyclic anhydride unit was to be masked as a 
furan (Scheme 2.1). The C-6 ketone could be made from a terminal alkene, and the 
exocyclic allylic alcohol from the unsaturated lactone 186. Ring opening at the 
exocyclic α-hydroxy alkene functional group, between the C-5 and C-6 centres reveals 
187, the key NHK precursor in the revised strategy. It was anticipated that the closure 
of the nine-membered ring would favour the natural (R) configuration of the C-5 centre. 
Functional group interchanges leads to 237, which could be obtained through Stille 
coupling between the stannane 238 and the allyl chloride 239. 
 
 
 
Scheme 2.1 
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2.2 An approach using racemic material to the Nozaki-
Hiyama-Kishi cyclisation 
 
2.2.1 C-1 — C-5 Chloride fragment synthesis 
 
Following previous work carried out within the group,41,60 the synthesis of the C-1—C-5 
fragment 239 started from commercially available 3,4-dimethylfurandiester 127 
(Scheme 2.2). Global reduction of the ester functionalities with lithium aluminium 
hydride was followed by selective mono-oxidation using manganese dioxide. Protection 
of the remaining free hydroxyl group as a TBS-ether gave aldehyde 128. Direct 
alkylation of the crude aldehyde, with n-propylmagnesium chloride, gave alcohol 240 in 
69% yield over four steps. A second MnO2 oxidation of secondary alcohol 240 was 
followed by methylenation under Wittig conditions to give alkene 241. Hydroboration of 
the 1,1-disubstituted alkene was accomplished with 9-BBN and upon oxidation primary 
alcohol 242 was formed, in 88% yield. 
 
 
Scheme 2.2 – Reagents & conditions: a) LiAlH4, THF, −78 ºC to rt; b) MnO2, CH2Cl2, rt; c) TBSCl, 
imidazole, DMAP, CH2Cl2, rt; d) n-PrMgCl, THF, −78 ºC to rt [69% (4 steps)]; e) MnO2, CH2Cl2, 
reflux [86%]; f) Ph3PCH3Br, NaHMDS, THF, 0 ºC to rt [95%]; g) (i) 9-BBN, THF, 55 ºC; (ii) EtOH, 
3 M NaOH, 0 ºC; (iii) 30% H2O2, 50 ºC [88%]. 
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For strategic purposes, protection of the free hydroxyl group of 242 as a silyl-ether 
would be advantageous, as a subsequent double cleavage of silyl groups within coupled 
fragment 243 would save a step in the synthesis (Scheme 2.3). 
 
 
Scheme 2.3 
 
Due to the requirement for an orthogonal protecting group, the primary alcohol 242 
was protected as a TBDPS-ether to afford bis-protected diol 245 in good yield (Scheme 
2.4). Attempted removal of the TBS group of 245, using CSA in methanol, led to the loss 
of both silyl groups to give diol 246. As this first attempt was unsuccessful, protection 
of 242 as a PMB-ether was investigated next. 
 
 
Scheme 2.4 – Reagents & conditions: a) TBDPSCl, Et3N, DMAP, CH2Cl2, rt [91%]; b) CSA (30 mol%), 
MeOH, rt [30%]; c) PMBTCA, CSA (10 mol%), CH2Cl2, rt [35%]. 
 
Basic conditions using PMBCl and sodium hydride failed to deliver the desired product. It 
was assumed that the TBS-ether was too labile because traces of bis-PMB-ether were 
detected among other decomposition products. The use of PMBTCA with a catalytic 
amount of CSA allowed the formation of 247, albeit slowly and in a disappointing yield. 
As the PMB protection was not adequate, other selective desilylation methods were 
investigated. Fortunately, treatment of 245 with PPTS in ethanol allowed for the 
selective cleavage of the TBS group in excellent yield (Scheme 2.5). The next step was 
the formation of chloride 249, which was accomplished in 85% yield through mesylation 
of alcohol 248 and chloride substitution using conditions previously optimised by the 
group.41,60 Although this reaction gave acceptable results, alternative conditions 
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designed for allylic alcohols were also successful, allowing for the improved formation 
of the chloride fragment in 92% yield.99 This method has the advantage of substituting 
dimethylformamide for dichloromethane as the solvent, thus facilitating the work-up of 
the reaction. Additionally mesyl chloride acts as the chloride source for the reaction, 
removing the requirement for a secondary chloride salt source. The synthesis of the 
desired chloride fragment 249 was completed in 10 steps from 127, in an overall yield 
of 40%.  
 
 
Scheme 2.5 – Reagents & conditions: a) PPTS (50 mol%), EtOH, 40 ºC, [95%]; b) MeSO2Cl, LiCl, 
2,4,6-collidine, DMF, 0 ºC [85%] or c) MeSO2Cl, Et3N, CH2Cl2, rt [92%]. 
 
2.2.2 Synthesis of the stannane fragment 
 
Formation of the triflate 
 
The synthesis began with the silyl protection of the terminal alkyne CH group of 
propargyl bromide 250 (Scheme 2.26). The bulky TIPS group was selected to protect the 
terminal alkyne. Treatment of the lithium acetylide of 250 with TIPSCl afforded silyl 
alkyne 251 in 72% yield.100 Alternatively, substituting LiHMDS for n-butyllithium allowed 
isolation of alkyne 251 in quantitative yield. 
 
 
Scheme 2.6 – Reagents & conditions: a) n-BuLi, TIPSCl, THF, −78 ºC to rt [72%]; b) LiHMDS, 
TIPSCl, THF, −78 ºC to rt [quant.]; c) pyrrolidine, toluene, 50 ºC, reduced pressure [81%]; 
d) t-BuLi, THF, −78 ºC to rt [70 to 90%]. 
 
The conversion of tetronic acid 131 into the vinylogous carbamate 132 through 
condensation with pyrrolidine had been described by our group previously,41,60 and using 
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this methodology, carbamate 132 was obtained in 81% yield. Deprotonation of 
compound 132 with t-butyllithium and treatment of the resulting anion with 251 
afforded the alkylated product 252 in 70 to 90% yield. The isolated yield was dependent 
on the amount of propargyl bromide used, and the use of five equivalents was found to 
give the best yield. Hydrolysis of the pyrrolidine moiety using aqueous hydrochloric acid 
as previously described (cf. Section 1.4.2, Scheme 1.31) was unsuccessful due to poor 
substrate solubility. However, it was found that the hydrolysis using hydrochloric acid in 
refluxing ethanol was a good alternative (Scheme 2.7). Instead of purifying the keto-
enol product 253, which dramatically reduced the isolated yield of the reaction, the 
crude material was used directly in the formation of the triflate 254, which was 
obtained in good yield over both steps (80%). It is worth noting that the triflate could be 
purified under normal chromatography conditions without the use of triethylamine 
deactivated silica. The material is a stable solid which can be stored indefinitely at 
room temperature. 
 
 
Scheme 2.7 – Reagents & conditions: a) HCl (1.26 M in EtOH), H2O, 80 ºC; b) Tf2O, i-Pr2NEt, 
CH2Cl2, −78 ºC [80% (2 steps)]. 
 
Conversion of the triflate to the stannane 
 
Investigations into the conversion of the triflate 254 to the corresponding vinyl 
stannane were then attempted. The first conditions examined involved the use of 
bis(tributyltin), Pd(PPh3)4 and lithium chloride in refluxing THF (Table 2.1, entry 
1).41,60,56 The results were disappointingly poor and proved to be irreproducible with 
yields varying from 5 to 33% (entry 2). On the other hand, the formation of 
trimethylstannane 256 was accomplished in a reproducible manner and with a better 
yield of 54% (entries 3 and 4). As the reaction became sluggish after one or two hours at 
reflux, almost certainly because of the deactivation of catalyst, further addition of 
Pd(PPh3)4 during the reaction helped to improve the rate of the reaction. 
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entry R 
LiCl 
(equiv)a 
catalyst 
loading (mol%) 
yield (%) 
1 Bu 3.0 5 traces 
2 Bu 8.0 5 5 to 32 
3 Me 6.0 5 34 
4 Me 8.0 7b 54 
 
Table 2.1 – aLiCl was thoroughly flame-dried prior use; b4 mol% of Pd(PPh3)4 added straight, 
3 mol% added to the mixture after 1.5 h.  
 
Attempted Suzuki coupling 
 
The use of toxic tin reagents is not optimal for large scale synthesis, therefore a Suzuki 
coupling of the two fragments was attempted as there are numerous examples of sp2-sp3 
coupling in the literature.101 The bromo and iodo equivalents of chloride 249 were 
prepared using standard conditions (Scheme 2.8).102 Although bromide 257 was stable 
enough to allow characterisation, the iodo compound 258 was not and had to be used 
immediately on isolation. 
 
 
Scheme 2.8 – Reagents & conditions: a) NBS, PPh3, Ch2Cl2, rt [88%]; b) I2, PPh3, imidazole, THF, 
0 ºC [22%]. 
 
Conversion of the triflate 254 into the corresponding boronic ester 259 was 
accomplished following Levacher’s procedure,103 and Suzuki coupling between 259 and 
halides 249, 257 and 258 was subsequently investigated (Scheme 2.9). Variation in 
base (K3PO4, CsCO4, K2CO3) and palladium source [Pd(PPh3)4, PdCl2(dppf)] in combination 
with halides 249, 257 or 258 provided no evidence of cross-coupling during the 
reaction. The possible instability of boronic ester 259 led to its use immediately on 
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isolation but attempts to confirm the formation of 259 through characterisation failed. 
The conditions used for the conversion of the triflate could potentially lead to the 
formation of the corresponding dimer rather than affording boronic ester 259. 
Alternative conditions were applied to form the boronic ester — for example variation in 
catalyst104 — but the desired material was not isolated. Due to these results the Suzuki 
approach was abandoned. 
 
 Scheme 2.9 – Reagents & conditions: a) bis(pinacolato)diboron, Pd(PPh3)4 (5 mol%), Et3N, 
dioxane, 80 ºC; b) bis(pinacolato)diboron, (PPh3)2PdCl2 (5 mol%), PPh3, K2CO3, dioxane, 80 ºC. 
 
 
2.2.3 Stille coupling and efforts towards the Nozaki-Hiyama-Kishi 
reaction 
 
Stille cross-coupling 
 
With the unsuccessful application of the Suzuki protocols, the Stille cross-coupling 
reaction was reconsidered. The modest yield obtained for stannane formation precedes 
the coupling of the two fragments, so a low yield for this process rather than after 
coupling is less penalising in terms of the strategy. As shown in Scheme 2.10, the cross-
coupling conditions optimised by the Clark group gave compounds 260 with excellent 
yield when applied to substrate 249, with no preference with regards to the stannane 
derivative (255 or 256). Coupled products 260 were obtained as an inseparable mixture 
of the expected diastereoisomers (dr 1:1). However, subsequent treatment of the 
mixture with TBAF to remove both silyl groups led to the decomposition of alkynes 260, 
showing the lability of these compounds under basic conditions. This problem was 
overcome through the addition of acetic acid as a buffer, allowing access to alcohols 
261 in 87% yield.105 Interestingly, the silicon-oxygen bond was cleaved first and was 
followed by subsequent cleavage of the carbon-silicon bond. 
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Scheme 2.10 – Reagents & conditions: a) Pd2(dba)3 (6 mol%), AsPh3 (24 mol%), THF, reflux 
[82% from 255, 95% from 256, dr 1:1]; b) n-Bu4NF, AcOH, THF, 0 ºC to rt [87%]. 
 
Conversion of the terminal alkyne to vinyl halide using direct 
methods 
 
Conversion of the terminal alkynes 261 into their corresponding vinyl halides was 
considered next (Table 2.2). Standard conditions, using sodium iodide with 
trimethylsilyl chloride,106 were tested (entry 1), leading only to the recovery of starting 
material. Entries 2 and 3 showed that the use of stronger reducing reagents like iodo- or 
bromo-9-BBN did not deliver the desired vinyl halides, as no reaction occurred.107  
 
 
entry conditions temperature result 
1 NaI, TMSCl, H2O, MeCN rt no reaction 
2 B-iodo-9-BBN (1 M in hexane), AcOH, CH2Cl2  −25 ºC to rt no reaction 
3 B-bromo-9-BBN, AcOH, CH2Cl2  0 ºC to rt no reaction 
 
Table 2.2 
 
It was believed that the presence of the free hydroxyl group may be impeding the 
reaction, therefore the diastereoisomeric primary alcohols 261 were protected as the 
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corresponding PMB-ethers 264 (Scheme 2.11). Once again, the use of sodium hydride 
and PMBCl108 led to decomposition (cf. Section 2.2.1), but acid-catalysed imidate 
protection allowed the formation of the desired products 264 in 81% yield.109 
Unfortunately, subsequent iodination or bromination led only to decomposition of 264. 
 
 
Scheme 2.11 – Reagents & conditions: a) PMBTCA, CSA (5 mol%), CH2Cl2, 0 ºC to rt [80%]; 
b) B-iodo-9-BBN (1 M in hexane), CH2Cl2, −20 ºC; c) B-bromo-9-BBN, CH2Cl2, 0 ºC. 
 
Promising recent methodology developed by Bartoli and co-workers was then 
explored.110 This work demonstrated the regio- and stereocontrolled hydroiodination of 
alkynes, following the proposed mechanism shown in Scheme 2.12, using sodium iodide 
and CeCl3·7H2O as a mild Lewis acid. Three steps are believed to be involved: 
(i) coordination of alkyne 267 to the Ce(III) salt to form complex A; (ii) nucleophilic 
attack of the iodide anion to give organocerium intermediates B or C; (iii) 
protodemetalation by coordinated water molecules to afford diastereoisomeric halo-
alkenes (Z)-268 or (E)-268. Path a is believed to occur in polar solvents, such as 
acetonitrile, where a slow addition of the iodide anion leads to the formation of the 
thermodynamically more stable Z isomer. In non-polar solvents, such as toluene, rapid 
syn addition following path b provides the E isomer. Interestingly, hydrated CeCl3 is 
essential for the reaction to proceed; no product was obtained when using anhydrous 
CeCl3. 
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Scheme 2.12
110
 
 
Application of this protocol to the free alkynes 261 was attempted (Scheme 2.13). After 
reaction a reaction time of eight hours, only starting material was isolated. After 48 
hours there was complete consumption of the starting material, but no evidence for the 
formation of the desired vinyl iodides 262. Reaction with PMB-ethers 264 gave 
comparable results, with indications of PMB cleavage. The TBS-ether equivalents 269 
were synthesised, but under the reaction conditions the desired products 270 were not 
isolated. 
 
 
Scheme 2.13 – Reagents & conditions: a) NaI, CeCl3·7H2O, MeCN, 80 ºC; b) TBSCl, Et3N, DMAP, 
CH2Cl2, 0 ºC to rt [54%]. 
 
A final attempt to effect direct hydroiodination of the terminal alkynes 269 using a 
combination of diphenylphosphine oxide and iodine was undertaken (Scheme 2.14).111 
The substrates were submitted to the illustrated reaction conditions but were recovered 
unreacted. The low dilution conditions required for this reaction (1.2 M and 0.4 M) could 
not be reproduced on the test reactions (0.05 M), which is believed to be responsible for 
the failure of the reaction. 
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Scheme 2.14 – Reagents & conditions: a) Ph2P(O)H, I2, CHCl3, rt. 
 
Conversion of the terminal alkyne into a vinyl halide through 
metal-catalysed silylation reaction 
 
In view of the results described before, an alternative route was sought. Methodology 
developed by Trost112 for the regioselective conversion of a terminal alkyne into a vinyl 
silane was applied to substrates 261 (Scheme 2.15). This ruthenium-catalysed 
hydrosilylation proceeded quickly to give only the desired proximal silanes 271-1 and 
271-2 as a separable mixture of the two diastereoisomers in good yield. 
 
 
Scheme 2.15 – Reagents & conditions: a) Et3SiH, Cp*Ru(MeCN)3PF6 (5 mol%), CH2Cl2, 0 ºC to rt 
[81%, dr 1:1]. 
 
Various conditions were tested for the silicon-halogen exchange of vinyl silane 271-1 or 
271-2 (Table 2.3). The use of iodine, in the presence or absence of silver 
tetrafluoroborate led only to the recovery of the starting material (entries 1 and 2).113 
Bromine proved too reactive for the substrate, resulting in complete decomposition 
(entry 3).114 Reactions using NIS (entries 4 and 5) were sluggish, with a mixture of 
starting material and other unidentified side-products obtained.115 Finally iodine 
monochloride showed similar reactivity to bromine, leading to substrate decomposition 
with no traces of vinyl halide formation (entry 6).116 
  
 72 
 
entry substrate conditions temperature result 
1 271-1 I2, CH2Cl2 0 ºC to rt no reaction 
2 271-1 I2, AgBF4, CH2Cl2 0 ºC to rt no reaction 
3 271-2 Br2, CH2Cl2 −78 ºC decomposition 
4 271-1 NIS, CH2Cl2 rt decomposition 
5 271-1 NIS, MeCN/THF rt decomposition 
6 271-2 ICl, CH2Cl2, n-Bu4NF, AcOH −78 ºC decomposition 
 
Table 2.3 
 
Successful conversion of the terminal alkyne to vinyl halide 
using tin chemistry 
 
Considering the disappointing results obtained until this point, an alternative method of 
alkyne conversion to alkenyl halide was required. During his work towards the total 
synthesis of several amphidinolides, Fürstner reported the use of a regioselective 
palladium-catalysed silylstannation of a terminal alkyne with yields varying from 79 to 
85%.117 The main drawback of this approach would be the requirement for subsequent 
TMS group removal, which would add an additional step to the synthesis. Trimethylsilyl 
tri-n-butylstannane 272 was prepared efficiently in one step and in quantitative 
yield,118 and the application of this reagent to alkynes 261, under Paige’s protocol,119 
afforded silylstannanes 273 in good yield (Scheme 2.16). From a theoretical study of the 
mechanism of the palladium-catalysed silylstannation reaction carried out by the group 
of Ito and Nakatsuji,120 the regioselective outcome of the reaction could be the result of 
the insertion of the terminal alkyne into the Pd—Sn bond, due to the larger 
electrophilicity of Sn compared to Si, and the steric repulsion between the 
triphenylphosphine ligands in the palladium(II) complex and the substituents of the 
alkyne group.  
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Scheme 2.16 – Reagents & conditions: a) i-PrNH, n-BuLi, THF, −78 ºC to rt [quant.]; b) Pd(PPh3)4 
(5 mol%), THF, 70 ºC [75 to 83%, dr 1:1]. 
 
The subsequent desilylation using TBAF was attempted, with the addition of acetic acid 
to buffer the reaction (entry 1, Table 2.4). Unsurprisingly, no reaction occurred at rt or 
at reflux in THF. Substituting DMSO for THF and increasing the temperature of the 
reaction mixture to 80 ºC, which are the conditions reported by Fürstner and 
Paquette,117,121 led to the recovery of the starting material after two hours (entry 2). It 
is known that the reactivity of TBAF is generally reduced when buffered with acetic 
acid, and so the reaction time was progressively increased. Unfortunately, heating the 
reaction mixture at 80 ºC for one day resulted in the complete decomposition of the 
starting materials 273 with no sign of the formation of vinyl stannanes 274. 
Subsequently, other fluoride sources were tested. TBAT (n-Bu4NSiPh3F2), which is known 
to be less basic than TBAF, was also tested with the same outcome (entry 3).122 The use 
of TAS-F reagent (275) was investigated next, but complete product decomposition was 
observed when the reaction was conducted at 0 ºC (entry 4).123 Finally, hydrogen 
fluoride buffered with pyridine resulted only in recovery of the starting materials 273 
(entry 5).124 It has been reported that p-TSA can selectively remove a TMS group in the 
presence of trimethylgermanium,125 but exposure of 273 to p-TSA in acetonitrile or 
dichloromethane failed to deliver the desired product (entries 6 and 7).  
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entry conditions temperature result 
1 n-Bu4NF, AcOH, THF rt to reflux  no reaction 
2 n-Bu4NF, AcOH, DMSO 80 ºC decomposition 
3 TBAT, THF rt to reflux no reaction 
4 TAS-F, DMF 0 ºC decomposition 
5 HF·pyridine, THF—pyridine 0 ºC to rt no reaction 
6 p-TSA, MeCN rt decomposition 
7 p-TSA, CH2Cl2 rt decomposition 
 
Table 2.4 
 
It was next decided to convert the vinyl stannanes 273 into the corresponding vinyl 
iodides 276 (Scheme 2.17).119 The reaction was complete in 20 minutes and the excess 
iodine was immediately quenched after complete consumption of the starting material 
to avoid subsequent iododesilylation. At this point, the diastereoisomers 276-1 and 
276-2 could be separated fully. TMS removal from 276-1 and 276-2 using buffered 
TBAF proved unsuccessful, leading only to double elimination and recovery of the 
terminal alkynes 261. Unable to remove the TMS group at this stage, it was hoped that 
the cleavage of the carbon—silicon bond would be possible after cyclisation. 
 
 
Scheme 2.17 – Reagents & conditions: a) I2, CH2Cl2, 0 ºC [95%, dr 1:1]; b) n-Bu4NF, AcOH, THF 
[recovery of 261]. 
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Now that the vinyl iodides 276-1 and 276-2 had been obtained, one step was remaining 
before the key NHK cyclisation reaction. However, during the previously described 
struggle to achieve the desilylation of 273 (Table 2.4), another interesting approach 
inspired by the research group of Pancrazi and Prunet was found.126 Unexpected 
outcomes during their work towards the total synthesis of Taxol126a led them to further 
investigate the hydrostannylation of enyne systems using several methods.126b The 
palladium-catalysed hydrostannylation of enynes 277 and 280 was of particular interest 
(Scheme 2.18 and 2.19). 
 
 
Scheme 2.18 – Reagents & conditions: a) Bu3SnH, PdCl2(PPh3)2 (2 mol%), THF, 20 ºC [60% (278), 
40% (279)].
126
 
 
Reaction of (E)-enyne 277 with tributyltin hydride and palladium(II) led to the expected 
formation of distal stannane 278, along with the destannylated diene derivative 279, in 
a 3:2 ratio (Scheme 2.18). Interestingly with (Z)-enyne 280, both distal and proximal 
stannane 281 and 282 were obtained in a 12:88 ratio in favour of the proximal 
regioisomer 282 (Scheme 2.19). 
  
Scheme 2.19 – Reagents & conditions: a) Bu3SnH, PdCl2(PPh3)2 (2 mol%), THF, 20 ºC [6% (281), 
48% (282)].
126
 
 
The proposed explanation for this regioselective outcome relies on the stabilisation of 
the intermediate palladium complex by the hydroxyl group on (Z)-enyne 280, resulting 
in the preferential formation of proximal dienylstannane 282 (Scheme 2.20). For 
(E)-enyne 277 this stabilisation cannot occur, thus only distal stannane 278 was formed. 
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Scheme 2.20 – Reagents & conditions: a) Bu3SnH, PdCl2(PPh3)2 (2 mol%), THF, 20 ºC. 
 
It was proposed that an equivalent stabilising effect could be induced by the 
β-unsaturated lactone moiety of 261, leading to the preferential formation of 274 
(Scheme 2.20). 
Pleasingly, when alkynes 261 were subjected to the palladium-catalysed hydro-
stannylation conditions (Scheme 2.21), it was clear, based on the analysis of the proton 
NMR of the crude mixture, that the major products formed during the reaction were the 
proximal vinyl stannanes 274 along with their distal regioisomers (3:1 ratio). Most of the 
undesired distal regioisomers could be removed by column chromatography. The 
subsequent metal/halogen exchange on the remaining mixture afforded vinyl iodides 
262-1 and 262-2 as a separable mixture of the two diastereoisomers, in 62% yield over 
both steps. Following formation of the vinyl iodides 262 and 276 (cf. Scheme 2.17), the 
key NHK cyclisation reaction could be investigated. 
 
 
Scheme 2.21 – Reagents & conditions: a) Bu3SnH, Pd(PPh3)4 (5 mol%), THF, rt [rr (proximal—
distal) 3:1]; b) I2, CH2Cl2, 0 ºC [62% (2 steps), dr 1:1]. 
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2.2.4 Nozaki-Hiyama-Kishi cyclisation 
 
First approach of the NHK cyclisation 
 
There are numerous examples of NHK reactions in the literature, both inter- and 
intramolecular, in which the variation of reaction conditions is expansive.97,127  
Reagents, chromium salts purity, catalyst loadings, nature of the solvent, 
concentration, the use of additives, work-up or time of reaction appear to be extremely 
substrate dependant. Initial investigations of the reaction conditions were conducted 
using the vinyl iodides 276-1 and 276-2, bearing the TMS group (Table 2.5). At this late 
stage of the synthesis, the reactions were performed on a small scale, which made the 
isolation of products difficult. Aldehydes 283-1 and 283-2 were obtained using DMP 
oxidation of 276-1 and 276-2, respectively. After a rapid purification through a plug of 
silica, the two aldehydes were subjected to the cyclisation conditions. 
 
Entries 1 to 3 in Table 2.5 were adapted from the conditions optimised by Corminboeuf 
et al. during their total syntheses of the briarellins.97 For both diastereoisomers 276-1 
and 276-2, the reaction was sluggish and the products were obtained in poor yields over 
the two steps. Each diastereoisomer seemed to form one product selectively and the 
nature of the diastereoisomer used had no effect on the isolated yield of the reaction. 
In entry 3, the concentration was increased to 0.005 M but no product was isolated from 
this reaction. It seemed unrealistic that a minor change in the dilution of the reaction 
would have such a drastic effect on the yield of the reaction. The inferior quality of the 
batch of chromium(II) dichloride used for this reaction might offer a more reasonable 
explanation for the reaction’s outcome, further demonstrating the importance of 
keeping CrCl2 thoroughly anhydrous and under argon.  
The loadings of the two metals were increased with no improvement on the yield of the 
reaction (entries 4 and 5). Entry 6 was inspired by the conditions used by Yadav in his 
total synthesis of amphidinolactone A.127a When a stoichiometric amount of NiCl2 was 
used and the reaction mixture was seven times more concentrated than in the previous 
entries, the isolated yield in our case was lower. The use of DMS as an additive for 
intramolecular NHK reactions is widespread in the literature with no rational 
explanation for its actual effect in the cyclisation. Entries 6 and 7 showed that its 
absence was not an important factor for our substrate. Changing the solvent system to 
DMF127b,127c resulted in a decrease in the yield to 11% (entry 8). Finally, in the absence of 
NiCl2 and using THF as solvent no products were isolated from the reaction (entry 
9).127d,127e 
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Table 2.5 – Reagents & conditions: a) DMP, CH2Cl2, 0 ºC to rt;
 aCrCl2 was obtained from Strem 
Chemicals, inc. (99%) and carefully stored under argon; bDMSO was degassed using 3 freeze-thaw 
cycles; cDMS added as additive in a 100:1 DMSO—DMS ratio; dmolecular sieves (4 Å) were added to 
the reaction in THF (entry 9); eisolated yield over two steps; ffor entries 3 and 9, no products 
were isolated. 
 
For most of the reactions, traces of other products could be detected, possibly dimers. 
Unfortunately, the low yields obtained combined with the small scale under which the 
reactions were performed prevented full characterisation of the reaction products. 
Following Kishi’s report of possible improvements to the NHK reaction,128 work-up 
protocols with saturated aqueous NH4Cl or with a solution of potassium (D,L)-serinate 
were tested with no effect on the isolated yield obtained.  
In summary, the first approach, although not as successful as expected, provided the 
cyclononanone core in 11 to 31% yield. It is proposed that this low yield is due to the 
presence of the bulky TMS group, impeding the cyclisation reaction. There is actually no 
literature precedent of a NHK cyclisation using a substrate bearing a trisubstituted 
(Z)-alkenyl halide. 
 
entry 
substrate 
used 
CrCl2
a 
(equiv) 
NiCl2 
(equiv) 
solventb-d 
dilution 
(M) 
reaction 
time 
resulte,f 
1 276-1 10  0.1 DMSO—DMS 0.0025 3 d 31% 
2 276-2 10 0.1 DMSO—DMS 0.0025
 
3 d 28% 
3 276-2 10 0.1 DMSO—DMS 0.005 3 d — 
4 276-2 20 0.2 DMSO—DMS 0.0025 1.5 d 27% 
5 276-1 30 0.3 DMSO—DMS 0.0025 3 d 26% 
6 276-1 20 2 DMSO 0.018 1.5 d 14% 
7 276-2 7.6 0.06 DMSO 0.005 3 d 22% 
8 276-2 10 0.01 DMF 0.01 3 d 11% 
9 276-2 20 0 THF 0.001 3 d — 
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Second approach of the NHK reaction  
 
After the relatively frustrating first study concerning the key reaction of the project, it 
was anticipated that the cyclisation reaction would be more successful with vinyl 
iodides 262-1 and 262-2, not bearing the bulky TMS group. A first attempt was carried 
out on small scale with 262-1 (Scheme 2.22). The conditions previously demonstrated to 
be optimal (cf. Table 2.5, entries 1,2) were applied to aldehyde 285-1, previously 
obtained from Dess-Martin oxidation of alcohol 262-1. After purification, two separable 
products 286-1 and 286-2 were obtained in a 1:1.4 ratio. These two products almost 
certainly corresponded to the two possible diastereoisomeric products expected from 
the cyclisation. Further investigations of the reaction were carried out, leading to the 
gratifying results highlighted in Table 2.6. 
 
 
Scheme 2.22 – Reagents & conditions: a) DMP, CH2Cl2, 0 ºC to rt; b) CrCl2 (10 equiv), NiCl2 
(10 mol%), DMSO—DMS (100:1), rt, 5 d [45% (2 steps), dr 1:1.4]. 
 
On scales of around 50 mg and higher reaction concentration, the products could be 
separated to give the two diastereoisomers in a 2.5:1 ratio, with a combined 45% yield 
over the two steps (Table 6, entry 1). Pleasingly, well-formed single crystals were 
obtained from the major isomer and X-Ray crystallography confirmed the relationship 
between C-4, C-5 and C-8 stereocentres (Figure 2.1). Starting from 262-syn, the major 
product 286-syn of the NHK reaction bore the natural configuration at C-5. A higher 
concentration did not have a negative effect on the outcome of the reaction, and 
heating the reaction at 50 ºC overnight improved the rate of the reaction and delivered 
an increased yield of 75% (entry 2).98 However, using the same reaction conditions but 
heating the reaction at 50 ºC for three days had a modest influence on the ratio 
between 286-syn and 5-epi-286-syn (entry 3). The 1:1 ratio obtained showed that the 
temperature of the reaction was an important factor on the selectivity of the reaction. 
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entry concentration 
reaction time, 
temperature 
yielda 
ratio (286-syn—5-epi-286-syn)
b 
1 0.007 M 3 d, rt 
45% 
2.5:1  
2 0.01 M 
1 d, rt then 
15 h, 50 ºC 
75% 
3.5:1 (2.4:1) 
3 0.01 M 3 d, 50 ºC 
52% 
ca 1:1 
 
Table 2.6 – Reagents & conditions: a) DMP, CH2Cl2, 0 ºC to rt; b) CrCl2 (10 equiv), NiCl2 
(10 mol%), DMSO; aisolated yield over two steps and sum of the two diastereoisomers obtained; 
bisolated ratio after purification, based on crude 1H NMR analysis in brackets. 
 
  
Figure 2.1 – X-Ray crystallography of the NHK product 286-syn. 
 
The confirmation of the relative configuration of 286-syn by X-Ray crystallography also 
determined that the relationship between the two stereocentres C-4 and C-8 of the 
aldehyde 285-syn, the precursor to the cyclisation, was not that found in the natural 
product. Alcohol 262-anti bearing the natural configuration on C-4 and C-8 was oxidised 
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using DMP and subjected to the NHK cyclisation conditions, affording 286-anti in 50% 
yield and 2.4:1 dr (Scheme 2.23). Unfortunately, despite a good overall yield the two 
diastereoisomers could not be separated using column chromatography. It was therefore 
not possible to confirm the configuration of the major diastereoisomer. 
 
 
Scheme 2.23 – Reagents & conditions: a) DMP, CH2Cl2, 0 ºC to rt; b) CrCl2 (10 equiv), NiCl2 
(10 mol%), DMSO, 50 ºC, 3 d [50% (2 steps), dr 2.4:1]. 
 
Oxidation — reduction sequence 
 
In an attempt to improve the diastereoisomeric ratio obtained from the NHK reaction, a 
post-cyclisation oxidation—reduction sequence was undertaken on the mixture 286-anti 
(Scheme 2.24). A similar study was published by the group of Fujiwara for the synthesis 
of FGHI ring system of ciguatoxins.129 Oxidation of alcohols 286-anti using DMP, then 
reduction under Luche conditions at −78 ºC altered the diastereoisomeric ratio between 
the two diastereoisomers, from 2.4:1 to 3:1. When enone 287-anti was reduced using L-
selectride and CeCl3, [1,4]-reduction occurred, yielding 288-anti as two separable 
diastereoisomers with a ratio of 1:1. Other reduction conditions were not studied owing 
to a lack of material and time constraints. 
 
 
Scheme 2.24 – Reagents & conditions: a) DMP, CH2Cl2, 0 ºC to rt; b) NaBH4, CeCl3·7H2O, MeOH, 
−78 ºC [quant. (2 steps), dr 1:3]; c) L-Selectride, CeCl3, THF, −78 ºC [68% (2 steps), dr 1.3:1]. 
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2.2.5 Approach using racemic material — key elements 
 
In summary, the two racemic fragments were prepared and coupled using a Stille cross-
coupling reaction (Scheme 2.25). The conversion of the alkyne into the corresponding 
vinyl iodide was accomplished using a regioselective palladium-catalysed 
hydrostannylation reaction. The study of the intramolecular NHK reaction on 
diastereoisomers 262-syn and 262-anti gave important insights into the reaction. 
(1) Formation of the nine-membered ring was possible from substrates 262-syn and 
262-anti, which implied that the relationship between C-4 and C-8 was not important 
for the cyclisation reaction to proceed. 
(2) The modest diastereoisomeric ratios obtained for the new C-5 stereocentre formed 
during the intramolecular NHK reaction suggested that there was little facial selectivity 
during the nucleophilic attack of the organochromium species onto the aldehyde, which 
was confirmed by the loss of selectivity for the NHK reaction conducted at 50 ºC. 
Consequently, the four possible diastereoisomers obtained from the NHK cyclisation on 
the aldehyde of 262-syn or 262-anti could potentially be used to make analogues of 
hydroxycornexistins. More importantly, compounds possessing the natural configuration 
at C-5 were obtained using the NHK cyclisation reaction. This was not the case with the 
previous RCM strategy, and with the use of an appropriate chiral ligand, the 
predominant formation of the natural C-5 stereocentre might be achieved using the NHK 
reaction.  
Finally, the oxidation—reduction sequence on the mixture of products 286-anti showed 
that the two faces of the carbonyl group in the nine-membered ring were still accessible 
to reducing agents (Scheme 2.24), which was not the case with the substrates made 
previously in the group (cf. Section 1.4.4).  
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Scheme 2.25 
 
At this point of the synthesis, with promising results having been obtained from the NHK 
cyclisation reaction, it was decided to investigate an enantioselective synthesis of 
hydroxycornexistin. 
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2.3 An approach to the enantioselective synthesis of 
hydroxycornexistin 
 
2.3.1 Chloride fragment synthesis 
 
Study of the asymmetric approaches for the chloride fragment 
 
The formation of the chloride fragment 249 was initially performed to give a racemate, 
and enough material was synthesised to test the NHK reaction. However, an asymmetric 
synthesis using the same route was unlikely to deliver the desired fragment in a highly 
enantioselective manner, so several routes were considered.  
 
As highlighted by Aggarwal, achieving high enantioselectivity for the hydroboration of a 
1,1-disubstituted alkene remains a challenge (e.g. 241, Scheme 2.26).130 Only 
Soderquist’s organoboron reagent 289 gives enantioselectivities up to 92% for suitable 
systems. Unfortunately, for a similar substrate bearing a phenyl group on one side of 
the double bond and a methyl group on the other side, the enantiomeric excess drops to 
78%.131 It is unlikely that this methodology would afford primary alcohol (S)-242 with 
acceptable enantiopurity. 
 
 
Scheme 2.26 
 
Enzymatic resolution using esterase or lipase-catalysed trans-esterification of primary 
alcohol 242 was also considered, but no examples could be found which matched our 
substrate (Scheme 2.27).132 Acylation of 242 with (−)-menthyl chloroformate133 to form 
the corresponding diasteroisomeric menthyl carbonates was considered, but the two 
diastereoisomers obtained could not be separated by column chromatography or 
recrystallisation. Conversion of the 1,1-disubstituted alkene 241 into the epoxide 290, 
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followed by a kinetic resolution using Jacobsen’s salen complex 211 (Figure 1.11) 
seemed unlikely to be an efficient process due to the presumed instability of an epoxide 
conjugated with the furan ring.134 
 
 
Scheme 2.27 
 
An organocatalytic approach to the synthesis of the fragment had already been 
attempted in the group without success (cf. Section 1.4.3). Two recent reports from 
MacMillan135 and Fu136 were potentially appropriate for the asymmetric synthesis of the 
chloride fragment (Scheme 2.28). MacMillan obtained excellent results for the 
enantioselective α-arylation of aldehydes, using diaryliodonium salts, the organocatalyst 
293 and copper bromide (Eq. 1, Scheme 2.28). The approach chosen by Fu proceeded 
through an asymmetric Suzuki cross-coupling, using racemic α-haloamides. It was found 
that a sub-stoichiometric amount of NiBr2·diglyme combined with the chiral ligand 297 
catalysed the reaction and delivered good isolated yields of the products with high 
enantioselectivities (Eq. 2, Scheme 2.28). 
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Scheme 2.28
135,136
 
 
Applying these methodologies to the synthesis of (S)-301 was attractive but the 
synthesis of the required starting materials 299 and 300 would be complicated (Scheme 
2.29). 
 
 
Scheme 2.29 
 
Finally, methodology developed by Jarvo and co-workers seemed appropriate for our 
substrate (Scheme 2.30).137 The published work described a stereospecific nickel-
catalysed substitution reaction using a Grignard reagent, with inversion of configuration 
at the α-position of an aryl group. 
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Scheme 2.30
137
 
 
It was thought that the same methodology could be adapted for our synthesis, starting 
from the enantiopure version of methyl-ether 304 and using vinyl magnesium bromide 
instead of methyl magnesium iodide as Grignard nucleophile (Scheme 2.31). The 
starting material 304 was easily prepared as a racemate from alcohol 240. 
Unfortunately, when applying the reported reaction conditions, no reaction occurred 
and only starting material was recovered. A few details are worth mentioning. The 
Grignard reagent used was commercially sourced and not freshly prepared, due to the 
difficulties associated with handling vinyl bromide. Furthermore, the protocol describes 
the use of a glove-box for the reaction. Without access to a glove-box, it was extremely 
difficult in our hands to avoid decomposition of the nickel complex, even with very 
careful handling. With the absence of any evidence for the formation of the new 
product, and the high instability of the metal source, no further efforts were made and 
an alternative approach was sought. 
 
 
Scheme 2.31 – Reagents & conditions: a) MeI, NaH, THF, 0 ºC to rt [95%]; b) vinyl magnesium 
bromide (1 M in THF), Ni(cod)2 (5 mol%), (S)-BINAP (10 mol%), toluene, rt [recovery of 304]. 
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New strategy for the chloride fragments synthesis 
 
No suitable direct asymmetric approach to the synthesis of the chloride fragment 
seemed appropriate, so a new route was designed, involving the [3,3]-sigmatropic 
rearrangement reaction detailed in Scheme 2.32. From the allylic glycolate 306, the 
unsaturated acid should be obtained as a single diastereoisomer by 1,3-chirality transfer 
through a chelation-controlled chair-like transition state, following the Buke-Fujisawa-
Kallmerten modification of the Ireland-Claisen rearrangement.138,139 
 
 
Scheme 2.32 
 
With this in mind, the new approach for the chloride fragment would begin with the 
addition of a carbonyl functional group to chloride 239, leading to acid 309 (Scheme 
2.33). The acid would be obtained using the [3,3]-sigmatropic rearrangement of allylic 
ester 310. The ester would be derived from enantiopure allylic alcohol 311. For the 
synthesis of 311, two options could be envisaged; either an asymmetric reduction of 
enone 312, or a cross metathesis reaction between vinyl furan 313 and allylic alcohol 
314. CBS-reduction140 has been reported on a similar substrate, bearing a phenyl group 
instead of the furan unit, demonstrating the potential for good yields and high 
enantioselectivities in the reduction reaction.141 However, the use of CBS reagent at an 
early stage in the synthesis seemed costly, thus the cross-coupling reaction was 
favoured. 
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Scheme 2.33 
 
Asymmetric synthesis of allylic alcohol 314 
 
Four main methods have been published for the synthesis of (S)-(+)-but-3-en-2-ol 314. 
The first method used a Sharpless catalytic asymmetric epoxidation of crotyl alcohol 
315 to afford the epoxy toluene-p-sulphonate 316 in moderate yield (Scheme 2.34).142 
Subsequent treatment with sodium iodide and zinc-copper complex in ethylene glycol 
allowed for the isolation of 314, by fractional distillation. It was also mentioned that 
epoxide 316 was commercially available, unfortunately neither of the two possible 
starting materials 315 and 316 are easy to access. 
 
 
Scheme 2.34 – Reagents & conditions: a) (+)-DIPT, t-BuOH, MS (3 Å), Ti(Oi-Pr)4, P(OMe)3, TsCl, 
Et3N, DMAP [50-68%]; b) Zn(Cu), NaI, ethylene glycol, 70 ºC [90%].
142
 
 
A second pathway was detailed by Ibrahim et al.143 Starting from 3-chlorobutan-2-one 
317, enzymatic reduction using a specific strain of yeast provided (2S)-3-chlorobutan-2-
ol 318 (Scheme 2.35). Etherification with 2-methoxypropene under acidic catalysis 
furnished acetals 319. Allylic alcohol 314 was finally obtained after 
dehydrohalogenation using potassium tert-butoxide and acidic hydrolysis of the acetal. 
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Scheme 2.35 – Reagents & conditions: a) yeast (Saccharomyces cerevisiae), sucrose, H2O, 30 ºC 
[55-64%]; b) 2-methoxypropene, oxalic acid dehydrate, Et2O, rt [quant.]; c) KOt-Bu, DMF, rt 
[80%]; d) oxalic acid dehydrate, H2O, rt [83%].
143
 
 
A third option published by Höck et al. involves catalytic reduction of (2S)-but-3-yn-2-ol 
320 with Lindlar’s catalyst (Scheme 2.36).144 The enantiomeric excess obtained was 
excellent (≥ 98% ee), but the rate of the reaction, the cost of the terminal alkyne 320 
along with the moderate yield meant that that the method was not suitable. 
 
 
Scheme 2.36 – Reagents & conditions: a) H2, Lindlar’s catalyst, diethylene glycol, rt, 13 d 
[50%].
144 
 
The chosen method involves a four-step sequence starting from ethyl-L-lactate 321 
(Scheme 2.37).145 THP-ether 322 was obtained cleanly from alcohol 321 after a simple 
work-up. For DIBAL-H reduction to the corresponding aldehyde, dichloromethane was 
chosen instead of toluene as solvent and the temperature was lowered to −78 ºC instead 
of −40 ºC to avoid potential epimerisation issues. Potassium tert-butoxide was used in 
preference to n-butyllithium as a base for the methylenation conditions and filtration 
through a plug of silica gel removed the excess unreacted ylide and the 
triphenylphosphine oxide formed. Special care was required for the concentration in 
vacuo after work-up and filtration because allylic ether 323 is very volatile. Finally, 
acid-mediated removal of the THP-ether 323 afforded (+)-but-3-en-2-ol (+)-314 after 
distillation under reduced pressure, in 56% yield over the four steps. Albeit that a good 
overall yield was obtained, the preparation of this alcohol in large quantities was very 
time consuming. 
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Scheme 2.37 – Reagents & conditions, published:
145
 a) DHP, PPTS (10 mol%), CH2Cl2, rt [84%]; 
b) DIBAL-H, toluene, −40 ºC [55%]; c) PPh3MeBr, n-BuLi, THF, rt [50%]; d) p-TSA (10 mol%), 
ethylene glycol, rt [64%]. Reagents & conditions, experimental: a) DHP, PPTS (10 mol%), CH2Cl2, 
rt; b) DIBAL-H, CH2Cl2, −78 ºC; c) PPh3MeBr, KOt-Bu, THF, rt; d) p-TSA (5 mol%), ethylene glycol, 
rt [56% over 4 steps]. 
 
Cross-metathesis reaction using allylic alcohol (+)-314 
 
With the allylic alcohol (+)-314 available in sufficient quantities, its cross-coupling 
partner 324 was prepared (Scheme 2.38). The first three steps were identical to those 
reported previously (cf. Scheme 2.2), and were followed by Wittig methylenation, 
providing vinyl furan 324 in 62% yield over four steps. 
 
 
Scheme 2.38 – Reagents & conditions: a) LiAlH4, THF, −78 ºC to rt; b) MnO2, CH2Cl2, rt; c) TBSCl, 
imidazole, DMAP, CH2Cl2, rt; d) PPh3MeBr, KOt-Bu, THF, 0 ºC to rt [62% (4 steps)]. 
 
The cross-metathesis reaction between (+)-314 and 324 was conducted as shown in 
Table 2.7, using Grubbs 2nd generation 90 as catalyst.146 First, two equivalents of allylic 
alcohol (+)-314 and 5 mol% of Grubbs II catalyst were used (entry 1). After 24 h at 40 ºC 
in 1,2-DCE, (−)-325 was obtained in 47% yield. The catalyst loading was then increased 
to 10 mol% and four equivalents of the allylic alcohol were added, in DCE, CH2Cl2 and 
toluene respectively (entries 2 to 4). After 24 h at 40 ºC, the best isolated yield was 
obtained for the reaction performed in dichloromethane (entry 3). As a first approach, 
this was an encouraging result, especially as the unreacted vinyl furan 324 could be 
recovered from the reaction mixture. A 9:1 (trans/cis) ratio was determined by NMR 
analysis of the crude mixture. The minor cis product could be separated from the 
desired alcohol (−)-325 but was not isolated. This first study showed that it was possible 
to use this cross-metathesis reaction for the asymmetric synthesis of (−)-325 despite 
the relatively high loading of allylic alcohol (+)-314. 
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entry 
(+)-314 
loading (equiv) 
solvent 
cat. loadinga 
(mol%) 
yieldb 
(%) 
1 2.0 1,2-DCE 5 47 (96) 
2 4.0 1,2-DCE 10 58 (73) 
3 4.0 CH2Cl2 10 68 (80) 
4 4.0 toluene 10 58 (75) 
 
Table 2.7 – a5 mol% added straight, and further 5 mol% added after 5 h; byield in brackets is 
based on the recovery of the starting material (brsm), 324. 
 
At this point, the enantiopurity of the coupled allylic alcohol (−)-325 was considered. 
Racemic alcohol (±)-325 was obtained through an alternative five-step sequence 
described in Scheme 2.39. Once again, a Wittig reagent provided the α,β-unsaturated 
ketone 326 in 57% yield over four steps, and further Luche reduction led to the 
formation (±)-325 in good yield. 
 
 
Scheme 2.39 – Reagents & conditions: a) LiAlH4, THF, −78 ºC to rt; b) MnO2, CH2Cl2, rt; c) TBSCl, 
imidazole, DMAP, CH2Cl2, rt; d) 1-(triphenylphosphoranylidene)acetone, toluene, 100 ºC [57% 
(4 steps)]; e) NaBH4, CeCl3·7H2O, MeOH, 0 ºC [90%]. 
 
The enantioselectivity was determined by chiral HPLC following similar conditions to 
those reported for a similar substrate.141 The enantiomeric excess of alcohol (−)-325 
(Table 2.7) was determined to be 73%. This was disappointing considering that the 
approach chosen for the synthesis of the allylic alcohol (+)-314 began from an 
enantiopure starting material. Furthermore, similar conditions had been used for the 
preparation of other compounds, which were obtained in excellent enantiopurities.147 
Epimerisation during the cross metathesis reaction is highly unlikely, and partial 
racemisation most probably occurred during the synthesis of the allylic alcohol (+)-314. 
Low purity of ethyl-L-lactate or racemisation during the DIBAL-H reduction of the ester 
322 (cf. Scheme 2.38), the Wittig methylenation or acidic removal of the THP moiety 
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are all possible explanations. Only Balmer, optimising the synthesis of the alcohol (+)-
314 by Sharpless epoxidation, stated a comparable 74% ee measured from the Mosher 
ester derived from (+)-314 (cf. Scheme 2.34).142b 
 
Inspired by the work of Brenna et al. an enzymatic resolution reaction was undertaken, 
in an attempt to improve the enantiopurity of the allylic alcohol (−)-325 (Scheme 
2.40).148 Alcohol (−)-325 was subjected to the reported reaction conditions, 
unfortunately no reaction seemed to occur and chiral HPLC analysis of (−)-325, 
recovered from the reaction, showed that it had exactly the same enantiomeric excess 
as the starting material. 
 
 
 
Scheme 2.40 – Reagents & conditions: a) vinyl acetate, lipase PS (Burk-holderia cepacia), TBME, 
rt [(S)-327 45% (99% ee), (R)-328 46% (99% ee)];
148
 b) vinyl acetate, lipase PS (Burk-holderia 
cepacia), TBME, rt [25% recovered (−)-325 (73% ee)]. 
 
Alternative cross-coupling reaction 
 
Despite this disappointing outcome, much effort had been expended during the 
synthesis of this fragment, so that the decision was taken to continue the synthesis. 
During the initial cross-metathesis reactions (cf. Table 2.7), the amount of allylic 
alcohol partner (+)-314 was high, and the volatile alcohol proved impossible to recover 
after the reaction. Another approach was explored, in which the alcohol was protected 
as an ester (Scheme 2.41). PMB-ether 330 was easily prepared by SN2 reaction between 
bromoacetic acid and p-anisyl alcohol.149 Trans-esterification using commercially 
available alcohol (±)-314 provided the cross metathesis partner (±)-331.  
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Scheme 2.41 – Reagents & conditions: a) 1-bromoacetic acid, PMBOH, NaH, THF, 70 ºC [84%]; 
b) (±)-314, EDCI, DMAP, CH2Cl2, 0 ºC to rt [99%]. 
 
The subsequent cross-coupling reaction of 324 and (±)-331 was examined (Table 2.8). 
Ester (±)-331 was first used in excess compared to vinyl furan 324 (entry 1). Using 
5 mol% of Grubbs II catalyst 90 and toluene as solvent, a complex mixture was obtained. 
Monitoring the reaction by 1H NMR was difficult and after work-up, nearly half of the 
vinyl furan 324 was recovered and the metathesis product (±)-333 proved inseparable 
from starting ester (±)-331. With equal amounts of starting materials, the result was 
identical using toluene or dichloromethane as solvents (entries 2 and 3). Using an excess 
of ester (±)-331 allowed for the isolation of coupled ester (±)-333 in a poor yield, after 
48 h at 80 ºC (entry 4). Alternative conditions, using refluxing dichloromethane and 
Grubbs II or Hoveyda-Grubbs I catalysts led to a marginal improvement in the yield of 
the reaction (35 and 37% yield for entries 5 and 6, respectively). At such an early stage 
of the synthesis, the yield obtained for the cross-metathesis of 324 and (±)-331 was 
unsatisfactory in comparison to the previous coupling reaction of vinyl furan 324 and 
allylic alcohol (+)-314. 
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entry 
324— 
(±)-331 
ratio 
cat. 
cat. 
loading 
(mol%) 
 solvent 
temperature 
(ºC) 
reaction 
time (h) 
result 
1 1 : 1.5 90 5  toluene 80 24 
complex 
mixture 
2 1 : 1 90 5  toluene 80 24 
complex 
mixture 
3 1 : 1 90 5  CH2Cl2 reflux 24 
complex 
mixture 
4 1.5 : 1 90 10  toluene 80 48 12% yield 
5 2 : 1 90 5  CH2Cl2 reflux 48 35% yield 
6 2 : 1 332 5  CH2Cl2 reflux 48 37% yield 
 
Table 2.8 
  
Modified Ireland-Claisen rearrangement and synthesis of the 
chloride fragment 
 
The next crucial step in the revised synthetic route was the modified Ireland-Claisen 
rearrangement (Scheme 2.42). The coupling reaction of 324 and (+)-314 proved to be 
reproducible with 73% as the best isolated yield; recovery of most of the unreacted 
starting furan 324 was an additional benefit. Esterification of (−)-325 with the 
previously prepared acid 330 (Scheme 2.41) proceeded in good yield. Pleasingly, 
following a reported procedure,150 the [3,3]-sigmatropic rearrangement took place 
efficiently, affording the acid (+)-334 in 85% isolated yield.  
 
 96 
 
 
Scheme 2.42 – Reagents & conditions: a) Grubbs II (8 mol%), (+)-314 (4 equiv), CH2Cl2, 45 ºC 
[73% (91% brsm)]; b) 330, EDCI, DMAP, CH2Cl2, 0 ºC to rt [90%]; c) LiHMDS, TMSCl, THF, −78 ºC to 
rt [85%]. 
 
The acid (+)-334 was next reduced to the corresponding alcohol (+)-335 using lithium 
aluminium hydride in diethyl ether (Scheme 2.43).151 For the subsequent reduction of 
the alkene in (+)-335, some concerns were raised regarding the stability of either the 
furan or the PMB group under hydrogenation conditions.152 Accordingly, the 
hydrogenation reaction was carefully monitored by 1H NMR and stopped as soon as the 
starting material was consumed, typically after 15 to 20 minutes of reaction, affording 
(+)-336 in excellent yield. No signs of competing reductions were apparent and, in fact, 
leaving the reaction for a longer period of time, or substituting the solvent system for 
protic media (ethanol or ethyl acetate) to cleave the PMB group only lowered the yield 
of the reaction with only traces of the diol being formed. 
 
 
Scheme 2.43 – Reagents & conditions: a) LiAlH4, Et2O, 0 ºC [95%]; b) H2, Pd/C (10 mol%), 
acetone, rt [99%]. 
 
At this point, three possible routes were investigated to complete the synthesis of the 
chloride fragment (Scheme 2.44). The first option involved protection of alcohol 
(+)-336 as a PMP-acetal (path A). This was briefly investigated, with the use of DDQ and 
molecular sieves (3 Å) in dichloromethane,153 but these conditions led to decomposition 
of the starting material. This approach was abandoned due to this result and the fact 
that there would be no control of the new stereocentre formed in 337. 
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Scheme 2.44 
 
The formation of the bis-PMB ether 338 was investigated next (path B). Nucleophilic 
substitution of PMBCl under basic conditions resulted in the decomposition of the 
starting material (±)-336 (Table 2.9, entry 1). The use of acid-catalysed imidate 
protection methodology promoted by either scandium triflate or lanthanum triflate as 
an acid catalyst was investigated (entries 2 and 3).154,155 Using scandium triflate, the bis-
PMB ether (±)-338 was obtained in a disappointing yield (entry 2). Lanthanum triflate 
was a surprisingly effective catalyst, furnishing (±)-338 in 51% yield after a reaction 
time of five minutes. This process could have been further optimised, but isolating the 
desired product was difficult because of the amounts of impurities formed.  
 
 
entry conditions  result 
1 NaH, PMBCl, n-Bu4NI, DMF, rt  decomposition 
2 PMBTCA, Sc(OTf)3 (2 mol%), toluene, MeCN, 0 ºC  34% 
3 PMBTCA, La(OTf)3 (2 mol%), toluene, rt  51% 
 
Table 2.9 
 
The cleavage of the PMB-ether to form diol (+)-339 was subsequently examined (path 
C).The first results obtained using standard conditions156 were not promising (Table 
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2.10). The use of DDQ in a mixture of dichloromethane and water or phosphate buffer 
yielded diol (+)-339 in poor yield (entries 1 and 2). Treatment of PMB-ether (+)-336 
with triflic acid157 at 0 ºC led to the decomposition of the starting material (entry 3). 
From the two unsuccessful attempts using DDQ, the complex mixtures obtained hinted 
that cleavage of a PMB-ether on a substrate bearing an α-hydroxyl group is difficult and 
is complicated by the formation of acetals and other by-products. 
 
 
entry conditions  result 
1 DDQ (1.1 equiv), CH2Cl2—H2O (5:1), rt  34% 
2 DDQ (1.2 equiv), CH2Cl2—pH 7 buffer (5:1), 0 ºC  19% 
3 TFA, CH2Cl2, H2O, 0 ºC  decomposition 
 
Table 2.10 
 
In 1988, Jadav et al. took advantage of this reactivity for the synthesis of propargylic 
alcohols (Scheme 2.45).158 For alkyne 340, the use of two equivalents of DDQ in a 
mixture of dichloromethane and water induced the formation of diol 341, whereas 
using only one equivalent of DDQ in dry media produced the benzylidene derivatives 
342. Another equivalent of DDQ promoted opening of acetals, affording the mixture of 
esters 343 and 344, the saponification of which furnished diol 341. 
 
 
Scheme 2.45
158
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The same conditions were employed on substrate (+)-336 with two equivalents of DDQ 
in a 17:1 mixture of CH2Cl2—H2O (Scheme 2.46). Instead of yielding diol (+)-339 directly, 
a complex mixture was obtained. Examination of the crude mixture suggested that the 
five potential products described by Yadav were indeed formed during the reaction. The 
crude mixture was therefore submitted to basic hydrolysis conditions leading to the 
formation of the desired diol (+)-339 in good yield (75%). The process proved to be 
generally reliable, and depending on the progression of the DDQ reaction, PMP acetals 
and unreacted starting material could be recycled and submitted to the same 
conditions. 
 
From this point, the completion of the chloride fragment synthesis was trivial. 
Acetonide protection159 of the diol (+)-339, followed by removal of the TBS ether using 
TBAF and final chloride substitution of the hydroxyl group in allylic position led to 
chloride (+)-347; all three steps were achieved in excellent yield. 
 
 
Scheme 2.46 – Reagents & conditions: a) (i) DDQ, CH2Cl2—H2O (17:1), rt; (ii) K2CO3, MeOH, rt 
[75%]; b) 2,2-dimethoxypropane, PPTS (5 mol%), CH2Cl2, rt [96%]; c) n-Bu4NF, THF, 0 ºC to rt 
[93%]; d) MsCl, Et3N, CH2Cl2, 0 ºC to rt [95%]. 
 
Overall, the asymmetric synthesis of the chloride fragment was accomplished in 
14 steps (longest linear sequence), 21% overall yield (86% average yield per step), and 
featured a cross-metathesis and [3,3]-sigmatropic rearrangement reactions as key steps 
in the strategy (Scheme 2.47). 
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Scheme 2.47 
 
2.3.2 Asymmetric synthesis of the stannane fragment 
 
Sharpless dihydroxylation approach 
 
Now that the new strategy for the chloride fragment had been validated, its Stille 
coupling partner had to be prepared. An asymmetric approach to the synthesis of the 
unsaturated lactone, using a chiral auxiliary in place of the pyrrolidine (cf. Section 
1.4.3), had been attempted previously in the group with success.41,60 An alternative 
approach based on the work of Harcken et al. to access to alkyne 349 was explored first 
(Scheme 2.48).160 
 
 
Scheme 2.48 – Reagents & conditions: a) AD mix-α, methylsulfonamide, t-BuOH—H2O (1:1), 0 ºC 
 [74% (93% ee)].
160
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In published work it had been shown that asymmetric Sharpless dihydroxylation of 
β,γ-unsaturated ester 348 using AD mix-α afforded dihydrofuran (4S,5S)-349 in good 
yield and with high selectivity. Accordingly, its antipode was expected to be accessible 
using AD mix-β.  The synthesis of ester 348 is shown in Scheme 2.49. Starting from 4-
pentyn-1-ol, Swern oxidation161 afforded aldehyde 351. Due to the volatility of this 
aldehyde, the crude product was used directly in the deconjugative Knoevenagel 
reaction using malonic acid.162 Subsequent esterification with concentrated hydrochloric 
acid and methanol afforded the β,γ-unsaturated ester 348 in good yield over three 
steps. However, the product was inseparable from the undesired minor α,β-unsaturated 
ester 352. To circumvent this issue another set of conditions was explored, using 
piperidinium acetate as catalyst.162b,163 Although the reaction appeared more selective, 
the resulting yield of the reaction was poor.  
 
 
Scheme 2.49 – Reagents & conditions: a) (COCl)2, DMSO, CH2Cl2, −78 ºC then Et3N, −78 ºC to rt; 
b) malonic acid, Et3N, 80 ºC; c) HCl (conc.), MeOH, 60 ºC [71% (3 steps using b), 348—352 (3:1), 
11% (3 steps using d), only 348]; d) malonic acid, piperidinium acetate (2 mol%), DMSO, 90 ºC. 
 
The Sharpless dihydroxylation reaction was attempted on the mixture of unsaturated 
esters following the procedure of Kaferer and co-workers (Scheme 2.50).162a After 48 h 
the lactone (+)-349 was isolated in 40% yield (53% yield based upon the purity of the 
starting material). 
 
 
Scheme 2.50 – Reagents & conditions: a) AD mix-β, methylsulfonamide, t-BuOH—H2O (1:1), 0 ºC 
[40%]. 
 
A sufficient amount of material was obtained to check the enantiopurity of the 
β-hydroxylactone (+)-349 by 1H NMR analysis of the corresponding Mosher ester (Scheme 
2.51).164 Two sets of conditions were applied to the synthesis of the Mosher ester 354, 
in which either pyridine or triethylamine was used as the base, but both reactions led to 
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decomposition of starting material. Oxidation of (+)-349 using DMP to form the tetronic 
acid derivative 355 was also unsuccessful. Looking through the literature, the same 
issue was reported by Wrobel and co-workers.165 They suggested that these substrates 
were prone to undergo β-elimination or retro-aldol fragmentation. They obtained better 
results using Swern oxidation conditions, but it was obvious that the route was 
inappropriate for large scale synthesis. 
 
 
Scheme 2.51 – Reagents & conditions: a) pyridine, CH2Cl2, 0 ºC to rt; b) Et3N, DMAP, CH2Cl2, 0 ºC 
to rt; c) DMP, CH2Cl2, 0 ºC. 
 
Synthesis of the chiral proline derivative 
 
Promising results were obtained by Northall and Marlin by use of the chiral proline 
derivative (−)-360 as an auxiliary (cf. Section 1.4.3).41,60 Consequently, a similar 
outcome was expected for our synthesis, and (−)-360 was prepared in a large scale 
following the original synthesis achieved by the group of Enders (Scheme 2.52).63 It is 
noteworthy that the asymmetric synthesis of cornexistins requires the preparation of 
the auxiliary starting from D-proline. Due to the cost of the unnatural enantiomer, it 
was decided instead to use L-proline 356, and investigate the asymmetric route using a 
model system. Once the asymmetric synthesis optimised, the steps would subsequently 
be repeated starting from the D-proline.   
 
Concerning the first two reactions in one-pot (Scheme 2.52), Enders conditions for the 
amino-benzylation involved the use of the isourea, prepared from DCC and benzyl 
alcohol, with copper(I) acting as catalyst for the reaction. In our hands, the yield 
obtained was lower than expected, but an alternative method for this transformation,166 
using DIPEA and benzyl bromide, afforded ester 357 cleanly.  The crude ester could be 
used directly in the next step. Grignard addition of phenyl magnesium bromide to the 
ester was successful, and more than 50 g of (+)-358 could be obtained after a single 
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recrystallisation. After work-up of the methylation step, no further purification was 
required. Due to poor solubility, the hydrogenation conditions reported by Enders for 
N-benzyl cleavage were unsuccessful, but addition of concentrated hydrochloric acid to 
the reaction mixture allowed the salt of (−)-360 to be isolated.166b The proline salt 
could be washed with cold diethyl ether to remove most of the organic impurities. 
Treatment of the salt with potassium carbonate followed by extraction with 
diethylether furnished the desired proline derivative (−)-360, without any further 
purification required. Pleasingly, the whole sequence was achieved without the 
requirement for column chromatography; the major purification step in the sequence 
being the recrystallisation.  
 
 
Scheme 2.52 – Reagents & conditions: a) (i) SOCl2, MeOH, 0 ºC to 65 ºC; (ii) BnBr, i-Pr2NEt, 
toluene, 0 ºC to 65 ºC; b) PhBr, Mg, I2 (crystal), Et2O, 0 ºC to reflux [64% (3 steps)]; c) MeI, NaH, 
THF, 0 ºC to reflux; d) H2, Pd/C (15 mol%), HCl (conc.), EtOH, rt [90% (2 steps)]. 
 
Condensation of the proline derivative 
 
Following the previously described condensation of pyrrolidine with tetronic acid (cf. 
Scheme 2.6), the same method was employed for the condensation of (−)-360 (Table 
2.11). Under a range of conditions, carbamate (−)-160 was obtained, but always in a 
moderate yield close to 50% (entries 1 and 2). At first the stability of the product during 
the purification on silica gel was questioned. Neutralisation of the silica gel with 
triethylamine, or purification with neutral aluminium oxide did not improve the yield. 
Using the crude product directly in the next step was also attempted but this resulted in 
a poor alkylation yield. In entry 3, molecular sieves were added to force the 
thermodynamic equilibrium of the condensation reaction towards the product, but 
without success. Higher temperature and the use of Dean Stark apparatus also proved 
unsuccessful (entry 4). The condensation of pyrrolidine with methyl tetronate 361 has 
been reported by Guo et al.167 Applying the reported conditions on the proline 
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derivative (−)-360 led only to the recovery of both starting materials (entry 5). Addition 
of potassium carbonate did not change the outcome of the reaction (entry 6). The same 
reported condensation of pyrrolidine with methyl tetronate 361 was attempted (entry 
7), resulting in the expected complete conversion of 361 to the vinylogous carbamate 
132. In resignation, entry 8 was the method chosen; a mixture of toluene and ethanol 
was used to improve the solubility of the two starting materials, but with no major 
improvement in the isolated yield of the reaction. 
 
 
entry reactant 
amount of (−)-360 
(equiv)  
conditions  yield 
1 131 1 toluene, 45 ºC, in vacuo  50% 
2 131 0.8 toluene, 45 ºC, in vacuo  53% 
3 131 1.1 toluene, 4 Å MS, 45 ºC, in vacuo  42% 
4 131 1.1 toluene, Dean Stark, 115 ºC  37% 
5 361 2.7 EtOH, 80 ºC  no reaction 
6 361 2.7 EtOH, K2CO3, 80 ºC  no reaction 
7 361 0 pyrrolidine, EtOH, 80 ºC  quant.a 
8 131 1.1 toluene, EtOH, 45 ºC, in vacuo  53% 
 
Table 2.11 – a132 was obtained from the reaction. 
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Marlin and Northall had taken a different approach to the formation of (−)-160 (Scheme 
2.53) inspired by the work of Schlessinger et al.41,60,168 Initially, this approach was not 
adopted because of the four-step sequence required, as opposed to one step in the 
condensation strategy. However, owing to the difficulties encountered, this route could 
have been a viable alternative.  
 
 
Scheme 2.53 – Reagents & conditions: a) TBSCl, imidazole, CH2Cl2, reflux [96%], b) n-BuLi, 
methyl chloroformate, THF, −78 ºC to rt [89%]; c) (−)-360, t-BuOH, 60 ºC; d) n-Bu4NF, THF, rt 
[89% (2 steps)].
41,60,168
 
 
Completion of the stannane fragment 
 
Deprotonation of vinylogous carbamate (−)-160 with tert-butyllithium and subsequent 
nucleophilic attack of the resulting anion on propargylic bromide 251 afforded the 
alkylated products (−)-364-1 and (−)-364-2 in good yield (Scheme 2.54). Based on 1H 
NMR analysis of the crude mixture, it was difficult to determine the diastereoisomeric 
ratio because the two products formed rotamers at room temperature when solvated in 
deuterated chloroform or benzene. The diastereoisomers were separated by flash 
column chromatography but the diastereoisomeric ratio obtained (4:1) was not 
comparable to the ratio previously reported (8:1) by Northall for his allylation step (cf. 
Section 1.4.3, Scheme 1.44).41 
 
 
Scheme 2.54 – Reagents & conditions: a) t-BuLi, THF, −78 ºC [(−)-364-1 75%, (−)-364-2 19%]. 
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It is assumed that the effect of the pyrrolidine substituent depends on its proximity to 
the reacting carbon centre (Scheme 2.55). Assuming there is free rotation about the C-N 
bond, the most reactive species is expected to be A, with the bulky substituent situated 
away from the nucleophilic site. Better selectivity has been reported with larger 
substituents on the auxiliary, but in this case the electrophile was allyl bromide (cf. 
Section 1.4.3). The lower selectivity during the alkylation reaction using TIPS-protected 
propargylic bromide could be explained by the bulk of the TIPS group although it is far 
from the reactive site. The separation of the diastereoisomers using column 
chromatography and the larger scale employed seem more reasonable explanations to 
the different selectivity observed. The use of a C-2 symmetrical auxiliary might have 
given high selectivity but this approach had been unsuccessful (cf. Section 1.4.3, 
Scheme 1.42). 
 
 
Scheme 2.55 
 
Little could be done to improve the ratio of diastereoisomers, but the excellent yield 
obtained for this alkylation reaction allowed for the preparation of enough of the major 
diastereoisomer (−)-364-1 to complete the synthesis of the fragment (Scheme 2.56). 
The stannane (+)-256 was prepared using an analogous approach as in the synthesis of 
the racemate. Hydrochloric acid in solution with ethanol solved the solubility issue 
encountered originally by Northall and Marlin, so that triflate (+)-254 was obtained in 
good yield. The excellent enantiopurity of triflate (+)-254, determined by chiral HPLC, 
was in agreement with previous work.41 Ultimately, the triflate was converted into the 
corresponding stannane (+)-256 in an expected yield of 52% (compared to 54% for 
(±)-256, Section 2.2.2). 
 
 
Scheme 2.56 – Reagents & conditions: a) HCl (1.26 M in EtOH), H2O, reflux; b) Tf2O, i-Pr2NEt, 
CH2Cl2, −78 ºC [82% (2 steps), 93% ee]; c) (SnMe3)2, Pd(PPh3)4 (3 mol%), THF, reflux [52%]. 
 
 107 
2.3.3 Efforts toward the Nozaki-Hiyama-Kishi cyclisation 
  
Strategy overview 
 
The two coupling fragments have been synthesised in an asymmetric fashion. In 
accordance with the synthesis of the racemate, the Stille cross-coupling was expected 
to afford 365 in high yield (Scheme 2.57). Deprotection of the alkyne and acetonide 
removal in a one-pot reaction was envisaged, due to the required buffering of TBAF 
with acetic acid. Regioselective palladium-catalysed hydrostannylation followed by tin-
iodine exchange would provide diol 367. Finally, oxidative cleavage would afford the 
precursor for the NHK reaction. After the cyclisation, it was envisaged that the previous 
sequence would be followed using this time the enantiomer of stannane (+)-256, 
leading to the synthesis of hydroxycornexistin (2). It turned out not to be that 
straightforward. 
 
 
Scheme 2.57 
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Stille coupling and epimerisation issue 
 
The Stille coupling reaction proved highly reliable, affording (+)-365 in 95% yield 
(Scheme 2.58). Given that the enantiomeric purity of the chloride fragment (+)-347 
was 73% ee, the diastereomeric ratio of products observed was as expected (6.4:1). The 
two diastereoisomers could not be separated by column chromatography on silica gel or 
silica gel coated with silver nitrate. Following the previous synthesis, TBAF buffered 
with acetic acid was employed to remove the TIPS group on alkyne (+)-365 but in this 
case no reaction occurred. Depending on the quality of the TBAF used, an excess of 
acetic acid can reduce the reactivity of the TBAF. To avoid this problem, it was decided 
to attempt to remove the TIPS group using TBAF without buffer. The reaction was 
carefully monitored and quenched after 30 min at 0 ºC. The terminal alkyne 368 was 
obtained in 63% yield, but unfortunately, as a 1:1 mixture of inseparable 
diastereoisomers. This suggested that the unsaturated lactone moiety was sensitive to 
basic conditions. More importantly, the epimerisation at C-8 could not be observed in 
the racemic approach of the synthesis. The same result was obtained with the use of a 
new bottle of TBAF buffered with acetic acid, confirming the high sensitivity of the α,β-
unsaturated lactone. 
 
 
Scheme 2.58 – Reagents & conditions: a) Pd2(dba)3 (6 mol%), AsPh3 (25 mol%), THF, 70 ºC [95%, 
dr 6.4:1]; b) n-Bu4NF, THF, 0 ºC [63%, dr 1:1]; c) n-Bu4NF, AcOH, 0 ºC to rt [57%, dr 1:1]. 
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The TIPS-protected alkyne (+)-365 was next subjected to alternative fluoride sources; 
however similar results were obtained for both TBAT and TAS-F (275) (Scheme 2.59). 
Treatment of (+)-365 under acidic conditions, using hydrofluoric acid, cleaved the 
acetonide after three days without any effect on the TIPS group. 
 
 
Scheme 2.59 – Reagents & conditions: a) TBAT, THF, 0 ºC to rt [dr 1:1 from 1H NMR analysis of 
the crude mixture]; b) TAS-F, DMF, 0 ºC to rt [44%, dr 1:1]; c) HF (5% in MeCN), MeCN, 0 ºC to rt 
[67%]. 
 
An interesting silver(I)-catalysed protodesilylation of TMS-protected alkyne was 
reported by Carpita et al. using a catalytic amount of silver nitrate169 and so this 
reaction was investigated. Unfortunately, application of this methodology to the 
deprotection of (+)-365 afforded only recovered starting material (Scheme 2.60). The 
difficulty of cleaving a TIPS-protected acetylene using silver sources was emphasized by 
the studies of Kim, who reported the use of silver(I) fluoride.170 Under these conditions, 
terminal alkyne (+)-368 could be isolated without epimerisation, albeit in only 29% 
yield. 
 
 
Scheme 2.60 – Reagents & conditions: a) AgNO3 (10 mol%), H2O, acetone, rt [no reaction]; 
b) (i) AgF, MeCN, rt; (ii) HCl (1 M), 0 ºC [29%]. 
 
Modification of the post-coupling strategy 
 
The unsaturated lactone was highly sensitive to epimerisation, and it was therefore 
decided to reduce the lactone to the diol 372 prior to desilylation (Scheme 2.61). In 
terms of strategy, the NHK cyclisation had always been conducted in presence of the 
α,β-unsaturated lactone; without it, the selectivity of the NHK cyclisation would be 
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unknown. Apart from this, the overall strategy remained similar; the NHK precursor 
would be obtained by oxidative cleavage of diol 371. Conversion of the vinyl iodide to 
protected alkyne would lead to 372. The bis-protected diol 372 would be obtained via 
reduction of the α,β-unsaturated lactone and subsequent protection of the diol. From 
previous studies,41 protection of both hydroxyl groups as PMB-ethers was the first 
choice. 
 
 
Scheme 2.61 
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Reduction of the unsaturated lactone and protection of the 
diol 
 
The reduction of similar α,β-unsaturated lactones has been described by Northall, 
Marlin41,60 (cf. Section 1.4.2) and Masse and co-workers58 as a difficult reaction. After 
significant effort to optimise the reaction conditions, the best yield was obtained by use 
of conditions reported by Marlin: LiAlH4 and TMEDA, and warming the reaction mixture 
progressively from −78 to 0 ºC (Scheme 2.62).  
 
 
Scheme 2.62 – Reagents & conditions: a) LiAlH4, TMEDA, Et2O, −78 ºC to 0 ºC [53%]. 
 
A two-step reduction—protection approach could have been envisaged, but the reaction 
generated substantial amounts of side products. The formation of furan or acetal side- 
product was expected, but isolation of one of the reaction’s side-products revealed the 
presence of the [1,4]-reduced lactone (+)-374 which had not been reported before 
(Figure 2.2). Furthermore, the desired product (+)-373 was obtained as an inseparable 
mixture of two products. Although the second product could not be purified for 
complete characterisation, it is most likely the diol 375 obtained following [1,4]-
reduction. The ratio between those two products, (+)-373 and 375, was highly 
dependent on the reduction conditions, especially the temperature. Using LiAlH4—
TMEDA or DIBAL-H—LiAlH4 protocols, the ratio (6:1) was largely in favour of the desired 
diol (+)-373. Refluxing LiAlH4 in diethylether
171 decreased the ratio of the reaction to 
2.2:1. The use of Red-Al in THF at 60 ºC171 even reversed the ratio to 1:2 in favour of 
the reduced diol 375. Reduction with DIBAL-H followed by the addition of NaBH4 could 
possibly lead to better results but this reaction was not explored.172 
 
 
Figure 2.2 
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In 2008, the group of Slater and Xie at GlaxoSmithKline reported a unique set of 
conditions for the reduction of a methyl ester, using sodium borohydride and 5 mol% of 
NaB(OAc)3H (Scheme 2.63).
173 When these conditions were implemented on (+)-365, 
only starting material was recovered.  
 
 
Scheme 2.63 – Reagents & conditions: a) NaBH4, NaB(OAc)3H (5 mol%), MeOH, THF, 78 ºC [89%]. 
 
Diol (+)-373 was then protected as the bis-PMB ether (Scheme 2.64) in moderate yield 
through nucleophilic substitution of PMBCl. Interestingly, when a large excess of sodium 
hydride was used in the reaction, the terminal alkyne (+)-378 was obtained directly. 
This was observed on a small scale but was not reproducible. The use of TBAF resulted 
in removal of the TIPS-silyl group, to furnish terminal alkyne (+)-378 in good yield.  
 
 
Scheme 2.64 – Reagents & conditions: a) PMBCl, NaH, n-Bu4NI (12 mol%), DMF, 0 ºC to rt [55%]; 
b) n-Bu4NF, THF, 0 ºC [96%]. 
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 Conversion of the terminal alkyne to vinyl halide 
 
During the synthesis of the racemic NHK cyclisation precursor, the formation of the vinyl 
iodide unit was accomplished using a palladium-catalysed hydrostannylation reaction 
followed by tin-halogen exchange (cf. Section 2.2.3). With the reduction of the lactone 
and the presence of the acetonide unit, it was thought that the use of alternative 
methods could allow formation of the vinyl iodide from substrate (+)-378 (Table 2.12). 
In agreement with the synthesis of racemic material, the hydro-iodination conditions 
using sodium iodide resulted in the decomposition of the starting alkyne (+)-378 
(entries 1 and 2). Acetonide cleavage, consequent to the formation of hydroiodic acid 
during the reaction was expected, but the PMB-ethers did not survive the reactions 
conditions either. Hoveyda and co-workers reported the hydroalumination of alkynes, 
catalysed by a nickel complex, to form the internal vinyl aluminium species.174 The 
corresponding vinyl halide was obtained by the addition of NIS in the mixture. The same 
conditions were adopted for reaction of substrate (+)-378, but only starting material 
was recovered in this case (entry 3). 
 
 
entry conditions  result 
1 NaI, TMSCl, H2O, rt  decomposition 
2 NaI, CeCl3·7H2O, MeCN, reflux   decomposition 
3 
(i) DIBAL-H, Ni(dppp)Cl2 (3 mol%), THF, 
reflux to rt; (ii) NIS, THF, 0 ºC 
 77% recovery 
 
Table 2.12 
 
The ruthenium-catalysed hydrosilylation reaction was attempted again, using a different 
silyl group (Scheme 2.65).175 Following Trost’s protocol,112b,112c the internal silane 
(+)-380 was obtained in good yield. Unfortunately, the subsequent silicon/halogen 
exchange reaction failed, using iodine or iodine monochloride176 and both reactions 
resulted in decomposition of the vinylic silane with no evidence of vinyl iodide 
formation.  
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Scheme 2.65 – Reagents & conditions: a) HSi(OTMS)2Me, Cp*Ru(CH3CN)3PF6 (5 mol%), CH2Cl2, 0 ºC 
to rt [68%]; b) I2, CH2Cl2, 0 ºC to rt; c) ICl, THF, 0 ºC to rt. 
 
Conversion of the terminal alkyne to vinyl iodide using 
palladium-catalysed stannylation reactions 
 
The palladium-catalysed hydrostannylation reaction, having proved high-yielding and 
regioselective previously (cf. Scheme 2.21), was applied to alkyne (+)-378 (Scheme 
2.66). After the hydrostannylation reaction, the ratio between the internal and external 
regioisomers was difficult to determine. The subsequent metal halogen exchange 
reaction was attempted, using iodine in dichloromethane on the mixture of isomers. 
However, even when the reaction mixture was maintained at 0 ºC, the PMB-ether 
groups and acetonide were not stable, and only small amounts of 381 and 382 could be 
isolated, as an inseparable mixture. Based on 1H NMR analysis, equimolar amounts of 
the two regioisomers were produced at this stage.  
 
 
Scheme 2.66 – Reagents & conditions: a) Bu3SnH, Pd(PPh3)4 (5 mol%), THF, rt; b) I2, CH2Cl2, 0 ºC 
[<9%, 381—382 (1:1)]. 
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Reduction of the unsaturated lactone had a dramatic impact on the regioselectivity of 
the palladium-catalysed hydrostannylation reaction. However, the sequence of 
palladium-catalysed silylstannylation followed by TMS removal using TBAF that had been 
unsuccessful during the synthesis of racemic material due to the presence of the 
unsaturated lactone could now be attempted (cf. Section 2.2.3, Table 2.4). The 
acetonide was cleaved using p-TSA177 to afford the 1,2-diol and subsequent palladium-
catalysed silylstannylation furnished (−)-383 in 66% yield (Scheme 2.67). 
 
 
Scheme 2.67 – Reagents & conditions: a) p-TSA, MeOH, rt [95%]; b) 272, Pd(PPh3)4 (5 mol%), 
THF, 70 ºC [66%]. 
 
This time, using Fürstner’s conditions,117 desilylation of (−)-383 using TBAF was 
accomplished without decomposition of the molecule (Scheme 2.68). However, the 
reaction required careful monitoring to minimise the formation of the destannylated 
product. The vinyl iodide (−)-384 was subsequently formed at −78 ºC using NIS,178 again 
with no sign of decomposition. 
 
 
Scheme 2.68 – Reagents & conditions: a) n-Bu4NF, DMSO, 80 ºC [77%]; b) NIS, CH2Cl2, −78 ºC 
[96%]. 
 
At this stage only a small amount of material was available for the intramolecular NHK 
reaction, and only one attempt to perform the reaction could be made. Oxidative 
cleavage of diol (−)-384 provided the corresponding aldehyde smoothly and in a good 
yield (Scheme 2.69).179 The conditions previously demonstrated to be optimal (cf. 
Section 2.2.4) for the NHK reaction were applied to the aldehyde, providing a mixture 
that was difficult to purify, especially due to the small scale of the reaction. Around 
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25% yield of the desired cyclised product could be isolated as an inseparable mixture of 
two diastereoisomers 385 (dr 3:1). The presence of homocoupled aldehyde in the 
mixture suggested that performing the reaction at lower concentration would have 
probably been beneficial. Unfortunately, there was insufficient quantity of substrate to 
permit a comprehensive study of this reaction.  
 
 
Scheme 2.69 – Reagents & conditions: a) NaIO4, MeOH, H2O, 0 ºC [73%]; b) CrCl2 (10 equiv), 
NiCl2 (10 mol%), DMSO (0.007 M), 25 ºC [ca 25%, dr 3:1]. 
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2.4 Summary and Future work 
 
There has been an abundance of work from several research groups concerning the 
synthesis of the cornexistins and despite their apparent simple structure, the first total 
synthesis remains elusive. The first generation synthesis showed that the formation of 
the nine-membered ring could be achieved by NHK coupling (Scheme 2.70). The 
formation of the nine-membered ring was possible from 262-syn and 262-anti, and the 
diastereoisomeric mixture obtained proved that the natural C-5 configuration of 
cornexistins could be installed. 
 
 
Scheme 2.70 
 
An asymmetric synthesis was also investigated (Scheme 2.71). The strength of the 
enantioselective strategy is the possible large scale synthesis of both chloride and 
stannane fragments, followed by their union through an efficient Stille coupling 
reaction. Epimerisation problems at C-8 necessitated a change in the post-coupling 
strategy, with reduction of the α,β-unsaturated lactone and protection of the diol to 
form (+)-386. After protecting group removal, a palladium-catalysed silylstannylation 
reaction, followed by TMS removal using TBAF, and tin-halogen exchange allowed 
formation of vinyl iodide (−)-384. Finally, a first approach to the intramolecular NHK 
reaction could be attempted on the aldehyde derived from (−)-384, and the ratio of 
diastereoisomers obtained from the reaction seemed to indicate a similar behaviour to 
that of the corresponding racemic intermediate. However, ending the project at such 
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an exciting stage is deeply frustrating. Improvements and a proposed strategy for the 
completion of the synthesis will be described briefly in the following section. 
 
 
Scheme 2.71 
 
2.4.1 Improvements to the syntheses of the chloride and stannane 
fragments 
 
Asymmetric allylic alcohol synthesis  
 
Although the chloride fragment synthesis was high-yielding, the method for the 
asymmetric synthesis of allylic alcohol (+)-314 was difficult and unsatisfactory in terms 
of purity (Scheme 2.72). Accordingly, the method  optimized by Ibrahim et al.143 using a 
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specific strain of yeast to reduce selectively 3-chlorobutan-2-one 317 would certainly 
allow for an easier access to alcohol (+)-314, with improved purity. 
 
 
Scheme 2.72 – a) DHP, PPTS (10 mol%), CH2Cl2, rt; b) DIBAL-H, CH2Cl2, −78 ºC; c) PPh3MeBr, 
KOt-Bu, THF, rt; d) p-TSA (5 mol%), ethylene glycol, rt [56% over 4 steps]; 
 
Alternatively, enone 326 is easily accessible and CBS reduction of this compound could 
be envisaged to introduce the desired stereocentre (Scheme 2.73).140-141 
 
 
Scheme 2.73 – Reagents & conditions: a) LiAlH4, THF, −78 ºC to rt; b) MnO2, CH2Cl2, rt; c) TBSCl, 
imidazole, DMAP, CH2Cl2, rt; d) 1-(triphenylphosphoranylidene)acetone, toluene, 100 ºC [57% 
(4 steps)]. 
 
Asymmetric stannane synthesis  
 
Considering the work done so far, the use of a chiral auxiliary offered an efficient 
approach to the enantioselective synthesis of hydroxycornexistin. Its preparation could 
be conducted on large scale with a single purification step (Scheme 2.74). Direct 
condensation of the proline derivative proved to be less efficient than the method 
previously described by Northall and Marlin,41,60 which should be the method of choice. 
The subsequent alkylation was not as highly selective as it could have been in the case 
of a C-2 symmetrical auxiliary, but the yield was high, and the diastereoisomers 
obtained were separable. 
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Scheme 2.74 
 
2.4.2 Coupled fragments and future work 
 
Improvement of the reduction—protection sequence 
 
The reduction—protection sequence remains to be improved (Scheme 2.75). Although 
lactone reduction with lithium aluminium hydride and TMEDA gave respectable results, 
milder conditions like DIBAL-H—NaBH4 might avoid the formation of the undesired 1,4-
reduction products.180 
 
 
Scheme 2.75 – Reagents & conditions: a) LiAlH4, TMEDA, Et2O, −78 ºC to 0 ºC [53%]; b) PMBCl, 
NaH, n-Bu4NI (12 mol%), DMF, 0 ºC to rt [55%]; b) TBAF, THF, 0 ºC [96%]. 
 
Diastereoselectivity of the NHK 
 
For the NHK cyclisation, a closer study of the dilution factor is needed to improve the 
yield of the reaction. If the yield of the cyclisation reaction is actually improved for the 
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model substrate, a similar yield could be obtained with the desired C-8 isomer 389 
(Scheme 2.76), and its synthesis could be accomplished. This would require starting 
from the more expensive D-proline, but all the steps in the reaction sequence leading to 
the NHK are operational. The diastereoselectivity of the NHK reaction could be 
improved using a chiral ligand, or by further investigating an oxidation—reduction 
sequence analogous to that attempted during the first generation synthesis (cf. Scheme 
2.24). For the completion of the target, Sharpless epoxidation should be a suitable 
method for the kinetic resolution of the mixture (Scheme 2.76). The use of diethyl 
tartrate (−)-390 would furnished the desired epoxide 391,181 and the undesired 
diastereoisomer 392 could be recovered and converted to the desired diastereoisomer 
via a Mitsunobu inversion sequence.  
 
 
Scheme 2.76 
 
Although the inversion of the C-5 stereocentre has been attempted by Northall and 
found to be problematic, the substrates are different (cf. Section 1.4.4).41 In this case, 
the alcohol 392 is allylic and there is a literature precedent for inversion of 
configuration in related systems.182 Using p-nitrobenzoic acid and DIAD, the C-5 
stereocentre could be inverted to provide 391 after epoxidation (Scheme 2.77).  
 
 
Scheme 2.77 
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Completion of the total synthesis of hydroxycornexistin 
 
The final steps of the synthesis are proposed below (Scheme 2.78). There is a precedent 
in the literature for the PMB protection of an alcohol in the presence of an epoxide, 
followed by basic epoxide hydrolysis.183 Subsequent oxidative cleavage of the diol would 
deliver ketone 394. Finally, the furan oxidation—deprotection sequence has already 
been achieved by Northall during his synthesis of 5-epi-hydroxycornexistin.41,51b 
 
 
Scheme 2.78 
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Alternative to the NHK cyclisation 
 
In 2006, the group of Takai reported the hydrochromination of alkynes using a nickel 
catalyst. The reductive couplings of alkynes and aldehydes shown were mostly 
intermolecular aside from the reaction shown in Scheme 2.79.184 The substrate 398 
presents a considerable challenge (nine-membered ring) when compared with the 
reported example 396 (five-membered ring) but this approach is worth considering, 
given the efficiency that would be achieved. 
 
 
Scheme 2.79 – Reagents & conditions: a) CrCl2, H2O, NiCl2 (cat.), PPh3 (cat.), DMF, 25 ºC 
[64%].
184 
  
 124 
Part III: Experimental part 
 
General remarks 
 
Air and/or moisture sensitive reactions were performed under an atmosphere of Argon 
in flame dried apparatus. Organic solvents were dried using a Pure Solv™ solvent 
purification system (SPS). All reagents were purchased from commercial suppliers and 
used without further purification, unless otherwise stated. All reactions were monitored 
by thin layer chromatography using Merck silica gel 60 covered alumina plates F254. Thin 
layer chromatography plates were viewed under UV light or were visualised using either 
potassium permanganate solution or acidic ethanolic anisaldehyde solution. Column 
chromatography was performed under pressure using silica gel (Fluorochem LC60A, 35-
70 micron, 60 Å) as solid support and HPLC-graded solvents as eluent. Petroleum ether 
used for column chromatography was 40—60 ºC fraction. 
IR spectra were recorded using a type IIa diamond single reflection element on a 
Shimadzu FTIR-8400 instrument. The IR spectrum of the compound (solid or liquid) was 
directly detected as a thin layer at ambient temperature. 
1H NMR spectra were recorded on a Bruker 400 MHz or 500 MHz Spectrospin 
spectrometer at ambient temperature. IUPAC numbering is used for the molecule 
names. Numbers assigned for the molecule characterisations are not related to the 
name of the molecule. Data are reported as follows: chemical shift in ppm relative to 
CDCl3 (7.26) on the δ scale, integration, multiplicity (s = singlet, d = doublet, t = triplet, 
q = quartet, p = pentet, m = multiplet, br = broad, app = apparent or a combination of 
these), coupling constant(s) J (Hz) and assignment. 13C NMR spectra were recorded on a 
Bruker 400 MHz or 500 MHz Spectrospin spectrometer at 101 MHz or 126 MHz at ambient 
temperature and multiplicities were obtained using a DEPT sequence. Data are reported 
as follows: chemical shift in ppm relative to CHCl3 (77.16) on the δ scale and 
assignment. High resolution mass spectra (HRMS) were obtained under EI, FAB, CI and 
ESI conditions by the analytical services of the University of Glasgow on a Jeol MStation 
JMS-700 instrument. Low resolution mass spectra (LRMS) were carried out on the same 
instrument; the intensity of each peak is quoted as a percentage of the largest, where 
this information was available. 
Elemental analyses were carried out on an Exeter Analytical Elemental Analyser EA 440. 
Melting points were recorded with an Electrothermal IA 9100 apparatus. 
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1-[4-(tert-Butyldimethylsilyloxy)methylfuran-3-yl]butan-1-ol (240) 
 
 
To a suspension of LiAlH4 (4.74 g, 125 mmol, 2.30 equiv) in THF (200 mL) at −78 ºC was 
added a solution of diester 127 (10.0 g, 54.3 mmol) in THF (200 mL) over 20 min at 
−78 ºC. The solution was gently warmed to rt over 2 h and stirred overnight. The 
reaction was cooled to 0 ºC and quenched carefully with successively water (4.7 mL), 
aqueous NaOH (1 M, 4.7 mL) and water (13 mL). After warming up to rt and stirring for 
1 h, a cloudy white suspension was formed. MgSO4 (ca 15 g) was added and the mixture 
was filtered through a pad of Celite and washed with EtOAc (1 L). After concentration in 
vacuo, the pale yellow oil obtained was used directly for the next step. 
To a solution of the crude oil obtained (6.95 g, ~54.3 mmol) in CH2Cl2 (450 mL) was 
added activated MnO2 (28.3 g, 326 mmol, 6.00 equiv) at rt. The mixture was stirred 
vigorously for 2.5 h and MnO2 (9.50 g, 108 mmol, 2.00 equiv) was added 3 times at 
regular intervals. The black suspension was then filtered through a pad of Celite and 
washed with CH2Cl2 (1.5 L). After concentration in vacuo, the crude yellow oil was 
separated in two fractions: A (3.46 g) and B (3.72 g) and used in the next step without 
any further purification. 
To a solution of the crude aldehyde A (3.46 g, ~27.5 mmol) in CH2Cl2 (250 mL), 
imidazole (2.24 g, 33.0 mmol, 1.20 equiv), DMAP (336 mg, 2.75 mmol, 0.100 equiv) and 
TBSCl (4.55 g, 30.2 mmol, 1.10 equiv) were added sequentially. The solution was stirred 
for 20 min at rt, before water (60 mL) was added. The phases were separated, the 
aqueous phase was extracted with CH2Cl2 (2 × 60 mL) and the organic extracts were 
combined, washed with brine (100 mL), dried over MgSO4, filtered and concentrated in 
vacuo. The pale yellow oil was used immediately in the next step. 
To a solution of the silylated aldehyde 128 (~27.5 mmol) in THF (250 mL) at −78 ºC was 
added dropwise n-propylmagnesium chloride (23.3 mL of a 1.0 M solution in THF, 
46.7 mmol, 1.70 equiv). The solution was stirred at −78 ºC for 1.5 h, warmed to 0 ºC and 
the reaction was quenched with saturated aqueous NH4Cl (35 mL). Water (35 mL) and 
Et2O (60 mL) were added and the phases separated. The aqueous phase was extracted 
with Et2O (2 × 60 mL), the organic extracts washed with brine (120 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The crude oil was purified by flash column 
chromatography (PE—Et2O, 9:1) to give the desired colourless oil. 
The same procedure was adapted for aldehyde B, affording once combined 10.7 g (69% 
over 4 steps) of the corresponding alcohol 240. 
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C15H28O3Si     Molecular weight: 284.47 g·mol
−1 
Rf = 0.34 (PE—Et2O, 9:1); 
IR νmax 3349, 2955, 2929, 2858, 1749, 1521 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.30 (2H, s, CH-C2 and CH-C5), 4.65 (1H, d, J = 12.2 Hz, 
CH2-C10), 4.61 (1H, d, J = 12.2 Hz, CH2-C10), 4.60 (1H, dt, J = 7.9, 5.6 Hz, CH-C6), 3.58 
(1H, d, J = 5.6 Hz, OH), 1.84 (1H, dddd, J = 13.4, 9.8, 7.9, 5.5 Hz, CH2-C7), 1.73 (1H, 
dddd, J = 13.4, 9.8, 5.9, 5.6 Hz, CH2-C7), 1.57—1.48 (1H, m, CH2-C8), 1.43—1.34 (1H, 
m, CH2-C8), 0.96 (3H, t, J = 7.4 Hz, CH3-C9), 0.91 (9H, s, 3×CH3-tBu), 0.12 (3H, s, CH3-
SiMe2), 0.12 (3H, s, CH3-SiMe2); 
13C NMR (101 MHz, CDCl3) δ 140.6 (CH-C2 or CH-C5), 140.1 (CH-C2 or CH-C5), 128.5 (C-
C3 or C-C4), 123.7 (C-C3 or C-C4), 65.8 (CH-C6), 56.8 (CH2-C10), 38.5 (CH2-C7), 26.0 
(3×CH3-tBu), 19.5 (CH2-C8), 18.4 (C-tBu), 14.1 (CH3-C9), −5.2 (CH3-SiMe2),  −5.2 (CH3-
SiMe2); 
LRMS (CI, Me3CH): m/z (int) 267 (31), 135 (49), 107 (9), 89 (100), 69 (20). HRMS (CI, 
Me3CH) calculated for C15H27O2Si [M−OH]
+: 267.1780, found 267.1775, Δ −1.9 ppm. 
 
1-[4-(tert-Butyldimethylsilyloxy)methylfuran-3-yl]butan-1-one (399) 
 
 
To a solution of alcohol 240 (522 mg, 1.94 mmol) in CH2Cl2 (20 mL) was added activated 
MnO2 (3.43 g, 38.9 mmol, 20.0 equiv). The mixture was stirred at rt for 2 h, then 2 h at 
reflux, and stirred overnight at rt. The suspension was filtered through a pad of Celite 
and washed with CH2Cl2 (500 mL). The filtrate was concentrated in vacuo and the 
residue was purified by flash column chromatography (PE—Et2O, 95:5), affording the 
desired ketone 399 (468 mg, 86%) as a colourless oil. 
C15H26O3Si     Molecular weight: 282.45 g·mol
−1 
Rf = 0.63 (PE—Et2O, 9:1); 
IR νmax 2957, 2929, 2885, 2858, 2361, 1676, 1535, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.98 (1H, d, J = 1.7 Hz, CH-C2), 7.40 (1H, dd, J = 1.7, 
1.7 Hz, CH-C5), 4.87 (2H, d, J = 1.7 Hz, CH2-C10), 2.69 (2H, t, J = 7.3 Hz, CH2-C7), 1.72 
(2H, qt, J = 7.4, 7.3 Hz, CH2-C8), 0.97 (3H, t, J = 7.4 Hz, CH3-C9), 0.93 (9H, s, 
3×CH3-tBu), 0.10 (6H, s, 2×CH3-SiMe2); 
13C NMR (101 MHz, CDCl3) δ 196.3 (C-C6), 148.5 (CH-C2 or CH-C5), 141.6 (CH-C2 or CH-
C5), 127.1 (C-C3 or C-C4), 125.4 (C-C3 or C-C4), 58.8 (CH2-C10), 42.3 (CH2-C7), 26.1 
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(3×CH3-tBu), 18.5 (C-tBu), 17.9 (CH2-C8), 14.0 (CH3-C9), −5.3 (CH3-SiMe2), −5.3 (CH3-
SiMe2); 
LRMS (CI, Me3CH): m/z (int) 283 (46), 225 (8), 89 (100), 69 (10). HRMS (CI, Me3CH) 
calculated for C15H27O3Si [M+H]
+: 283.1729, found 283.1732, Δ +0.7 ppm. 
 
tert-Butyldimethyl[4-(pent-1-en-2-yl)furan-3-yl]methoxysilane (241) 
 
 
To a suspension of methyltriphenylphosphonium bromide (2.87 g, 8.03 mmol, 
5.00 equiv) in THF (7.5 mL) at 0 ºC was added dropwise a solution of NaHMDS (6.4 mL of 
a 1.0 M solution in THF, 6.4 mmol, 4.0 equiv). The bright yellow suspension was warmed 
to rt and stirred for 1 h, before being cooled down to 0 ºC. A solution of ketone 399 
(453 mg, 1.60 mmol) in THF (7 mL) was added dropwise and the mixture was stirred for 
1 h at rt. The reaction was quenched by the addition of saturated aqueous NH4Cl 
(10 mL) and the mixture was diluted with Et2O (30 mL). The phases were separated and 
the aqueous phase was extracted with Et2O (2 × 20 mL). The organic extracts were 
combined, washed with brine (40 mL), dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography (PE—Et2O, 99:1) to 
give the corresponding 1,1-disubstituted alkene 241 (426 mg, 95%) as a colourless oil. 
C16H28O2Si     Molecular weight: 280.48 g·mol
−1 
Rf = 0.91 (PE—Et2O, 95:5); 
IR νmax 2957, 2930, 2857, 1636, 1585, 1535, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.36 (1H, s, CH-C2), 7.34 (1H, s, CH-C5), 5.12 (1H, s, CH2-
C10), 5.00 (1H, d, J = 0.9 Hz, CH2-C10), 4.63 (2H, s, CH2-C11), 2.29 (2H, t, J = 7.4 Hz, 
CH2-C7), 1.51 (2H, qt, J = 7.4, 7.4 Hz, CH2-C8), 0.94—0.89 (12H, m, CH3-C9 and 3×CH3-
tBu), 0.08 (6H, s, 2×CH3-SiMe2); 
13C NMR (101 MHz, CDCl3) δ 141.4 (CH-C5), 140.5 (CH-C2), 139.8 (C-C6), 125.7 (C-C3 or 
C-C4), 124.7 (C-C3 or C-C4), 112.6 (CH2-C10), 57.6 (CH2-C11), 38.6 (CH2-C7), 26.0 
(3×CH3-tBu), 21.5 (CH2-C8), 18.5 (C-tBu), 14.0 (CH3-C9), −5.1 (2×CH3-SiMe2); 
HRMS (ESI) calculated for C16H28NaO2Si [M+Na]
+: 303.1751, found 303.1744, Δ −2.2 ppm. 
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2-[4-(tert-Butyldimethylsilyloxymethyl)furan-3-yl]pentan-1-ol (242) 
 
 
To a solution of 1,1-disubstituted alkene 241 (1.07 g, 3.83 mmol) in THF (4 mL), cooled 
to 0 ºC, was added dropwise a solution of 9-BBN (23.0 mL of a 0.5 M solution in THF, 
11.5 mmol, 3.01 equiv). The reaction was then warmed to 65 ºC for 75 min, cooled to 
0 ºC before careful addition of EtOH (18 mL) and aqueous NaOH (3 M, 11.5 mL). After 15 
min, aqueous H2O2 (30%, 18 mL) was added. The mixture was heated at reflux for 1 h, 
cooled to rt before the addition of Et2O (60 mL) and water (20 mL). The phases were 
separated and the aqueous phase was extracted with Et2O (2 × 50 mL). The organic 
extracts were combined and washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography 
(PE—Et2O, 9:1) to give the desired primary alcohol 242 (1.01 g, 88%) as a colourless oil. 
C16H30O3Si     Molecular weight: 298.49 g·mol
−1 
Rf = 0.18 (PE—Et2O, 9:1); 
IR νmax 3381, 2955, 2929, 2858, 1602, 1541, 1471, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.33 (1H, d, J = 1.6 Hz, CH-C5), 7.23 (1H, d, J = 1.6 Hz, CH-
C2), 4.55 (2H, d, J = 1.0 Hz, CH2-C11), 3.73 (1H, ddd, J = 10.8, 6.6, 4.9 Hz, CH2-C10), 
3.61 (1H, ddd, J = 10.8, 7.3, 6.0 Hz, CH2-C10), 2.83—2.75 (1H, m, CH-C6), 2.17 (1H, dd, 
J = 6.3, 6.0 Hz, OH), 1.67—1.57 (1H, m, CH2-C7), 1.56—1.48 (1H, m, CH2-C7), 1.38—1.27 
(2H, m, CH2-C8), 0.91 (9H, s, 3×CH3-tBu), 0.89 (3H, t, J = 5.9 Hz, CH3-C9), 0.10 (6H, s, 
2×CH3-SiMe2); 
13C NMR (126 MHz, CDCl3) δ 141.1 (CH-C5), 140.6 (CH-C2), 125.6 (C-C3 or C-C4), 124.9 
(C-C3 or C-C4), 66.8 (CH2-C10), 56.5 (CH2-C11), 38.1 (CH-C6), 33.8 (CH2-C7), 26.0 
(3×CH3-tBu), 20.8 (CH2-C8), 18.5 (C-tBu), 14.2 (CH3-C9), −5.2 (2×CH3-SiMe2); 
HRMS (ESI) calculated for C16H30NaO3Si [M+Na]
+: 321.1856, found 321.1846, Δ −3.1 ppm. 
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tert-Butyl-[4-(1-tert-butyldiphenylsilyloxypentan-2-yl)furan-3-yl]methoxy-
dimethylsilane (245) 
 
 
To a solution of alcohol 242 (1.72 g, 5.78 mmol) in CH2Cl2 (58 mL), DMAP (203 mg, 
2.98 mmol, 0.500 equiv), TBDPSCl (2.26 mL, 8.67 mmol, 1.50 equiv) and Et3N (1.37 mL, 
9.83 mmol, 1.70 equiv) were successively added at 0 ºC. The solution was stirred 
overnight at rt and quenched with saturated aqueous NH4Cl (20 mL). The phases were 
separated and the aqueous phase was extracted with CH2Cl2 (2 × 30 mL). The organic 
extracts were combined and washed with brine (40 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography 
(PE—CH2Cl2, 9:1) affording product 245 (2.81 g, 91%) as a colourless oil. 
C32H48O3Si2     Molecular weight: 536.89 g·mol
−1 
Rf = 0.50 (PE—CH2Cl2, 8:2); 
IR νmax 3073, 3049, 2955, 2930, 2857, 1589, 1541, 1471, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.59 (4H, ddd, J = 7.9, 4.9, 1.5 Hz, 4×CH-Ar), 7.44—7.33 
(6H, m, 6×CH-Ar), 7.27 (1H, d, J = 0.8 Hz, CH-C5), 7.17 (1H, d, J = 0.8 Hz, CH-C2), 4.45 
(2H, s, CH2-C11), 3.67 (1H, dd, J = 10.1, 5.8 Hz, CH2-C10), 3.63 (1H, dd, J = 10.1, 
6.4 Hz, CH2-C10), 2.75 (1H, dddd, J = 8.6, 6.4, 6.1, 5.8 Hz, CH-C6), 1.78 (1H, app ddt, 
J = 13.3, 9.7, 6.1 Hz, CH2-C7), 1.54—1.44 (1H, m, CH2-C7), 1.35—1.20 (2H, m, CH2-C8), 
1.02 (9H, s, 3×CH3-tBu), 0.90—0.84 (12H, m, 3×CH3-tBu and CH3-C9), 0.04 (3H, s, CH3-
SiMe2), 0.03 (3H, s, CH3-SiMe2); 
13C NMR (101 MHz, CDCl3) δ 140.4 (CH-C5 or CH-C2), 140.0 (CH-C2 or CH-C5), 135.8 
(2×CH-Ar), 135.7 (2×CH-Ar), 133.9 (2×C-Ar), 129.7 (CH-Ar), 129.7 (CH-Ar), 127.7 (4×CH-
Ar), 125.6 (C-C4 or C-C3), 125.5 (C-C4 or C-C3), 67.3 (CH2-C10), 56.9 (CH2-C11), 37.5 
(CH-C6), 34.0 (CH2-C7), 27.0 (3×CH3-tBu), 26.0 (3×CH3-tBu), 20.5 (CH2-C8), 19.4 (C-tBu), 
18.4 (C-tBu), 14.4 (CH3-C9), −5.2 (2×CH3-SiMe2); 
LRMS (CI, Me3CH): m/z (int) 537 (5), 461 (27), 447 (12), 405 (100), 133 (13). HRMS (CI, 
Me3CH) calculated for C32H49O3Si2 [M+H]
+: 537.3220, found 537.3221, Δ +0.1 ppm.  
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2-(4-Hydroxymethylfuran-3-yl)pentan-1-ol (246)
 
 
To a solution of the silylated product 245 (388 mg, 0.724 mmol) in MeOH (7 mL) was 
added CSA (50.4 mg, 0.217 mmol, 0.300 equiv) at rt and the mixture was stirred for 2 h 
at rt. K2CO3 (ca 100 mg) was added and the mixture was concentrated in vacuo. The 
residue was purified by flash column chromatography (PE—Et2O, 5:5 to 2:8) to give diol 
246 (40.0 mg, 30%) as a colourless oil. 
C10H16O3     Molecular weight: 184.23 g·mol
−1 
Rf = 0.25 (PE—Et2O, 2:8); 
IR νmax 3294, 2957, 2931, 2872, 2360, 1600, 1541, 1465 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.39 (1H, d, J = 1.5 Hz, CH-C5), 7.23 (1H, d, J = 1.5 Hz, CH-
C2), 4.46 (2H, s, CH2-C11), 3.79 (1H, dd, J = 10.2, 4.5 Hz, CH2-C10), 3.55 (1H, dd, 
J = 10.2, 8.5 Hz, CH2-C10), 3.18 (1H, br s, OH), 2.79 (1H, tdd, J = 8.5, 6.1, 4.5 Hz, CH-
C6), 2.67 (1H, br s, OH), 1.63—1.49 (2H, m, CH2-C7), 1.38—1.27 (2H, m, CH2-C8), 0.89 
(3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 141.4 (CH-C5), 140.3 (CH-C2), 126.3 (C-C3 or C-C4), 125.5 
(C-C3 or C-C4), 67.9 (CH2-C10), 54.9 (CH2-C11), 37.6 (CH-C6), 33.7 (CH2-C7), 20.8 (CH2-
C8), 14.2 (CH3-C9); 
HRMS (ESI) calculated for C10H16NaO3 [M+Na]
+: 207.0992, found 207.0995, Δ −1.4 ppm. 
 
tert-Butyl{4-[1-(4-methoxyphenyl)methoxypentan-2-yl]furan-3-
yl}methoxydimethylsilane (247) 
 
 
To a solution of alcohol 242 (54.8 mg, 0.184 mmol) in CH2Cl2 (1.8 mL) at rt was added 
freshly prepared PMBTCA (118 mg, 0.414 mmol, 2.25 equiv) and CSA (4.0 mg, 0.02 
mmol, 0.09 equiv). The mixture was stirred at rt for 48 h and the reaction was 
quenched with saturated aqueous NaHCO3 (5 mL). Et2O (15 mL) was added and the 
phases were separated. The aqueous phase was extracted with Et2O (2 × 10 mL). The 
organic extracts were combined, dried over MgSO4, filtered and concentrated in vacuo. 
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The crude product was purified by flash column chromatography (PE—Et2O, 95:5) 
affording PMB-ether 247 (26.9 mg, 35%) as a colourless oil. 
C24H38O4Si     Molecular weight: 418.64 g·mol
−1 
Rf = 0.93 (PE—Et2O, 8:2); 
IR νmax 2955, 2929, 2857, 2362, 2332, 1612, 1514, 1464 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.28 (1H, t, J = 0.9 Hz, CH-C5), 7.22 (2H, d, J = 8.7 Hz, 
2×CH-PMB), 7.18 (1H, d, J = 1.6 Hz, CH-C2), 6.87 (2H, d, J = 8.7 Hz, 2×CH-PMB), 4.53 
(2H, d, J = 0.9 Hz, CH2-C11), 4.42 (2H, s, CH2-PMB), 3.80 (3H, s, CH3-PMB), 3.51 (1H, dd, 
J = 9.1, 5.5 Hz, CH2-C10), 3.44 (1H, dd, J = 9.1, 7.0 Hz, CH2-C10), 2.83 (1H, app ddt, J = 
9.0, 7.0, 5.5 Hz, CH-C6), 1.74 (1H, app ddt, J = 13.3, 10.1, 5.5 Hz, CH2-C7), 1.49 (1H, 
app ddt, J = 13.3, 9.0, 5.2 Hz,  CH2-C7), 1.35—1.20 (2H, m, CH2-C8), 0.91 (9H, s, 3×CH3-
tBu), 0.87 (3H, t, J = 7.3 Hz, CH3-C9), 0.06 (6H, s, 2×CH3-SiMe2); 
13C NMR (126 MHz, CDCl3) δ 159.2 (C-PMB), 140.2 (CH-C2 or CH-C5), 140.2 (CH-C2 or 
CH-C5), 130.8 (C-PMB), 129.3 (2×CH-PMB), 125.6 (C-C3 or C-C4), 125.5 (C-C3 or C-C4), 
113.9 (2×CH-PMB), 74.0 (CH2-C10), 72.8 (CH2-PMB), 57.0 (CH2-C11), 55.4 (CH3-PMB), 
35.6 (CH-C6), 34.6 (CH2-C7), 26.1 (3×CH3-tBu), 20.6 (CH2-C8), 18.5 (C-tBu), 14.3 (CH3-
C9), −5.2 (2×CH3-SiMe2); 
HRMS (ESI) calculated for C24H38NaO4Si [M+Na]
+: 441.2432, found 441.2417, Δ +1.4 ppm.  
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[4-(1-tert-Butyldiphenylsilyloxypentan-2-yl)furan-3-yl]methanol (248) 
 
 
To a solution of silylated furan 245 (2.81 g, 5.24 mmol) in EtOH (18 mL) was added PPTS 
(660 mg, 2.62 mmol, 0.506 equiv) and the mixture was stirred overnight at 40 ºC. The 
reaction was quenched with saturated aqueous NaHCO3 (10 mL) and ethanol was 
removed in vacuo. The residue was diluted in Et2O (20 mL), the phases were separated 
and the aqueous phase was extracted with Et2O (2 × 10 mL). The organic extracts were 
combined and washed with brine (20 mL), dried over MgSO4, filtered and concentrated 
in vacuo. The crude product was purified by flash column chromatography (PE—Et2O, 
9:1) to give the desired alcohol 248 (2.09 g, 95%) as a colourless oil. 
C26H34O3Si     Molecular weight: 422.63 g·mol
−1 
Rf = 0.20 (PE—Et2O, 9:1); 
IR νmax 3366, 2042, 2893, 2866, 1757, 1600, 1541, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.62—7.53 (4H, m, 4×CH-Ar), 7.45—7.34 (7H, m, CH-C5, 
6×CH-Ar), 7.19 (1H, d, J = 1.5 Hz, CH-C2), 4.42 (2H, d, J = 5.4 Hz, CH2-C11), 3.72 (1H, 
dd, J = 9.8, 5.7 Hz, CH2-C10), 3.63 (1H, dd, J = 9.8, 7.0 Hz, CH2-C10), 2.81 (1H, ddt, 
J = 9.1, 6.8, 5.7 Hz, CH-C6), 1.95 (1H, t, J = 5.4 Hz, OH), 1.69 (1H, dddd, J = 13.1, 9.5, 
6.4, 5.7 Hz, CH2-C7), 1.54—1.42 (1H, m, CH2-C7), 1.37—1.20 (2H, m, CH2-C8), 1.02 (9H, 
s, 3×CH3-tBu), 0.87 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (101 MHz, CDCl3) δ 140.5 (CH-C5 or CH-C2), 140.5 (CH-C2 or CH-C5), 135.8 
(2×CH-Ar), 135.7 (2×CH-Ar), 133.4 (C-Ar), 133.4 (C-Ar), 129.8 (2×CH-Ar), 127.8 (2×CH-
Ar),127.7 (2×CH-Ar), 126.1 (C-C4 or C-C3), 125.4 (C-C4 or C-C3), 68.7 (CH2-C10), 55.5 
(CH2-C11), 37.3 (CH-C6), 34.0 (CH2-C7), 26.9 (3×CH3-tBu), 20.6 (CH2-C8), 19.3 (C-tBu), 
14.3 (CH3-C9); 
LRMS (CI, Me3CH): m/z (int) 405 (34), 365 (6), 341 (5), 265 (100), 237 (12), 217 (75) 135 
(9). HRMS (CI, Me3CH) calculated for C26H33O2Si [M−OH]
+: 405.2250, found 405.2252, 
Δ +0.5 ppm. 
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tert-Butyl[2-(4-chloromethylfuran-3-yl)pentyloxy]diphenylsilane (249) 
 
 
To a solution of allylic alcohol 248 (1.47 g, 3.48 mmol) in CH2Cl2 (12 mL) cooled to 0 ºC, 
Et3N (870 μL, 6.24 mmol, 1.80 equiv) and MsCl (405 μL, 5.21 mmol, 1.50 equiv), both 
freshly distilled, were successively added. The mixture was warmed to rt, stirred 
overnight and quenched with saturated aqueous NH4Cl (10 mL). The phases were 
separated and the aqueous phase was extracted with CH2Cl2 (2 × 15 mL). The organic 
extracts were combined and dried over MgSO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography (PE—CH2Cl2, 9:1) affording 
chloride 249 (1.38 g, 90%) as a colourless oil. 
C26H33ClO2Si     Molecular weight: 441.08 g·mol
−1 
Rf = 0.40 (PE—CH2Cl2, 9:1); 
IR νmax (cm
-1) 3071, 2943, 2910, 2862, 1589, 1543, 1460 cm−1; 
1H NMR (400 MHz, CDCl3) δ 7.61—7.57 (4H, m, 4×CH-Ar), 7.44—7.33 (7H, m, CH-C2, 
6×CH-Ar), 7.20 (1H, d, J = 1.5 Hz, CH-C5), 4.35 (2H, s, CH2-C11), 3.67 (2H, d, J = 5.8 Hz, 
CH2-C10), 2.82 (1H, dtd, J = 9.0, 5.8, 5.7 Hz, CH-C6), 1.81 (1H, dddd, J = 13.2, 9.3, 6.5, 
5.7 Hz, CH2-C7), 1.59—1.46 (1H, m, CH2-C7), 1.37—1.25 (2H, m, CH2-C8), 1.03 (9H, s, 
3×CH3-tBu), 0.90 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (101 MHz, CDCl3) δ 141.5 (CH-C2), 140.9 (CH-C5), 135.8 (2×CH-Ar), 135.7 
(2×CH-Ar), 133.8 (C-Ar), 133.7 (C-Ar), 129.8 (CH-Ar), 129.7 (CH-Ar), 127.8 (4×CH-Ar), 
126.1 (C-C3 or C-C4), 122.5 (C-C3 or C-C4), 67.8 (CH2-C10), 37.2 (CH-C6), 36.4 (CH2-
C11), 34.1 (CH2-C7), 27.0 (3×CH3-tBu), 20.6 (CH2-C8), 19.4 (C-tBu), 14.3 (CH3-C9); 
LRMS (CI, Me3CH): m/z (int) 441 (60), 405 (98), 363 (72), 241 (61), 227 (77), 185 (100), 
149 (45), 91 (31). HRMS (CI, Me3CH) calculated for C26H34
35ClO2Si [M+H]
+: 441.2017, 
found 441.2015, Δ −0.4 ppm. Analytic. calculated for C26H33ClO2Si: C, 70.80; H, 7.54. 
Found: C, 70.96; H, 7.59. 
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1-Bromo-3-(triisopropylsilyl)-2-propyne (251) 
 
 
To a solution of propargyl bromide 250 (3.0 mL of an 80% solution in toluene, 27 mmol) 
in THF (130 mL) at −78 ºC was added dropwise LiHMDS (32 mL of a 1.0 M solution in THF, 
32 mmol, 1.2 equiv). The solution was stirred for 15 minutes before the addition of 
TIPSCl (7.5 mL, 35 mmol, 1.3 equiv). After 3 h at −78 ºC, the solution was allowed to 
warm up to rt. The reaction was quenched with saturated aqueous NH4Cl (40 mL) and 
diluted with EtOAc (100 mL). The phases were separated and the aqueous phase was 
extracted with EtOAc (2 × 50 mL). The organic extracts were combined and washed with 
brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo. The residue was 
purified by flash column chromatography (PE) to give the desired TIPS-protected 
propargyl bromide 251 (7.19 g, 97%) as a colourless oil. 
C12H23BrSi    Molecular weight: 275.30 g·mol
−1 
Rf = 0.80 (PE—CH2Cl2, 95:5); 
IR νmax 2943, 2866, 2176, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 3.95 (2H, s, CH2-C1), 1.07 (21H, br s, 3×iPr); 
13C NMR (101 MHz, CDCl3) δ 102.0 (C-C2), 89.3 (C-C3), 18.7 (6×CH3-iPr), 15.2 (CH2-C1), 
11.5 (3×CH-iPr); 
LRMS (CI, Me3CH): m/z (int) 277 (4), 275 (2), 239 (9), 197 (100), 155 (31), 107 (30), 71 
(89). 
 
4-(Pyrrolidin-1-yl)furan-2(5H)-one (132)41 
 
 
To a solution of tetronic acid 131 (500 mg, 5.00 mmol) in toluene (25 mL) was added 
pyrrolidine (2.50 mL, 30.0 mmol, 6.00 equiv) at 0 ºC. The reaction was stirred for 
30 min before concentration in vacuo. The residue was re-dissolved in toluene (25 mL), 
and the process was repeated twice. The residue was then dried at 50 ºC under high 
vacuum for 3 h. A solid was formed which was filtered through a pad of neutral 
aluminium oxide (Brockmann I, PE—EtOAc, 5:5) to give 132 (622 mg, 81%) as a 
colourless solid. The data obtained matches that reported previously.41 
C8H11NO2    Molecular weight: 153.18 g·mol
−1 
mp. 120—123 ºC; 
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Rf = 0.26 (PE—EtOAc, 1:9); 
IR νmax 2929, 2870, 1712, 1602, 1431 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 4.67 (2H, s, CH2-C5), 4.52 (1H, s, CH-C3), 3.27 (4H, t, J = 
6.7 Hz, 2×CH2-C6), 2.02 (4H, p, J = 6.7 Hz, 2×CH2-C7); 
13C NMR (101 MHz, CDCl3) δ 175.8 (C-C2), 166.2 (C-C4), 80.7 (CH-C3), 67.1 (CH2-C5), 
49.4 (CH2-C6), 47.4 (CH2-C6), 25.8 (CH2-C7), 25.0 (CH2-C7); 
LRMS (EI+): m/z (int) 153 (100), 124 (19), 108 (16), 95 (50), 70 (22), 43 (43). HRMS (EI+) 
calculated for C8H11NO2 [M]
+: 153.0790, found 153.0792, Δ +1.3 ppm. 
  
4-(Pyrrolidin-1-yl)-5-(3-triisopropylsilylprop-2-ynyl)furan-2(5H)-one (252)
 
 
To a solution of 132 (653 mg, 4.27 mmol) in THF (6 mL) at −78 ºC was carefully added a 
solution of t-BuLi (4.0 mL of a 1.6 M solution in hexane, 6.4 mmol, 1.5 equiv). The 
reaction was stirred for 30 min before a solution of the protected propargyl bromide 
251 (5.88 g, 21.4 mmol, 5.00 equiv) in THF (8 mL) cooled to −78 ºC was carefully 
added. After 3 h, the reaction was allowed to warm up to rt over 45 min, and the 
reaction was quenched with saturated aqueous NH4Cl (10 mL) and diluted with EtOAc 
(20 mL). The phases were separated and the aqueous phase was extracted with EtOAc 
(2 × 10 mL). The organic extracts were combined, washed with brine (20 mL), dried 
over MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (PE—EtOAc, 7:3) to give the desired product 252 (1.34 g, 90%) 
as a colourless solid. 
C20H33NO2Si    Molecular weight: 347.57 g·mol
−1 
mp. 122—125 ºC; 
Rf = 0.23 (PE—EtOAc, 5:5); 
IR νmax 2941, 2865, 2179, 1721, 1610, 1673, 1462 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 4.95 (1H, dd, J = 4.5, 3.5 Hz, CH-C5), 4.55 (1H, s, CH-C3), 
3.32 (4H, br s, 2×CH2-C9), 3.00 (1H, dd, J = 17.8, 3.5 Hz, CH2-C6), 2.80 (1H, dd, J = 
17.8, 4.5 Hz, CH2-C6), 2.12—2.02 (2H, m, CH2-C10), 1.99—1.90 (2H, m, CH2-C10), 1.03 
(21H, s, 3×iPr); 
13C NMR (101 MHz, CDCl3) δ 173.9 (C-C2), 167.1 (C-C4), 100.6 (C-C7), 84.5 (C-C8), 83.3 
(CH-C3), 76.0 (CH-C5), 24.2 (CH2-C6), 18.7 (6×CH3-iPr), 11.3 (3×CH-iPr); 
Carbon peaks not appearing:  
- CH2-C9, CH2-C10; 
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LRMS (CI, Me3CH): m/z (int) 348 (98), 137 (61), 121 (51), 89 (94). HRMS (CI, Me3CH) 
calculated for C20H34NO2Si [M+H]
+: 348.2359, found 348.2364, Δ +1.4 ppm. Analytic. 
calculated for C20H33NO2Si: C, 69.11; H, 9.57; N, 4.03. Found: C, 69.07; H, 9.65; N, 4.09. 
 
5-Oxo-2-{3-[tris(propan-2-yl)silyl]prop-2-yn-1-yl}-2,5-dihydrofuran-3-yl 
trifluoromethanesulfonate ((±)-254) 
 
 
To a solution of 252 (1.83 mg, 5.27 mmol) was added a solution of hydrochloric acid in 
EtOH (1.2 M, 30 mL, 38 mmol, 7.1 equiv) at 0 ºC followed by water (3.00 mL). The 
mixture was heated at 78 ºC for 5 h, cooled to rt and diluted with water (10 mL) and 
Et2O (40 mL). The phases were separated, the aqueous phase was extracted with Et2O 
(2 × 20 mL) and the organic extracts washed with brine (20 mL), dried over MgSO4, 
filtered and concentrated in vacuo. After azeotropic removal of water with toluene (3 × 
50 mL), the orange residue was directly used in the next step. 
To a solution of the crude acid in CH2Cl2 (53 mL) at −78 ºC was added dropwise freshly 
distilled DIPEA (1.40 mL, 7.98 mmol, 1.51 equiv), and after 5 min triflic anhydride 
(1.15 mL, 6.84 mmol, 1.30 equiv). The dark red solution was stirred for 1 h at −78 ºC, 
then diluted with CH2Cl2 (30 mL) and warmed to rt. The reaction was quenched with 
water (20 mL) and the phases were separated. The aqueous phase was extracted with 
CH2Cl2 (2 × 20 mL), the organic extracts were combined, washed with brine (50 mL), 
dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified 
by flash column chromatography (PE—Et2O, 9:1 to 8:2) to afford triflate (±)-254 (1.82 g, 
81% over two steps) as a colourless solid. 
C17H25F3O5SSi    Molecular weight: 426.52 g·mol
−1 
mp. 42—43 ºC; 
Rf = 0.81 (PE—Et2O, 5:5); 
IR νmax 2947, 2870, 2176, 1767, 1643, 1435 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 6.08 (1H, d, J = 1.2 Hz, CH-C3), 5.07 (1H, ddd, J = 4.8, 3.5, 
1.2 Hz, CH-C5), 3.09 (1H, dd, J = 17.7, 4.8 Hz, CH2-C6), 2.84 (1H, dd, J = 17.7, 3.5 Hz, 
CH2-C6), 1.03 (21H, s, 3×iPr); 
13C NMR (101 MHz, CDCl3) δ 167.8 (C-C2), 167.2 (C-C4), 118.6 (q, J = 322 Hz, CF3), 
104.8 (CH-C3), 97.3 (C-C8), 87.1 (C-C7), 76.3 (CH-C5), 23.0 (CH2-C6), 18.6 (6×CH3-iPr), 
11.2 (3×CH-iPr); 
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LRMS (CI, Me3CH): m/z (int) 427 (26), 334 (11), 279 (32), 276 (21), 235 (15), 181 (11), 
133 (27), 97 (35), 71 (100). HRMS (CI, Me3CH) calculated for C17H26F3O5SSi [M+H]
+: 
427.1222, found 427.1223, Δ +0.1 ppm. Analytic. calculated for C17H25F3O5SSi: C, 47.87; 
H, 5.91. Found: C, 47.79; H, 5.96. 
 
5-(3-Triisopropylsilylprop-2-ynyl)-4-(tributylstannyl)furan-2(5H)-one (255) 
 
 
To triflate (±)-254 (492 mg, 1.15 mmol) in THF (12 mL) was added thoroughly flame-
dried LiCl (360 mg, 8.49 mmol, 7.36 equiv) and Pd(PPh3)4 (64 mg, 0.055 mmol, 0.048 
equiv). After 5 min, bis(tributyl)ditin (758 µL, 1.50 mmol, 1.30 equiv) was added and 
the mixture was heated at 60 ºC for 4 h then cooled to 0 ºC. The reaction was quenched 
with saturated aqueous NaHCO3 (10 mL) and the mixture was diluted with Et2O (30 mL). 
The phases were separated and the aqueous phase was extracted with Et2O (2 × 20 mL). 
The organic extracts were combined, washed with brine (50 mL), dried with Na2SO4, 
filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (PE—Et2O, 9:1 to 8:2) to give stannane 255 (207 mg, 32%) as a pale 
yellow oil. 
C28H52O2SiSn    Molecular weight: 567.51 g·mol
−1 
Rf = 0.53 (PE—Et2O, 8:2); 
IR νmax 2924, 2866, 2176, 1751, 1612, 1642, 1420 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 6.22 (1H, d, J = 1.8 Hz, CH-C3), 5.19 (1H, ddd, J = 4.8, 3.9, 
1.8 Hz, CH-C5), 3.06 (1H, dd, J = 17.3, 4.8 Hz, CH2-C6), 2.59 (1H, dd, J = 17.3, 3.9 Hz, 
CH2-C6), 1.57—1.47 (6H, m, 3×CH2-SnBu3), 1.38—1.28 (6H, m, 3×CH2-SnBu3), 1.13—1.07 
(6H, m, 3×CH2-SnBu3), 1.02 (21H, br s, 3×iPr), 0.91 (9H, t, J = 7.3 Hz, 3×CH3-SnBu3); 
13C NMR (101 MHz, CDCl3) δ 175.9 (C-C2), 172.6 (C-C4), 131.4 (CH-C3), 100.5 (C-C8), 
86.3 (CH-C5 and C-C7),  29.1 (3×CH2-SnBu3), 27.4 (3×CH2-SnBu3), 25.2 (CH2-C6), 18.7 
(6×CH3-iPr), 13.7 (3×CH2-SnBu3), 11.3 (3×CH-iPr), 10.1 (3×CH3-SnBu3); 
LRMS (CI, Me3CH): m/z (int) 569 (14), 513 (25), 279 (100), 69 (98). HRMS (CI, Me3CH) 
calculated for C28H53O2Si
120Sn [M+H]+: 569.2842, found 569.2831, Δ −1.1 ppm. 
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4-Trimethylstannyl-5-{3-[tris(propan-2-yl)silyl]prop-2-yn-1-yl}-2,5-dihydrofuran-2-
one ((±)-256) 
 
 
In a 50 mL 3-necked flask containing thoroughly flame-dried LiCl (600 mg, 14.2 mmol, 
8.00 equiv) and Pd(PPh3)4 (80.1 mg, 0.0692 mmol, 0.0391 equiv) was added THF (5 mL). 
A solution of triflate (±)-254 (755 mg, 1.77 mmol) in THF (17 mL) was added. After 5 
min hexamethylditin (480 µL, 2.31 mmol, 1.31 equiv) was added and the mixture was 
heated at reflux for 1.5 h. Further Pd(PPh3)4 (67.8 mg, 0.0586 mmol, 0.0331 equiv) was 
then added and the mixture was stirred for 1.5 h. The mixture was cooled to 0 ºC and 
the reaction was quenched with saturated aqueous NaHCO3 (15 mL) and diluted with 
Et2O (40 mL). The phases were separated and the aqueous phase was extracted with 
Et2O (2 × 30 mL). The organic extracts were combined, washed with brine (40 mL), 
dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified 
by flash column chromatography (PE—Et2O, 95:5 to 8:2) to give the corresponding 
stannane (±)-256 (419 mg, 54%) as a pale yellow solid. 
C19H34O2SiSn    Molecular weight: 441.27 g·mol
−1 
mp. 69—72 ºC; 
Rf = 0.21 (PE—Et2O, 8:2); 
IR νmax 2940, 2863, 2176, 1751, 1643, 1466 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 6.22 (1H, d, J = 1.9 Hz, CH-C3), 5.21 (1H, ddd, J = 5.3, 3.6, 
1.9 Hz, CH-C5), 3.04 (1H, dd, J = 17.3, 5.3 Hz, CH2-C6), 2.65 (1H, dd, J = 17.3, 3.6 Hz, 
CH2-C6), 1.01 (21H, br s, 3×iPr), 0.36 (9H, s, SnMe3); 
13C NMR (101 MHz, CDCl3) δ 175.4 (C-C4), 172.4 (C-C2), 131.1 (CH-C3), 100.4 (C-C8), 
85.8 (CH-C5), 85.5 (C-C7), 25.1 (CH2-C6), 18.7 (6×CH3-iPr), 11.3 (3×CH-iPr), −9.2 (3×CH3-
SnMe3);  
LRMS (CI, Me3CH): m/z (int) 443 (76), 441 (57), 337 (11), 279 (48), 257 (15), 235 (12), 
113 (20), 69 (100). HRMS (CI, Me3CH) calculated for C19H35O2Si
120Sn [M+H]+: 443.1431, 
found 443.1424, Δ −1.1 ppm. 
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[2-(4-Bromomethylfuran-3-yl)pentyloxy]tert-butyldiphenylsilane (257) 
 
 
To a solution of alcohol 248 (204 mg, 0.483 mmol) in CH2Cl2 (5 mL) cooled to 0 ºC, PPh3 
(187 mg, 0.713 mmol, 1.48 equiv) and NBS (127 mg, 0.714 mmol, 1.48 equiv) were 
added successively. The mixture was stirred for 1 h at 0 ºC, diluted with CH2Cl2 
(5 mL), washed with brine (5 mL), dried over MgSO4, filtered and concentrated in vacuo. 
The crude product was purified by flash column chromatography (PE—CH2Cl2, 95:5) to 
give the desired bromide 257 (220 mg, 94%) as a pale yellow oil. 
C26H33BrO2Si     Molecular weight: 485.53 g·mol
−1 
Rf = 0.52 (PE—CH2Cl2, 95:5); 
IR νmax 3071, 3051, 2955, 2931, 2859, 1589, 1543, 1466 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.61—7.57 (4H, m, 4×CH-Ar), 7.44—7.33 (7H, m, CH-C2, 
6×CH-Ar), 7.20 (1H, d, J = 1.3 Hz, CH-C5), 4.25 (2H, s, CH2-C11), 3.66 (1H, dd, J = 9.8, 
6.2 Hz, CH2-C10), 3.66 (1H, dd, J = 9.8, 5.8 Hz, CH2-C10), 2.84 (1H, app dq, J = 9.1, 
5.8 Hz, CH-C6), 1.82 (1H, dddd, J = 12.8, 9.1, 6.5, 5.6 Hz, CH2-C7), 1.58—1.49 (1H, m, 
CH2-C7), 1.39—1.25 (2H, m, CH2-8), 1.03 (9H, s, 3×CH3-tBu), 0.91 (3H, t, J = 7.3 Hz, 
CH3-C9); 
13C NMR (101 MHz, CDCl3) δ 141.6 (CH-C2), 140.9 (CH-C5), 135.8 (2×CH-Ar), 135.7 
(2×CH-Ar), 133.8 (C-Ar), 133.7 (C-Ar), 129.8 (CH-Ar), 129.7 (CH-Ar), 127.8 (4×CH-Ar), 
126.2 (C-C3 or C-C4), 122.6 (C-C3 or C-C4), 67.8 (CH2-C10), 37.1 (CH-C6), 34.2 (CH2-C7), 
27.0 (3×CH3-tBu), 23.0 (CH2-C11), 20.6 (CH2-C8), 19.4 (C-tBu), 14.4 (CH3-C9);  
LRMS (CI, Me3CH): m/z (int) 487 (19), 463 (39), 405 (100), 349 (12), 231 (15), 207 (18), 
151 (27), 97 (18), 79 (42). HRMS (CI, Me3CH) calculated for C26H34
81BrO2Si [M+H]
+: 
487.1495, found 487.1492, Δ +0.1 ppm. 
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4-[4-(1-tert-Butyldiphenylsilyloxypentan-2-yl)furan-3-yl]methyl-5-[3-tris(propan-2- 
yl)silylprop-2-yn-1-yl]-2,5-dihydrofuran-2-one (260) 
 
 
To a solution of chloride 249 (449 mg, 1.02 mmol, 1.07 equiv) in THF (2 mL) was added 
Pd2(dba)3 (57 mg, 0.063 mmol, 0.066 equiv) and triphenylarsine (106 mg, 0.346 mmol, 
0.364 equiv). The purple to yellow mixture was stirred for 5 min at rt before a solution 
of stannane 256 (419 mg, 0.950 mmol, 1.00 equiv) in THF (9 mL) was added. The 
mixture was heated at 65 ºC overnight, cooled to rt and then diluted with Et2O (30 mL) 
and H2O (10 mL). The phases were separated, the aqueous phase was extracted with 
Et2O (2 × 20 mL) and the organic extracts were combined, washed with brine (30 mL), 
dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified 
by flash column chromatography (PE—Et2O, 95:5 to 92:8) to give the corresponding 
product 260 (605 mg, 93%) as a pale yellow oil and an inseparable mixture (1:1) of 
diastereoisomers. 
C42H58O4Si2   Molecular weight: 683.08 g·mol
−1 
Rf = 0.69 (PE—Et2O, 7:3); 
IR νmax 3071, 2931, 2862, 2175, 1759, 1643, 1589, 1543, 1466 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.58—7.54 (8H, m, 8×CH-Ar), 7.45—7.33 (12H, m, 12×CH-
Ar), 7.25 (1H, d, J = 1.6 Hz, CH-C2), 7.24—7.23 (2H, m, CH-C2 and CH-C5), 7.22 (1H, d, 
J = 1.5 Hz, CH-C5), 5.72 (1H, d, J = 1.3 Hz, CH-C13), 5.67 (1H, d, J = 1.5 Hz, CH-C13), 
4.82 (1H, app t, J = 5.0 Hz,  CH-C15), 4.80 (1H, app t, J = 5.0 Hz, CH-C15), 3.62—3.59 
(4H, m, 2×CH2-C10), 3.52 (1H, d, J = 17.7 Hz, CH2-C11), 3.43 (1H, d, J = 18.4 Hz, CH2-
C11), 3.24 (1H, dd, J = 17.7, 1.5 Hz, CH2-C11), 3.20 (1H, d, J = 18.4 Hz , CH2-C11), 2.90 
(1H, dd, J = 5.1, 2.0 Hz, CH2-C16), 2.86 (1H, dd, J = 5.1, 2.0 Hz, CH2-C16), 2.67 (1H, dd, 
J = 5.1, 4.0 Hz, CH2-C16),  2.63 (1H, dd, J = 5.1, 3.9 Hz, CH2-C16), 2.54 (1H, dq, J = 9.0, 
5.8 Hz, CH-C6), 2.49 (1H, dq, J = 8.7, 5.8 Hz, CH-C6), 1.79—1.69 (2H, m, CH2-C7), 1.51—
1.38 (2H, m, CH2-C7), 1.30—1.16 (4H, m, 2×CH2-C8), 1.05—0.98 (60H, m, 6×iPr and 
6×CH3-tBu), 0.86 (3H, t, J = 7.3 Hz, CH3-C9), 0.87 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (101 MHz, CDCl3) δ 171.9 (2×C-C12), 169.7 (C-C14), 169.5 (C-C14), 140.8 (CH-
C2 or CH-C5), 140.7 (CH-C2 or CH-C5), 140.4 (CH-C2 or CH-C5), 140.3 (CH-C2 or CH-C5), 
135.7 (4×CH-Ar), 135.6 (4×CH-Ar), 133.6 (2×C-Ar), 133.5 (2×C-Ar), 129.9 (2×CH-Ar), 
129.8 (2×CH-Ar), 127.8 (8×CH-Ar), 126.2 (2×C-C3 or 2×C-C4), 119.4 (2×C-C3 or 2×C-C4), 
118.4 (2×CH-C13), 99.7 (C-C17), 99.6 (C-C17), 85.4 (2×C-C18), 80.5 (CH- C15), 80.4 (CH-
C15), 67.9 (CH2-C10), 67.8 (CH2-C10), 37.5 (2×CH-C6), 34.2 (CH2-C7), 34.1 (CH2-C7), 
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27.0 (6×CH3-tBu), 23.6 (CH2-C16), 23.5 (CH2-C16), 23.1 (CH2-C11), 23.0 (CH2-C11), 20.7 
(2×CH2-C9), 19.4 (2×C-tBu), 18.7 (12×CH3-iPr), 14.4 (2×CH3-C9), 11.3 (6×CH-iPr); 
LRMS (FAB): m/z (int) 705 (100), 605 (67), 427 (9), 197 (40), 135 (73), 59 (42). HRMS 
(FAB) calculated for C42H58NaO4Si2 [M+Na]
+: 705.3771, found 705.3763, Δ −1.1 ppm. 
 
4-[4-(1-Hydroxypentan-2-yl)furan-3-yl]methyl-5-(prop-2-yn-1-yl)-2,5-dihydrofuran-
2-one (261) 
 
 
To a solution of 260 (1.23 g, 1.80 mmol) in THF (31 mL) was added at 0 ºC concentrated 
AcOH (400 µL, 6.99 mmol, 3.88 equiv) and TBAF (7.4 mL of a 1 M solution in THF, 
7.4 mmol, 4.1 equiv). The mixture was warmed slowly to rt, stirred for 24 h and then 
diluted with water (10 mL) and EtOAc (30 mL). The phases were separated and the 
aqueous phase was extracted with EtOAc (2 × 30 mL). The organic extracts were 
combined, washed with brine (50 mL), dried over MgSO4, filtered and concentrated in 
vacuo. The crude product was purified by flash column chromatography (PE—Et2O, 5:5 
to 2:8) to give the corresponding unprotected alcohols 261 (461 mg, 89%) as a pale 
yellow oil and a partially separable 1:1 mixture of diastereoisomers. 
C17H20O4   Molecular weight: 288.34 g·mol
−1 
Rf = 0.44 and 0.42 (PE—Et2O, 2:8); 
IR νmax 3446, 2954, 2933, 2869, 2360, 1742, 1645, 1417 cm
−1; 
Less polar diastereoisomer 
1H NMR (400 MHz, CDCl3) δ 7.30 (2H, s, CH-C2 and CH-C5), 5.78 (1H, ddd, J = 1.5, 1.5, 
1.2 Hz, CH-C13), 5.03 (1H, ddd, J = 5.6, 4.2, 1.2 Hz, CH-C15), 3.68—3.60 (2H, m, CH2-
C10), 3.59 (1H, dd, J = 18.3, 1.5 Hz, CH2-C11), 3.45 (1H, dd, J = 18.3, 1.5 Hz, CH2-C11), 
2.85 (1H, ddd, J = 17.3, 5.6, 2.6 Hz, CH2-C16), 2.73 (1H, ddd, J = 17.3, 4.2, 2.7 Hz, CH2-
C16), 2.59 (1H, dq, J = 8.6, 5.9 Hz, CH-C6), 2.07 (1H, dd, J = 2.7, 2.6 Hz, CH-C18), 
1.69—1.59 (1H, m, CH2-C7), 1.52—1.41 (1H, m, CH2-C7), 1.36—1.23 (2H, m, CH2-C8), 
0.89 (3H, t, J = 7.3 Hz, CH3-C10);  
13C NMR (101 MHz, CDCl3) δ 172.0 (C-C12), 169.9 (C-C14), 141.0 (CH-C2 or CH-C5), 
140.5 (CH-C2 or CH-C5), 126.0 (C-C3 or C-C4), 119.5 (C-C3 or C-C4), 118.5 (CH-C13), 
80.3 (CH-C15), 76.6 (C-C17), 72.6 (CH-C18), 66.7 (CH2-C10), 37.5 (CH-C6), 34.5 (CH2-
C7), 23.2 (CH2-C11), 22.6 (CH2-C16), 20.7 (CH2-C8), 14.3 (CH3-C9);  
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More polar diastereoisomer 
1H NMR (400 MHz, CDCl3) δ 7.30 (2H, s, CH-C2 and CH-C5), 5.81 (1H, ddd, J = 1.6, 1.6, 
1.5 Hz, CH-C13), 5.00 (1H, ddd, J = 6.3, 4.6, 1.5 Hz, CH-C15), 3.70—3.59 (2H, m, CH2-
C10), 3.59 (1H, dd, J = 18.3, 1.6 Hz, CH2-C11), 3.44 (1H, dd, J = 18.2, 1.6 Hz, CH2-C11), 
2.87 (1H, ddd, J = 17.3, 6.3, 2.5 Hz, CH2-C16), 2.74 (1H, ddd, J = 17.3, 4.6, 2.5 Hz, CH2-
C16), 2.68—2.55 (1H, m, CH-C6), 2.08 (1H, t, J = 2.5 Hz, CH-C18), 1.69—1.58 (1H, m, 
CH2-C7), 1.52—1.40 (1H, m, CH2-C7), 1.36—1.27 (2H, m, CH2-C8), 0.89 (3H, t, J = 7.3 Hz, 
CH3-C10);  
13C NMR (101 MHz, CDCl3) δ 172.0 (C-C12), 169.7 (C-C14), 141.1 (CH-C2 or CH-C5), 
140.6 (CH-C2 or CH-C5), 126.0 (C-C3 or C-C4), 119.4 (C-C3 or C-C4), 118.5 (CH-C13), 
80.2 (CH-C15), 76.5 (C-C17), 72.7 (CH-C18), 66.9 (CH2-C10), 37.5 (CH-C6), 34.2 (CH2-
C7), 23.2 (CH2-C11), 22.6 (CH2-C16), 20.6 (CH2-C8), 14.3 (CH3-C9);  
LRMS (CI, Me3CH): m/z (int) 289 (100), 71 (13). HRMS (CI, Me3CH) calculated for C17H21O4 
[M+H]+: 289.1440, found 289.1442, Δ +0.7 ppm. 
 
4-{4-[1-(4-Methoxyphenylmethoxy)pentan-2-yl]furan-3-yl}methyl-5-(prop-2-yn-1-yl)-
2,5-dihydrofuran-2-one (264) 
 
 
To a solution of alkynes 261 (18.3 mg, 0.0635 mmol) in CH2Cl2 (0.5 mL) were added 
freshly prepared PMBTCA (56.7 mg, 0.199 mmol, 3.13 equiv) and CSA (8.2 mg, 0.035 
mmol, 0.56 equiv). The mixture was stirred for 8 h at rt and the reaction was quenched 
with saturated aqueous NaHCO3 (5 mL). The mixture was diluted with Et2O (10 mL) and 
the phases were separated. The aqueous phase was extracted with Et2O (10 mL), the 
organic extracts were combined and washed with brine (15 mL). The organic phase was 
dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash 
column chromatography (PE—CH2Cl2, 1:9). Crystallisation of acetimidate impurities using 
PE and Et2O helped to give the desired products 264 (20.9 mg, 81%) as an inseparable 
mixture (1:1) of diastereoisomers. 
C25H28O5   Molecular weight: 408.49 g·mol
−1 
Rf = 0.55 (PE—Et2O, 4:6); 
IR νmax 3288, 2957, 2926, 2859, 1755, 1643, 1612, 1585, 1512, 1464, 1417 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.25 (2H, s, 2×CH-C2), 7.24 (2H, s, 2×CH-C5), 7.18 (4H, d, 
J = 8.6 Hz, 4×CH-PMB), 6.86 (4H, d, J = 8.6 Hz, 4×CH-PMB), 5.77 (1H, ddd, J = 1.6, 1.6, 
1.5 Hz, CH-C13), 5.76 (1H, ddd, J = 1.6, 1.6, 1.5 Hz, CH-C13), 4.92 (1H, app td, J = 5.5, 
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1.5 Hz, CH-C15), 4.91 (1H, app td, J = 5.5, 1.5 Hz, CH-C15), 4.42—4.34 (4H, m, 2×CH2-
PMB), 3.81 (6H, s, 2×CH3-PMB), 3.63—3.31 (8H, m, 2×CH2-C10 and 2×CH2-C11), 2.82—
2.73 (2H, m, 2×CH2-C16), 2.68—2.58 (4H, m, 2×CH2-C16, 2×CH-C6), 2.03 (2H, t, J = 2.6 
Hz, 2×CH-C18), 1.72—1.61 (2H, m, 2×CH2-C7), 1.50—1.39 (2H, m, 2×CH2-C7),1.34—1.18 
(4H, m, CH2-C8), 0.87 (3H, t, J = 7.3 Hz, CH3-C9), 0.86 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (101 MHz, CDCl3) δ 172.1 (2×C-C12), 170.0 (C-C14), 169.9 (C-C14), 159.3 (2×C-
PMB), 140.5 (2×CH-C2 or 2×CH-C5), 140.4 (CH-C2 or CH-C5), 140.3 (CH-C2 or CH-C5), 
130.5 (C-PMB), 130.4 (C-PMB), 129.4 (2×CH-PMB), 129.3 (2×CH-PMB), 126.8 (C-C3 or C-
C4), 126.7 (C-C3 or C-C4), 119.6 (C-C3 or C-C4), 119.5 (C-C3 or C-C4), 118.4 (2×CH-
C13), 113.9 (4×CH-PMB), 80.3 (CH-C15), 80.2 (CH-C15), 76.6 (2×C-C17), 74.8 (CH2-C10), 
74.4 (CH2-C10), 73.0 (2×CH-C18), 72.5 (CH2-PMB), 55.4 (2×CH3-PMB), 35.5 (CH-C6), 35.4 
(CH-C6), 35.0 (CH2-C7), 34.7 (CH2-C7), 23.3 (CH2-C11), 23.2 (CH2-C11), 22.5 (2×CH2-
C16), 20.7 (CH2-C8), 20.7 (CH2-C8), 14.3 (2×CH3-C9);  
LRMS (CI, Me3CH): m/z (int) 409 (26), 289 (41), 121 (100). HRMS (CI, Me3CH) calculated 
for C25H29O5 [M+H]
+: 409.2015, found 409.2017, Δ +0.5 ppm. 
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4-{[4-(1-tert-Butyldimethylsilyloxy-pentan-2-yl)furan-3-yl]methyl}-5-(prop-2-yn-1-
yl)-2,5-dihydrofuran-2-one (269) 
 
 
To a solution of alkynes 261 (22.2 mg, 0.0770 mmol) in CH2Cl2 (1 mL) at 0 ºC were 
successively added freshly distilled Et3N (18 µL, 0.13 mmol, 1.7 equiv), DMAP (2.7 mg, 
0.022 mmol, 0.040 equiv) and TBSCl (15.4 mg, 0.102 mmol, 1.33 equiv). The mixture 
was warmed to rt and stirred overnight. More Et3N (18 µL, 0.13 mmol, 1.7 equiv) and 
TBSCl (10 mg, 0.067 mmol, 0.87 equiv) were added and the reaction was stirred for a 
further 8 h. The reaction was quenched with saturated aqueous NH4Cl (5 mL) and 
diluted with CH2Cl2 (10 mL). The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (2 × 10 mL). The organic extracts were combined, washed with 
brine (20 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by flash column chromatography (PE—Et2O, 6:4) to afford the desired products 
269 (16.8 mg, 54%) as an inseparable mixture (1:1) of diastereoisomers, and recovered 
alcohols 261 (7.3 mg). 
C23H34O4Si   Molecular weight: 402.60 g·mol
−1 
Rf = 0.29 (PE—Et2O, 6:4); 
IR νmax 3309, 2955, 2929, 2857, 1755, 1643, 1541, 1464, 1417 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.28—7.23 (4H, m, 2×CH-C2, 2×CH-C5), 5.79 (1H, ddd, J = 
1.6, 1.6, 1.4 Hz, CH-C13), 5.76 (1H, ddd, J = 1.7, 1.7, 1.4 Hz, CH-C13), 5.01 (1H, ddd, 
J = 5.6, 4.1, 1.4 Hz, CH-C15), 4.97 (1H, ddd, J = 5.5, 4.3, 1.4 Hz, CH-C15), 3.64 (1H, dd, 
J = 18.1, 1.6 Hz, CH2-C11), 3.60—3.52 (5H, m, 2×CH2-C10, CH2-C11), 3.44 (1H, dd, J = 
18.1, 1.7 Hz, CH2-C11),  3.40 (1H, dd, J = 18.1, 1.7 Hz, CH2-C11), 2.86 (1H, ddd, J = 
17.2, 5.6, 2.6 Hz, CH2-C16), 2.84 (1H, ddd, J = 17.2, 5.5, 2.6 Hz, CH2-C16), 2.72 (1H, 
ddd, J = 17.2, 4.3, 2.6 Hz, CH2-C16), 2.71 (1H, ddd, J = 17.2, 4.1, 2.6 Hz, CH2-C16), 
2.56—2.46 (2H, m, 2×CH-C6), 2.06 (1H, t, J = 2.6 Hz, CH-C18), 2.06 (1H, t, J = 2.6 Hz, 
CH-C18), 2.05 (1H, t, J = 2.6 Hz, CH-C18), 1.71—1.61 (2H, m, 2×CH2-C7), 1.45—1.34 (2H, 
m, 2×CH2-C7), 1.34—1.18 (4H, m, CH2-C8), 0.88 (3H, t, J = 7.3 Hz, CH3-C9), 0.87 (3H, t, 
J = 7.3 Hz, CH3-C9), 0.86 (9H, s, 3×CH3-tBu), 0.85 (9H, s, 3×CH3-tBu), −0.02 (3H, s,CH3-
SiMe2), −0.02 (6H, s, 2×CH3-SiMe2), −0.03 (3H, s, CH3-SiMe2); 
13C NMR (101 MHz, CDCl3) δ 172.0 (C-C12), 171.9 (C-C12), 170.1 (C-C14), 169.9 (C-C14), 
140.5 (2×CH-C2 or 2×CH-C5), 140.3 (CH-C2 or CH-C5), 140.3 (CH-C2 or CH-C5), 126.7 (C-
C3 or C-C4), 126.7 (C-C3 or C-C4), 119.5 (C-C3 or C-C4), 119.5 (C-C3 or C-C4), 118.4 
(CH-C13), 118.4 (CH-C13), 80.3 (CH-C15), 80.2 (CH-C15), 76.6 (C-C17), 76.5 (C-C17), 
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72.6 (2×CH-C18), 67.7 (CH2-C10), 67.4 (CH2-C10), 37.4 (CH-C6), 37.4 (CH-C6), 34.7 (CH2-
C7), 34.3 (CH2-C7), 26.0 (3×CH3-tBu), 26.0 (3×CH3-tBu), 23.3 (CH2-C11), 23.2 (CH2-C11), 
22.6 (CH2-C16), 22.6 (CH2-C16), 20.7 (CH2-C8), 20.7 (CH2-C8), 18.5 (2×C-tBu), 14.4 
(2×CH3-C9), −5.4 (2×CH3-SiMe2), −5.4 (2×CH3-SiMe2); 
LRMS (CI, Me3CH): m/z (int) 403 (100), 378 (8), 345 (14), 271 (36), 133 (11), 85 (33). 
HRMS (CI, Me3CH) calculated for C23H35O4Si [M+H]
+: 403.2305, found 403.2303, 
Δ −0.4 ppm. 
 
4-[4-(1-Hydroxypentan-2-yl)furan-3-yl]methyl-5-(2-triethylsilylprop-2-en-1-yl)-2,5-
dihydrofuran-2-one (271-1 and 271-2) 
 
 
To a solution of alkynes 261 (63.7 mg, 0.221 mmol) in CH2Cl2 (1 mL) was added freshly 
distilled triethylsilane (43 µL, 0.27 mmol, 1.2 equiv) and Cp*Ru(MeCN)3PF6 (5.6 mg, 
0.011 mmol, 0.050 equiv). The mixture was stirred for 1 h at rt and directly 
concentrated in vacuo. The crude product was purified by flash column chromatography 
(PE—Et2O, 5:5 to 4:6) to give 271-1 and 271-2 as two separable diastereoisomers: 32.7 
mg (37%) of the less polar diastereoisomer 271-1 and 34.6 mg (39%) of the more polar 
diastereoisomer 271-2, both colourless oils. 
C23H36O4Si   Molecular weight: 404.62 g·mol
−1 
Less polar diastereoisomer 271-1 
Rf = 0.45 (PE—Et2O, 4:6); 
IR νmax 3458, 2955, 2933, 2912, 2874, 2361, 1749, 1637, 1541, 1458, 1417 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.31 (1H, d, J = 1.4 Hz, CH-C2), 7.28 (1H, s, CH-C5), 5.87 
(1H, dt, J = 2.0, 0.9 Hz, CH2-C18), 5.73 (1H, ddd, J = 1.5, 1.5, 1.5 Hz, CH-C13), 5.52 
(1H, dt, J = 2.0, 1.2 Hz, CH2-C18), 5.02 (1H, ddd, J = 9.7, 3.1, 1.5 Hz, CH-C15), 3.69—
3.57 (2H, m, CH2-C10), 3.53 (1H, dd, J = 18.1, 1.5 Hz, CH2-C11), 3.41 (1H, dd, J = 18.1, 
1.5 Hz, CH2-C11), 2.65 (1H, ddd, J = 15.2, 3.1, 1.2 Hz, CH2-C16), 2.56 (1H, dq, J = 8.5, 
6.0 Hz, CH-C6), 2.23 (1H, ddd, J = 15.2, 9.7, 0.9 Hz, CH2-C16), 1.67—1.57 (1H, m, CH2-
C7), 1.52—1.41 (1H, m, CH2-C7), 1.37 (1H, dd, J = 6.2, 5.5 Hz, OH), 1.34—1.23 (2H, m, 
CH2-C8), 0.93 (9H, t, J = 7.9 Hz, 3×CH3-SiEt3), 0.89 (3H, t, J = 7.3 Hz, CH3-C9), 0.62 (6H, 
q, J = 8.0 Hz, 3×CH2-SiEt3); 
13C NMR (126 MHz, CDCl3) δ 172.6 (C-C12), 171.4 (C-C14), 143.2 (C-C17), 140.9 (CH-C2 
or CH-C5), 140.6 (CH-C2 or CH-C5), 129.6 (CH2-C18), 126.0 (C-C4 or C-C3), 119.6 (C-C4 
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or C-C3), 117.6 (CH-C13), 83.0 (CH-C15), 66.8 (CH2-C10), 39.4 (CH2-C16), 37.5 (CH-C6), 
34.2 (CH2-C7), 23.4 (CH2-C11), 20.7 (CH2-C8), 14.3 (CH3-C9), 7.4 (3×CH3-SiEt3), 3.0 
(3×CH2-SiEt3);  
LRMS (CI, Me3CH): m/z (int) 405 (100), 389 (10), 289 (11), 251 (16), 133 (10), 85 (12), 71 
(15). HRMS (CI, Me3CH) calculated for C23H37O4Si [M+H]
+: 405.2461, found 405.2455, Δ 
−1.6 ppm. 
More polar diastereoisomer 271-2 
Rf = 0.34 (PE—Et2O, 4:6); 
IR νmax 3449, 2955, 2878, 2360, 1743, 1643, 1543, 1458, 1419 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.30 (1H, d, J = 1.4 Hz, CH-C2), 7.28 (1H, s, CH-C5), 5.87 
(1H, dt, J = 2.0, 1.2 Hz, CH2-C18), 5.75 (1H, ddd, J = 1.5, 1.4, 1.4 Hz, CH-C13), 5.52 
(1H, dt, J = 2.0, 0.9 Hz, CH2-C18), 4.97 (1H, ddd, J = 9.7, 3.1, 1.5 Hz, CH-C15), 3.68—
3.60 (2H, m, CH2-C10), 3.59 (1H, dd, J = 17.8, 1.4 Hz, CH2-C11), 3.40 (1H, dd, J = 17.8, 
1.4 Hz, CH2-C11), 2.67 (1H, ddd, J = 15.1, 3.1, 1.2 Hz, CH2-C16), 2.57 (1H, dq, J = 8.5, 
6.0 Hz, CH-C6), 2.22 (1H, ddd, J = 15.1, 9.7, 0.9 Hz, CH2-C16), 1.67—1.57 (1H, m, CH2-
C7), 1.51—1.40 (2H, m, CH2-C7 and OH), 1.34—1.21 (2H, m, CH2-C8), 0.93 (9H, t, J = 
7.9 Hz, 3×CH3-SiEt3), 0.88 (3H, t, J = 7.3 Hz, CH3-C9), 0.62 (6H, q, J = 8.0 Hz, 3×CH2-
SiEt3); 
13C NMR (101 MHz, CDCl3) δ 172.5 (C-C12), 171.4 (C-C14), 143.2 (C-C17), 141.0 (CH-C2 
or CH-C5), 140.6 (CH-C2 or CH-C5), 129.7 (CH2-C18), 126.0 (C-C4 or C-C3), 119.6 (C-C4 
or C-C3), 117.7 (CH-C13), 83.0 (CH-C15), 66.8 (CH2-C10), 39.5 (CH2-C16), 37.6 (CH-C6), 
34.2 (CH2-C7), 23.5 (CH2-C11), 20.7 (CH2-C8), 14.3 (CH3-C9), 7.4 (3×CH3-SiEt3), 3.0 
(3×CH2-SiEt3);  
LRMS (CI, Me3CH): m/z (int) 405 (100), 97 (10), 81 (24). HRMS (CI, Me3CH) calculated for 
C23H37O4Si [M+H]
+: 405.2461, found 405.2460, Δ −0.2 ppm. 
 
4-[4-(1-Hydroxypentan-2-yl)furan-3-yl]methyl-5-[(2Z)-2-(tributylstannyl)-3-
(trimethylsilyl)prop-2-en-1-yl]-2,5-dihydrofuran-2-one (273) 
 
 
To a solution of alkynes 261 (325 mg, 1.13 mmol) in THF (2.3 mL) was added Pd(PPh3)4 
(69.8 mg, 0.0604 mmol, 0.0536 equiv) and stannane 272 (600 µL, 1.69 mmol, 
1.50 equiv) previously prepared in quantitative yield following the literature.118 The 
mixture was warmed to 70 ºC for 3 h and then cooled to rt. Saturated aqueous NH4Cl 
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(20 mL) and Et2O (50 mL) were added. The phases were separated and the aqueous 
phase was extracted with Et2O (30 mL). The organic extracts were combined, washed 
with brine (40 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography (PE—Et2O, 6:4 to 5:5) to give the 
corresponding stannanes 273 (550 mg, 75%) as a pale yellow oil and partially separable 
mixture (1:1) of two diastereoisomers. 
C32H56O4SiSn   Molecular weight: 651.58 g·mol
−1 
Rf = 0.73 and 0.64 (PE—Et2O, 7:3); 
IR νmax 3440, 2955, 2923, 2871, 2854, 1745, 1637, 1541, 1464 cm
−1; 
Less polar diastereoisomer 
1H NMR (400 MHz, CDCl3) δ 7.31 (1H, s, CH-C2 or CH-C5), 7.28 (1H, s, CH-C2 or CH-C5), 
6.56 (1H, s, CH-C18), 5.69 (1H, d, J = 1.0 Hz, CH-C13), 4.91 (1H, ddd, J = 8.7, 4.0, 
1.0 Hz, CH-C15), 3.68—3.59 (2H, m, CH2-C10), 3.49 (1H, d, J = 18.2 Hz, CH2-C11), 3.37 
(1H, d, J = 18.2 Hz, CH2-C11), 2.80 (1H, dd, J = 14.1, 4.0 Hz, CH2-C16), 2.57—2.54 (1H, 
m, CH-C6), 2.49 (1H, dd, J = 14.1, 8.7 Hz, CH2-C16), 1.67—1.59 (1H, m, CH2-C7), 1.53—
1.45 (7H, m, CH2-C7, 3×CH2-SnBu3), 1.39—1.27 (8H, m, CH2-C8, 3×CH2-SnBu3), 1.0—0.95 
(6H, m, 3×CH2-SnBu3), 0.91—0.86 (12H, m, CH3-C9, 3×CH3-SnBu3), 0.12 (9H, s, 3×CH3-
SiMe3); 
13C NMR (101 MHz, CDCl3) δ 172.4 (C-C12), 171.5 (C-C14), 158.9 (C-C17), 149.0 (CH-
C18), 141.0 (CH-C2 or CH-C5), 140.5 (CH-C2 or CH-C5), 125.9 (C-C3 or C-C4), 119.6 (C-
C3 or C-C4), 117.6 (CH-C13), 84.2 (CH-C15), 66.8 (CH2-C10), 49.5 (CH2-C16), 37.6 (CH-
C6), 34.2 (CH2-C7), 29.3 (3×CH2-SnBu3), 27.6 (3×CH2-SnBu3), 23.5 (CH2-C11), 20.7 (CH2-
C8), 14.3 (CH3-C9), 13.8 (3×CH3-SnBu3), 11.7 (3×CH2-SnBu3), 0.2 (3×CH3-SiMe3); 
More polar diastereoisomer 
1H NMR (400 MHz, CDCl3) δ 7.30 (1H, s, CH-C2 or CH-C5), 7.28 (1H, s, CH-C2 or CH-C5), 
6.55 (1H, s, CH-C18), 5.68 (1H, d, J = 1.5 Hz, CH-C13), 4.88 (1H, ddd, J = 9.1, 3.6, 
1.0 Hz, CH-C15), 3.68—3.59 (2H, m, CH2-C10), 3.53 (1H, d, J = 18.0 Hz, CH2-C11), 3.35 
(1H, d, J = 18.0 Hz, CH2-C11), 2.83—2.77 (1H, m, CH2-C16), 2.58—2.53 (1H, m, CH-C6), 
2.52—2.44 (1H, m, CH2-C16), 1.67—1.59 (1H, m, CH2-C7), 1.53—1.45 (7H, m, CH2-C7, 
3×CH2-SnBu3), 1.39—1.27 (8H, m, CH2-C8, 3×CH2-SnBu3), 1.0—0.95 (6H, m, 3×CH2-SnBu3), 
0.91—0.86 (12H, m, CH3-C9, 3×CH3-SnBu3), 0.12 (9H, s, 3×CH3-SiMe3); 
13C NMR (101 MHz, CDCl3) δ 172.4 (C-C12), 171.5 (C-C14), 158.9 (C-C17), 148.9 (CH-
C18), 141.0 (CH-C2 or CH-C5), 140.5 (CH-C2 or CH-C5), 125.8 (C-C3 or C-C4), 119.6 (C-
C3 or C-C4), 117.6 (CH-C13), 84.1 (CH-C15), 66.7 (CH2-C10), 49.3 (CH2-C16), 37.6 (CH-
C6), 34.2 (CH2-C7), 29.3 (3×CH2-SnBu3), 27.6 (3×CH2-SnBu3), 23.4 (CH2-C11), 20.7 (CH2-
C8), 14.3 (CH3-C9), 13.8 (3×CH3-SnBu3), 11.7 (3×CH2-SnBu3), 0.2 (3×CH3-SiMe3); 
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LRMS (CI, Me3CH): m/z (int) 653 (4), 595 (17), 593 (14), 403 (28), 363 (100), 361 (36), 
291 (28), 289 (22), 73 (18). HRMS (CI, Me3CH) calculated for C32H57O4Si
120Sn [M+H]+: 
653.3054, found 653.3060, Δ +1.8 ppm. 
 
4-[4-(1-Hydroxypentan-2-yl)furan-3-yl]methyl-5-((2Z)-2-iodo-3-trimethylsilylprop-2-
en-1-yl)-2,5-dihydrofuran-2-one (276-1 and 276-2) 
 
 
To a solution of stannanes 273 (533 mg, 0.818 mmol) in CH2Cl2 (8.5 mL) at 0 ºC was 
added I2 (230 mg, 0.906 mmol, 1.11 equiv). The reaction was stirred for 15 min, 
quenched with saturated aqueous Na2S2O3 (20 mL) and diluted with CH2Cl2 (30 mL). 
After 10 min, the phases were separated, the aqueous phase was extracted with CH2Cl2 
(2 × 20 mL). The organic extracts were combined, washed with brine (40 mL), dried 
with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
flash column chromatography (PE—Et2O, 7:3) to give the corresponding vinyl iodides 
276-1 and 276-2 (388 mg, 97%) as two separable diastereoisomers in a 1:1 ratio, both 
colourless oils. 
C20H29IO4Si   Molecular weight: 488.43 g·mol
−1 
Less polar diastereoisomer 276-1 
Rf = 0.48 (PE—Et2O, 3:7); 
IR νmax 3460, 2955, 2929, 2899, 2872, 2360, 1747, 1637, 1597, 1541, 1464 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.29 (2H, br s, CH-C2 and CH-C5), 6.61 (1H, d, J = 0.7 Hz, 
CH-C18), 5.72 (1H, ddd, J = 1.6, 1.0, 1.0 Hz, CH-C13), 5.21 (1H, ddd, J = 8.9, 3.4, 1.6 
Hz, CH-C15), 3.66—3.55 (2H, m, CH2-C10), 3.52 (1H, dd, J = 18.2, 1.0 Hz, CH2-C11), 3.44 
(1H, dd, J = 18.2, 1.0 Hz, CH2-C11), 3.06 (1H, ddd, J = 15.0, 3.4, 0.7 Hz, CH2-C16), 2.73 
(1H, dd, J = 15.0, 8.9 Hz, CH2-C16), 2.54 (1H, dq, J = 8.6, 5.9 Hz, CH-C6), 1.70 (1H, br 
s, OH), 1.62 (1H, ddt, J = 13.2, 9.9, 5.9 Hz, CH2-C7), 1.49—1.40 (1H, m, CH2-C7), 1.34—
1.21 (2H, m, CH2-C8), 0.87 (3H, t, J = 7.3 Hz, CH3-C9), 0.19 (9H, s, 3×CH3-SiMe3); 
13C NMR (101 MHz, CDCl3) δ 172.3 (C-C12), 170.5 (C-C14), 143.1 (C-C18), 141.0 (CH-C2 
or CH-C5), 140.5 (CH-C2 or CH-C5), 125.9 (C-C17), 119.3 (C-C3 or C-C4), 118.0 (CH-
C13), 112.4 (C-C3 or C-C4), 82.1 (CH-C15), 66.7 (CH2-C10), 53.3 (CH2-C16), 37.5 (CH-
C6), 34.4 (CH2-C7), 23.3 (CH2-C11), 20.7 (CH2-C8), 14.3 (CH3-C9), −1.3 (3×CH3-SiMe3); 
LRMS (CI, Me3CH): m/z (int) 489 (100), 361 (68), 345 (7). HRMS (CI, Me3CH) calculated 
for C20H30IO4Si [M+H]
+: 489.0958, found 489.0959, Δ +0.3 ppm. 
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More polar diastereoisomer 276-2 
Rf = 0.40 (PE—Et2O, 3:7); 
IR νmax 3458, 2955, 2928, 2872, 2359, 2340, 1751, 1637, 1597, 1466 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.31 (2H, s, CH-C2 and CH-C5), 6.62 (1H, dd, J = 1.0, 0.7 
Hz, CH-C18), 5.77 (1H, ddd, J = 1.4, 1.4, 1.4 Hz, CH-C13), 5.19 (1H, ddd, J = 9.0, 3.5, 
1.4 Hz, CH-C15), 3.67 (1H, dd, J = 10.5, 5.8 Hz , CH2-C10), 3.59 (1H, dd, J = 18.0, 1.4 
Hz, CH2-C11), 3.59 (1H, dd, J = 10.5, 6.8 Hz, CH2-C10), 3.43 (1H, dd, J = 18.0, 1.4 Hz, 
CH2-C11), 3.08 (1H, ddd, J = 14.8, 3.5, 1.0 Hz, CH2-C16), 2.73 (1H, ddd, J = 14.8, 9.0, 
0.7 Hz, CH2-C16), 2.57 (1H, dddd, J = 8.6, 6.8, 6.7, 5.8 Hz, CH-C6), 1.67—1.58 (1H, m, 
CH2-C7), 1.51—1.42 (2H, m, CH2-C7, OH), 1.33—1.25 (2H, m, CH2-C8), 0.89 (3H, t, J = 
7.3 Hz, CH3-C9), 0.21 (9H, s, 3×CH3-SiMe3); 
13C NMR (101 MHz, CDCl3) δ 172.2 (C-C12), 170.3 (C-C14), 143.3 (C-C18), 141.1 (CH-C2 
or CH-C5), 140.6 (CH-C2 or CH-C5), 125.9 (C-C17), 119.4 (C-C3 or C-C4), 118.1 (CH-
C13), 112.5 (C-C3 or C-C4), 82.1 (CH-C15), 67.0 (CH2-C10), 53.5 (CH2-C16), 37.6 (CH-
C6), 34.2 (CH2-C7), 23.4 (CH2-C11), 20.8 (CH2-C8), 14.3 (CH3-C9), −1.2 (3×CH3-SiMe3); 
LRMS (CI, Me3CH): m/z (int) 489 (100), 361 (37), 345 (5). HRMS (CI, Me3CH) calculated 
for C20H30IO4Si [M+H]
+: 489.0958, found 489.0955, Δ −0.7 ppm. 
 
4-[4-(1-Hydroxypentan-2-yl)furan-3-yl]methyl-5-[2-(tributylstannyl)prop-2-en-1-yl]-
2,5-dihydrofuran-2-one (274) 
 
 
To a solution of alkynes 261 (419 mg, 1.45 mmol) in THF (6.6 mL) at rt were added 
successively Pd(PPh3)4 (60.1 mg, 0.0520 mmol, 0.0358 equiv) and tributyltin hydride 
(425 µL, 1.60 mmol, 1.10 equiv). The mixture was stirred for 20 min and the reaction 
was quenched with saturated aqueous NaHCO3 (5 mL). The mixture was diluted with 
Et2O (10 mL) and the phases were then separated. The aqueous phase was extracted 
with Et2O (3 × 10 mL) and the organic extracts were combined, washed with brine 
(20 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography (PE—Et2O, 5:5 to 4:6) to give a partially 
separable mixture (1:3.2) in favour of the proximal stannane versus stannane in distal 
position. Most of the proximal stannanes 274 (572 mg) were isolated and taken straight 
to the next step for better characterisation. 
C29H48O4Sn   Molecular weight: 579.40 g·mol
−1 
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Rf = 0.68 and 0.76 (PE—Et2O, 2:8); 
1H NMR of the crude product showing the alkenyl regions for the internal—external ratio 
determination.  
 
 
(5S*)-4-[4-((2S*)-1-Hydroxypentan-2-yl)furan-3-yl]methyl-5-(2-iodoprop-2-en-1-yl)-
2,5-dihydrofuran-2-one (262-syn) 
and 
(5S*)-4-[4-((2R*)-1-Hydroxypentan-2-yl)furan-3-yl]methyl-5-(2-iodoprop-2-en-1-yl)-
2,5-dihydrofuran-2-one (262-anti) 
 
 
To a solution of stannanes 274 (572 mg, 0.988 mmol) in CH2Cl2 (10 mL) at 0 ºC was 
added I2 (289 mg, 1.14 mmol, 1.15 equiv). The mixture was stirred for 20 min and the 
reaction was then quenched with saturated aqueous Na2S2O3 (15 mL). The mixture was 
diluted with CH2Cl2 (20 mL) and after 10 min, the phases were separated. The aqueous 
phase was extracted with CH2Cl2 (2 × 20 mL) and the organic extracts were combined, 
washed with brine (30 mL), dried with Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography (PE—Et2O, 55:45) to give 
the corresponding vinyl iodides (378 mg, 62%) as separable diastereoisomers 262-syn 
and 262-anti; both colourless oils. 
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C17H21IO4   Molecular weight: 416.25 g·mol
−1 
Less polar diastereoisomer 262-syn 
Rf = 0.36 (PE—Et2O, 2:8); 
IR νmax 3446, 2955, 2929, 2870, 1743, 1637, 1618, 1541, 1466 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.30 (2H, s, CH-C2 and CH-C5), 6.25 (1H, d, J = 1.7 Hz, 
CH2-C18), 5.91 (1H, d, J = 1.7 Hz, CH2-C18), 5.75 (1H, ddd, J = 1.4, 1.1, 1.1 Hz, CH-
C13), 5.16 (1H, ddd, J = 8.7, 3.6, 1.4 Hz, CH-C15), 3.65 (1H, dd, J = 10.5, 5.6 Hz, CH2-
C10), 3.59 (1H, dd, J = 10.5, 6.8 Hz, CH2-C10), 3.55 (1H, dd, J = 17.8, 1.1 Hz, CH2-C11), 
3.46 (1H, dd, J = 17.8, 1.1 Hz, CH2-C11), 2.94 (1H, dd, J = 15.0, 3.6 Hz, CH2-C16), 2.64 
(1H, dd, J = 15.0, 8.7 Hz, CH2-C16), 2.56 (1H, dddd, J = 8.5, 6.8, 5.9, 5.6 Hz, CH-C6), 
1.69—1.58 (2H, m, CH2-C7 and OH), 1.51—1.40 (1H, m, CH2-C7), 1.36—1.23 (2H, m, CH2-
C8), 0.89 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (101 MHz, CDCl3) δ 172.0 (C-C12), 170.2 (C-C14), 141.0 (CH-C2 or CH-C5), 
140.5 (CH-C2 or CH-C5), 130.5 (CH2-C18), 126.0 (C-C3 or C-C4), 119.4 (C-C3 or C-C4), 
118.3 (CH-C13), 102.1 (C-C17), 81.9 (CH-C15), 66.8 (CH2-C10), 48.2 (CH2-C16), 37.6 (CH-
C6), 34.4 (CH2-C7), 23.4 (CH2-C11), 20.7 (CH2-C8), 14.3 (CH3-C9); 
LRMS (EI+): m/z (int) 416 (100), 385 (10), 289 (56), 271 (20), 215 (33), 161 (35), 119 
(21), 91 (45), 77 (20), 55 (10). HRMS (EI+) calculated for C17H21IO4 [M]
+: 416.0485, found 
416.0488, Δ +0.8 ppm. 
More polar diastereoisomer 262-anti 
Rf = 0.31 (PE—Et2O, 2:8); 
IR νmax 3446, 2955, 2928, 2869, 1746, 1638, 1618, 1539, 1465 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.30 (2H, s, CH-C2 and CH-C5), 6.26 (1H, dd, J = 1.7, 
0.8 Hz, CH2-C18), 5.91 (1H, d, J = 1.7 Hz, CH2-C18), 5.78 (1H, ddd, J = 1.5, 1.4, 1.1 Hz, 
CH-C13), 5.13 (1H, ddd, J = 8.6, 3.6, 1.5 Hz, CH-C15), 3.67 (1H, dd, J = 10.5, 5.5 Hz, 
CH2-C10), 3.60 (1H, dd, J = 18.1, 1.1 Hz, CH2-C11), 3.59 (1H, dd, J = 10.5, 6.9 Hz, CH2-
C10), 3.44 (1H, dd, J = 18.1, 1.4 Hz, CH2-C11), 2.95 (1H, dd, J = 15.0, 3.6 Hz, CH2-C16), 
2.63 (1H, ddd, J = 15.0, 8.6, 0.8 Hz, CH2-C16), 2.57 (1H, dddd, J = 8.6, 6.9, 5.6, 5.5 Hz, 
CH-C6), 1.63 (1H, dddd, J = 13.1, 9.6, 6.1, 5.5 Hz, CH2-C7), 1.55 (1H, br s, OH), 1.51—
1.41 (1H, m, CH2-C7), 1.36—1.22 (2H, m, CH2-C8), 0.89 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (101 MHz, CDCl3) δ 172.0 (C-C12), 170.1 (C-C14), 141.0 (CH-C2 or CH-C5), 
140.6 (CH-C2 or CH-C5), 130.5 (CH2-C18), 126.0 (C-C3 or C-C4), 119.4 (C-C3 or C-C4), 
118.3 (CH-C13), 102.2 (C-C17), 81.8 (CH-C15), 67.0 (CH2-C10), 48.2 (CH2-C16), 37.6 (CH-
C6), 34.2 (CH2-C7), 23.4 (CH2-C11), 20.7 (CH2-C8), 14.3 (CH3-C9); 
LRMS (CI, Me3CH): m/z (int) 417 (69), 291 (100), 273 (46), 251 (10), 97 (13), 71 (28). 
HRMS (CI, Me3CH) calculated for C17H22IO4 [M+H]
+: 417.0563, found 417.0564, Δ +0.3 
ppm. 
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(10Z)-9-Hydroxy-8-propyl-10-(trimethylsilyl)methylidene-5,13- 
dioxatricyclo[10.3.0.03,7]pentadeca-1(15),3,6-trien-14-one (284-1) 
 
 
To a solution of vinyl iodide 276-1 (12.5 mg, 0.0256 mmol) in CH2Cl2 (0.5 mL) was added 
DMP (31 mg, 0.073 mmol, 2.9 equiv) and the mixture was stirred at rt for 2.5 h, then 
cooled to 0 ºC. The reaction was quenched with saturated aqueous Na2S2O3 (3 mL) and 
the mixture diluted with water (5 mL) and CH2Cl2 (5 mL). After 10 min, the phases were 
separated and the aqueous phase was extracted with CH2Cl2 (3 × 5 mL). The organic 
extracts were combined, washed with brine (10 mL), dried with Na2SO4, filtered and 
concentrated in vacuo. The residue was quickly purified by passage through small plug 
of silica (PE—Et2O, 8:2) to give the corresponding aldehyde (11.8 mg, 95%) as a 
colourless oil. 
To a solution of the aldehyde (11.8 mg, 0.0242 mmol) in degassed DMSO (three freeze-
thaw cycles, 9.5 mL) were successively added DMS (97 µL), CrCl2 (61.8 mg, 0.505 mmol, 
20.8 equiv) and NiCl2 (0.9 mg, 0.007 mmol, 0.3 equiv). The dark green mixture was 
stirred at rt for 35 h and then cooled to 0 ºC. The reaction was quenched with a solution 
of serinate (0.5 g of serine diluted in 10 mL H2O, buffered to pH = 8 with Na2CO3) and 
the mixture diluted with EtOAc (10 mL). The biphasic mixture was stirred for 40 min, 
the phases were separated and the aqueous phase was extracted with EtOAc (3 × 10 
mL). The organic extracts were combined, washed with brine (10 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (PE—Et2O, 6:4) to give the corresponding tricyclic product 
284-1 (2.7 mg, 29% over two steps) as a colourless oil. One diastereoisomer only was 
isolated. 
C20H28O4Si   Molecular weight: 360.52 g·mol
−1 
Rf = 0.35 (PE—Et2O, 4:6); 
IR νmax 3451, 2955, 2934, 2872, 2359, 1753, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.27 (1H, d, J = 1.2 Hz, CH-C2 or CH-C5), 7.23 (1H, d, J = 
1.5 Hz, CH-C2 or CH-C5), 5.93 (1H, s, CH-C18), 5.84 (1H, s, CH-C13), 4.84 (1H, dd, J = 
11.7, 3.0 Hz, CH-C15), 4.41 (1H, dd, J = 5.2, 2.6 Hz, CH-C10), 3.69 (1H, d, J = 15.0 Hz, 
CH2-C11), 3.47 (1H, d, J = 15.0 Hz, CH2-C11), 2.98—2.92 (2H, m, CH-C6 and CH2-C16), 
2.34 (1H, dd, J = 13.8, 11.7 Hz, CH2-C16), 1.90 (1H, dddd, J = 11.8, 8.8, 6.8, 5.2 Hz, 
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CH2-C7), 1.75 (1H, d, J = 5.2 Hz, OH), 1.55—1.46 (1H, m, CH2-C7), 1.30—1.20 (2H, m, 
CH2-C8), 0.91 (3H, t, J = 7.3 Hz, CH3-C9), 0.15 (9H, s, 3×CH3-SiMe3); 
 13C NMR (101 MHz, CDCl3) δ 172.8 (C-C12), 172.6 (C-C14), 154.7 (C-C17), 142.7 (CH-C2 
or CH-C5), 142.2 (CH-C2 or CH-C5), 133.1 (CH-C18), 123.2 (C-C3 or C-C4), 120.0 (C-C3 
or C-C4), 114.9 (CH-C13), 77.4 (CH-C10), 42.9 (CH-C6), 23.7 (CH2-C11), 21.1 (CH2-C8), 
14.1 (CH3-C9), 0.1 (3×CH3-SiMe3); 
Carbon peaks missing:  
- From HSQC: CH-C15 (ca 83); 
- CH2-C7, CH2-C16; 
LRMS (CI, Me3CH): m/z (int) 361 (100), 343 (12), 237 (11), 213 (32), 133 (10), 85 (28), 69 
(29). HRMS (CI, Me3CH) calculated for C20H29O4Si [M+H]
+: 361.1835, found 361.1836, 
Δ +0.2 ppm. 
 
(10Z)-9-Hydroxy-8-propyl-10-(trimethylsilyl)methylidene-5,13- 
dioxatricyclo[10.3.0.03,7]pentadeca-1(15),3,6-trien-14-one (284-2) 
 
 
To a solution of vinyl iodide 276-2 (52.6 mg, 0.108 mmol) in CH2Cl2 (2.2 mL) was added 
DMP (132 mg, 0.311 mmol, 2.89 equiv). The mixture was stirred at rt for 2.5 h and then 
cooled to 0 ºC. The reaction was quenched with saturated aqueous Na2S2O3 (5 mL) and 
the mixture was diluted with water (5 mL) and CH2Cl2 (5 mL). After 10 min, the phases 
were separated and the aqueous phase was extracted with CH2Cl2 (3 × 5 mL). The 
organic extracts were combined and washed with brine (10 mL), then dried with Na2SO4, 
filtered and concentrated in vacuo. The residue was quickly purified by passage through 
a small plug of silica (PE—Et2O, 8:2) to give the corresponding aldehyde (41.5 mg, 79%) 
as a colourless oil.  
To a solution of the aldehyde (41.5 mg, 0.0853 mmol) in degassed DMSO (three freeze-
thaw cycles, 24 mL) were successively added DMS (240 µL), CrCl2 (211 mg, 1.72 mmol, 
20.2 equiv) and NiCl2 (5.5 mg, 0.042 mmol, 0.50 equiv). The dark green mixture was 
stirred at rt for 35 h and then cooled to 0 ºC. The reaction was quenched with a solution 
of serinate (3.0 g of serine diluted in 30 mL H2O, buffered to pH = 8 with Na2CO3) and 
the mixture diluted with EtOAc (30 mL). The biphasic mixture was stirred for 40 min, 
the phases were separated and the aqueous phase was extracted with EtOAc (3 × 30 
mL). The organic extracts were combined, washed with brine (50 mL), dried over 
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MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (PE—Et2O, 6:4) to give the corresponding tricyclic product 
284-2 (8.4 mg, 22% over two steps) as a colourless oil. One diastereoisomer only was 
isolated. 
C20H28O4Si   Molecular weight: 360.52 g·mol
−1 
Rf = 0.35 (PE—Et2O, 4:6); 
IR νmax 3458, 2958, 2928, 2868, 2359, 1751, 1629, 1606, 1541, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.25 (1H, d, J = 1.5 Hz, CH-C2 or CH-C5), 7.16 (1H, d, J = 
1.5 Hz, CH-C2 or CH-C5), 5.87 (1H, app ddd, J = 1.6, 1.3, 1.3 Hz, CH-C13), 5.49 (1H, s, 
CH-C18), 4.68 (1H, d, J = 9.4 Hz, CH-C15), 3.99 (1H, d, J = 9.4 Hz , CH-C10), 3.83 (1H, 
d, J = 18.0 Hz, CH2-C11), 3.63 (1H, d, J = 18.0 Hz, CH2-C11), 2.82 (1H, app dt, J = 15.5, 
1.5 Hz, CH2-C16), 2.56 (1H, ddd, J = 11.6, 9.4, 3.4 Hz, CH-C6), 2.50 (1H, dd, J = 15.5, 
9.4 Hz, CH2-C16), 2.11 (1H, dddd, J = 13.2, 9.9, 6.4, 3.4 Hz, CH2-C7), 1.80 (1H, s, OH), 
1.55—1.43 (1H, m, CH2-C7), 1.35—1.16 (2H, m, CH2-C8), 0.89 (3H, t, J = 7.3 Hz, CH3-C9), 
0.08 (9H, s, 3×CH3-SiMe3); 
13C NMR (101 MHz, CDCl3) δ 172.3 (C-C12), 172.2 (C-C14), 154.4 (C-C17), 141.1 (CH-C2 
or CH-C5), 140.2 (CH-C2 or CH-C5), 134.1 (CH-C18), 125.3 (C-C3 or C-C4), 119.3 (C-C3 
or C-C4), 115.9 (CH-C13), 86.2 (CH-C10), 85.8 (CH-C15), 39.4 (CH-C6), 35.7 (CH2-C7), 
31.7 (CH2-C16), 22.6 (CH2-C11), 21.0 (CH2-C8), 14.3 (CH3-C9), −0.3 (3×CH3-SiMe3); 
LRMS (CI, Me3CH): m/z (int) 361 (100), 160 (22), 85 (32), 71 (35). HRMS (CI, Me3CH) 
calculated for C20H29O4Si [M+H]
+: 361.1835, found 361.1833, Δ −0.5 ppm. 
 
(8S*,9*,12S*)-9-Hydroxy-10-methylidene-8-propyl-5,13-
dioxatricyclo[10.3.0.03,7]pentadeca-1(15),3,6-trien-14-one (286-syn) 
and 
(8S*,9S*,12S*)-9-Hydroxy-10-methylidene-8-propyl-5,13- 
dioxatricyclo[10.3.0.03,7]pentadeca-1(15),3,6-trien-14-one (5-epi-286-syn) 
 
 
To a solution of vinyl iodide 262-syn (59.2 mg, 0.142 mmol) in CH2Cl2 (2.8 mL) was 
added DMP (132 mg, 0.279 mmol, 1.96 equiv). The mixture was stirred at rt for 2 h and 
then cooled to 0 ºC. The reaction was quenched with saturated aqueous Na2S2O3 (5 mL) 
and the mixture diluted with water (5 mL) and CH2Cl2 (5 mL). After 10 min, the phases 
were separated, the aqueous phase was extracted with CH2Cl2 (3 × 5 mL), the organic 
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extracts were combined and washed with brine (10 mL), then dried with Na2SO4, 
filtered and concentrated in vacuo. The crude product was quickly purified by passage 
through a small plug of silica (PE—Et2O, 8:2) to afford the corresponding aldehyde (50.1 
mg, 85%) as a colourless oil. 
To a solution of CrCl2 (200 mg, 1.63 mmol, 13.5 equiv) and NiCl2 (1.6 mg, 0.012 mmol, 
0.10 equiv) in previously degassed DMSO (three freeze-thaw cycles, 6 mL) was added a 
solution of aldehyde (50.1 mg, 0.121 mmol) in degassed DMSO (three freeze-thaw 
cycles, 6 mL) at rt. The dark green mixture was stirred for 24 h at rt and for 16 h at 50 
ºC. The reaction was quenched with saturated aqueous NH4Cl (15 mL) and the mixture 
diluted with EtOAc (30 mL). The biphasic mixture was stirred for 30 min, the phases 
were separated and the aqueous phase was extracted with EtOAc (3 × 30 mL). The 
organic extracts were combined, washed with brine (50 mL), dried over MgSO4, filtered 
and concentrated in vacuo. The crude product was purified by flash column 
chromatography (PE—Et2O, 45:55) allowing the separation of minor diastereoisomer 
5-epi-286-syn (5.5 mg, 13% over two steps) as a colourless oil and major 
diastereoisomer 286-syn (20.2 mg, 49% over two steps) as a colourless solid. The crystal 
structure of the major diastereoisomer was obtained, confirming its structure (cf. 
Annexe 15). 
C17H20O4   Molecular weight: 288.34 g·mol
−1 
Less polar diastereoisomer 5-epi-286-syn 
mp. 140—143 ºC; 
Rf = 0.53 (PE—Et2O, 2:8); 
IR νmax 3454, 2955, 2930, 2870, 2366, 1743, 1635, 1537, 1456 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.37 (1H, d, J = 1.5 Hz, CH-C5), 7.23 (1H, d, J = 1.5 Hz, CH-
C2), 5.89 (1H, ddd, J = 1.6, 1.1, 1.1 Hz, CH-C13), 5.23 (1H, ddd, J = 3.6, 2.7, 1.6 Hz, 
CH-C15), 4.97 (1H, s, CH2-C18), 4.94 (1H, s, CH2-C18), 4.12 (1H, d, J = 1.5 Hz, CH-C10), 
3.68 (1H, dd, J = 14.7, 1.1 Hz, CH2-C11), 3.01 (1H, dd, J = 14.7, 1.1 Hz, CH2-C11), 2.97 
(1H, ddd, J = 8.6, 6.5, 1.5 Hz, CH-C6), 2.91 (1H, dd, J = 16.4, 2.7 Hz, CH2-C16), 2.45 
(1H, dd, J = 16.4, 3.6 Hz, CH2-C16), 1.84—1.65 (2H, m, CH2-C7), 1.57 (1H, br s, OH), 
1.40—1.29 (2H, m, CH2-C8), 0.92 (3H, t, J = 7.4 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 172.6 (C-C12), 170.3 (C-C14), 143.2 (C-C17), 140.8 (CH-
C2), 140.5 (CH-C5), 122.5 (C-C3 or C-C4), 122.0 (C-C3 or C-C4), 120.0 (CH-C13), 113.5 
(CH2-C18), 83.9 (CH-C15), 74.8 (CH-C10), 38.0 (CH-C6), 30.5 (CH2-C16), 30.2 (CH2-C7), 
21.5 (CH2-C11), 21.1 (CH2-C8), 14.1 (CH3-C9); 
LRMS (CI, Me3CH): m/z (int) 289 (72), 273 (12), 137 (13), 113 (68), 97 (68), 81 (73), 71 
(100). HRMS (CI, Me3CH) calculated for C17H21O4 [M+H]
+: 289.1440, found 289.1438, 
Δ −0.7 ppm. 
More polar diastereoisomer 286-syn 
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mp. 140—142 ºC; 
Rf = 0.44 (PE—Et2O, 2:8); 
IR νmax 3400, 2957, 2928, 2872, 1744, 1636, 1537, 1444 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.34 (1H, s, CH-C5), 7.23 (1H, s, CH-C2), 5.93 (1H, s, CH-
C13), 5.15 (1H, s, CH-C15), 4.92 (1H, s, CH2-C18), 4.87 (1H, s, CH2-C18), 3.90 (1H, d, J = 
4.3 Hz, CH-C10), 3.68 (1H, d, J = 16.0 Hz, CH2-C11), 3.27 (1H, br s, CH2-C11), 2.81—2.71 
(2H, m, CH-C6 and CH2-C16), 2.55 (1H, br s, CH2-C16), 1.85 (2H, br s, CH2-C7 and OH), 
1.55—1.44 (1H, m, CH2-C7), 1.39—1.28 (1H, m, CH2-C8), 1.27—1.14 (1H, m, CH2-C8), 
0.89 (3H, t, J = 7.4 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 172.8 (C-C12), 170.4 (C-C14), 141.9 (C-C17), 141.5 (CH-
C2), 140.0 (CH-C5), 123.3 (C-C3 or C-C4), 121.1 (C-C3 or C-C4), 119.7 (CH-C13), 118.6 
(CH2-C18), 83.2 (CH-C15), 81.5 (CH-C10), 39.7 (CH-C6), 32.7 (CH2-C7), 28.9 (CH2-C16), 
22.8 (CH2-C11), 20.9 (CH2-C8), 14.2 (CH3-C9); 
LRMS (EI+): m/z (int) 288 (100), 270 (43), 259 (36), 219 (64), 173 (51), 129 (39), 91 (81), 
77 (47), 43 (47). HRMS (EI+) calculated for C17H20O4 [M]
+: 288.1362, found 288.1360, 
Δ −0.6 ppm. 
 
(8S*,12R*)-9-Hydroxy-10-methylidene-8-propyl-5,13- 
dioxatricyclo[10.3.0.03,7]pentadeca-1(15),3,6-trien-14-one (286-anti) 
 
 
To a solution of vinyl iodide 262-anti (59.2 mg, 0.123 mmol) in CH2Cl2 (2.5 mL) was 
added DMP (80.2 mg, 0.189 mmol, 1.54 equiv). The mixture was stirred at rt for 40 min, 
cooled to 0 ºC and the reaction was quenched with saturated aqueous Na2S2O3 (5 mL). 
The mixture was diluted with water (5 mL) and CH2Cl2 (5 mL) and after 10 min, the 
phases were separated. The aqueous phase was extracted with CH2Cl2 (3 × 5 mL), the 
organic extracts were combined and washed with brine (10 mL), dried with Na2SO4, 
filtered and concentrated in vacuo. The crude product was quickly purified by passage 
through a small plug of silica (PE—Et2O, 8:2) to afford the corresponding aldehyde 
(50.9 mg, 100%) as a colourless oil. 
To a solution of CrCl2 (215 mg, 1.76 mmol, 14.3 equiv) and NiCl2 (2.5 mg, 0.019 mmol, 
0.16 equiv) in degassed DMSO (three freeze-thaw cycles, 6 mL) was added a solution of 
aldehyde (50.9 mg, 0.123 mmol) in degassed DMSO (three freeze-thaw cycles, 6.5 mL) 
at rt. The dark green mixture was stirred for 48 h at 50 ºC. The reaction was quenched 
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with saturated aqueous NH4Cl (15 mL) and the mixture diluted with EtOAc (30 mL). The 
biphasic mixture was stirred for 30 min and the phases were separated. The aqueous 
phase was extracted with EtOAc (3 × 30 mL) and the organic extracts were combined, 
washed with brine (50 mL), dried over MgSO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography (PE—Et2O, 45:55) to give an 
inseparable mixture (1:2.4 based on 1H NMR) of the two diastereoisomers 286-anti 
(17.8 mg, 50%). 
C17H20O4   Molecular weight: 288.34 g·mol
−1 
Rf = 0.25 (PE—Et2O, 4:6); 
IR νmax 3448, 2957, 2928, 2872, 2360, 1748, 1633, 1541, 1465 cm
−1; 
Minor diastereoisomer 
1H NMR (500 MHz, CDCl3) δ 7.34 (1H, d, J = 1.4 Hz, CH-C5), 7.32 (1H, d, J = 1.4 Hz, CH-
C2), 6.02 (1H, dd, J = 1.1, 0.8 Hz, CH-C13), 5.14 (1H, s, CH2-C18), 5.05 (1H, s, CH2-C18), 
4.98 (1H, ddd, J = 4.5, 3.6, 1.0 Hz, CH-C15), 4.14 (1H, s, CH-C10), 3.76 (1H, dd, J = 
18.0, 0.8 Hz, CH2-C11), 3.67 (1H, d, J = 18.0 Hz, CH2-C11), 2.60—2.48 (2H, m, CH-C6 
and CH2-C16), 2.05 (1H, app ddd, J = 15.2, 3.6, 1.3 Hz, CH2-C16), 2.11 (1H, br s, CH2-
C7), 1.92 (1H, br s, OH), 1.56—1.49 (1H, m, CH2-C7), 1.37—1.24 (1H, m, CH2-C8), 1.23—
1.11 (1H, m, CH2-C8), 0.87 (3H, t, J = 7.4 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 172.6 (C-C12), 171.4 (C-C14), 146.4 (C-C17), 142.1 (CH-
C2), 140.4 (CH-C5), 123.7 (C-C3 or C-C4), 119.5 (CH2-C18), 119.4 (C-C3 or C-C4), 119.2 
(CH-C13), 82.6 (CH-C15), 77.8 (CH-C10), 39.6 (CH-C6), 35.2 (CH2-C7), 30.9 (CH2-C16), 
24.2 (CH2-C11), 20.7 (CH2-C8), 14.0 (CH3-C9); 
Major diastereoisomer 
1H NMR (500 MHz, CDCl3) δ 7.28 (1H, s, CH-C5), 7.23 (1H, d, J = 1.5 Hz, CH-C2), 5.90 
(1H, s, CH-C13), 5.13 (1H, s, CH2-C18), 5.05 (1H, s, CH2-C18), 4.75 (1H, br s, CH-C15), 
3.98 (1H, d, J = 7.4 Hz, CH-C10), 3.83—3.73 (1H, m, CH2-C11), 3.61 (1H, d, J = 17.9 Hz, 
CH2-C11), 2.60—2.48 (2H, m, CH-C6 and CH2-C16), 2.39 (1H, d, J = 15.4 Hz, CH2-C16), 
1.92 (1H, br s, OH), 1.78—1.61 (2H, m, CH2-C7), 1.37—1.24 (1H, m, CH2-C8), 1.23—1.11 
(1H, m, CH2-C8), 0.87 (3H, t, J = 7.4 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 172.5 (C-C12), 168.6 (C-C14), 143.4 (C-C17), 141.2 (CH-
C2), 140.4 (CH-C5), 123.7 (C-C3 or C-C4), 119.1 (C-C3 or C-C4), 116.9 (CH2-C18), 116.4 
(CH-C13), 86.2 (CH-C15), 81.5 (CH-C10), 40.0 (CH-C6), 37.1 (CH2-C7), 31.1 (CH2-C16), 
22.5 (CH2-C11), 20.8 (CH2-C8), 14.2 (CH3-C9); 
LRMS (CI, Me3CH): m/z (int) 289 (100), 271 (24), 137 (10), 71 (13). HRMS (CI, Me3CH) 
calculated for C17H21O4 [M+H]
+: 289.1440, found 289.1436, Δ −1.4 ppm. 
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(8S*,12R*)-10-Methylidene-8-propyl-5,13-dioxatricyclo[10.3.0.03,7]pentadeca-
1(15),3,6-triene-9,14-dione (287-anti)  
and 
(8S*,12R*)-10-Methyl-8-propyl-5,13-dioxatricyclo[10.3.0.03,7]pentadeca-1(15),3,6- 
triene-9,14-dione (288-anti) 
 
 
 
To a solution of the diastereoisomeric mixture 286-anti (7.1 mg, 0.025 mmol) in CH2Cl2 
(1 mL) was added DMP (15.6 mg, 0.0368 mmol, 1.49 equiv). The solution was stirred at 
rt for 1 h and then cooled to 0 ºC. The reaction was quenched with saturated aqueous 
Na2S2O3 (5 mL) and the mixture diluted with water (5 mL) and CH2Cl2 (5 mL). After 
10 min, the phases were separated and the aqueous phase was extracted with CH2Cl2 
(3 × 5 mL). The organic extracts were combined and washed with brine (10 mL), dried 
with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
passage through a small plug of silica (PE—Et2O, 5:5) to give 7.0 mg (99%) of a colourless 
oil. 1H NMR confirmed that one enone 287-anti was obtained from the mixture of the 
two diastereoisomers 286-anti. 
To a solution of the enone 287-anti (7.0 mg, 0.024 mmol) in THF (2.4 mL) at −78 ºC 
were successively added CeCl3 (12 mg, 0.049 mmol, 2.0 equiv) and L-selectride (29 µL of 
a 1 M solution in THF, 0.029 mmol, 1.2 equiv). The mixture was stirred for 1 h and more 
L-selectride (29 µL of a 1 M solution in THF, 0.029 mmol, 1.2 equiv) was added. After a 
further 30 min, the reaction was quenched with saturated aqueous NH4Cl (5 mL) and the 
mixture was warmed to rt. Et2O (10 mL) was added and the phases were separated. The 
aqueous phase was extracted with Et2O (3 × 5 mL) and the organic extracts were 
combined, washed with brine (10 mL), dried over MgSO4, filtered and concentrated in 
vacuo. The crude product was purified by flash column chromatography (PE—Et2O, 6:4) 
to give 288-anti as two separable diastereoisomers: 2.7 mg (38%, 2 steps) of the less 
polar diastereoisomer, 2.1 mg (30%, 2 steps) of the more polar diastereoisomer, both 
colourless oils. 
287-anti 
C17H18O4   Molecular weight: 286.32 g·mol
−1 
Rf = 0.50 (PE—Et2O, 2:8); 
IR νmax 3153, 3099, 2958, 2932, 2872, 2355, 1755, 1687, 1633, 1534, 1464 cm
−1; 
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1H NMR (500 MHz, CDCl3) δ 7.29 (1H, d, J = 1.2 Hz, CH-C2 or CH-C5), 7.28 (1H, s, CH-C2 
or CH-C5), 5.88 (1H, td, J = 1.9, 1.3 Hz, CH-C13), 5.74 (1H, d, J = 1.2 Hz, CH2-C18), 
5.70 (1H, d, J = 1.2 Hz, CH2-C18), 4.81 (1H, ddd, J = 8.6, 5.2, 1.3 Hz, CH-C15), 4.09 
(1H, ddd, J = 10.3, 4.2, 1.2 Hz, CH2-C6), 3.62 (2H, d, J = 1.9 Hz, CH2-C11), 3.46 (1H, dd, 
J = 13.9, 5.2 Hz, CH2-C16), 2.42 (1H, dd, J = 13.9, 8.6 Hz, CH2-C16), 2.19—2.12 (1H, m, 
CH2-C7), 1.75 (1H, dddd, J = 13.0, 8.5, 7.7, 4.2 Hz, CH2-C7), 1.39 (2H, app tq, J = 7.3, 
7.3 Hz, CH2-C8), 0.99 (3H, t, J = 7.3 Hz, CH3-C9); 
288-anti 
C17H20O4   Molecular weight: 288.34 g·mol
−1 
Less polar diastereoisomer 
Rf = 0.35 (PE—Et2O, 4:6); 
IR νmax 2963, 2931, 2870, 2337, 1759, 1705, 1636, 1543, 1458 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.41 (1H, app t, J = 1.3 Hz, CH-C2), 7.33 (1H, s, CH-C5), 
5.84 (1H, app t, J = 1.9 Hz, CH-C13), 4.55 (1H, dd, J = 9.3, 3.8 Hz, CH-C15), 3.73 (1H, 
d, J = 17.4 Hz, CH2-C11), 3.55 (1H, ddd, J = 9.6, 5.5, 1.3 Hz, CH-C6), 3.34 (1H, dd, J = 
17.4, 1.9 Hz, CH2-C11), 2.87—2.79 (1H, m, CH-C17), 2.06—2.00 (2H, m, CH2-C16), 1.97—
1.90 (1H, m, CH2-C7), 1.89—1.81 (1H, m, CH2-C7), 1.50—1.33 (2H, m, CH2-C8), 1.13 (3H, 
d, J = 6.9 Hz, CH3-C18), 0.99 (3H, t, J = 7.4 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 216.0 (C-C10), 171.9 (C-C12), 170.7 (C-C14), 142.5 (CH-
C5), 140.5 (CH-C2), 122.5 (C-C3 or C-C4), 119.3 (C-C3 or C-C4), 116.7 (CH-C13), 82.9 
(CH-C15), 50.5 (CH-C6), 39.2 (CH-C17), 38.4 (CH2-C16), 31.7 (CH2-C7), 22.4 (CH2-C11), 
21.2 (CH3-C18), 20.6 (CH2-C8), 14.0 (CH3-C9); 
LRMS (CI, Me3CH): m/z (int) 289 (100), 113 (14), 85 (26), 73 (47). HRMS (CI, Me3CH) 
calculated for C17H21O4 [M+H]
+: 289.1440, found 289.1438, Δ −0.7 ppm. 
More polar diastereoisomer 
Rf = 0.20 (PE—Et2O, 4:6); 
IR νmax 2962, 2924, 2360, 1751, 1712, 1635, 1535, 1458 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.31 (1H, s, CH-C2 or CH-C5), 7.26 (1H, s, CH-C2 or CH-C5), 
5.92 (1H, s, CH-C13), 4.91 (1H, dd, J = 5.3, 3.5 Hz, CH-C15), 3.67 (1H, dd, J = 8.7, 5.6 
Hz, CH-C6), 3.61 (1H, dd, J = 17.3, 1.3 Hz, CH2-C11), 3.28 (1H, d, J = 17.3 Hz, CH2-C11), 
2.80 (1H, dqd, J = 9.5, 6.8, 2.5 Hz, CH-C17), 2.30 (1H, ddd, J = 14.9, 9.5, 3.5 Hz, CH2-
C16), 2.08 (1H, ddd, J = 14.9, 5.3, 2.5 Hz, CH2-C16), 1.94—1.85 (1H, m, CH2-C7), 1.76—
1.67 (1H, m, CH2-C7), 1.39—1.29 (2H, m, CH2-C8), 1.14 (3H, d, J = 6.8 Hz, CH3-C18), 
0.95 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 216.8 (C-C10), 170.0 (C-C12), 170.0 (C-C14), 141.3 (CH-C2 
or CH-C5), 141.2 (CH-C2 or CH-C5), 124.2 (C-C3 or C-C4), 119.8 (C-C3 or C-C4), 118.8 
(CH-C13), 81.8 (CH-C15), 49.9 (CH-C6), 42.1 (CH-C17), 37.4 (CH2-C16), 33.9 (CH2-C7), 
23.6 (CH2-C11), 21.2 (CH2-C8), 18.3 (CH3-C18), 14.4 (CH3-C9); 
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LRMS (CI, Me3CH): m/z (int) 289 (82), 113 (18), 89 (100), 85 (42), 73 (55), 69 (59). HRMS 
(CI, Me3CH) calculated for C17H21O4 [M+H]
+: 289.1440, found 289.1444, Δ +1.5 ppm. 
 
tert-Butyl[4-(1-methoxybutyl)furan-3-yl]methoxydimethylsilane (304) 
 
 
To a solution of alcohol 240 (1.14 g, 4.01 mmol, 1.00 equiv) in THF (41 mL) at 0 ºC was 
added NaH (257 mg of a 60% dispersion in mineral oil, 6.43 mmol, 1.60 equiv) 
portionwise. After 5 min, iodomethane (520 µL, 8.35 mmol, 2.08 equiv) was added and 
the mixture was warmed to rt and stirred overnight. The reaction was quenched with 
saturated aqueous NH4Cl (10 mL) and the mixture diluted with Et2O (40 mL). The phases 
were separated and the aqueous phase was extracted with Et2O (2 × 20 mL). The 
organic extracts were combined and washed with brine (40 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (PE—Et2O, 95:5) to give the desired product 304 (1.14 g, 95%) as a 
colourless oil. 
C16H30O3Si    Molecular weight: 298.49 g·mol
−1 
Rf = 0.90 (PE—Et2O, 9:1); 
IR νmax 2957, 2930, 2859, 2819, 2339, 1544, 1472, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.33 (1H, dd, J = 1.3, 1.3 Hz, CH-C5), 7.28 (1H, d, J = 1.7 
Hz, CH-C2), 4.63 (1H, dd, J = 13.4, 1.3 Hz, CH2-C10), 4.59 (1H, dd, J = 13.4, 1.3 Hz, 
CH2-C10), 4.16 (1H, dd, J = 7.3, 6.8 Hz, CH-C6), 3.22 (3H, s, CH3-OMe), 1.77 (1H, dddd, 
J = 13.5, 10.0, 7.3, 5.6 Hz, CH2-C7), 1.63 (1H, dddd, J = 13.5, 9.8, 6.8, 6.8 Hz, CH2-C7), 
1.45—1.25 (2H, m, CH2-C8), 0.92 (9H, s, 3×CH3-tBu), 0.91 (3H, t, J = 7.4 Hz, CH3-C9), 
0.09 (3H, s, CH3-SiMe2), 0.08 (3H, s, CH3-SiMe2); 
13C NMR (101 MHz, CDCl3) δ 141.1 (CH-C2 or CH-C5), 141.0 (CH-C2 or CH-C5), 125.1 (C-
C3 or C-C4), 124.6 (C-C3 or C-C4), 75.9 (CH-C6), 57.2 (CH2-C10), 56.2 (CH3-OMe), 38.2 
(CH2-C7), 26.1 (3×CH3-tBu), 19.2 (CH2-C8), 18.5 (C-tBu), 14.1 (CH3-C9), −5.2 (2×CH3-
SiMe2); 
LRMS (CI, Me3CH): m/z (int) 299 (21), 267 (76), 241 (10), 193 (33), 179 (21), 135 (100), 
87 (12). HRMS (CI, Me3CH) calculated for C16H31O3Si [M+H]
+: 299.2042, found 299.2043, 
Δ +0.3 ppm. 
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(S)-But-3-en-2-ol ((+)-314)145,143 
 
 
To a solution of (−)-Ethyl-L-lactate 321 (15.0 mL, 132 mmol) in CH2Cl2 (130 mL), DHP 
(14.5 mL, 159 mmol, 1.20 equiv) and PPTS (3.3 g, 13 mmol, 0.10 equiv) were added to 
the solution at rt. The mixture was stirred overnight and the reaction was quenched 
with saturated aqueous NaHCO3 (50 mL). The two phases were separated and the 
aqueous phase was extracted with PE (2 × 60 mL). The organic extracts were combined, 
washed with brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo. 
To a solution of the crude ester 322 in CH2Cl2 (660 mL) at −78 ºC, DIBAL-H (134 mL of a 
1 M solution in hexane, 134 mmol, 1.01 equiv) was added dropwise over 25 min at 
−78 ºC. The mixture was stirred for 1 h and the reaction was quenched with MeOH 
(10 mL). The solution was stirred for 10 min and poured onto a saturated solution of 
Rochelle salt (1 L) at 0 ºC. Et2O (1.5 L) was added and the solution was warmed to rt 
and stirred vigorously until clear separation of the phases (typically 1 to 1.5 h). Once 
the phases had separated, the aqueous phase was extracted with Et2O (2 × 500 mL). The 
organic extracts were combined, dried over MgSO4, filtered and concentrated in vacuo, 
delivering the aldehyde that was used directly without further purification. 
To a suspension of methyltriphenylphosphonium bromide (142 g, 397 mmol, 3.01 equiv) 
in THF (660 mL) at 0 ºC was added portionwise potassium tert-butoxide (37.1 g, 
331 mmol, 2.50 equiv). The bright yellow suspension was warmed to rt and stirred for 
1 h, before being cooled to 0 ºC and slowly added to a solution of crude aldehyde in THF 
(660 mL). The addition of the ylide was stopped when the colour of the mixture 
remained bright yellow. The mixture was stirred then warmed to rt and stirred for 
30 min before being quenched with a saturated solution of NH4Cl (300 mL), and diluted 
with Et2O (800 mL). The phases were separated and the aqueous phase was extracted 
with Et2O (2 × 500 mL). The organic extracts were combined, dried over MgSO4, filtered 
and concentrated in vacuo. The residue was filtered through a plug of silica (PE—Et2O, 
95:5) to remove the triphenylphosphonium oxide and the volatile colourless oil was used 
for the next step immediately. 
Alkene 323 was diluted in ethylene glycol (40 mL) and p-TSA (1.3 g, 6.8 mmol, 
0.05 equiv) was added. The mixture was stirred at rt for 2 days. The product was 
obtained from the solution by distillation (46 mbar, 80 to 95 ºC) to afford allylic alcohol 
(+)-314 (5.35 g, 56% over 4 steps) as a colourless oil. 
C4H8O    Molecular weight: 72.11 g·mol
-1 
bp. 97 ºC (1 bar); 
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Rf = 0.4 (PE—Et2O, 5:5); 
[α]D
24  
+16.7 (c = 1.12, CHCl3) {Lit.
145 [α]D
20  
+31.5 (neat), Lit.143 [α]D
24  
+25.9 (c = 1.2, 
Et2O)}; 
IR νmax 3331, 2974, 2929, 2874, 1645, 1452, 1422 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 5.91 (1H, dddd, J = 17.2, 10.4, 6.0, 0.8 Hz, CH-C3), 5.21 
(1H, ddd, J = 17.2, 2.4, 1.2 Hz, CH2-C4), 5.06 (1H, ddd, J = 10.4, 2.4, 1.2 Hz, CH2-C4), 
4.30 (1H, qdd, J = 6.4, 6.0, 1.2 Hz, CH-C2), 1.67—1.57 (1H, m, OH), 1.27 (3H, d, J = 
6.4 Hz, CH3-C1); 
 13C NMR (126 MHz, CDCl3) δ 142.5 (CH-C3), 113.8 (CH2-C4), 69.2 (CH-C2), 23.2 (CH3-
C1). 
 
tert-Butyl(4-ethenylfuran-3-yl)methoxydimethylsilane (324) 
 
 
To a suspension of methyltriphenylphosphonium bromide (68.5 g, 192 mmol, 4.00 equiv) 
in THF (300 mL) at 0 ºC was added potassium tert-butoxide (16.1 g, 144 mmol, 
3.00 equiv). The bright yellow suspension was warmed to rt, stirred for 1 h and cooled 
to 0 ºC. A solution of the crude, previously prepared aldehyde 128 (13.0 g, ~54.3 mmol) 
in THF (140 mL) was added slowly to the solution. The mixture was stirred for 1 h at rt 
and the reaction was quenched with saturated aqueous NH4Cl (60 mL). The mixture was 
diluted with Et2O (200 mL) and the phases were separated. The aqueous phase was 
extracted with Et2O (2 × 60 mL) and the organic extracts were combined, washed with 
brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo. The residue was 
purified by flash column chromatography (PE—Et2O, 95:5 to 9:1) to deliver the 
corresponding alkene 324 (8.14 g, 62% over 4 steps) as a colourless oil. 
C13H22O2Si     Molecular weight: 238.40 g·mol
−1 
Rf = 0.95 (PE—Et2O, 8:2); 
IR νmax 2955, 2932, 2886, 2859, 1643, 1582, 1535, 1470 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.44 (1H, d, J = 1.5 Hz, CH-C2), 7.32 (1H, app d, J = 1.1 Hz, 
CH-C5), 6.53 (1H, dd, J = 17.8, 11.3 Hz, CH-C6), 5.47 (1H, dd, J = 17.8, 1.5 Hz, CH2-C7), 
5.17 (1H, dd, J = 11.3, 1.5 Hz, CH2-C7), 4.66 (2H, d, J = 1.1 Hz, CH2-C8), 0.92 (9H, s, 
3×CH3-tBu), 0.09 (6H, s, 2×CH3-SiMe2); 
13C NMR (101 MHz, CDCl3) δ 141.5 (CH-C2), 141.2 (CH-C5), 126.6 (CH-C6), 124.5 (C-C4), 
123.7 (C-C3), 114.9 (CH2-C7), 57.2 (CH2-C8), 26.0 (3×CH3-tBu), 18.5 (C-tBu), 
−5.2 (2×CH3-SiMe2);  
 163 
LRMS (CI, Me3CH): m/z (int) 239 (32), 230 (9), 181 (30), 163 (9), 137 (9), 107 (100), 81 
(30). HRMS (CI, Me3CH) calculated for C13H23O2Si [M+H]
+: 239.1467, found 239.1468, 
Δ +0.1 ppm. Analytic. calculated for C13H22O2Si: C, 65.50; H, 9.30. Found: C, 65.61; H, 
9.45. 
 
(2S,3E)-4-(4-tert-Butyldimethylsilyloxymethylfuran-3-yl)but-3-en-2-ol ((−)-325) 
 
 
To a solution of vinyl furan 324 (1.01 g, 4.24 mmol) in CH2Cl2 (22 mL) was added allylic 
alcohol (+)-314 (1.5 mL, 17 mmol, 4.1 equiv) and Grubbs II catalyst (180 mg, 0.212 
mmol, 0.0500 equiv). The solution was stirred at reflux for 48 h; two further portions of 
Grubbs II catalyst (57.2 mg, 0.674 mmol, 0.0159 equiv and 60.4 mg, 0.0711 mmol, 
0.0168 equiv) were added at 12 h intervals. The mixture was concentrated in vacuo and 
purified by flash column chromatography (PE—Et2O, 92:8 to 9:1) to give the colourless 
oil (−)-325 (878 mg, 73%) and unreacted vinyl furan 324 (200 mg, 20%).  Enantiomeric 
purity was 73%, as determined by normal phase chiral HPLC analysis.141 
C15H26O3Si    Molecular weight: 282.45 g·mol
−1 
Rf = 0.30 (PE—Et2O, 7:3); 
[α]D
26  −9.8 (c = 1.11, CHCl3); 
IR νmax 3562, 2958, 2929, 2857, 2361, 1667, 1538, 1472 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.42 (1H, d, J = 1.6 Hz, CH-C2), 7.30 (1H, app d, J = 1.1 Hz, 
CH-C5), 6.40 (1H, d, J = 16.1 Hz, CH-C6), 6.05 (1H, dd, J = 16.1, 6.4 Hz, CH-C7), 4.64 
(2H, d, J = 1.1 Hz, CH2-C10), 4.41 (1H, dqd, J = 6.4, 6.4, 0.8 Hz, CH-C8), 1.57 (1H, br s, 
OH), 1.34 (3H, d, J = 6.4 Hz, CH3-C9), 0.91 (9H, s, CH3-tBu), 0.08 (3H, s, CH3-SiMe2), 
0.08 (3H, s, CH3-SiMe2); 
13C NMR (126 MHz, CDCl3) δ 141.4 (CH-C2 or CH-C5), 141.3 (CH-C2 or CH-C5), 134.5 
(CH-C7), 124.3 (C-C3 or C-C4), 122.6 (C-C3 or C-C4), 119.1 (CH-C6), 69.4 (CH-C8), 57.0 
(CH2-C10), 26.0 (CH3-tBu), 23.6 (CH3-C9), 18.4 (C-tBu), −5.1 (2×CH3-SiMe2); 
LRMS (FAB): m/z (int) 265 (100), 253 (10), 237 (10), 195 (13), 133 (26), 121 (92), 105 
(20), 73 (83). HRMS (FAB) calculated for C15H25O2Si [M-OH]
+: 265.1624, found 265.1619, 
Δ −2.0 ppm. 
HPLC analysis : tR (R enantiomer) = 27.9 min, tR (S enantiomer) = 35.3 min, Chiracel OD-
H, 2.5% propan-2-ol in n-hexane, flowrate 1.00 mL.min−1, detection 254 nm, 
temperature oven 20 ºC (cf. Annexes 16 and 17). 
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(3E)-4-[4-(tert-Butyldimethylsilyloxymethyl)furan-3-yl]but-3-en-2-one (326) 
 
 
Crude aldehyde 128 (1.30 g, ~5.42 mmol), prepared according to previously reported 
protocols, and 1-(triphenylphosphoranylidene)acetone185 (5.16 g, 16.2 mmol, 3.00 
equiv) were dissolved in toluene (54 mL). The resulting mixture was heated at 100 ºC 
and stirred at this temperature for 5 h. The solution was concentrated in vacuo and 
purified by flash column chromatography (PE—Et2O, 9:1) to give the desired unsaturated 
ketone 326 (871 mg, 57% over 4 steps) as a colourless oil. 
C15H24O3Si    Molecular weight: 280.43 g·mol
−1 
Rf = 0.39 (PE—Et2O, 8:2); 
IR νmax 2955, 2929, 2857, 1667, 1615 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.68 (1H, d, J = 1.4 Hz, CH-C2), 7.43 (1H, d, J = 16.4 Hz, 
CH-C7), 7.38 (1H, t, J = 0.8 Hz, CH-C5), 6.55 (1H, d, J = 16.4 Hz, CH-C6), 4.68 (2H, d, 
J = 0.8 Hz, CH2-C10), 2.32 (3H, s, CH3-C9), 0.91 (9H, s, 3×CH3-tBu), 0.09 (6H, s, 2×CH3-
SiMe2); 
13C NMR (101 MHz, CDCl3) δ 198.6 (C-C8), 145.9 (CH-C2), 142.2 (CH-C5), 133.4 (CH-C7), 
127.8 (CH-C6), 124.5 (C-C3 or C-C4), 121.8 (C-C3 or C-C4), 56.8 (CH2-C10), 27.7 (CH3-
C9), 26.0 (3×CH3-tBu), 18.4 (C-tBu), −5.1 (2×CH3-SiMe2); 
LRMS (CI, Me3CH): m/z (int) 281 (98), 223 (13), 149 (32). HRMS (CI, Me3CH) calculated 
for C15H25O3Si [M+H]
+: 281.1573, found 281.1575, Δ +0.6 ppm. 
 
(3E)-4-[4-(tert-Butyldimethylsilyloxymethyl)furan-3-yl]but-3-en-2-ol ((±)-325) 
 
 
To a solution of the unsaturated ketone 326 (1.09 g, 3.89 mmol) in MeOH (40 mL) at 
0 ºC were successively added CeCl3·7H2O (2.90 g, 7.78 mmol, 2.00 equiv) and NaBH4 
(176 mg, 4.67 mmol, 1.20 equiv). The solution was stirred for 1 h at 0 ºC and the 
reaction was quenched with saturated aqueous NaHCO3 (10 mL). The mixture was 
diluted with Et2O (50 mL) and water (10 mL), the phases were separated and the 
aqueous phase was extracted with Et2O (3 × 50 mL). The organic extracts were 
combined and washed with brine (50 mL), dried over MgSO4, filtered and concentrated 
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in vacuo. The residue was purified by flash column chromatography (PE—Et2O, 8:2) to 
give the desired alcohol (±)-325 (991 mg, 90%) as a colourless oil. 
C15H26O3Si   Molecular weight: 282.45 g·mol
−1 
Rf = 0.38 (PE—Et2O, 7:3); 
IR νmax (cm
-1) 3356, 2955, 2928, 2827, 1472 cm−1; 
1H NMR (400 MHz, CDCl3) δ 7.42 (1H, d, J = 1.6 Hz, CH-C2), 7.31 (1H, t, J = 1.2 Hz, CH-
C5), 6.40 (1H, d, J = 16.1 Hz, CH-C6), 6.05 (1H, dd, J = 16.1, 6.4 Hz, CH-C7), 4.64 (2H, 
d, J = 1.2 Hz, CH2-C10), 4.41 (1H, qdd, J = 6.4, 6.4, 3.9 Hz,  CH-C8), 1.50 (1H, d,  J = 
3.9 Hz, OH), 1.34 (3H, d, J = 6.4 Hz, CH3-C9), 0.91 (9H, s, 3×CH3-tBu), 0.08 (6H, s, 
2×CH3-SiMe2); 
13C NMR (101 MHz, CDCl3) δ 141.5 (CH-C2), 141.3 (CH-C5), 134.5 (CH-C7), 124.3 (C-C4 
or C-C3), 122.6 (C-C4 or C-C3), 119.1 (CH-C6), 69.4 (CH-C8), 57.0 (CH2-C10), 26.0 
(3×CH3-tBu), 23.6 (CH3-C9), 18.4 (C-tBu), −4.9 (2×CH3-SiMe2). 
 
2-(4-Methoxybenzyloxy)acetic acid (330)149 
 
 
To a solution of 1-bromoacetic acid 329 (1.2 g, 8.6 mmol, 1.0 equiv) and 
p-methoxybenzyl alcohol (1.1 mL, 8.8 mmol, 1.0 equiv) in THF (15 mL) at 0 ºC was 
added portionwise NaH (827 mg of a 60% dispersion in mineral oil, 20.7 mmol, 2.40 
equiv). For a better suspension, THF (10 mL) was added. The resulting suspension was 
heated at reflux overnight. The reaction was quenched with MeOH (5 mL) and the 
mixture was concentrated and partitioned between Et2O (20 mL) and water (20 mL). 
The organic phase was extracted with water (3 × 20 mL) and the aqueous phase was 
acidified with aqueous HCl until pH = 3 (1 M, 15 mL) and then extracted with CH2Cl2 
(3 × 70 mL). The organic extracts were combined, dried over MgSO4 and concentrated in 
vacuo. The resulting oil was crystallised with PE, and re-crystallised with PE and EtOAc 
to give the desired acid 330 (1.43 g, 84%) as a colourless solid. The data obtained for 
this compound matches that published in the literature.149 
C10H12O4    Molecular weight: 196.20 g·mol
−1 
mp. 53—54 ºC; 
Rf = 0.05 (PE—EtOAc, 5:5); 
IR νmax (cm
-1) 3127, 1757, 1725, 1512 cm−1; 
1H NMR (400 MHz, CDCl3) δ 10.70 (1H, br s, OH), 7.29 (2H, d, J = 8.7 Hz, 2×CH-C6), 
6.90 (2H, d, J = 8.7 Hz, 2×CH-C5), 4.58 (2H, s, CH2-C2), 4.11 (2H, s, CH2-C3), 3.81 (3H, 
s, CH3-OMe); 
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13C NMR (101 MHz, CDCl3) δ 159.8 (C-C1), 130.0 (2×CH-C6), 128.6 (C-C4 or C-C7), 128.6 
(C-C4 or C-C7), 114.1 (2×CH-C5), 73.3 (CH2-C2), 66.4 (CH2-C3), 55.4 (CH3-OMe); 
LRMS (EI+): m/z (int) 196 (25), 137 (88), 121 (98), 109 (15), 82 (44), 77 (24). HRMS (EI+) 
calculated for C10H12O4 [M]
+: 196.0736, found 196.0733, Δ −1.3 ppm. 
 
But-3-en-2-yl-2-(4-methoxyphenyl)methoxyacetate ((±)-331) 
 
 
To a solution of but-3-en-2-ol (270 µL, 3.14 mmol, 1.00 equiv) and carboxylic acid 330 
(803 mg, 4.10 mmol, 1.31 equiv) in CH2Cl2 (10.5 mL) at 0 ºC were successively added 
DMAP (534 mg, 7.85 mmol, 2.50 equiv) and EDCI (1.50 g, 7.82 mmol, 2.49 equiv). The 
mixture was warmed to rt and stirred overnight. The reaction was quenched with 
addition of water (15 mL). The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3 × 20 mL). The organic extracts were combined, washed with 
brine (40 mL), dried over MgSO4, filtered and concentrated in vacuo. The residue was 
purified by flash column chromatography (PE—Et2O, 80:20) to give the desired ester 
(±)-331 as a colourless oil (780 mg, 99%). 
C14H18O4    Molecular weight: 250.29 g·mol
−1 
Rf = 0.85 (PE—Et2O, 5:5); 
IR νmax (cm
-1) 2982, 2934, 2900, 2837, 2359, 1749, 1732, 1612, 1586, 1513, 1464 cm−1; 
1H NMR (500 MHz, CDCl3) δ 7.30 (2H, d, J = 8.7 Hz, 2×CH-PMB), 6.88 (2H, d, J = 8.7 Hz, 
2×CH-PMB), 5.85 (1H, ddd, J = 17.3, 10.5, 6.0 Hz, CH-C3), 5.45 (1H, qdt, J = 6.5, 6.0, 
1.2 Hz, CH-C2), 5.26 (1H, dt, J = 17.3, 1.2 Hz, CH2-C4), 5.16 (1H, dt, J = 10.5, 1.2 Hz, 
CH2-C4), 4.57 (2H, s, CH2-PMB), 4.06 (2H, s, CH2-C6),  3.81 (3H, s, CH3-PMB), 1.34 (3H, 
d, J = 6.5 Hz, CH3-C1); 
13C NMR (126 MHz, CDCl3) δ 169.9 (C-C5), 159.6 (C-PMB), 137.4 (CH-C3), 129.9 (2×CH-
PMB), 129.3 (C-PMB), 116.5 (CH2-C4), 114.0 (2×CH-PMB), 73.1 (CH2-PMB), 71.8 (CH-C2), 
67.1 (CH2-C6), 55.4 (CH3-PMB), 20.1 (CH3-C1); 
LRMS (EI+): m/z (int) 250 (11), 195 (80), 137 (91), 121 (100), 91 (10), 78 (15), 55 (18). 
HRMS (EI+) calculated for C14H18O4 [M]
+: 250.1205, found 250.1204, Δ −0.3 ppm. 
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(2S,3E)-4-(4-tert-Butyldimethylsilyloxymethylfuran-3-yl)but-3-en-2-yl 2-(4-
methoxyphenylmethoxy)acetate ((−)-333) 
 
 
To a solution of the allylic alcohol (−)-325 (6.51 g, 23.9 mmol, 1.00 equiv) and 
carboxylic acid 330 (6.85 g, 34.9 mmol, 1.50 equiv) in CH2Cl2 (78 mL) at 0 ºC were 
successively added DMAP (3.97 g, 58.2 mmol, 2.50 equiv) and EDCI (11.2 g, 58.2 mmol, 
2.50 equiv). The mixture was warmed to rt and stirred for 2 h. The reaction was 
quenched by the addition of water (50 mL), the phases separated and the aqueous 
phase extracted with CH2Cl2 (3 × 50 mL). The organic extracts were combined and 
washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The residue 
was purified by flash column chromatography (PE—Et2O, 9:1 to 85:15) to give the 
desired ester (−)-333 as a colourless oil (9.52 g, 90%). 
C25H36O6Si    Molecular weight: 460.64 g·mol
−1 
Rf = 0.51 (PE—Et2O, 7:3); 
[α]D
26  −32.7 (c = 1.06, CHCl3); 
IR νmax 2949, 2929, 2857, 1752, 1613, 1513, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.43 (1H, d, J = 1.6 Hz, CH-C2), 7.31 (1H, d, J = 1.6 Hz, CH-
C5), 7.30 (2H, d, J = 8.7 Hz, 2×CH-PMB), 6.88 (2H, d, J = 8.7 Hz, 2×CH-PMB), 6.46 (1H, 
d, J = 16.1 Hz, CH-C6), 6.02 (1H, dd, J = 16.1, 7.0 Hz, CH-C7), 5.56 (1H, dqd, J = 7.0, 
6.5, 0.9 Hz, CH-C8), 4.61 (2H, d, J = 0.9 Hz, CH2-C12), 4.57 (2H, s, CH2-C11), 4.06 (2H, 
s, CH2-PMB), 3.80 (3H, s, CH3-PMB), 1.40 (3H, d, J = 6.5 Hz, CH3-C9), 0.90 (9H, s, CH3-
tBu), 0.08 (6H, s, 2×CH3-SiMe2); 
13C NMR (126 MHz, CDCl3) δ 169.9 (C-C10), 159.6 (C-PMB), 142.1 (CH-C2), 141.5 (CH-
C5), 129.9 (2×CH-PMB), 129.4 (C-PMB), 129.2 (CH-C7), 124.1 (C-C3 or C-C4), 122.5 (C-C3 
or C-C4), 121.9 (CH-C6), 114.0 (2×CH-PMB), 73.1 (CH2-C11), 72.2 (CH-C8), 67.2 (CH2-
PMB), 56.8 (CH2-C12), 55.4 (CH3-PMB), 26.0 (CH3-tBu), 20.6 (CH3-C9), 18.4 (C-tBu), −5.1 
(2×CH3-SiMe2); 
LRMS (CI, Me3CH): m/z (int) 461 (8), 321 (65), 265 (78), 133 (56), 121 (100). HRMS (CI, 
Me3CH) calculated for C25H37O6Si [M+H]
+: 461.2359, found 461.2356, Δ −0.8 ppm. 
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(2S,3S,4E)-3-(4-tert-Butyldimethylsilyloxymethylfuran-3-yl)-2-(4-
methoxyphenylmethoxy)hex-4-enoic acid ((+)-334) 
 
 
To a solution of LiHMDS (31 mL of a 1 M solution in THF, 31 mmol, 1.5 equiv) in THF 
(200 mL) at −78 ºC was slowly added a solution of ester (−)-333 (9.28 g, 20.1 mmol) in 
THF (210 mL) over 15 min. The solution was stirred for 1.5 h at −78 ºC before dropwise 
addition of freshly distilled TMSCl (10.4 mL, 81.4 mmol, 4.05 equiv). The mixture was 
stirred for 1 h at −78 ºC then allowed to slowly warm up to rt over 1 h. The reaction was 
quenched with saturated aqueous NH4Cl (200 mL) and the mixture was diluted with Et2O 
(600 mL). The phases were separated and the aqueous phase was extracted with Et2O 
(3 × 200 mL). The organic extracts were combined and washed with brine, dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (PE—Et2O, 85:15) to give the desired acid (+)-334 as a colourless oil 
(7.91 g, 85%). 
C25H36O6Si    Molecular weight: 460.64 g·mol
−1 
Rf = 0.13 (PE—Et2O, 7:3); 
[α]D
23  
+9.3 (c = 1.01, CHCl3); 
IR νmax 3100, 2999, 2955, 2929, 2883, 2857, 2368, 1719, 1612, 1514 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 9.33 (1H, br s, COOH), 7.34 (1H, d, J = 1.5 Hz, CH-C2), 7.27 
(1H, dt, J = 1.5, 0.9 Hz, CH-C5), 7.23 (2H, d, J = 8.7 Hz, 2×CH-PMB), 6.88 (2H, d, J = 8.7 
Hz, 2×CH-PMB), 5.59—5.46 (2H, m, CH-C7 and CH-C8), 4.71 (1H, d, J = 11.3 Hz, CH2-
PMB), 4.52 (1H, dd, J = 12.9, 0.9 Hz, CH2-C12), 4.48 (1H, dd, J = 12.9, 0.9 Hz, CH2-C12), 
4.41 (1H, d, J = 11.3 Hz, CH2-PMB), 4.13 (1H, d, J = 5.0 Hz, CH-C10), 3.81 (3H, s, CH3-
PMB), 3.77 ( 1H, dd, J = 5.0, 5.0 Hz, CH-C6), 1.65 (3H, d, J = 4.7 Hz, CH3-C9), 0.90 (9H, 
s, CH3-tBu), 0.05 (3H, s, CH3-SiMe2), 0.04 (3H, s, CH3-SiMe2); 
13C NMR (126 MHz, CDCl3) δ 176.0 (C-C11), 159.6 (C-PMB), 141.4 (CH-C2), 140.1 (CH-
C5), 129.9 (2×CH-PMB), 129.6 (CH-C7 or CH-C8), 129.2 (C-CPMB), 127.9 (CH-C7 or CH-
C8), 125.3 (C-C3 or C-C4), 121.6 (C-C3 or C-C4), 113.9 (2×CH-PMB), 81.0 (CH-C10), 73.1 
(CH2-PMB), 56.9 (CH2-C12), 55.4 (CH3-PMB), 41.8 (CH-C6), 26.0 (CH3-tBu), 18.5 (C-tBu), 
17.9 (CH3-C9), −5.3 (2×CH3-SiMe2); 
LRMS (CI, Me3CH): m/z (int) 461 (84), 385 (14), 329 (72), 265 (12), 221 (32), 209 (26), 
163 (12), 121 (100). HRMS (CI, Me3CH) calculated for C25H37O6Si [M+H]
+: 461.2359, found 
461.2351, Δ −1.9 ppm. 
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(2S,3S,4E)-3-(4-tert-Butyldimethylsilyloxymethylfuran-3-yl)-2-(4-
methoxyphenylmethoxy)hex-4-en-1-ol ((+)-335) 
 
 
To a solution of acid (+)-334 (7.61 g, 16.5 mmol) in Et2O (170 mL) at 0 ºC was added 
LiAlH4 (1.40 g, 36.9 mmol, 2.23 equiv) portionwise. The suspension was allowed to warm 
to rt and stirred for 2.5 h. The reaction was quenched by dropwise addition of water 
(1.4 mL), aqueous NaOH (1 M, 1.4 mL) and water (2.8 mL) at 0 ºC. The resulting 
suspension was warmed to rt and stirred for 0.5 h before the addition of MgSO4 (10 g). 
The mixture was then filtered through a pad of Celite and washed with Et2O (800 mL). 
After concentration in vacuo the resulting colourless oil could be used without 
purification (6.99 g, 95%). A small portion was purified by flash column chromatography 
(PE—Et2O, 7:3) for characterisation purpose. 
C25H38O5Si    Molecular weight: 446.65 g·mol
−1 
Rf = 0.53 (PE—Et2O, 5:5); 
[α]D
23  
+19.5 (c = 1.00, CHCl3); 
IR νmax 3451, 2953, 2930, 2857, 1612, 1514, 1513, 1464 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.31 (1H, s, CH-C5), 7.29 (1H, d, J = 1.3 Hz, CH-C2), 7.19 
(2H, d, J = 8.6 Hz, 2×CH-PMB), 6.86 (2H, d, J = 8.6 Hz, 2×CH-PMB), 5.60 (1H, ddd, J = 
15.2, 8.0, 1.1 Hz, CH-C7), 5.53 (1H, dq, J = 15.2, 5.9 Hz, CH-C8), 4.55 (1H, d, J = 12.6 
Hz, CH2-C12), 4.51 (1H, d, J = 12.6 Hz, CH2-C12), 4.49 (1H, d, J = 11.1 Hz, CH2-PMB), 
4.46 (1H, d, J = 11.1 Hz, CH2-PMB), 3.80 (3H, s, CH3-PMB), 3.70—3.62 (1H, m, CH-C10), 
3.62—3.54 (2H, m, CH-C6 and CH2-C11), 3.53—3.46 (1H, m, CH2-C11), 2.47 (1H, t, J = 
6.7 Hz, OH), 1.67 (3H, d, J = 5.9 Hz, CH3-C9), 0.91 (9H, s, CH3-tBu), 0.09 (3H, s, CH3-
SiMe2), 0.08 (3H, s, CH3-SiMe2); 
13C NMR (126 MHz, CDCl3) δ 159.4 (C-PMB), 141.2 (CH-C2), 140.3 (CH-C5), 131.0 (CH-
C7), 130.7 (C-PMB), 129.5 (2×CH-PMB), 126.9 (CH-C8), 125.1 (C-C3), 123.3 (C-C4), 113.9 
(2×CH-PMB), 82.3 (CH-C10), 72.6 (CH2-PMB), 62.2 (CH2-C11), 56.7 (CH2-C12), 55.4 (CH3-
PMB), 40.2 (CH-C6), 26.1 (CH3-tBu), 18.6 (C-tBu), 18.1 (CH3-C9), −5.1 (CH3-SiMe2),  −5.2 
(CH3-SiMe2); 
LRMS (EI+): m/z (int) 446 (8), 386 (53), 329 (72), 314 (10), 265 (100), 237 (10), 
121 (100), 105 (18), 73 (24). HRMS (EI+) calculated for C25H38O5Si [M]
+: 446.2489, found 
446.2495, Δ +1.4 ppm. 
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(2S,3S)-3-(4-tert-Butyldimethylsilyloxymethylfuran-3-yl)-2-(4-
methoxyphenylmethoxy)hexan-1-ol ((+)-336) 
 
 
To a solution of alcohol (+)-335 (6.90 g, 15.4 mmol) in acetone (300 mL) was added 
Pd/C (1.6 g, 1.5 mmol, 0.10 equiv). The reaction vessel was purged twice with H2 and 
the mixture was stirred for 30 min under H2 atmosphere at rt. The heterogeneous 
mixture was then filtered twice through a pad of Celite washing with Et2O. The filtrate 
was concentrated in vacuo and the resulting colourless oil (6.85 g, 99%) was used in the 
next step without any further purification. 
A small portion was purified by flash column chromatography (PE—Et2O, 7:3) for 
characterisation purpose. 
C25H40O5Si    Molecular weight: 448.67 g·mol
−1 
Rf = 0.58 (PE—Et2O, 5:5); 
[α]D
23  
+0.2 (c = 1.00, CHCl3); 
IR νmax 3441, 2955, 2929, 2856, 1612, 1587, 1541, 1514, 1465 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.30 (1H, d, J = 1.4 Hz, CH-C5), 7.28 (1H, d, J = 1.4 Hz, CH-
C2), 7.25 (2H, d, J = 8.6 Hz, 2×CH-PMB), 6.88 (2H, d, J = 8.6 Hz, 2×CH-PMB), 4.55 (1H, 
d, J = 11.3 Hz, CH2-PMB), 4.54 (1H, d, J = 12.5 Hz, CH2-C12), 4.51 (1H, d, J = 11.3 Hz, 
CH2-PMB), 4.51 (1H, d, J = 12.5 Hz, CH2-C12), 3.81 (3H, s, CH3-PMB), 3.63 (1H, ddd, J = 
7.3, 5.7, 3.7 Hz, CH-C10), 3.54 (1H, ddd, J = 11.6, 6.9, 5.7 Hz, CH2-C11), 3.33 (1H, ddd, 
J = 11.6, 7.3, 6.9 Hz, CH2-C11), 2.98 (1H, t, J = 6.9 Hz, OH), 2.93 (1H, ddd, J = 9.4, 6.6, 
3.7 Hz, CH-C6), 1.66—1.59 (2H, m, CH2-C7), 1.31—1.17 (2H, m, CH2-C8), 0.91 (9H, s, 
CH3-tBu), 0.86 (3H, t, J = 7.3 Hz, CH3-C9), 0.11 (3H, s, CH3-SiMe2), 0.10 (3H, s, CH3-
SiMe2); 
13C NMR (126 MHz, CDCl3) δ 159.3 (C-PMB), 141.8 (CH-C2), 140.2 (CH-C5), 131.0 (C-
PMB), 129.4 (2×CH-PMB), 125.3 (C-C4), 123.8 (C-C3), 113.9 (2×CH-PMB), 81.4 (CH-C10), 
72.6 (CH2-PMB), 61.5 (CH2-C11), 56.5 (CH2-C12), 55.4 (CH3-PMB), 35.8 (CH-C6), 35.6 
(CH2-C7), 26.1 (CH3-tBu), 21.1 (CH2-C8), 18.7 (C-tBu), 14.4 (CH3-C9), −5.1 (CH3-SiMe2),  
−5.2 (CH3-SiMe2); 
LRMS (CI, Me3CH): m/z (int) 449 (6), 317 (13), 289 (10), 197 (10), 137 (16), 133 (24), 
113 (35), 97 (30), 73 (100). HRMS (CI, Me3CH) calculated for C25H41O5Si [M+H]
+: 449.2723, 
found 449.2729, Δ +1.4 ppm. 
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{4-[(2S*,3S*)-1,2-bis(4-Methoxyphenylmethoxy)hexan-3-yl]furan-3-yl}methoxy-tert-
butyldimethylsilane ((±)-338) 
 
 
To a solution of alcohol (±)-336 (43.4 mg, 96.7 µmol) in toluene (2.4 mL) were added 
PMBTCA (31 μL, 0.15 mmol, 1.5 equiv) and La(OTf)3 (1.1 mg, 0.0019 mmol, 0.019 equiv) 
at rt. The mixture was stirred for 10 min, concentrated in vacuo and purified by flash 
column chromatography (PE—Et2O, 92:8) to afford the desired product (±)-338 
(28.2 mg, 51%) as a colourless oil. 
C33H48O6Si    Molecular weight: 568.82 g·mol
−1 
Rf = 0.49 (PE—Et2O, 7:3); 
IR νmax 2953, 2929, 2856, 1613, 1512, 1464 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.30—7.26 (2H, m, CH-C2 and CH-C5), 7.23 (2H, d, 
J = 8.6 Hz, 2×CH-PMB), 7.22 (2H, d, J = 8.6 Hz, 2×CH-PMB), 6.87 (2H, d, J = 8.6 Hz, 
2×CH-PMB), 6.86 (2H, d, J = 8.6 Hz, 2×CH-PMB), 4.66 (1H, d, J = 11.2 Hz, CH2-PMB), 
4.53 (1H, dd, J = 13.0, 0.9 Hz, CH2-C12), 4.49 (1H, dd, J = 13.0, 0.9 Hz, CH2-C12), 4.48 
(1H, d, J = 11.2 Hz, CH2-PMB), 4.40 (1H, d, J = 12.0 Hz, CH2-PMB), 4.37 (1H, d, 
J = 12.0 Hz, CH2-PMB), 3.81 (3H, s, CH3-PMB), 3.81 (3H, s, CH3-PMB), 3.72 (1H, ddd, J = 
6.0, 4.9, 3.9 Hz, CH-C10), 3.48 (1H, dd, J = 9.9, 6.0 Hz, CH2-C11), 3.39 (1H, dd, J = 9.9, 
4.9 Hz, CH2-C11), 2.79 (1H, ddd, J = 9.4, 5.9, 3.9 Hz, CH-C6), 1.66—1.50 (2H, m, CH2-
C7), 1.30—1.16 (2H, m, CH2-C8), 0.90 (9H, s, CH3-tBu), 0.84 (3H, t, J = 7.3 Hz, CH3-C9), 
0.03 (3H, s, CH3-SiMe2), 0.03 (3H, s, CH3-SiMe2); 
13C NMR (126 MHz, CDCl3) δ 159.3 (C-PMB), 159.1 (C-PMB), 141.4 (CH-C2 or CH-C5), 
139.8 (CH-C2 or CH-C5), 131.4 (C-PMB), 130.6 (C-PMB), 129.4 (2×CH-PMB), 129.3 (2×CH-
PMB), 126.2 (C-C3 or C-C4), 123.6 (C-C3 or C-C4), 113.9 (2×CH-PMB), 113.8 (2×CH-PMB), 
80.1 (CH-C10), 73.1 (CH2-PMB), 72.8 (CH2-PMB), 71.8 (CH2-C11), 57.3 (CH2-C12), 55.4 
(2×CH3-PMB), 37.5 (CH-C6), 34.9 (CH2-C7), 26.1 (CH3-tBu), 21.0 (CH2-C8), 18.5 (C-tBu), 
14.3 (CH3-C9), −5.2 (2×CH3-SiMe2); 
LRMS (CI, Me3CH): m/z (int) 569 (4), 137 (17), 121 (100), 69 (11). HRMS (ESI) calculated 
for C33H48NaO6Si [M+Na]
+: 591.3097, found 591.3112, Δ +2.6 ppm. 
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(2S,3S)-3-(4-tert-Butyldimethylsilyloxymethylfuran-3-yl)hexane-1,2-diol ((+)-339)
 
 
To a solution of alcohol (+)-336 (6.83 g, 15.2 mmol) in a mixture of CH2Cl2/H2O (17:1, 
152 mL) was added DDQ (7.27 g, 32.0 mmol, 2.11 equiv) at rt. The resulting dark 
biphasic mixture was stirred vigorously for 1.5 h and the reaction was then quenched 
with saturated aqueous Na2CO3 (150 mL). The phases were separated following the 
addition of CH2Cl2 (500 mL) and a large volume of water (ca 1 L). The aqueous phase 
was extracted with CH2Cl2 (3 × 300 mL). The organic extracts were combined, dried over 
MgSO4 and concentrated in vacuo. The yellow residue was diluted with MeOH (153 mL) 
and K2CO3 (3.9 g, 28 mmol, 1.8 equiv) was added. The mixture was stirred at rt for 2 h 
and the reaction was quenched by the addition of saturated aqueous NH4Cl (100 mL). 
The mixture was diluted in Et2O (300 mL) and the phases were separated. The aqueous 
phase was extracted with Et2O (4 × 200 mL) and the organic extracts were combined, 
dried over MgSO4 and concentrated in vacuo. The crude oil was purified by flash column 
chromatography (PE—Et2O, 8:2 to 6:4) to afford the desired diol (+)-339 (3.54 g, 71%) as 
a colourless oil. From a recovered mixture of starting material and uncharacterised 
acetals (1.5 g of mixture), the same procedure was used to give a further 222 mg (4%) 
of product. 
C17H32O4Si    Molecular weight: 328.52 g·mol
−1 
Rf = 0.28 (PE—Et2O, 5:5); 
[α]D
23  
+2.5 (c = 1.13, CHCl3); 
IR νmax 3341, 2955, 2929, 2858, 1539, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.35 (1H, d, J = 1.4 Hz, CH-C5), 7.26 (1H, br s, CH-C2), 4.56 
(1H, d, J = 12.2 Hz, CH2-C12), 4.51 (1H, d, J = 12.2 Hz, CH2-C12), 3.76 (1H, dddd, J = 
6.6, 6.4, 4.9, 4.7 Hz, CH-C10), 3.55 (1H, ddd, J = 11.3, 7.6, 4.7 Hz, CH2-C11), 3.47 (1H, 
ddd, J = 11.3, 6.4, 5.4 Hz, CH2-C11), 2.80 (1H, d, J = 6.6 Hz, OH), 2.77 (1H, ddd, J = 
9.1, 5.6, 4.7 Hz, CH-C6), 2.52 (1H, dd, J = 7.6, 5.4 Hz, OH), 1.66—1.57 (2H, m, CH2-C7), 
1.31—1.20 (2H, m, CH2-C8), 0.92 (9H, s, CH3-tBu), 0.87 (3H, t, J = 7.3 Hz, CH3-C9), 0.13 
(6H, s, 2×CH3-SiMe2); 
13C NMR (126 MHz, CDCl3) δ 141.5 (CH-C5), 141.4 (CH-C2), 124.5 (C-C3 or C-C4), 123.7 
(C-C3 or C-C4), 74.3 (CH-C10), 65.3 (CH2-C11), 56.4 (CH2-C12), 38.1 (CH-C6), 35.0 (CH2-
C7), 26.0 (CH3-tBu), 20.9 (CH2-C8), 18.6 (C-tBu), 14.2 (CH3-C9),  −5.2 (2×CH3-SiMe2); 
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LRMS (CI, Me3CH): m/z (int) 329 (10), 253 (14), 197 (100), 179 (25), 165 (15), 133 (16). 
HRMS calculated for C17H32NaO4Si [M+Na]
+: 351.1960, found 351.1962, Δ +0.5 ppm. 
 
tert-Butyl{4-[(1S)-1-((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)butyl]furan-3-
yl}methoxydimethylsilane ((+)-345) 
 
 
To a solution of diol (+)-339 (1.70 g, 5.17 mmol) in a mixture of CH2Cl2 (10 mL) and 2,2-
dimethoxypropane (17 mL) was added PPTS (65 mg, 0.26 mmol, 0.050 equiv). The 
mixture was stirred at rt for 1 h and Na2CO3 (ca 60 mg) was then added. The 
heterogeneous mixture was concentrated in vacuo and purified by flash column 
chromatography (PE—Et2O, 96:4) to afford the desired product (+)-345 (1.83 g, 96%) as 
a colourless oil. 
C20H36O4Si    Molecular weight: 368.58 g·mol
−1 
Rf = 0.61 (PE—Et2O, 9:1); 
[α]D
23  
+16.95 (c = 1.00, CHCl3); 
IR νmax 2983, 2955, 2929, 2858, 1541, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.29 (1H, br s, CH-C5), 7.25 (1H, d, J = 1.6 Hz, CH-C2), 4.55 
(2H, d, J = 0.6 Hz, CH2-C12), 4.24 (1H, ddd, J = 7.9, 6.3, 6.0 Hz, CH-C10), 3.94 (1H, dd, 
J = 7.9, 6.3 Hz, CH2-C11), 3.55 (1H, t, J = 7.9 Hz, CH2-C11), 2.74 (1H, ddd, J = 9.5, 6.0, 
5.5 Hz, CH-C6), 1.61—1.54 (2H, m, CH2-C7), 1.37 (3H, s, CH3-CMe2), 1.33 (3H, s, CH3-
CMe2),1.35—1.20 (2H, m, CH2-C8), 0.91 (9H, s, CH3-tBu), 0.87 (3H, t, J = 7.3 Hz, CH3-
C9), 0.08 (6H, s, 2×CH3-SiMe2); 
13C NMR (126 MHz, CDCl3) δ 140.7 (CH-C2), 140.1 (CH-C5), 125.8 (C-C4), 123.9 (C-C3), 
109.0 (C-CMe2), 78.8 (CH-C10), 67.6 (CH2-C11), 56.9 (CH2-C12), 37.6 (CH-C6), 34.4 (CH2-
C7), 26.7 (CH3-CMe2), 26.1 (3×CH3-tBu), 25.6 (CH3-CMe2), 20.8 (CH2-C8), 18.5 (C-tBu), 
14.3 (CH3-C9),  −5.2 (2×CH3-SiMe2); 
LRMS (CI, Me3CH): m/z (int) 369 (38), 311 (11), 237 (100), 179 (18), 133 (10). HRMS (CI, 
Me3CH) calculated for C20H36O4Si [M]
+: 369.2461, found 369.2463, Δ +0.5 ppm. 
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[4-(1S)-1-((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)butylfuran-3-yl]methanol ((+)-346) 
 
 
To a solution of acetonide (+)-345 (1.81 g, 4.91 mmol) in THF (49 mL), TBAF (7.4 mL of 
a 1 M solution in THF, 7.4 mmol, 1.5 equiv) was added dropwise at 0 ºC. The mixture 
was warmed to rt and stirred for 40 min. Water (20 mL) and Et2O (60 mL) were added 
and the phases separated. The aqueous phase was extracted with Et2O (3 × 40 mL) and 
the combined organic extracts were dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography (PE—Et2O, 7:3) to 
afford the desired allylic alcohol (+)-346 (1.16 g, 93%) as a colourless oil. 
C14H22O4    Molecular weight: 254.32 g·mol
−1 
Rf = 0.32 (PE—Et2O, 5:5); 
[α]D
23 +34.75 (c = 1.00, CHCl3); 
IR νmax 3428, 2983, 2957, 2934, 2873, 1541, 1456 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.39 (1H, d, J = 1.5 Hz, CH-C5), 7.24 (1H, d, J = 1.5 Hz, CH-
C2), 4.46 (1H, dd, J = 12.7, 4.7 Hz, CH2-C12), 4.43 (1H, dd, J = 12.7, 6.4 Hz, CH2-C12), 
4.09 (1H, ddd, J = 7.6, 7.5, 5.9 Hz, CH-C10), 4.05 (1H, dd, J = 7.5, 5.9 Hz, CH2-C11), 
3.60 (1H, t, J = 7.5 Hz, CH2-C11), 3.03 (1H, dd, J = 6.4, 4.7 Hz, OH), 2.69 (1H, ddd, J = 
11.1, 7.6, 3.9 Hz, CH-C6), 1.60 (1H, dddd, J = 12.9, 11.1, 9.6, 5.4 Hz, CH2-C7), 1.44 
(1H, m, CH2-C7), 1.37 (3H, s, CH3-CMe2), 1.38—1.28 (1H, m, CH2-C8), 1.30 (3H, s, CH3-
CMe2), 1.28—1.14 (1H, m, CH2-C8), 0.86 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 141.1 (CH-C5), 140.6 (CH-C2), 125.8 (C-C3 or C-C4), 124.8 
(C-C3 or C-C4), 109.4 (C-CMe2), 80.7 (CH-C10), 68.7 (CH2-C11), 55.1 (CH2-C12), 38.4 
(CH-C6), 34.3 (CH2-C7), 26.5 (CH3-CMe2), 25.7 (CH3-CMe2), 20.6 (CH2-C8), 14.0 (CH3-C9); 
LRMS (EI+): m/z (int) 254 (23), 239 (12), 161 (13), 154 (10), 101 (100), 73 (11), 42 (14). 
HRMS (EI+) calculated for C14H22O4 [M]
+: 254.1518, found 254.1520, Δ +0.7 ppm. 
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(4S)-4-(1S)-1-(4-Chloromethylfuran-3-yl)butyl-2,2-dimethyl-1,3-dioxolane ((+)-347)
 
 
 
To a solution of allylic alcohol (+)-346 (1.02 g, 4.01 mmol) in CH2Cl2 (16 mL) cooled to  
0 ºC, Et3N (840 µL, 6.03 mmol, 1.51 equiv) and MsCl (410 µL, 5.29 mmol, 1.32 equiv), 
both freshly distilled, were successively added. The mixture was warmed to rt, stirred 
for 15 h and quenched with saturated aqueous NH4Cl (20 ml). The phases were 
separated and the aqueous phase was extracted with CH2Cl2 (3 × 30 mL). The organic 
extracts were combined and dried with Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography (PE—Et2O, 95:5) to give 
1.03 g (95%) of the desired chloride (+)-347 as a colourless oil. 
C14H21ClO3    Molecular weight: 272.77 g·mol
−1 
Rf = 0.72 (PE—Et2O, 5:5); 
[α]D
26 +32.3 (c = 1.00, CHCl3); 
IR νmax 2984, 2959, 2934, 2872, 1541, 1456 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.43 (1H, d, J = 1.5 Hz, CH-C5), 7.29 (1H, d, J = 1.5 Hz, CH-
C2), 4.54 (1H, d, J = 12.1 Hz, CH2-C12), 4.48 (1H, d, J = 12.1 Hz, CH2-C12), 4.19 (1H, 
ddd, J = 8.1, 6.0, 6.0 Hz, CH-C10), 4.00 (1H, dd, J = 8.0, 6.0 Hz, CH2-C11), 3.54 (1H, 
dd, J = 8.1, 8.0 Hz, CH2-C11), 2.79 (1H, ddd, J = 9.3, 6.0, 5.7 Hz, CH-C6), 1.63—1.53 
(2H, m, CH2-C7), 1.37 (3H, s, CH3-CMe2), 1.33 (3H, s, CH3-CMe2), 1.36—1.24 (2H, m, CH2-
C8), 0.89 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 141.6 (CH-C5), 141.3 (CH-C2), 124.3 (C-C3 or C-C4), 122.8 
(C-C3 or C-C4), 109.1 (C-CMe2), 79.3 (CH-C10), 68.0 (CH2-C11), 37.5 (CH-C6), 36.6 (CH2-
C12), 35.0 (CH2-C7),  26.6 (CH3-CMe2), 25.7 (CH3-CMe2), 20.7 (CH2-C8), 14.2 (CH3-C9); 
LRMS (EI+): m/z (int) 274 (5), 272 (10), 101 (100), 73 (15), 43 (16). HRMS (EI+) 
calculated for C14H21
35ClO3 [M]
+: 272.1179, found 272.1182, Δ +0.9 ppm; Analytic. 
calculated for C14H21ClO3: C, 61.65; H, 7.76. Found: C, 61.73; H, 7.85. 
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(E)-Methyl hept-3-en-6-ynoate (348) and (E)-Methyl hept-2-en-6-ynoate (352)186 
 
 
A solution of oxalyl chloride (5.8 mL, 68 mmol, 1.5 equiv) in CH2Cl2 (60 mL) was cooled 
to −78 ºC before dropwise addition (20 min) of a solution of DMSO (8.00 mL, 113 mmol, 
2.49 equiv) in CH2Cl2 (30 mL). After 20 min, a solution of 4-pentyn-1-ol (4.2 mL, 45 
mmol) in CH2Cl2 (60 mL) was added carefully over 10 min. The mixture was stirred at 
−78 ºC for 1.5 h before dropwise addition of Et3N (38.0 mL, 273 mmol, 6.04 equiv). The 
solution was then warmed to rt over 1 h. The mixture was diluted with CH2Cl2 (60 mL) 
and washed with aqueous HCl (1 M, 2 × 80 mL), water (80 mL) and brine (80 mL). The 
organic phase was dried with Na2SO4, filtered, and concentrated in vacuo. The residue 
was used directly in the next step.  
The crude aldehyde was dissolved in Et3N (19.0 mL, 136 mmol, 3.02 equiv) and malonic 
acid (6.85 g, 67.8 mmol, 1.50 equiv) was added. The mixture was warmed to 80 ºC and 
stirred overnight. The mixture was then cooled down to rt, diluted with Et2O (100 mL) 
and the reaction was quenched with aqueous HCl (1 M, 100 mL). The phases were 
separated and the organic phase was washed with aqueous HCl (1 M, 50 mL), brine 
(80 mL) and then dried with Na2SO4, filtered and concentrated in vacuo. The residue 
was used in the next step without any further purification. 
To the crude acid in MeOH (20 mL) was added concentrated HCl (500 µL). The mixture 
was heated at reflux for 2 h, cooled to rt and the reaction was quenched with saturated 
aqueous NaHCO3 (25 mL). The mixture was diluted with EtOAc (50 mL), the phases were 
separated and the organic phase was washed with brine (50 mL) and dried over MgSO4. 
After filtration, the solution was carefully concentrated in vacuo and purified by flash 
column chromatography (PE—Et2O, 98:2) yielding an inseparable mixture (3:1) of 
β,γ-unsaturated ester 348 and minor α,β-unsaturated ester 352 (4.41 g, 71% over 3 
steps) as a colourless and volatile oil. 
C8H10O2     Molecular weight: 138.16 g·mol
−1 
Rf = 0.71 (PE—Et2O, 5:5); 
IR νmax 3292, 3001, 2953, 2908, 1732, 1660, 1435, 1422 cm
−1; 
Major isomer 348 
1H NMR (400 MHz, CDCl3) δ 5.85 (1H, dtt, J = 15.3, 7.0, 1.8 Hz, CH-C3), 5.57 (1H, dtt, 
J = 15.3, 5.6, 1.3 Hz, CH-C4), 3.69 (3H, s, OMe), 3.09 (2H, ddt, J = 7.0, 1.3, 1.3 Hz, 
CH2-C2), 2.98—2.95 (2H, m, CH2-C5), 2.11 (1H, t, J = 2.7 Hz, CH-C7); 
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13C NMR (126 MHz, CDCl3) δ 172.2 (C-C1), 127.9 (CH-C4), 124.1 (CH-C3), 81.3 (C-C6), 
70.5 (CH-C7), 52.0 (CH3-OMe), 37.7 (CH2-C2), 21.8 (CH2-C5); 
Minor isomer 352 
1H NMR (400 MHz, CDCl3) δ 6.98 (1H, dt, J = 15.7, 6.6 Hz, CH-C3), 5.91 (1H, dt, J = 
15.7, 1.6 Hz, CH-C2), 3.74 (3H, s, OMe), 2.44 (2H, tdd, J = 6.6, 6.6, 1.6 Hz, CH2-C4), 
2.35 (2H, td, J = 6.6, 2.6 Hz, CH2-C5), 2.00 (1H, t, J = 2.6 Hz, CH-C7); 
13C NMR (126 MHz, CDCl3) δ 166.9 (C-C1), 146.8 (CH-C3), 122.3 (CH-C2), 82.8 (C-C6), 
69.6 (CH-C7), 51.7 (CH3-OMe), 31.2 (CH2-C4), 17.6 (CH2-C5); 
LRMS (CI, Me3CH): m/z (int) 139 (95), 129 (100), 113 (52), 101 (34), 85 (59), 73 (95), 71 
(75). HRMS (CI, Me3CH) calculated for C8H11O2 [M+H]
+: 139.0759, found 139.0760, 
Δ +0.5 ppm. 
 
(4R,5R)-4-Hydroxy-5-(prop-2-yn-1-yl)oxolan-2-one ((+)-349)160 
 
 
AD-mix β (4.0 g, 1.4 g/mmol of starting material) and methanesulfonamide (306 mg, 
2.89 mmol, 1.00 equiv) were dissolved at rt in a 1:1 mixture of t-BuOH/water (20 mL). 
The mixture was stirred for 5 min at rt and cooled to 0 ºC before dropwise addition of a 
solution of esters 348 and 352 (399 mg, 2.89 mmol) in a 1:1 mixture of t-BuOH/water 
(8 mL). The mixture was stirred vigorously at 0 ºC for 48 h and the reaction was 
quenched with saturated aqueous Na2S2O3 (25 mL). The aqueous phase was extracted 
with EtOAc (3 × 30 mL) and the combined organic extracts were dried (MgSO4), filtered 
and concentrated in vacuo. The crude product was purified by flash column 
chromatography (PE—Et2O, 6:4) to give ester (+)-349 (164 mg, 40%) as a colourless oil. 
C7H8O3     Molecular weight: 140.14 g·mol
−1 
Rf = 0.27 (PE—Et2O, 5:5); 
[α]D
22  +3.1 (c = 1.05, CHCl3); 
IR νmax 3419, 3286, 2929, 1755, 1406, 1348, 1149 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 4.69 (1H, ddd, J = 5.9, 4.4, 1.0 Hz, CH-C3), 4.55 (1H, ddd, 
J = 9.1, 5.9, 3.8 Hz, CH-C4), 2.87—2.78 (2H, m, CH2-C2, CH2-C5), 2.74 (1H, ddd, J = 
16.6, 9.1, 2.7 Hz, CH2-C5), 2.62 (1H, dd, J = 17.9, 1.0 Hz, CH2-C2), 2.39 (1H, d, J = 4.4 
Hz, OH), 2.10 (1H, t, J = 2.7 Hz, CH-C7); 
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13C NMR (126 MHz, CDCl3) δ 174.9 (C-C1), 81.4 (CH-C4), 78.4 (C-C6), 71.6 (CH-C7), 68.4 
(CH-C3), 38.6 (CH2-C2), 18.8 (CH2-C5); 
LRMS (ESI): m/z (int) 163 (100), 153 (10). HRMS (ESI) calculated for C7H8NaO3 [M+Na]
+: 
163.0361, found 163.0366, Δ +3.0 ppm. 
 
((2S)-1-Benzylpyrrolidin-2-yl)diphenylmethanol ((+)-358)63,166b 
 
 
L-Proline 356 (30.0 g, 261 mmol) was dissolved in MeOH (500 mL). The solution was 
cooled to 0 ºC before dropwise addition of SOCl2 (23.0 mL, 317 mmol, 1.22 equiv). The 
mixture was then warmed to rt and heated at reflux for 2 h. After concentration in 
vacuo, the residue was diluted in toluene (50 mL) and concentrated in vacuo. The 
residue was used in the next step without further purification. 
To a solution of the salt in toluene (260 mL) at 0 ºC, DIPEA (202 mL, 1.16 mol, 
4.45 equiv) was added slowly. The slurry was warmed to rt and upon cessation of gas 
evolution, the reaction was cooled to 0 ºC and benzyl bromide (34.5 mL, 290 mmol, 
1.11 equiv) was added. The mixture was heated to reflux and stirred for 20 h. The 
mixture was allowed to cool to rt and the reaction was quenched with saturated 
aqueous NH4Cl (300 mL). The mixture was diluted with EtOAc (400 mL) and the phases 
were separated. The aqueous phase was extracted with EtOAc (2 × 300 mL) and the 
organic extracts were combined, washed with brine (300 mL), dried over MgSO4, filtered 
and concentrated in vacuo. The remaining orange oil was used in the next step without 
further purification. 
To a suspension of magnesium turnings (17.9 g, 736 mmol, 2.83 equiv) in Et2O (260 mL) 
was added bromobenzene (75.5 ml, 730 mmol, 2.80 equiv) dropwise. When the reflux 
generated from the reaction had slowed, the mixture was heated at reflux and stirred 
for a further 2 h. It was then cooled to 0 ºC and a solution of the crude ester in Et2O 
(200 mL) was added slowly. The heterogeneous mixture was stirred at rt and heated 
gently back to reflux during 3 h. The reaction was then quenched with the addition of 
saturated aqueous NH4Cl (500 mL) and the mixture was diluted with Et2O (600 mL). The 
phases were separated and the aqueous phase was extracted with Et2O (2 × 600 mL). 
The organic extracts were combined, washed with brine (300 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The residue was then re-crystallised in a 9:1 
mixture of PE—EtOAc (1 L) at −30 ºC for 16 h, to afford the desired tertiary alcohol 
(+)-358 (56.9 g, 64%) as a colourless solid. 
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C24H25NO    Molecular weight: 343.46 g·mol
−1 
Rf = 0.47 (PE—Et2O, 9:1); 
mp. 114—116 ºC {Lit.166b mp. 118—119 ºC, Lit.63 mp. 113—115 ºC}; 
[α]D
18 +98.4 (c = 1.23, CHCl3), [α]D
24 +86.0 (c = 1.05, CHCl3) {Lit.
166b [α]D
20 +86.6 (c = 1.00, 
CHCl3), Lit.
63 [α]D
20 +76.2 (c = 1.60, CH2Cl2)}; 
IR νmax 3333, 3088, 3059, 2968, 2874, 2800, 2364, 1597, 1495 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.75 (2H, d, J = 8.4 Hz, 2×CH-Ar), 7.61 (2H, d, J = 8.4 Hz, 
2×CH-Ar), 7.35—7.17 (8H, m, 8×CH-Ar), 7.12 (1H, t, J = 7.3 Hz, CH-Ar), 7.07 (2H, d, J = 
7.1 Hz, 2×CH-Ar), 4.97 (1H, s, OH), 4.00 (1H, dd, J = 9.1, 4.3 Hz, CH-C2), 3.25 (1H, d, 
J = 12.6 Hz, CH2-Bn), 3.05 (1H, d, J = 12.6 Hz, CH2-Bn), 2.94 (1H, ddd, J = 9.2, 5.9, 
3.3 Hz, CH2-C5), 2.38 (1H, ddd, J = 9.6, 9.2, 7.0 Hz, CH2-C5), 2.04—1.95 (1H, m, 
CH2-C3), 1.82—1.76 (1H, m, CH2-C3), 1.71—1.61 (2H, m, CH2-C4); 
13C NMR (126 MHz, CDCl3) δ 148.2 (C-Ar), 146.8 (C-Ar), 139.8 (C-Ar), 128.7 (2×CH-Ar), 
128.3 (2×CH-Ar), 128.3 (2×CH-Ar), 128.2 (2×CH-Ar), 127.0 (CH-Ar), 126.5 (CH-Ar), 126.4 
(CH-Ar), 125.8 (2×CH-Ar), 125.7 (2×CH-Ar), 78.1 (C-C6), 70.8 (CH-C2), 60.7 (CH2-Bn), 
55.7 (CH2-C5), 27.9 (CH2-C3), 24.3 (CH2-C4); 
HRMS (ESI) calculated for C24H26NO [M+H]
+: 344.2009, found 344.2003, Δ +1.8 ppm. HRMS 
(ESI) calculated for C24H25NaNO [M+Na]
+: 366.1828, found 366.1816, Δ +3.5 ppm. 
 
(2S)-2-(Methoxydiphenylmethyl)pyrrolidine ((−)-360)63,60
  
 
 
To a solution of alcohol (+)-358 (59.9 g, 166 mmol) in THF (500 mL) at 0 ºC was added 
NaH (8.60 g of a 60% dispersion in mineral oil, 215 mmol, 1.30 equiv) portionwise. After 
5 min, iodomethane (14.5 mL, 233 mmol, 1.41 equiv) was added and the mixture was 
slowly heated to reflux, with an outlet allowing the release of the hydrogen formed 
during the reaction, and stirred overnight. The mixture was cooled to 0 ºC and the 
reaction was quenched with saturated aqueous NH4Cl (200 mL). The mixture was diluted 
with Et2O (500 mL) and the phases were separated. The aqueous phase was extracted 
with Et2O (3 × 400 mL) and the organic extracts were combined, washed with brine (300 
mL), dried over MgSO4, filtered and concentrated in vacuo. Without further purification 
the residue was then diluted in EtOH (166 mL). Concentrated HCl (20 mL) was added 
and the mixture was stirred vigorously at 50 ºC until the solid was completely 
solubilised. The solution was cooled to rt and Pd/C (1.8 g, 17 mmol, 0.10 equiv) was 
added. The reaction vessel was purged 3 times with H2 and the mixture was stirred 
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vigorously under H2 atmosphere for 14 h. Further Pd/C (0.90 g, 0.05 equiv) was added 
and the mixture was stirred under H2 atmosphere for a further 24 h. The heterogeneous 
mixture was then filtered through a pad of Celite washing with Et2O (500 mL). After 
concentration in vacuo, the salt was washed with cold Et2O (200 mL). The salt was then 
suspended in Et2O (500 mL) and saturated aqueous K2CO3 (300 mL) added. After stirring 
for 1 h, the phases were separated, the aqueous phase was extracted with Et2O (2 × 
300 mL) and the combined organic extracts washed with brine and dried over MgSO4. 
Concentration in vacuo gave the desired product as a colourless oil (−)-360 (39.8 g, 90% 
over two steps). The filtrate was concentrated in vacuo, diluted with Et2O (100 mL) and 
a saturated aqueous solution of K2CO3 (100 mL) added and stirred for 1 h.  The phases 
were separated, the aqueous phase was extracted with Et2O (2 × 100 mL), the combined 
organic extracts were washed with brine and dried over MgSO4. The organic extracts 
were concentrated in vacuo and purification by flash column chromatography (PE—
EtOAc, 6:4) gave a further 2.0 g (4%) of the desired product. 
C18H21NO    Molecular weight: 267.37 g·mol
−1 
Rf = 0.29 (PE—EtOAc, 5:5); 
[α]D
26 −10.9 (c = 1.05, CHCl3) {Lit.
60 [α]D
22  1.1 (c = 1.0, CHCl3), Lit.
63 [α]D
22  −110.2  (c = 
1.23, CHCl3)}; 
IR νmax 3352, 3057, 2941, 2872, 1957, 1890, 1817, 1493, 1446 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.45—7.38 (4H, m, 4×CH-Ph), 7.33—7.26 (6H, m, 6×CH-Ph), 
4.15 (1H, t, J = 7.4 Hz, CH-C2), 3.08 (3H, s, CH3-OMe), 2.74 (1H, dt, J = 10.4, 7.1 Hz, 
CH2-C5), 2.56 (1H, ddd, J = 10.4, 7.2, 5.6 Hz, CH2-C5), 2.27 (1H, br s, NH), 1.87 (1H, 
dddd, J = 13.4, 8.0, 7.4, 5.8 Hz, CH2-C3), 1.64 (1H, dddd, J = 13.4, 8.7, 7.4, 7.1 Hz, 
CH2-C3), 1.59—1.49 (1H, m, CH2-C4), 1.13—1.02 (1H, m, CH2-C4); 
13C NMR (126 MHz, CDCl3) δ 142.9 (C-Ph), 141.9 (C-Ph), 129.4 (2×CH-Ph), 129.2 (2×CH-
Ph), 127.8 (2×CH-Ph), 127.6 (2×CH-Ph), 127.3 (CH-Ph),127.3 (CH-Ph), 85.4 (C-C6), 62.3 
(CH-C2), 51.5 (CH3-OMe), 47.0 (CH2-C5), 27.6 (CH2-C3), 25.5 (CH2-C4); 
LRMS (CI, Me3CH): m/z (int) 268 (42), 236 (100), 183 (45), 70 (38). HRMS (CI, Me3CH) 
calculated for C18H22NO [M+H]
+: 268.1701, found 268.1697, Δ −1.6 ppm. 
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4-[(2S)-2-(Methoxydiphenylmethyl)pyrrolidin-1-yl]-2,5-dihydrofuran-2-one ((−)-
160)41 
 
 
Tetronic acid (4.19 g, 41.8 mmol, 1.00 equiv) and pyrrolidine derivative (−)-360 (12.3 g, 
46.1 mmol, 1.10 equiv) were diluted in EtOH (10 mL) and toluene (20 mL). The solvents 
were removed in vacuo using a rotary evaporator at 45 ºC and the residue was dried 
under vaccum pump for 30 min. The residue was diluted with the same amount of EtOH 
and toluene and the process was repeated 5 times. The residue was purified by flash 
column chromatography (PE—EtOAc, 6:4) to afford the desired product (−)-160 (7.73 g, 
53%) as a colourless foam. 
C22H23NO3    Molecular weight: 349.42 g·mol
−1 
Rf = 0.36 (PE—EtOAc, 5:5); 
[α]D
18 −126.0 (c = 1.07, CHCl3) {Lit.
41 [α]D
20 −135.2 (c = 0.50, CHCl3)}; 
IR νmax 2970, 2935, 2359, 1724, 1593, 1492 cm
−1; 
1H NMR (400 MHz, C6D6, 65 ºC) δ 7.30—7.10 (10H, m, 10×CH-Ph), 4.89 (1H, d, 
J = 15.0 Hz, CH2-C5), 4.72 (1H, s, CH-C3), 4.50 (1H, d, J = 15.0 Hz, CH2-C5), 4.43 (1H, 
dd, J = 9.2, 2.1 Hz, CH-C6), 2.54 (3H, s, CH3-OMe), 2.54—2.48 (1H, m, CH2-C9), 1.86—
1.70 (2H, m, CH2-C9, CH2-C7), 1.60—1.52 (1H, m, CH2-C7), 1.15—1.03 (1H, m, CH2-C8), 
0.72—0.58 (1H, m, CH2-C8); 
13C NMR (101 MHz, C6D6, 65 ºC) δ 174.6 (C-C2), 168.8 (C-C4), 138.3 (C-Ph), 137.7 (C-
Ph), 130.2 (2×CH-Ph), 130.1 (2×CH-Ph), 128.4 (2×CH-Ph), 128.2 (2×CH-Ph), 128.0 (2×CH-
Ph), 88.6 (C-C10), 84.7 (CH-C3), 68.7 (CH-C6), 68.4 (CH2-C5), 51.1 (CH3-OMe), 50.8 
(CH2-C9), 28.2 (CH2-C7), 22.6 (CH2-C8); 
HRMS (ESI) calculated for C22H24NO3 [M+H]
+: 350.1751, found 350.1738, Δ +3.7 ppm. 
HRMS (ESI) calculated for C22H23NaNO3 [M+Na]
+: 372.1570, found 372.1588, Δ −4.9 ppm. 
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(5S)-4-[(2S)-2-(Methoxydiphenylmethyl)pyrrolidin-1-yl]-5-{3-[tris(propan-2-
yl)silyl]prop-2-yn-1-yl}-2,5-dihydrofuran-2-one ((−)-364-1) 
and 
(5R)-4-[(2S)-2-(Methoxydiphenylmethyl)pyrrolidin-1-yl]-5-{3-[tris(propan-2-
yl)silyl]prop-2-yn-1-yl}-2,5-dihydrofuran-2-one ((−)-364-2) 
 
 
To a solution of furanone (−)-160 (7.67 g, 22.0 mmol) in THF (110 mL) at −78 ºC was 
added a solution of t-BuLi (14.4 mL of a 1.6 M solution in hexane, 23.0 mmol, 1.05 
equiv) dropwise. The reaction was stirred for 1 h before the protected propargylic 
bromide 251 (6.40 g, 34.4 mmol, 1.50 equiv) was added dropwise over 15 min. After 2 h 
the reaction was quenched with saturated aqueous NH4Cl (30 mL). The mixture was 
diluted with EtOAc (100 mL) and allowed to warm to rt over 45 min. The phases were 
separated and the aqueous phase was extracted with EtOAc (3 × 50 mL). The organic 
extracts were combined and washed with brine (50 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography 
(PE—EtOAc, 8:2 to 75:25) to give the diastereoisomers (−)-364-1 (8.89 g, 75%) and 
(−)-364-2 (2.21 g, 19%), both colourless foams. 
C34H45NO3Si    Molecular weight: 543.81 g·mol
−1 
Major diastereoisomer (−)-364-1 
Rf = 0.52 (PE—EtOAc, 5:5); 
[α]D
18 −103.8 (c = 1.02, CHCl3); 
IR νmax 2941, 2864, 2363, 1734, 1606, 1462 cm
−1; 
1H NMR (400 MHz, C6D6, 70 ºC) δ 7.33—7.11 (10H, m, 10×CH-Ph), 4.99 (2H, br s, CH-C3 
and CH-C5), 4.62 (1H, d, J = 6.7 Hz, CH-C9), 2.79 (1H, br d, J = 17.3 Hz, CH2-C6), 2.63 
(3H, s, CH3-OMe), 2.61—2.48 (2H, m, CH2-C6 and CH2-C12), 1.84—1.73 (1H, m, CH2-C10), 
1.73—1.64 (1H, m, CH2-C12), 1.58 (1H, dddd, J = 8.9, 6.7, 5.3, 3.8 Hz, CH2-C10), 1.25—
1.21 (21H, m, 3×iPr), 1.20—1.04 (1H, m, CH2-C11), 0.88—0.73 (1H, m, CH2-C11); 
13C NMR (101 MHz, C6D6, 70 ºC) δ 172.4 (C-C2), 168.8 (C-C4), 138.6 (C-Ph), 137.5 (C-
Ph), 130.3 (2×CH-Ph), 130.1 (2×CH-Ph), 128.4 (CH-Ph), 128.2 (2×CH-Ph), 128.1 (CH-Ph), 
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127.9 (2×CH-Ph), 103.3 (C-C7), 89.2 (CH-C3), 87.9 (CH-C13), 84.5 (C-C8), 76.6 (CH-C5), 
68.8 (CH-C9), 51.4 (CH3-OMe), 50.8 (CH2-C12), 28.1 (CH2-C10), 25.6 (CH2-C6), 23.1 (CH2-
C11), 19.0 (6×CH3-iPr), 12.0 (3×CH-iPr); 
HRMS (ESI) calculated for C34H46NO3Si [M+H]
+: 544.3241, found 544.3229, Δ +2.3 ppm. 
HRMS (ESI) calculated for C34H45NaNO3Si [M+Na]
+: 566.3061, found 566.3054, 
Δ +1.3 ppm. 
Minor diastereoisomer (−)-364-2 
Rf = 0.66 (PE—EtOAc, 5:5); 
[α]D
18 −128.9 (c = 1.01, CHCl3); 
IR νmax 2941, 2864, 2363, 1734, 1604, 1464 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.45—7.33 (10H, m, 10×CH-Ph), 5.24 (1H, s, CH-C3), 4.86 
(1H, dd, J = 4.2, 3.1 Hz, CH-C5), 4.72 (1H, dd, J = 9.3, 3.9 Hz, CH-C9), 3.08 (1H, ddd, 
J = 10.7, 8.2, 3.9 Hz, CH2-C12), 2.94 (1H, dd, J = 17.9, 3.1 Hz, CH2-C6), 2.79 (3H, s, 
CH3-OMe), 2.77 (1H, dd, J = 17.9, 4.2 Hz, CH2-C6), 2.09 (1H, dddd, J = 13.7, 9.7, 9.3, 
5.8 Hz, CH2-C10), 1.89—1.81 (1H, m, CH2-C10), 1.70 (1H, dt, J = 10.7, 8.0 Hz, CH2-C12), 
1.53—1.42 (1H, m, CH2-C11), 1.25—1.15 (1H, m, CH2-C11), 1.07—1.01 (21H, m, 3×iPr); 
13C NMR (126 MHz, CDCl3) δ 174.5 (C-C2), 168.8 (C-C4), 137.8 (C-Ph), 137.0 (C-Ph), 
129.9 (2×CH-Ph), 129.6 (2×CH-Ph), 128.3 (CH-Ph), 128.1 (2×CH-Ph), 128.0 (CH-Ph), 
127.8 (2×CH-Ph), 101.0 (C-C7), 88.7 (C-C13), 87.9 (CH-C3), 84.4 (C-C8), 76.4 (CH-C5), 
70.5 (CH-C9), 51.3 (CH3-OMe), 49.1 (CH2-C12), 28.1 (CH2-C10), 25.3 (CH2-C6), 23.6 (CH2-
C11), 18.6 (6×CH3-iPr), 11.2 (3×CH-iPr); 
HRMS (ESI) calculated for C34H45NO3Si [M+H]
+: 544.3241, found 544.3227, Δ +2.6 ppm. 
HRMS (ESI) calculated for C34H45NaNO3Si [M+Na]
+: 566.3061, found 566.3050, 
Δ +2.0 ppm. 
 
(2S)-5-Oxo-2-{3-[tris(propan-2-yl)silyl]prop-2-yn-1-yl}-2,5-dihydrofuran-3-yl 
trifluoromethanesulfonate ((+)-254) 
 
 
(−)-364-1 (8.36 g, 15.4 mmol) was dissolved in HCl (98 mL of a 1.25 M solution in EtOH, 
123 mmol, 7.97 equiv) at rt followed by the addition of water (9.80 ml, 544 mmol, 35.4 
equiv). The mixture was heated at 78 ºC overnight, HCl (12.4 mL of a 1.25 M solution in 
EtOH, 15.5 mmol, 1.01 equiv) and water (1.20 mL, 66.7 mmol, 4.34 equiv) were added. 
The mixture was heated at 78 ºC for a further 8 h, cooled to rt and diluted with water 
(60 mL) and Et2O (500 mL). The phases were separated, the aqueous phase was 
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extracted with Et2O (2 × 50 mL) and the organic extracts were combined, dried over 
MgSO4, filtered and concentrated in vacuo. After azeotropic removal of water with 
toluene (3 × 50 mL), the orange residue was directly used in the next step. 
To a solution of the crude enol lactone in CH2Cl2 (153 mL) at −78 ºC was added dropwise 
freshly distilled DIPEA (4.1 mL, 23 mmol, 1.5 equiv). After 5 min triflic anhydride 
(3.4 mL, 20 mmol, 1.3 equiv) was added and the solution was stirred for 1 h at −78 ºC. 
The reaction was quenched with water (30 mL) and the mixture was diluted with CH2Cl2 
(100 mL) and slowly warmed to rt over 50 min. The phases were separated and the 
aqueous phase was extracted with CH2Cl2 (3 × 50 mL), the organic extracts were 
combined, washed with brine (50 mL), dried with Na2SO4, filtered and concentrated in 
vacuo. The crude product was purified by flash column chromatography (PE—Et2O, 9:1 
to 8:2) affording triflate (+)-254 (5.35 g, 82%) as a colourless solid. Enantiomeric purity 
was 93% as determined by normal-phase chiral HPLC analysis. (S)-Configuration for 
(+)-254 was assigned by comparison with previous studies on similar substrates.41,187 The 
data of (+)-254 matches with triflate (±)-254 reported previously. Additional data are 
described below. 
[α]D
23 +57.2 (c = 1.04, CHCl3); 
HPLC analysis: tR (R enantiomer) = 8.4 min, tR (S enantiomer) = 10.9 min, Chiracel AD-H, 
2.0% propan-2-ol in n-hexane, flowrate 0.50 mL.min−1, detection 220 nm, temperature 
oven 20 ºC (cf. Annexes 18 and 19). 
 
(5S)-4-Trimethylstannyl-5-{3-[tris(propan-2-yl)silyl]prop-2-yn-1-yl}-2,5-
dihydrofuran-2-one ((+)-256) 
 
 
In a 250 mL flask containing thoroughly flame-dried LiCl (3.49 g, 82.3 mmol, 6.56 equiv) 
and Pd(PPh3)4 (349 mg, 0.302 mmol, 0.02 equiv) was added a solution of triflate (+)-254 
(5.35 g, 12.5 mmol) in THF (126 mL) followed by hexamethylditin (3.65 mL, 17.6 mmol, 
1.40 equiv). The mixture was heated at reflux for 40 min. When the solution turned 
darker, further Pd(PPh3)4 (52.4 mg, 0.045 mmol, 0.004 equiv) was added and the 
mixture was stirred for 40 min at reflux. Further Pd(PPh3)4 (66.7 mg, 0.058 mmol, 0.005 
equiv) was added and the mixture was stirred at reflux for a further 1 h and cooled to 
0 ºC. The reaction was quenched with saturated aqueous NaHCO3 (30 mL) and the 
mixture was diluted with Et2O (200 mL). The phases were separated and the aqueous 
phase was extracted with Et2O (3 × 50 mL). The organic extracts were combined, dried 
with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
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flash column chromatography (PE—Et2O, 9:1 to 8:2) to give the corresponding stannane 
(+)-254 (2.85 g, 52 %) as a pale yellow solid. The data of (+)-256 matches with 
stannane (±)-256 described previously. Additional data are described below. 
[α]D
23 +57.2 (c = 1.04, CHCl3). 
 
(5S)-4-{4-[(1S)-1-((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)butyl]furan-3-yl}methyl-5-{3-
[tris(propan-2-yl)silyl]prop-2-yn-1-yl}-2,5-dihydrofuran-2-one ((+)-365) 
 
 
To a solution of chloride (+)-347 (73% ee, 840 mg, 3.08 mmol, 1.01 equiv) in THF 
(10 mL) were added Pd2(dba)3 (168 mg, 0.184 mmol, 0.0604 equiv) and AsPh3 (232 mg, 
0.758 mmol, 0.249 equiv). The mixture was stirred for 5 min at rt before a solution of 
stannane (+)-365 (1.34 g, 3.04 mmol, 1.00 equiv) in THF (22 mL) was added. The 
mixture was heated at reflux and stirred at this temperature for 24 h and then cooled 
to rt. The reaction was quenched with saturated aqueous NaHCO3 (20 mL) and the 
mixture was diluted with Et2O (40 mL). The phases were separated and the aqueous 
phase was extracted with Et2O (3 × 30 mL). The combined organic extracts were dried 
over MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (PE—Et2O, 92:8 to 6:4) to afford the coupled product (+)-365 
(1.49 g, 95%) as a colourless oil and as an inseparable mixture (6.4:1) of 
diastereoisomers. 
C30H46O5Si    Molecular weight: 514.77 g·mol
−1 
Rf = 0.17 (PE—Et2O, 7:3); 
[α]D
25 +84.8 (c = 1.23, CHCl3); 
IR νmax 2942, 2864, 2357, 2332, 2177, 1755, 1643, 1541, 1464 cm
−1; 
Major diastereoisomer 
1H NMR (500 MHz, CDCl3) δ 7.31 (1H, d, J = 1.5 Hz, CH-C2), 7.16 (1H, s, CH-C5), 5.80 
(1H, d, J = 1.1 Hz, CH-C14), 5.01 (1H, ddd, J = 5.3, 3.9, 1.1 Hz, CH-C16), 4.06 (1H, app 
q, J = 6.8 Hz, CH-C10), 4.00 (1H, dd, J = 7.7, 6.1 Hz, CH2-C11), 3.63 (1H, d, J = 18.1 Hz, 
CH-C12), 3.49 (1H, appt, J = 7.9 Hz, CH2-C11), 3.44 (1H, d, J = 18.1 Hz, CH2-C12), 2.94 
(1H, dd, J = 17.5, 5.3 Hz, CH2-C17), 2.78 (1H, dd, J = 17.5, 3.9 Hz, CH2-C17), 2.46 (1H, 
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app q, J = 7.1 Hz, CH-C6), 1.48 (2H, app q, J = 7.9 Hz , CH2-C7), 1.35 (3H, s, CH3-CMe2), 
1.35—1.24 (1H, m, CH2-C8), 1.30 (3H, s, CH3-CMe2), 1.23—1.12 (1H, m, CH2-C8), 1.03 
(21H, s, 3×iPr), 0.86 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 172.0 (C-C13), 169.7 (C-C15), 140.8 (CH-C2), 140.6 (CH-
C5), 125.2 (C-C3 or C-C4), 119.8 (C-C3 or C-C4), 118.6 (CH-C14), 109.2 (C-CMe2), 99.8 
(C-C18 or C-C19), 85.4 (C-C18 or C-C19), 80.6 (CH-C16), 79.7 (CH-C10), 68.2 (CH2-C11), 
38.4 (CH-C6), 34.6 (CH2-C7), 26.7 (CH3-CMe2), 25.6 (CH3-CMe2), 23.7 (CH2-C17), 23.4 
(CH2-C12), 20.6 (CH2-C8), 18.7 (6×CH3-iPr), 14.3 (CH3-C9), 11.3 (3×CH-iPr); 
LRMS (CI, Me3CH): m/z (int) 515 (56), 457 (14), 369 (10), 293 (100). HRMS (CI, Me3CH) 
calculated for C30H47O5Si [M+H]
+: 515.3193, found 515.3218, Δ +2.1 ppm. 
 
4-{4-[(1S)-1-((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)butyl]furan-3-yl}methyl-5-(prop-2-
yn-1-yl)-2,5-dihydrofuran-2-one (368) 
 
 
To a solution of alkyne (+)-365 (37.8 mg, 0.0734 mmol) in THF (1.2 mL) at 0 ºC was 
added dropwise TBAF (110 µL of a 1 M solution in THF, 110 µmol, 1.51 equiv). The 
mixture was stirred for 30 min at 0 ºC and the reaction was quenched by the addition of 
water (5 mL). The mixture was diluted in Et2O (10 mL) and the phases were separated. 
The aqueous phase was extracted with Et2O (2 × 10 mL) and the organic extracts were 
combined, dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography (PE—Et2O, 6:4) affording terminal alkynes 368 
in an inseparable mixture (1:1) of two diastereoisomers (16.5 mg, 63%). (+)-368 and 
epi-368 could be differenciated thanks to the synthesis of enantiopure (+)-368 detailed 
further down (page 188).    
C21H26O5    Molecular weight: 358.43 g·mol
−1 
Rf = 0.31 (PE—Et2O, 4:6); 
IR νmax 3284, 2984, 2957, 2933, 2873, 1753, 1643, 1540, 1458 cm
−1; 
(+)-368 
1H NMR (400 MHz, CDCl3) δ 7.32 (1H, d, J = 1.4 Hz, CH-C2), 7.28 (1H, br s, CH-C5), 5.83 
(1H, d, J = 1.1 Hz, CH-C14), 5.02 (1H, ddd, J = 5.5, 4.2, 1.1 Hz, CH-C16), 4.09 (1H, ddd, 
J = 7.7, 6.7, 6.1 Hz, CH-C10), 4.00 (1H, dd, J = 7.8, 6.1 Hz, CH2-C11), 3.59 (1H, d, J = 
18.2 Hz, CH2-C12), 3.50 (1H, dd, J = 7.8, 7.7 Hz, CH2-C11), 3.46 (1H, d, J = 18.2 Hz, 
 187 
CH2-C12), 2.85 (1H, ddd, J = 17.3, 5.5, 2.7 Hz, CH2-C17), 2.71 (1H, ddd, J = 17.5, 4.2, 
2.7 Hz, CH2-C17), 2.50 (1H, ddd, J = 9.1, 6.7, 5.3 Hz, CH-C6), 2.07 (1H, t, J = 2.7 Hz, 
CH-C19), 1.52—1.45 (2H, m, CH2-C7), 1.36 (3H, s, CH3-CMe2), 1.31 (3H, s, CH3-CMe2), 
1.29—1.11 (2H, m, CH2-C8), 0.86 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 171.9 (C-C13), 169.6 (C-C15), 140.8 (CH-C2 or CH-C5), 
140.7 (CH-C2 or CH-C5), 125.3 (C-C3 or C-C4), 119.8 (C-C3 or C-C4), 118.7 (CH-C14), 
109.2 (C-CMe2), 80.3 (CH-C16), 79.6 (CH-C10), 76.7 (C-C18), 72.6 (CH-C19), 68.2 (CH2-
C11), 38.3 (CH-C6), 34.9 (CH2-C7), 26.7 (CH3-CMe2), 25.6 (CH3-CMe2), 23.3 (CH2-C12), 
22.6 (CH2-C17), 20.6 (CH2-C8), 14.3 (CH3-C9); 
epi-368 
1H NMR (400 MHz, CDCl3) δ 7.30 (1H, d, J = 1.4 Hz, CH-C2’), 7.28 (1H, s, CH-C5’), 5.82 
(1H, d, J = 1.2 Hz, CH-C14’), 5.00 (1H, ddd, J = 5.3, 4.2, 1.2 Hz, CH-C16’), 4.12—3.97 
(2H, m, CH-C10’, CH2-C11’), 3.66 (1H, d, J = 18.2 Hz, CH2-C12’), 3.50 (1H, app t, J = 7.8 
Hz, CH2-C11’), 3.44 (1H, d, J = 18.2 Hz, CH2-C12’), 2.88 (1H, ddd, J = 17.2, 5.3, 2.7 Hz, 
CH2-C17’), 2.72 (1H, ddd, J = 17.2, 4.2, 2.7 Hz, CH2-C17’), 2.59—2.45 (1H, m, CH-C6’), 
2.06 (1H, t, J = 2.7 Hz, CH-C19’), 1.53—1.44 (2H, m, CH2-C7’), 1.35 (3H, s, CH3-CMe2), 
1.30 (3H, s, CH3-CMe2), 1.27—1.09 (2H, m, CH2-C8’), 0.86 (3H, t, J = 7.3 Hz, CH3-C9’); 
13C NMR (126 MHz, CDCl3) δ 171.8 (C-C13’), 169.6 (C-C15’), 140.9 (CH-C2’ or CH-C5’), 
140.7 (CH-C2’ or CH-C5’), 125.3 (C-C3’ or C-C4’), 119.9 (C-C3’ or C-C4’), 118.8 (CH-
C14’), 109.2 (C-CMe2), 80.4 (CH-C16’), 80.0 (CH-C10’), 76.8 (C-C18’), 72.5 (CH-C19’), 
68.3 (CH2-C11’), 38.3 (CH-C6’), 34.4 (CH2-C7’), 26.7 (CH3-CMe2), 25.7 (CH3-CMe2), 23.4 
(CH2-C12’), 22.7 (CH2-C17’), 20.7 (CH2-C8’), 14.2 (CH3-C9’); 
LRMS (EI+): m/z (int) 358 (5), 343 (30), 258 (55), 220 (22), 205 (65), 149 (28), 101 (100), 
83 (96), 43 (40). HRMS (EI+) calculated for C21H26O5 [M]
+: 358.1780, found 358.1777, 
Δ −0.8 ppm. 
 
(5S)-4-[4-((2S,3S)-1,2-Dihydroxyhexan-3-yl)furan-3-yl]methyl-5-{3-[tris(propan-2-
yl)silyl]prop-2-yn-1-yl}-2,5-dihydrofuran-2-one ((+)-369) 
 
 
To a solution of alkyne (+)-365 (32.1 mg, 0.0624 mmol) in MeCN (0.5 mL) was added HF 
(5% in MeCN, 1.5 mL) at 0 ºC. The mixture was warmed to rt and stirred for 3 days at rt. 
After cooling the solution to 0 ºC, the reaction was very carefully quenched with 
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NaHCO3 (10 mL) and the mixture was diluted with CH2Cl2 (20 mL). The phases were 
separated and the aqueous phase was extracted with CH2Cl2 (2 × 20 mL). The organic 
extracts were combined, washed with brine (20 mL), dried over MgSO4, filtered and 
concentrated. The crude product was purified by flash column chromatography (PE—
EtOAc, 5:5) affording diol (+)-369 (19.9 mg, 67%) as a colourless oil. 
C27H42O5Si    Molecular weight: 474.70 g·mol
−1 
Rf = 0.34 (PE—EtOAc, 5:5); 
[α]D
24 +59.6 (c = 1.10, CHCl3); 
IR νmax 3427, 2957, 2943, 2865, 2177, 1745, 1642, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.32 (1H, d, J = 1.5 Hz, CH-C2), 7.28 (1H, s, CH-C5), 5.75 
(1H, d, J = 1.3 Hz, CH-C14), 5.02 (1H, ddd, J = 5.3, 3.8, 1.3 Hz, CH-C16), 3.71 (1H, ddd, 
J = 7.4, 5.5, 3.4 Hz, CH-C10), 3.61 (1H, d, J = 18.6 Hz, CH2-C12), 3.93 (1H, dd, J = 10.9, 
3.4 Hz, CH2-C11), 3.48—3.37 (1H, m, CH2-C11), 3.40 (1H, d, J = 18.6 Hz, CH2-C12), 2.94 
(1H, dd, J = 17.5, 5.3 Hz, CH2-C17), 2.80 (1H, dd, J = 17.5, 3.8 Hz, CH2-C17), 2.52 (1H, 
ddd, J = 10.3, 5.5, 5.3 Hz, CH-C6), 2.35 (2H, br s, 2×OH), 1.66—1.56 (1H, m, CH2-C7), 
1.55—1.44 (1H, m, CH2-C7), 1.31—1.14 (2H, m, CH2-C8), 1.02 (21H, s, 3×iPr), 0.85 (3H, 
t, J = 7.3 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 172.1 (C-C13), 170.0 (C-C15), 141.3 (CH-C2), 140.0 (CH-
C5), 124.6 (C-C3 or C-C4), 120.1 (C-C3 or C-C4), 118.5 (CH-C14), 100.0 (C-C18), 85.6 (C-
C19), 80.8 (CH-C16), 74.6 (CH-C10), 65.0 (CH2-C11), 37.7 (CH-C6), 35.0 (CH2-C7), 23.8 
(CH2-C17), 23.3 (CH2-C10), 20.8 (CH2-C8), 18.7 (6×CH3-iPr), 14.1 (CH3-C9), 11.4 (3×CH-
iPr); 
HRMS (ESI) calculated for C27H42NaO5Si [M+Na]
+: 497.2694, found 497.2677, Δ +3.3 ppm. 
 
(5S)-4-{4-[(1S)-1-((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)butyl]furan-3-ylmethyl-5-
prop-2-yn-1-yl-2,5-dihydrofuran-2-one (+)-368 
 
 
TIPS-protected alkyne (+)-365 (44.8 mg, 0.0870 mmol) was dissolved in MeCN (1 mL). At 
rt, AgF (21.2 mg, 0.167 mmol, 1.92 equiv) was added and the mixture was stirred for 
3 h excluded from light. The reaction was quenched by the addition of aqueous HCl 
(1 M, 0.1 mL) at 0 ºC. The dark solution was stirred for 10 min and diluted with water 
(5 mL) and Et2O (10 mL). The phases were separated and the aqueous phase was 
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extracted with Et2O (2 × 10 mL). Brine (10 mL) was added to the aqueous phase for a 
better separation. The organic extracts were combined, dried over MgSO4, filtered and 
concentrated. The crude product was purified by flash column chromatography (PE—
Et2O, 5:5) to afford the terminal alkyne (+)-368 (9.0 mg, 29%) as a colourless oil. NMR 
data are previously described on page 186. Additional data are described below. 
C21H26O5    Molecular weight: 358.43 g·mol
−1 
Rf = 0.31 (PE—Et2O, 4:6); 
[α]D
19 +58.6 (c = 0.40, CHCl3); 
IR νmax 3282, 2958, 2933, 2874, 2364, 1759, 1643, 1541, 1456 cm
−1; 
LRMS (CI, Me3CH): m/z (int) 359 (100), 301 (64), 113 (22), 73 (56). HRMS (CI, Me3CH) 
calculated for C21H27O5 [M+H]
+: 359.1858, found 359.1868, Δ +2.6 ppm. 
 
(2Z,4S)-3-[4-(1S)-1-((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)butylfuran-3-yl]methyl-7-
tris(propan-2-yl)silyl-hept-2-en-6-yne-1,4-diol ((+)-373) 
 
 
To a suspension of LiAlH4 (40.7 mg, 1.07 mmol, 2.75 equiv) in Et2O (1 mL) at 0 ºC was 
added TMEDA (590 µL, 3.94 mmol, 10.1 equiv) dropwise. The suspension was stirred for 
10 min at 0 ºC and cooled to −78 ºC. A solution of the unsaturated lactone (+)-365 
(200 mg, 0.389 mmol) in Et2O (4 mL) was added dropwise and the mixture was stirred at 
−78 ºC for 1 h before being slowly warmed to 0 ºC over 1 h. The mixture was stirred 
30 min at 0 ºC and the reaction was quenched by the addition of saturated aqueous 
Rochelle salt (10 mL). Et2O (20 mL) was added and the mixture was warmed to rt and 
stirred for 1 h. The phases were separated and the aqueous phase was extracted with 
Et2O (3 × 20 mL). The organic extracts were combined and dried over MgSO4. After 
filtration and concentration in vacuo, the residue was purified by flash column 
chromatography (PE—Et2O, 5:5) to afford the diol (+)-373 (106 mg, 53%) as a colourless 
oil and as an inseparable mixture (6:1) with reduced diol 375. Purification using silica 
impregnated with 10% AgNO3 was possible on small scale (less than 10 mg) but was 
inefficient on larger scale. Another by-product, the conjugated reduction product 
(+)-374, was also detected from the reaction and characterised. 
Diol (+)-373 
C30H50O5Si    Molecular weight: 518.80 g·mol
−1 
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Rf = 0.20 (PE—Et2O, 4:6); 
[α]D
25 +20.8 (c = 1.00, CHCl3); 
IR νmax 3778, 2940, 2891, 2864, 2174, 1539, 1464, 1381, 1369 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.27 (1H, d, J = 1.5 Hz, CH-C2), 7.20 (1H, d, J = 1.5 Hz, CH-
C5), 5.52 (1H, dd, J = 7.4, 7.0 Hz, CH-C14), 4.67 (1H, dd, J = 7.6, 6.5 Hz, CH-C16), 4.26 
(1H, dd, J = 12.9, 7.4 Hz, CH2-C13), 4.22—4.15 (1H, m, CH-C10), 4.17 (1H, dd, J = 12.9, 
7.0 Hz, CH2-C13), 3.94 (1H, dd, J = 7.9, 6.2 Hz, CH2-C11), 3.55 (1H, t, J = 7.9 Hz, CH2-
C11), 3.26 (1H, d, J = 16.7 Hz, CH2-C12), 3.18 (1H, d, J = 16.7 Hz, CH2-C12), 2.78 (1H, 
br s, OH), 2.66 (1H, dd, J = 16.7, 7.6 Hz, CH2-C17), 2.68—2.60 (1H, m, CH-C6), 2.55 (1H, 
dd, J = 16.7, 6.5 Hz, CH2-C17), 2.03 (1H, br s, OH), 1.60—1.45 (2H, m, CH2-C7), 1.38 
(3H, s, CH3-CMe2), 1.32 (3H, s, CH3-CMe2), 1.34—1.18 (2H, m, CH2-C8), 1.06 (21H, s, 
3×iPr), 0.87 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 141.8 (C-C15), 140.9 (CH-C5), 140.5 (CH-C2), 128.5 (CH-
C14), 125.2 (C-C3 or C-C4), 122.6 (C-C3 or C-C4), 109.1 (C-CMe2), 104.5 (C-C18), 83.9 
(C-C19), 79.1 (CH-C10), 69.2 (CH-C16), 67.5 (CH2-C11), 58.4 (CH2-C13), 37.2 (CH-C6), 
34.7 (CH2-C7), 27.8 (CH2-C17), 26.7 (CH3-CMe2), 26.3 (CH2-C12), 25.6 (CH3-CMe2), 20.7 
(CH2-C8), 18.7 (6×CH3-iPr), 14.3 (CH3-C9), 11.4 (3×CH-iPr); 
HRMS (ESI) calculated for C30H50NaO5Si [M+Na]
+: 541.3299, found 541.3320, Δ +3.9 ppm. 
 
(5S)-4-{4-[(1S)-1-((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)butyl]furan-3-yl}methyl-5-{3-
[tris(propan-2-yl)silyl]prop-2-yn-1-yl}oxolan-2-one ((+)-374) 
 
C30H48O5Si    Molecular weight: 516.78 g·mol
−1 
Rf = 0.58 (PE—Et2O, 4:6); 
[α]D
25 +7.0 (c = 0.99, CHCl3); 
IR νmax 2943, 2820, 2367, 2174, 1782, 1541, 1464 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.27 (1H, d, J = 1.5 Hz, CH-C2), 7.20 (1H, d, J = 1.5 Hz, CH-
C5), 4.36 (1H, dt, J = 5.9, 4.1 Hz, CH-C16), 4.11 (1H, dt, J = 7.9, 6.2 Hz, CH-C10), 3.99 
(1H, dd, J = 7.9, 6.2 Hz, CH2-C11), 3.51 (1H, t, J = 7.9 Hz, CH2-C11), 2.86 (1H, dd, J = 
17.8, 9.1 Hz, CH2-C14), 2.78—2.49 (6H, m, CH-C6, CH-C15, CH2-C12, CH2-C17), 2.28 (1H, 
dd, J = 17.8, 5.3 Hz, CH2-C14), 1.58—1.48 (2H, m, CH2-C7), 1.35 (3H, s, CH3-CMe2), 1.31 
(3H, s, CH3-CMe2), 1.33—1.16 (2H, m, CH2-C8), 1.05 (21H, br s, 3×iPr), 0.87 (3H, t, J = 
7.3 Hz, CH3-C9); 
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13C NMR (126 MHz, CDCl3) δ 175.9 (C-C13), 140.5 (CH-C2), 139.5 (CH-C5), 125.0 (C-C3 
or C-C4), 122.1 (C-C3 or C-C4), 109.2 (C-CMe2), 102.0 (C-C18), 84.8 (C-C19), 82.3 (CH-
C16), 79.5 (CH-C10), 67.9 (CH2-C11), 38.8 (CH-C15), 38.0 (CH-C6), 35.0 (CH2-C14), 34.7 
(CH2-C7), 28.4 (CH2-C17), 26.6 (CH3-CMe2), 26.3 (CH2-C12), 25.6 (CH3-CMe2), 20.7 (CH2-
C8), 18.7 (6×CH3-iPr), 14.3 (CH3-C9), 11.4 (3×CH-iPr); 
HRMS (ESI) calculated for C30H48NaO5Si [M+Na]
+: 539.3163, found 539.3146, Δ +3.3 ppm. 
 
(4S)-3-{4-[(1S)-1-((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)butyl]furan-3-yl}methyl-7-
[tris(propan-2-yl)silyl]hept-6-yne-1,4-diol (375) 
 
C30H52O5Si    Molecular weight: 520.82 g·mol
−1 
Rf = 0.20 (PE—Et2O, 4:6); 
HRMS (ESI) calculated for C30H52NaO5Si [M+Na]
+: 543.3476, found 543.3452, Δ +4.4 ppm. 
 
((4S,5Z)-5-{4-[(1S)-1-((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)butyl]furan-3-yl}methyl-
4,7-bis(4-methoxyphenylmethoxy)hept-5-en-1-yn-1-yl)tris(propan-2-yl)silane  
((+)-386) 
 
 
To a solution of diol (+)-373 (157 mg, 0.303 mmol) in DMF (3.0 mL) at 0 ºC were added 
successively NaH (36.6 mg  of a 60% dispersion in mineral oil, 1.53 mmol, 5.04 equiv), 
TBAI (11 mg, 0.030 mmol, 0.10 equiv) and PMBCl (180 µL, 1.24 mmol, 4.09 equiv). The 
mixture was allowed to slowly warm to rt and was stirred for 24 h. The reaction was 
quenched by careful addition of water (1 mL) and the mixture was diluted with EtOAc 
(10 mL). The phases were separated and the aqueous phase was extracted with EtOAc 
(3 × 10 mL). The organic extracts were combined, dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography 
(PE—Et2O, 9:1) to afford bis-PMB ether (+)-386 (126 mg, 55%) as a colourless oil. 
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C46H66O7Si    Molecular weight: 759.10 g·mol
−1 
Rf = 0.56 (PE—Et2O, 6:4); 
[α]D
22 +0.1 (c = 1.00, CHCl3); 
IR νmax 2938, 2864, 2174, 1728, 1613, 1586, 1512, 1464 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 7.28 (1H, d, J = 1.5 Hz, CH-C2), 7.25—7.20 (1H, m, CH-C5), 
7.23 (2H, d, J = 8.6 Hz, 2×CH-PMB), 7.22 (2H, d, J = 8.6 Hz, 2×CH-PMB), 6.85 (2H, d, J = 
8.6 Hz, 2×CH-PMB), 6.84 (2H, d, J = 8.6 Hz, 2×CH-PMB), 5.53 (1H, dd, J = 7.0, 5.2 Hz, 
CH-C14), 4.46 (1H, d, J = 11.5 Hz, CH2-PMB),  4.43—4.42 (1H, m, CH-C16), 4.40 (1H, d, 
J = 11.5 Hz, CH2-PMB), 4.37 (1H, d, J = 11.5 Hz, CH2-PMB), 4.26 (1H, d, J = 11.5 Hz, CH2-
PMB), 4.17 (1H, dd, J = 12.4, 7.0 Hz, CH2-C13), 4.14 (1H, ddd, J = 7.9, 6.3, 5.2 Hz, CH-
C10), 3.93 (1H, dd, J = 12.4, 5.2 Hz, CH2-C13), 3.89 (1H, dd, J = 7.9, 6.3 Hz, CH2-C11), 
3.81 (3H, s, CH3-PMB), 3.79 (3H, s, CH3-PMB), 3.52 (1H, t, J = 7.9 Hz, CH2-C11), 3.21 
(1H, d, J = 17.7 Hz, CH2-C12), 3.16 (1H, d, J = 17.7 Hz, CH2-C12), 2.68 (1H, dd, J = 16.8, 
6.5 Hz, CH2-C17), 2.63—2.53 (1H, m, CH-C6), 2.53 (1H, dd, J = 16.8, 7.9 Hz, CH2-C17), 
1.61—1.45 (2H, m, CH2-C7), 1.37 (3H, s, CH3-CMe2), 1.31 (3H, s, CH3-CMe2), 1.36—1.15 
(2H, m, CH2-C8), 1.04 (21H, s, 3×iPr), 0.84 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 159.3 (2×C-PMB), 141.0 (CH-C5), 140.3 (CH-C2), 139.4 (C-
C15), 130.5 (C-PMB), 130.4 (C-PMB), 129.4 (2×CH-PMB), 129.3 (2×CH-PMB), 128.1 (CH-
C14), 125.1 (C-C3 or C-C4), 122.4 (C-C3 or C-C4), 114.0 (2×CH-PMB), 113.9 (2×CH-PMB), 
108.9 (C-CMe2), 104.8 (C-C18), 82.2 (C-C19), 78.9 (CH-C10), 75.3 (CH-C16), 72.4 (CH2-
PMB), 70.5 (CH2-PMB), 67.4 (CH2-C11), 65.8 (CH2-C13), 55.4 (CH3-PMB), 55.4 (CH3-PMB), 
37.1 (CH-C6), 34.7 (CH2-C7), 26.7 (CH3-CMe2), 25.8 (CH2-C17), 25.6 (CH3-CMe2), 24.3 
(CH2-C12), 20.8 (CH2-C8), 18.7 (6×CH3-iPr), 14.4 (CH3-C9), 11.4 (3×CH-iPr); 
HRMS (ESI) calculated for C46H66NaO7Si [M+Na]
+: 781.4440, found 781.4470, Δ +3.9 ppm. 
 
(4S)-4-((1S)-1-{4-[(2Z,3S)-3-(4-Methoxyphenylmethoxy)-2-[2-(4-
methoxyphenylmethoxy)ethylidene]hex-5-yn-1-yl]furan-3-yl}butyl)-2,2-dimethyl-
1,3-dioxolane ((+)-378) 
  
 
To a solution of TIPS-protected alkyne (+)-386 (126 mg, 0.166 mmol) in THF (2 mL) at 
0 ºC was added TBAF (330 µL of a 1 M solution in THF, 0.330 mmol, 1.99 equiv) 
dropwise. After 30 min the mixture was allowed to warm to rt and stirred for a further 
 193 
3 h. The solution was concentrated in vacuo and the residue purified by flash column 
chromatography (PE—Et2O, 8:2) to afford terminal alkyne (+)-378 (95.7 mg, 96%) as a 
colourless oil. 
C37H46O7    Molecular weight: 602.76 g·mol
−1 
Rf = 0.43 (PE—Et2O, 6:4); 
[α]D
25 +2.7 (c = 1.02, CHCl3); 
IR νmax 3284, 2956, 2935, 2870, 2368, 1612, 1585, 1514, 1465 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.28 (1H, d, J = 1.4 Hz, CH-C2), 7.25—7.21 (1H, m, CH-C5), 
7.24 (2H, d, J = 8.6 Hz, 2×CH-PMB), 7.23 (2H, d, J = 8.6 Hz, 2×CH-PMB), 6.86 (4H, d, J = 
8.6 Hz, 4×CH-PMB), 5.52 (1H, dd, J = 7.4, 5.2 Hz, CH-C14), 4.49 (1H, d, J = 11.6 Hz, 
CH2-PMB),  4.41 (1H, d, J = 11.5 Hz, CH2-PMB), 4.43—4.36 (1H, m, CH-C16), 4.37 (1H, d, 
J = 11.5 Hz, CH2-PMB), 4.25 (1H, d, J = 11.6 Hz, CH2-PMB), 4.16—4.09 (2H, m, CH-C10 
and CH2-C13), 3.95 (1H, dd, J = 12.4, 5.2 Hz, CH2-C13), 3.91 (1H, dd, J = 7.8, 6.2 Hz, 
CH2-C11), 3.81 (3H, s, CH3-PMB), 3.80 (3H, s, CH3-PMB), 3.51 (1H, t, J = 7.8 Hz, CH2-
C11), 3.18 (2H, s, CH2-C12), 2.64—2.59 (1H, m, CH-C6), 2.59 (1H, ddd, J = 16.7, 6.4, 
2.7 Hz, CH2-C17), 2.47 (1H, ddd, J = 16.7, 8.0, 2.7 Hz, CH2-C17), 1.95 (1H, t, J = 2.7 Hz, 
CH-C19), 1.55—1.48 (2H, m, CH2-C7), 1.37 (3H, s, CH3-CMe2), 1.31 (3H, s, CH3-CMe2), 
1.34—1.15 (2H, m, CH2-C8), 0.83 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (101 MHz, CDCl3) δ 159.4 (C-PMB), 159.3 (C-PMB), 141.0 (CH-C5), 140.3 (CH-
C2), 139.0 (C-C15), 130.4 (C-PMB), 130.1 (C-PMB), 129.5 (2×CH-PMB), 129.4 (2×CH-PMB), 
128.4 (CH-C14), 125.2 (C-C3 or C-C4), 122.2 (C-C3 or C-C4), 113.9 (4×CH-PMB), 108.9 
(C-CMe2), 80.8 (C-C18), 79.2 (CH-C10), 74.5 (CH-C16), 72.4 (CH2-PMB), 70.3 (2C, CH2-
PMB and CH-C19), 67.6 (CH2-C11), 65.8 (CH2-C13), 55.4 (CH3-PMB), 55.4 (CH3-PMB), 37.1 
(CH-C6), 34.7 (CH2-C7), 26.7 (CH3-CMe2), 25.6 (CH3-CMe2), 24.3 and 24.3 (2C, CH2-C12 
and CH2-C17), 20.7 (CH2-C8), 14.5 (CH3-C9); 
LRMS (EI+): m/z (int) 602 (10), 483 (11), 345 (25), 328 (30), 287 (17), 227 (31), 171 (18), 
121 (100), 101 (100), 77 (29). HRMS (EI+) calculated for C37H46O7 [M]
+: 602.3244, found 
602.3246, Δ +0.4 ppm. 
 
4-((4S,5Z)-5-{4-[(1S)-1-((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)butyl]furan-3-yl}methyl-
4,7-bis(4-methoxyphenylmethoxy)hepta-1,5-dien-2-yl)-2,2,4,6,6-pentamethyl-3,5-
dioxa-2,4,6-trisilaheptane ((+)-380) 
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To a solution of terminal alkyne (+)-378 (18.4 mg, 30.5 µmol) in CH2Cl2 (500 µL) was 
added 1,1,1,3,5,5,5-heptamethyltrisiloxane (12 µL, 44 µmol, 1.4 equiv) and 
[Cp*Ru(MeCN)3]PF6 (1.2 mg, 2.4 µmol, 0.078 equiv). The mixture was stirred at rt for 1 h 
and then concentrated in vacuo. The crude product was purified by flash column 
chromatography (PE—Et2O, 9:1 to 85:15) to afford product (+)-380 (19.9 mg, 79%) as a 
colourless oil. 
C44H68O9Si3    Molecular weight: 825.26 g·mol
−1 
Rf = 0.56 (PE—Et2O, 6:4); 
[α]D
24 +9.95 (c = 0.87, CHCl3); 
IR νmax 2957, 2933, 2866, 2362, 1612, 1514 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.28 (1H, d, J = 1.5 Hz, CH-C2), 7.21 (2H, d, J = 8.7 Hz, 
2×CH-PMB), 7.20 (2H, d, J = 8.7 Hz, 2×CH-PMB), 7.17 (1H, d, J = 1.5 Hz, CH-C5), 6.85 
(2H, d, J = 8.7 Hz, 2×CH-PMB), 6.84 (2H, d, J = 8.7 Hz, 2×CH-PMB), 5.61 (1H, d, J = 
3.0 Hz, CH2-C19), 5.52 (1H, d, J = 3.0 Hz, CH2-C19), 5.42 (1H, dd, J = 7.3, 5.6 Hz, CH-
C14), 4.40 (2H, 2×d, J = 11.3 Hz, 2×CH2-PMB),  4.38 (1H, d, J = 11.3 Hz, CH2-PMB), 4.34 
(1H, dd, J = 8.4, 5.0 Hz, CH-C16), 4.22 (1H, d, J = 11.3 Hz, CH2-PMB), 4.20—4.11 (2H, 
m, CH-C10, CH2-C13), 3.97 (1H, dd, J = 12.2, 5.6 Hz, CH2-C13), 3.87 (1H, dd, J = 7.8, 
6.2 Hz, CH2-C11), 3.80 (3H, s, CH3-PMB), 3.79 (3H, s, CH3-PMB), 3.51 (1H, t, J = 7.8 Hz, 
CH2-C11), 3.21 (1H, d, J = 17.4 Hz, CH2-C12), 3.13 (1H, d, J = 17.4 Hz, CH2-C12), 2.61 
(1H, dt, J = 9.7, 4.8 Hz, CH-C6), 2.57 (1H, dd, J = 14.5, 8.4 Hz, CH2-C17), 2.27 (1H, dd, 
J = 14.5, 5.0 Hz, CH2-C17), 1.65—1.56 (1H, m, CH2-C7), 1.56—1.49 (1H, m, CH2-C7), 1.36 
(3H, s, CH3-CMe2), 1.30 (3H, s, CH3-CMe2), 1.35—1.18 (2H, m, CH2-C8), 0.84 (3H, t, J = 
7.3 Hz, CH3-C9), 0.11 (9H, s, 3×CH3-SiMe3), 0.11 (9H, s, 3×CH3-SiMe3),  0.08 (3H, s, CH3-
SiMe); 
13C NMR (126 MHz, CDCl3) δ 159.5 (C-PMB), 159.4 (C-PMB), 146.5 (C-C18), 141.0 (CH-
C5), 140.9 (C-C15), 140.4 (CH-C2), 139.4 (C-C15), 131.1 (C-PMB), 130.8 (C-PMB), 129.4 
(2×CH-PMB), 129.3 (2×CH-PMB), 128.2 (CH2-C19), 126.7 (CH-C14), 125.3 (C-C3 or C-C4), 
122.5 (C-C3 or C-C4), 114.1 (2×CH-PMB), 113.9 (2×CH-PMB), 109.0 (C-CMe2), 78.8 (CH-
C10), 76.7 (CH-C16), 72.4 (CH2-PMB), 70.4 (CH2-PMB), 67.4 (CH2-C11), 66.2 (CH2-C13), 
55.5 (CH3-PMB), 55.4 (CH3-PMB), 39.3 (CH2-C17), 37.1 (CH-C6), 34.7 (CH2-C7), 26.7 (CH3-
CMe2), 25.7 (CH3-CMe2), 25.1 (CH2-C12), 20.9 (CH2-C8), 2.0 (6×CH3-SiMe3), −0.2 (CH3- 
SiMe); 
LRMS (EI+): m/z (int) 824 (10), 550 (47), 450 (15), 325 (16), 221 (87), 205 (23), 121 
(100), 101 (55), 73 (30). HRMS (EI+) calculated for C44H68O9Si3 [M]
+: 824.4171, found 
824.4175, Δ +0.5 ppm. 
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(4S)-4-[(1S)-1-(4-{(2Z,3S,5Z)-5-Iodo-3-(4-methoxyphenylmethoxy)-2-[2-(4-
methoxyphenylmethoxy)ethylidene]hex-5-en-1-yl}furan-3-yl)butyl]-2,2-dimethyl-
1,3-dioxolane (381) 
and 
(4S)-4-[(1S)-1-(4-{(2Z,3S,5E)-6-Iodo-3-(4-methoxyphenylmethoxy)-2-[2-(4-
methoxyphenylmethoxy)ethylidene]hex-5-en-1-yl}furan-3-yl)butyl]-2,2-dimethyl-
1,3-dioxolane (382) 
 
 
To a solution of terminal alkyne (+)-378 (11.6 mg, 0.0192 mmol) in THF (1 mL) at rt was 
added Pd(PPh3)4 (1.2 mg, 1.0 µmol, 0.054 equiv) and Bu3SnH (10 µL, 0.038 mmol, 
2.0 equiv) dropwise. The mixture was stirred at rt for 30 min and the reaction was 
quenched with saturated aqueous NaHCO3 (5 mL). The mixture was diluted with Et2O 
(10 mL) and the phases were separated. The aqueous phase was extracted with Et2O 
(2 × 10 mL) and the organic extracts were combined, dried with Na2SO4, filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography (PE—
Et2O, 95:5 to 9:1) to give an inseparable mixture (13.0 mg) that was directly used in the 
next step without further characterisation. 
To a solution of the mixture (13.0 mg) in CH2Cl2 (1 mL) at 0 ºC was added I2 (10.2 mg, 
0.0402 mmol, 2.09 equiv). The mixture was stirred for 20 min and the reaction was 
quenched with saturated aqueous Na2S2O3 (5 mL). The mixture was then diluted with 
CH2Cl2 (10 mL) and stirred 10 min. The phases were separated and the aqueous phase 
was extracted with CH2Cl2 (2 × 10 mL). The organic extracts were combined, washed 
with brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography (PE—Et2O, 55:45) to give the 
corresponding vinylic iodides 381 and 382 (1.3 mg, 9%) as an inseparable mixture (1:1). 
C37H47IO7    Molecular weight: 730.67 g·mol
-1 
Rf = 0.36 (PE—Et2O, 7:3); 
1H NMR of the crude product showing the alkenyl regions for the internal—external ratio 
determination. 
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(2S,3S)-3-(4-{(2Z,3S)-3-(4-Methoxyphenylmethoxy)-2-[2-(4-
methoxyphenylmethoxy)ethylidene]hex-5-yn-1-yl}furan-3-yl)hexane-1,2-diol  
((−)-387) 
 
 
To a solution of terminal alkyne (+)-378 (95.7 mg, 0.159 mmol) in MeOH (1.6 mL) was 
added p-TSA (2.8 mg, 15 µmol, 0.093 equiv) at rt and the mixture was stirred for 15 h. 
Further p-TSA (10 mg, 52 µmol) was added and the mixture was stirred for 8 h at rt. 
After addition of K2CO3 (20 mg, 0.14 mmol), the mixture was concentrated in vacuo and 
the residue was purified by flash column chromatography (PE—Et2O, 4:6 to 3:7) to afford 
the diol (−)-387 (85.0 mg, 95%) as a colourless oil. 
C34H42O7    Molecular weight: 562.69 g·mol
−1 
Rf = 0.26 (PE—Et2O, 2:8); 
[α]D
26 −11.5 (c = 1.00, CHCl3); 
IR νmax 3442, 3292, 2998, 2955, 2870, 2358, 1513, 1464 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.32 (1H, d, J = 1.4 Hz, CH-C2), 7.26—7.21 (5H, m, J = 8.8 
Hz, CH-C5, 4×CH-PMB), 6.87 (2H, d, J = 8.7 Hz, CH-PMB), 6.86 (2H, d, J = 8.8 Hz, CH-
PMB), 5.50 (1H, dd, J = 8.2, 5.2 Hz, CH-C14), 4.49 (1H, d, J = 11.6 Hz, CH2-PMB), 4.41 
(1H, d, J = 11.4 Hz, CH2-PMB),  4.38 (1H, d, J = 11.4 Hz, CH2-PMB), 4.36 (1H, dd, J = 
8.1, 6.5 Hz, CH-C16), 4.27 (1H, d, J = 11.6 Hz, CH2-PMB), 4.12 (1H, dd, J = 11.8, 8.2 Hz, 
CH2-C13), 3.92 (1H, dd, J = 11.8, 5.2 Hz, CH2-C13), 3.80 (3H, s, CH3-PMB), 3.79 (3H, s, 
CH3-PMB), 3.77-3.73 (1H, m, CH-C10), 3.57—3.50 (1H, m, CH2-C11), 3.41—3.33 (1H, m, 
CH2-C11), 3.20 (1H, d, J = 17.4 Hz, CH2-C12), 3.15 (1H, d, J = 17.4 Hz, CH2-C12), 2.65 
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(1H, dt, J = 10.1, 5.1 Hz, CH-C6), 2.60 (1H, ddd, J = 16.7, 6.5, 2.6 Hz, CH2-C17), 2.47 
(1H, ddd, J = 16.7, 8.1, 2.6 Hz, CH2-C17), 2.31 (1H, t, J = 8.6 Hz, OH), 2.24 (1H, d, J = 
4.5 Hz, OH), 1.96 (1H, t, J = 2.6 Hz, CH-C19), 1.63—1.54 (1H, m, CH2-C7), 1.49—1.41 
(1H, m, CH2-C7), 1.28—1.17 (2H, m, CH2-C8), 0.83 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 159.4 (C-PMB), 159.4 (C-PMB), 141.4 (CH-C5), 140.6 (CH-
C2), 139.5 (C-C15), 130.1 (C-PMB), 130.0 (C-PMB), 129.6 (2×CH-PMB), 129.5 (2×CH-PMB), 
127.8 (CH-C14), 125.1 (C-C3 or C-C4), 122.1 (C-C3 or C-C4), 114.0 (2×CH-PMB), 113.9 
(2×CH-PMB), 77.4 (C-C18), 74.5 (CH-C16), 74.4 (CH-C10), 72.6 (CH2-PMB), 70.4 (CH2-
PMB), 70.3 (CH-C19), 65.7 (CH2-C13), 64.7 (CH2-C11), 55.4 (CH3-PMB), 55.4 (CH3-PMB), 
37.5 (CH-C6), 35.2 (CH2-C7), 24.4 (CH2-C12), 24.2 (CH2-C17), 20.8 (CH2-C8), 14.4 (CH3-
C9); 
HRMS (ESI) calculated for C34H42NaO7 [M+Na]
+: 585.2823, found 585.2808, Δ +2.5 ppm. 
 
(2S,3S)-3-(4-{(2Z,3S,5Z)-3-(4-Methoxyphenylmethoxy)-2-[2-(4-
methoxyphenylmethoxy)ethylidene]-5-tributylstannyl-6-trimethylsilyl-hex-5-en-1-
yl}furan-3-yl)hexane-1,2-diol ((−)-383) 
 
 
To a solution of alkyne (−)-387 (89.3 mg, 0.159 mmol) in THF (0.5 mL) were added 
Pd(PPh3)4 (18 mg, 0.016 mmol, 0.10 equiv) and previously prepared silyl-stannane 272 
(80 µL, 0.23 mmol, 1.4 equiv). The mixture was heated to reflux and stirred for 1 h. 
Further Pd(PPh3)4 (9.4 mg, 8.1 µmol, 0.051 equiv) and stannane 272 (20 µL, 
0.056 mmol, 0.35 equiv) were added to the mixture. The mixture was stirred for 1.5 h, 
cooled to rt and the reaction was quenched with saturated aqueous NH4Cl (5 mL). The 
mixture was diluted with Et2O (20 mL) and the phases were separated. The aqueous 
phase was extracted with Et2O (2 × 10 mL) and the organic extracts were combined, 
washed with brine (20 mL), dried with Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography (PE—Et2O, 5:5 to 4:6) 
affording the corresponding stannane (−)-383 (97.3 mg, 66%) as a pale yellow oil. 
C49H78O7SiSn    Molecular weight: 925.93 g·mol
−1 
Rf = 0.38 (PE—Et2O, 3:7); 
[α]D
26 −18.0 (c = 1.00, CHCl3); 
IR νmax 3439, 2955, 2929, 2924, 2869, 2854, 2361, 2329, 1612, 1513, 1464 cm
−1; 
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1H NMR (500 MHz, CDCl3) δ 7.33 (1H, d, J = 1.4 Hz, CH-C2), 7.24—7.18 (1H, m, CH-C5), 
7.23 (2H, d, J = 8.7 Hz, 2×CH-PMB), 7.20 (2H, d, J = 8.7 Hz, 2×CH-PMB),  6.86 (2H, d, 
J = 8.7 Hz, 2×CH-PMB), 6.84 (2H, d, J = 8.7 Hz, 2×CH-PMB), 6.38 (1H, s, CH-C19), 5.36 
(1H, dd, J = 8.8, 4.7 Hz, CH-C14), 4.43 (1H, d, J = 11.5 Hz, CH2-PMB), 4.41 (1H, d, J = 
11.3 Hz, CH2-PMB),  4.38 (1H, d, J = 11.3 Hz, CH2-PMB), 4.16 (1H, d, J = 11.5 Hz, CH2-
PMB), 4.14 (1H, dd, J = 7.6, 4.9 Hz, CH-C16), 4.08 (1H, dd, J = 11.2, 8.8 Hz, CH2-C13), 
3.83 (1H, dd, J = 11.2, 4.7 Hz, CH2-C13), 3.80 (3H, s, CH3-PMB), 3.79 (3H, s, CH3-PMB), 
3.79—3.72 (1H, m, CH-C10), 3.55 (1H, ddd, J = 10.6, 6.1, 4.4, CH2-C11), 3.37 (1H, ddd, 
J = 10.6, 6.6, 4.9, CH2-C11), 3.21 (1H, d, J = 17.5 Hz, CH2-C12), 3.15 (1H, d, J = 
17.5 Hz, CH2-C12), 2.74 (1H, dd, J = 13.1, 7.6 Hz, CH2-C17), 2.63 (1H, dt, J = 10.1, 
5.1 Hz, CH-C6), 2.38 (1H, dd, J = 13.1, 4.9 Hz, CH2-C17), 2.27 (1H, dd, J = 6.6, 4.4 Hz, 
OH), 2.17 (1H, d, J = 5.1 Hz, OH), 1.64—1.54 (1H, m, CH2-C7), 1.51—1.38 (7H, m, CH2-
C7, 3×CH2-SnBu3), 1.29 (6H, qt, J = 7.3, 7.3 Hz, 3×CH2-SnBu3), 1.34—1.16 (2H, m, CH2-
C8), 0.93—0.84 (6H, m, 3×CH2-SnBu3), 0.88 (9H, t, J = 7.3 Hz, 3×CH3-SnBu3), 0.82 (3H, t, 
J = 7.3 Hz, CH3-C9), 0.09 (9H, s, 3×CH3-SiMe3); 
13C NMR (126 MHz, CDCl3) δ 168.9 (C-C18), 159.5 (C-PMB), 159.2 (C-PMB), 147.7 (CH-
C19), 141.2 (CH-C5), 140.9 (C-C15), 140.5 (CH-C2), 130.6 (C-PMB), 129.9 (C-PMB), 129.6 
(2×CH-PMB), 129.4 (2×CH-PMB), 126.0 (CH-C14), 125.3 (C-C3 or C-C4), 122.3 (C-C3 or C-
C4), 114.0 (2×CH-PMB), 113.8 (2×CH-PMB), 76.7 (CH-C16), 74.5 (CH-C10), 72.8 (CH2-
PMB), 70.2 (CH2-PMB), 66.1 (CH2-C13), 64.6 (CH2-C11), 55.4 (2×CH3-PMB), 50.3 (CH2-
C17), 37.6 (CH-C6), 35.6 (CH2-C7), 29.3 (3×CH2-SnBu3), 27.7 (3×CH2-SnBu3), 24.9 (CH2-
C12), 20.9 (CH2-C8), 14.4 (CH3-C9), 13.8 (3×CH3-SnBu3), 11.6 (3×CH2-SnBu3), 0.3 (3×CH3-
SiMe3); 
HRMS (ESI) calculated for C49H78NaO7Si
120Sn [M+Na]+: 949.4395, found 949.4431, 
Δ +3.8 ppm. 
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(2S,3S)-3-(4-{(2Z,3S)-3-(4-Methoxyphenylmethoxy)-2-[2-(4-
methoxyphenylmethoxy)ethylidene]-5-tributylstannylhex-5-en-1-yl}furan-3-
yl)hexane-1,2-diol ((−)-400) 
 
 
Diol (−)-383 (42.8 mg, 0.0462 mmol) was diluted in DMSO (0.93 mL). TBAF (165 µL of a 
1 M solution in THF, 165 µmol, 3.59 equiv) was added and the mixture was heated to 
reflux and stirred for 80 min at this temperature. The orange brown solution was cooled 
to rt and diluted with water (5 mL) and Et2O (10 ml). The phases were separated, the 
aqueous phase was extracted with Et2O (4 × 10 mL). The organic extracts were 
combined and dried over MgSO4. After filtration and concentration in vacuo, the crude 
product was purified by flash column chromatography (PE—Et2O, 5:5) affording stannane 
(−)-400 (30.4 mg, 77%) as a pale yellow oil. 
C46H70O7Sn    Molecular weight: 853.75 g·mol
−1 
Rf = 0.42 (PE—Et2O, 1:9); 
[α]D
23 −13.0 (c = 0.99, CHCl3); 
IR νmax 3423, 2955, 2926, 2870, 2854, 1612, 1587, 1514, 1464 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.32 (1H, d, J = 1.3 Hz, CH-C2), 7.23 (2H, d, J = 8.6 Hz, 
2×CH-PMB), 7.24—7.20 (1H, m, CH-C5), 7.21 (2H, d, J = 8.7 Hz, 2×CH-PMB),  6.86 (2H, 
d, J = 8.6 Hz, 2×CH-PMB), 6.84 (2H, d, J = 8.7 Hz, 2×CH-PMB), 5.70 (1H, d, J = 2.5 Hz, 
CH-C19), 5.37 (1H, dd, J = 8.5, 5.0 Hz, CH-C14), 5.21 (1H, d, J = 2.5 Hz, CH-C19), 4.43 
(1H, d, J = 11.6 Hz, CH2-PMB), 4.41 (1H, d, J = 11.6 Hz, CH2-PMB), 4.39 (1H, d, J = 
11.6 Hz, CH2-PMB), 4.22—4.16 (1H, m, CH-C16), 4.18 (1H, d, J = 11.6 Hz, CH2-PMB), 4.12 
(1H, dd, J = 11.3, 8.5 Hz, CH2-C13), 3.87 (1H, dd, J = 11.3, 5.0 Hz, CH2-C13), 3.80 (3H, 
s, CH3-PMB), 3.79 (3H, s, CH3-PMB), 3.75 (1H, dq, J = 6.3, 5.2 Hz, CH-C10), 3.53 (1H, 
ddd, J = 10.7, 5.2, 5.2, CH2-C11), 3.36 (1H, ddd, J = 10.7, 6.3, 4.1, CH2-C11), 3.19 (1H, 
d, J = 17.7 Hz, CH2-C12), 3.14 (1H, d, J = 17.7 Hz, CH2-C12), 2.68 (1H, dd, J = 14.0, 8.3 
Hz, CH2-C17), 2.61 (1H, dt, J = 10.3, 5.2 Hz, CH-C6), 2.36 (1H, dd, J = 14.0, 4.6 Hz, CH2-
C17), 2.24 (1H, dd, J = 5.2, 4.1 Hz, OH), 2.15 (1H, d, J = 5.2 Hz, OH), 1.62—1.52 (1H, 
m, CH2-C7), 1.51—1.37 (7H, m, CH2-C7, 3×CH2-SnBu3), 1.28 (6H, qt, J = 7.2, 7.2 Hz, 
3×CH2-SnBu3), 1.24—1.13 (2H, m, CH2-C8), 0.87 (9H, t, J = 7.3 Hz, 3×CH3-SnBu3), 0.85—
0.79 (9H, m, 3×CH2-SnBu3, CH3-C9); 
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13C NMR (126 MHz, CDCl3) δ 159.5 (C-PMB), 159.2 (C-PMB), 151.1 (C-C18), 141.4 (C-
C15), 141.2 (CH-C5), 140.5 (CH-C2), 130.6 (C-PMB), 129.9 (C-PMB), 129.6 (2×CH-PMB), 
129.3 (2×CH-PMB), 128.2 (CH2-C19), 125.9 (CH-C14), 125.3 (C-C3 or C-C4), 122.2 (C-C3 
or C-C4), 114.0 (2×CH-PMB), 113.8 (2×CH-PMB), 76.7 (CH-C16), 74.5 (CH-C10), 72.8 
(CH2-PMB), 70.2 (CH2-PMB), 65.9 (CH2-C13), 64.7 (CH2-C11), 55.4 (CH3-PMB), 55.4 (CH3-
PMB), 45.5 (CH2-C17), 37.6 (CH-C6), 35.5 (CH2-C7), 29.2 (3×CH2-SnBu3), 27.6 (3×CH2-
SnBu3), 25.0 (CH2-C12), 20.8 (CH2-C8), 14.4 (CH3-C9), 13.9 (3×CH3-SnBu3), 9.8 (3×CH2-
SnBu3); 
HRMS (ESI) calculated for C46H70NaO7
116Sn [M+Na]+: 873.4031, found 873.3991, Δ +4.6 
ppm. 
 
(2S,3S)-3-(4-{(2Z,3S)-5-Iodo-3-(4-methoxyphenylmethoxy)-2-[2-(4-
methoxyphenylmethoxy)ethylidene]hex-5-en-1-yl}furan-3-yl)hexane-1,2-diol 
((−)-384) 
 
 
Stannane (−)-400 (19.1 mg, 0.0224 mmol) was diluted in CH2Cl2 (1 mL). The solution 
was cooled to −78 ºC before the addition of NIS (9.2 mg, 0.036 mmol, 1.8 equiv). The 
mixture was stirred for 40 min and the reaction was quenched with aqueous saturated 
Na2S2O3 (3 mL). The mixture was diluted with CH2Cl2 (5 mL) and warmed to rt. The 
phases were separated and the aqueous phase was extracted with CH2Cl2 (4 × 10 mL). 
The organic extracts were combined, dried over MgSO4, filtered and concentrated in 
vacuo. The crude product was purified by flash column chromatography (PE—Et2O, 5:5) 
affording 16.6 mg of vinylic iodide (−)-384 (14.9 mg, 96% based on 1H NMR) as an 
inseparable mixture with succinimide formed during the reaction. 
C34H43IO7    Molecular weight: 690.61 g·mol
−1 
Rf = 0.37 (PE—Et2O, 1:9); 
[α]D
20 −9.6 (c = 0.75, CHCl3); 
IR νmax 3450, 2953, 2933, 2864, 2359, 1776, 1710, 1612, 1585, 1514, 1464 cm
−1; 
1H NMR (500 MHz, CDCl3) δ 7.31 (1H, d, J = 1.2 Hz, CH-C2), 7.25 (2H, d, J = 8.6 Hz, 
2×CH-PMB), 7.23—7.21 (1H, m, CH-C5), 7.22 (2H, d, J = 8.6 Hz, 2×CH-PMB),  6.86 (4H, 
d, J = 8.6 Hz, 4×CH-PMB), 6.08 (1H, s, CH-C19), 5.76 (1H, s, CH-C19), 5.46 (1H, dd, J = 
8.3, 5.5 Hz, CH-C14), 4.47 (1H, dd, J = 8.5, 4.5 Hz, CH-C16), 4.46 (1H, d, J = 11.4 Hz, 
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CH2-PMB), 4.46—4.39 (2H, m, CH2-PMB), 4.27 (1H, d, J = 11.4 Hz, CH2-PMB), 4.16 (1H, 
dd, J = 11.4, 8.3 Hz, CH2-C13), 3.95 (1H, dd, J = 11.4, 5.5 Hz, CH2-C13), 3.81 (3H, s, 
CH3-PMB), 3.79 (3H, s, CH3-PMB), 3.73 (1H, app dq, J = 6.2, 5.2 Hz, CH-C10), 3.51 (1H, 
ddd, J = 11.0, 6.2, 4.5, CH2-C11), 3.37 (1H, ddd, J = 11.0, 6.4, 5.2, CH2-C11), 3.20 (1H, 
d, J = 17.3 Hz, CH2-C12), 3.10 (1H, d, J = 17.3 Hz, CH2-C12), 2.77 (1H, dd, J = 14.5, 8.5 
Hz, CH2-C17), 2.62 (1H, dt, J = 10.1, 5.2 Hz, CH-C6), 2.47 (1H, dd, J = 14.5, 4.5 Hz, CH2-
C17), 2.29—2.26 (1H, m, OH), 2.22 (1H, d, J = 5.2 Hz, OH), 1.61—1.53 (1H, m, CH2-C7), 
1.45—1.37 (1H, m, CH2-C7), 1.27—1.15 (2H, m, CH2-C8), 0.82 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 159.5 (C-PMB), 159.4 (C-PMB), 141.3 (CH-C5), 140.6 (CH-
C2), 140.6 (C-C15),130.2 (C-PMB), 129.9 (C-PMB), 129.8 (2×CH-PMB), 129.6 (2×CH-PMB), 
128.4 (CH2-C19), 126.8 (CH-C14), 125.2 (C-C3 or C-C4), 122.2 (C-C3 or C-C4), 114.0 
(2×CH-PMB), 113.9 (2×CH-PMB), 107.2 (C-C18), 75.1 (CH-C16), 74.5 (CH-C10), 72.9 (CH2-
PMB), 70.8 (CH2-PMB), 65.7 (CH2-C13), 64.5 (CH2-C11), 55.4 (CH3-PMB), 55.4 (CH3-PMB), 
50.1 (CH2-C17), 37.5 (CH-C6), 35.4 (CH2-C7), 25.3 (CH2-C12), 20.9 (CH2-C8), 14.4 (CH3-
C9); 
HRMS (ESI) calculated for C34H43INaO7 [M+Na]
+: 713.1946, found 713.1936, Δ +1.4 ppm. 
 
(2S)-2-(4-{(2Z,3S)-5-Iodo-3-(4-methoxyphenylmethoxy)-2-[2-(4-
methoxyphenylmethoxy)ethylidene]hex-5-en-1-yl}furan-3-yl)pentanal (401) 
 
 
To a solution of diol (−)-384 (14.9 mg, 0.0216 mmol) in MeOH (1 mL) and water (0.5 mL) 
at 0 ºC was added NaIO4 (51.2 mg, 0.239 mmol, 11.1 equiv). The mixture was warmed to 
rt and stirred for 50 min. The reaction was quenched with water (2 mL) and the mixture 
was diluted with Et2O (10 mL). The phases were separated and the aqueous phase was 
extracted with Et2O (3 × 10 mL). The organic extracts were combined, dried with 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (PE—Et2O, 70:30) affording aldehyde 401 (10.4 mg, 73%) as a 
colourless oil. 
C33H39IO6    Molecular weight: 658.56 g·mol
−1 
Rf = 0.57 (PE—Et2O, 6:4); 
IR νmax 2957, 2926, 2856, 1724, 1612, 1514, 1464 cm
−1; 
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1H NMR (400 MHz, CDCl3) δ 9.41 (1H, d, J = 2.9 Hz, HCO-C10), 7.30 (1H, d, J = 1.2 Hz, 
CH-C2), 7.24 (2H, d, J = 8.7 Hz, 2×CH-PMB), 7.26—7.21 (1H, m, CH-C5), 7.23 (2H, d, J = 
8.7 Hz, 2×CH-PMB),  6.86 (4H, d, J = 8.7 Hz, 4×CH-PMB), 6.11 (1H, d, J = 1.2 Hz, CH-
C18), 5.77 (1H, d, J = 1.2 Hz, CH-C18), 5.40 (1H, dd, J = 7.3, 5.7 Hz, CH-C13), 4.46 (1H, 
dd, J = 8.1, 4.7 Hz, CH-C15), 4.44 (1H, d, J = 11.4 Hz, CH2-PMB), 4.43—4.39 (2H, br s, 
CH2-PMB), 4.26 (1H, d, J = 11.4 Hz, CH2-PMB), 4.13 (1H, dd, J = 12.2, 7.3 Hz, CH2-C12), 
4.01 (1H, dd, J = 12.2, 5.7 Hz, CH2-C12), 3.80 (3H, s, CH3-PMB), 3.79 (3H, s, CH3-PMB), 
3.25 (1H, app td, J = 7.3, 2.9 Hz, CH-C6), 3.18 (1H, d, J = 17.3 Hz, CH2-C11), 3.07 (1H, 
d, J = 17.3 Hz, CH2-C11), 2.76 (1H, dd, J = 14.7, 8.1 Hz, CH2-C16), 2.48 (1H, dd, J = 
14.7, 4.7 Hz, CH2-C16), 1.92—1.81 (1H, m, CH2-C7), 1.68—1.57 (1H, m, CH2-C7), 1.35—
1.25 (2H, m, CH2-C8), 0.88 (3H, t, J = 7.3 Hz, CH3-C9); 
HRMS (ESI) calculated for C33H39INaO6 [M+Na]
+: 681.1684, found 681.1670, Δ +2.0 ppm. 
 
(4S,8S,9Z)-8-(4-Methoxyphenylmethoxy)-9-[2-(4-
methoxyphenylmethoxy)ethylidene]-6-methylidene-4-propyl-
4H,5H,6H,7H,8H,9H,10H-cyclonona[c]furan-5-ol (385) 
 
 
To a solution of CrCl2 (23.2 mg, 0.190 mmol, 12.0 equiv) and NiCl2 (0.6 mg, 0.05 μmol, 
0.3 equiv) in degassed DMSO (three freeze-thaw cycles, 0.7 mL) was added a solution of 
aldehyde 401 (10.4 mg, 15.8 μmol) in degassed DMSO (three freeze-thaw cycles, 
1.5 mL) at rt. The dark green mixture was stirred at 25 ºC for 3 days. The reaction was 
quenched with saturated aqueous NH4Cl (5 mL) and the mixture was diluted with EtOAc 
(10 mL). The biphasic mixture was stirred for 30 min, the phases were separated and 
the aqueous phase was extracted with EtOAc (3 × 10 mL). The organic extracts were 
combined, washed with brine (10 mL), dried over MgSO4, filtered and concentrated in 
vacuo. The crude product was purified by flash column chromatography (PE—Et2O, 8:2 
to 6:4) affording bicycle 385 in an inseparable 3:1 ratio of diastereoisomers along with 
an uncharacterised by-product (4.2 mg in total). From this mixture, 385 (2.0 mg, 24%) 
was isolated after several purifications by flash column chromatography, with the same 
diastereoisomeric ratio. 
C33H40O6    Molecular weight: 532.67 g·mol
−1 
Rf = 0.29 (PE—Et2O, 5:5); 
IR νmax 3419, 2957, 2932, 2868, 2732, 2333, 1764, 1724, 1612, 1585, 1514, 1464 cm
−1; 
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Major diastereoisomer 
1H NMR (500 MHz, CDCl3) δ 7.27—7.21 (6H, m, CH-C2, CH-C5, 4×CH-PMB), 6.91—6.85 
(4H, m, J = 8.8 Hz, 4×CH-PMB), 5.86 (1H, dd, J = 7.8, 4.6 Hz, CH-C13), 5.02 (1H, s, CH2-
C18), 4.75 (1H, s, CH2-C18), 4.48 (1H, d, J = 11.7 Hz, CH2-PMB), 4.44 (1H, d, J = 11.3 
Hz, CH2-PMB), 4.40 (1H, d, J = 11.3 Hz, CH2-PMB), 4.35 (1H, dd, J = 10.6, 6.7 Hz, CH-
C15), 4.21 (1H, d, J = 11.7 Hz, CH2-PMB), 4.06 (1H, dd, J = 12.6, 7.8 Hz, CH2-C12), 3.98 
(1H, d, J = 9.5 Hz, CH-C10), 3.83 (1H, ddd, J = 12.6, 4.6, 1.3 Hz, CH2-C12), 3.81 (6H, s, 
2×CH3-PMB), 3.75 (1H, d, J = 15.5 Hz, CH2-C11), 3.11 (1H, d, J = 15.5 Hz, CH2-C11), 3.05 
(1H, dd, J = 9.1, 6.6 Hz, CH-C6), 2.26 (1H, dd, J = 13.5, 6.7 Hz, CH2-C16), 2.00 (1H, dd, 
J = 13.5, 10.6 Hz, CH2-C16), 1.75 (1H, d, J = 9.5 Hz, OH), 1.72—1.65 (1H, m, CH2-C7), 
1.63 (1H, dddd, J = 13.7, 7.5, 7.5, 6.6 Hz, CH2-C7), 1.31 (2H, tq, J = 7.5, 7.3 Hz, CH2-
C8), 0.86 (3H, t, J = 7.3 Hz, CH3-C9); 
13C NMR (126 MHz, CDCl3) δ 159.4 (C-PMB), 159.3 (C-PMB), 146.8 (C-C14 or C-C17), 
140.9 (CH-C2 or CH-C5), 140.3 (CH-C2 or CH-C5), 130.6 (CH-C13), 130.3 (C-PMB), 129.6 
(C-PMB), 129.5 (2×CH-PMB), 129.2 (2×CH-PMB), 116.6 (CH2-C18), 114.0 (2×CH-PMB), 
113.9 (2×CH-PMB), 77.7 (CH-C10), 72.5 (CH2-PMB), 69.8 (CH2-PMB), 66.3 (CH2-C12), 55.4 
(2×CH3-PMB), 38.7 (CH-C6), 36.6 (CH2-C7), 20.8 (CH2-C8),14.0 (CH3-C9); 
Carbon peaks missing:  
- From HSQC: CH-C15 (under CDCl3 peaks), CH2-C16 (ca 33.5), CH2-C11 (ca 29.5); 
- C-C4, C-C3, C-C14 or C-C17; 
HRMS (ESI) calculated for C33H40NaO6 [M+Na]
+: 555.2717, found 555.2691, Δ +4.7 ppm. 
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Table 1: Crystal data and structure refinement for 286-syn 
 
Empirical formula     C17 H20 O4 
Formula weight     288.33 
Temperature      100 K 
Wavelength      0.71073 Å 
Crystal system     Orthorhombic 
Space group      P212121 
Unit cell dimensions     a = 7.2695(5) Å  α = 90° 
b = 11.8269(10) Å  β = 90° 
c = 17.3278(12) Å  γ = 90° 
Volume      1489.77(19) Å3 
Z       4 
Density (calculated)     1.286 g/cm3 
Absorption coefficient    0.091 mm−1 
Crystal size      0.5 × 0.2 × 0.2 mm3 
F(000), F(000)’     616, 616.33 
Theta range for data collection   3.08 to 30.78° 
Index ranges      −10 ≤ h ≤ 10 
−16 ≤ k ≤ 17 
−24 ≤ l ≤ 24 
Reflections collected    2650 
Independent reflections   2468  
Data completness     1.00 / 0.57 
Theta (max)     30.780 
Absorption correction method   multi-scan 
Min. and max. transmission    0.902 and 0.982 
Refinement method     on F2 against all reflections 
Data / restraints / parameters   2650 / 0 / 192 
Goodness-of-fit on F2    1.041 
Final R indices [I>2sigma(I)]   R1 = 0.0386, wR2 = 0.0924 
R indices (all data)     R1 = 0.0347, wR2 = 0.0904 
Largest diff. peak and hole   0.283 and −0.248 e.Å−3 
 xvii 
Table 2: Atomic coordinates (× 104) and equivalent isotropic displacement 
parameters (Å2 × 103) for 286-syn. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
 
 x y z U(eq) 
     
C1 10184(19) 5274 (12) 4070 (7) 148(2) 
C2 8927(19) 6144(12) 3660(8) 155(3) 
C3 7407(19) 5673(12) 3156(8) 151(2) 
C4 8010(19) 4996(12) 2451(7) 172(3) 
C5 7012(19) 3871(13) 2324(8) 171(3) 
C6 6766(2) 3154(12) 3032(7) 161(3) 
C7 8350(2) 2816(12) 3541(8) 174(3) 
C8 8243(2) 3392(12) 4318(7) 155(2) 
C9 9050(19) 4463(12) 4545(8) 149(2) 
C11 11586(19) 5922(12) 4574(8) 169(3) 
C12 13040(2) 5185(13) 4971(8) 185(3) 
C13 14253(2) 5885(15) 5510(9) 239(3) 
C31 5661(2) 5948(13) 3301(9) 193(3) 
C61 4971(2) 2936(13) 3129(8) 190(3) 
C62 3937(2) 3504(12) 2517(8) 184(3) 
C81 7354(2) 2988(12) 4947(8) 182(3) 
C91 8592(2) 4597(13) 5302(8) 190(3) 
O1 7539(15) 3710(9) 5562(6) 206(2) 
O2 10109(14) 6841(9) 3191(6) 194(2) 
O3 5139(14) 4054(10) 2045(6) 194(2) 
O4 2284(15) 3553(10) 2406(7) 224(2) 
 
  
 xviii 
Table 3: Bond lengths (Å) and angles (°) for 286-syn. 
 
C1—C9   1.5096(19)  
C1—C11  1.5460(19) 
C1—C2   1.5482(19) 
C1—H1    1 
C2—O2   1.4420(17) 
C2—C3    1.5151(19) 
C2—H2    1 
C3—C31  1.335(2) 
C3—C4    1.5253(19)  
C4—C5    1.531(2) 
C4—H4A  0.99 
C4—H4B   0.99 
C5—O3    1.4611(17) 
C5—C6   1.502(2) 
C5—H5    1 
C6—C61  1.341(2) 
C6—C7    1.505(2) 
C7—C8   1.5108(19) 
C7—H7A  0.99 
C7—H7B  0.99 
C8—C81  1.3545(19) 
C8—C9    1.4494(19) 
C9—C91  1.3628(19) 
C11—C12  1.533(2) 
C11—H11A  0.99 
C11—H11B  0.99 
C12—C13  1.527(2) 
C12—H12A  0.99 
C12—H12B  0.99 
C13—H13A  0.98 
C13—H13B  0.98 
C13—H13C  0.98 
C31—H31A  0.95 
C31—H31B  0.95 
C61—C62  1.464(2) 
C61—H61  0.95 
C62—O4  1.2181(18) 
C62—O3  1.3623(18) 
C81—O1  1.3719(17) 
C81—H81  0.95 
C91—O1  1.3741(18) 
C91—H91  0.95 
O2—H2A  0.84 
 
C9—C1—C11  111.52(11) 
C9—C1—C2  110.51(11)  
C11—C1—C2  108.57(11) 
C9—C1—H1  108.7 
C11—C1—H1  108.7 
C2—C1—H1   108.7 
O2—C2—C3   108.63(11) 
O2—C2—C1   106.67(11) 
C3—C2—C1   116.74(11) 
O2—C2—H2   108.2 
C3—C2—H2  108.2 
C1—C2—H2  108.2 
C31—C3—C2  119.69(13) 
C31—C3—C4  123.51(13) 
C2—C3—C4  116.49(12) 
C3—C4—C5  115.80(11) 
C3—C4—H4A  108.3 
C5—C4—H4A  108.3 
C3—C4—H4B  108.3 
C5—C4—H4B  108.3  
H4A—C4—H4B  107.4  
O3—C5—C6  104.06(11) 
O3—C5—C4  111.10(12) 
C6—C5—C4   115.44(11) 
O3—C5—H5   108.7 
C6—C5—H5   108.7 
C4—C5—H5   108.7 
C61—C6—C5   109.14(13) 
 xix 
C61—C6—C7   128.25(13) 
C5—C6—C7   122.56(13) 
C6—C7—C8   111.30(12) 
C6—C7—H7A   109.4 
C8—C7—H7A   109.4 
C6—C7—H7B   109.4 
C8—C7—H7B   109.4 
H7A—C7—H7B   108 
C81—C8—C9   106.46(12) 
C81—C8—C7   125.60(13) 
C9—C8—C7   127.94(12) 
C91—C9—C8   105.29(13) 
C91—C9—C1   125.77(13) 
C8—C9—C1   128.94(12) 
C12—C11—C1   115.27(12) 
C12—C11—H11A  108.5 
C1—C11—H11A  108.5 
C12—C11—H11B  108.5 
C1—C11—H11B  108.5 
H11A—C11—H11B  107.5 
C13—C12—C11  111.39(12) 
C13—C12—H12A  109.4 
C11—C12—H12A  109.4 
C13—C12—H12B  109.4 
C11—C12—H12B  109.4 
H12A—C12—H12B  108 
C12—C13—H13A  109.5 
C12—C13—H13B  109.5 
H13A—C13—H13B  109.5 
C12—C13—H13C  109.5 
H13A—C13—H13C  109.5 
H13B—C13—H13C  109.5 
C3—C31—H31A  120 
C3—C31—H31B  120 
H31A—C31—H31B  120 
C6—C61—C62   108.64(13) 
C6—C61—H61   125.7 
C62—C61—H61  125.7 
O4—C62—O3   121.01(14) 
O4—C62—C61   129.97(15) 
O3—C62—C61   108.99(12) 
C8—C81—O1   110.98(12) 
C8—C81—H81   124.5 
O1—C81—H81   124.5 
C9—C91—O1   111.27(13) 
C9—C91—H91   124.4 
O1—C91—H91   124.4 
C81—O1—C91   105.99(11) 
C2—O2—H2A   109.5 
C62—O3—C5   109.16(11) 
Symmetry transformations used to generate equivalent atoms: 
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Table 4: Anisotropic displacement parameters (Å2 × 103) for 286-syn. The anisotropic 
displacement factor exponent takes the form: –2π2 [h2 a*2 U11 +...+ 2 h k a* b* U12]. 
 
 U11 U22 U33 U23 U13 U12 
       
C1 14(6) 15(6) 15(5) 0(4) 0(5) 0(5) 
C2 13(6) 15(6) 16(6) 2(5) 1(5) 0(5) 
C3 15(6) 15(6) 14(5) 3(4) 0(5) 0(5) 
C4 15(6) 21(6) 14(5) 2(5) 0(5) −1(5) 
C5 14(6) 21(7) 15(5) 0(5) 0(5) 1(5) 
C6 19(6) 15(6) 14(5) −1(5) −1(5) 0(5) 
C7 17(6) 16(6) 17(6) −1(5) −1(5) 2(5) 
C8 15(6) 15(6) 15(5) 0(5) −1(5) 1(5) 
C9 14(6) 14(6) 15(5) 1(5) −1(5) 0(5) 
C11 15(6) 16(6) 18(6) 0(5) −2(5) 0(5) 
C12 18(6) 16(6) 20(6) 0(5) −3(5) 0(5) 
C13 21(7) 26(8) 24(7) −4(6) −6(6) 0(6) 
C31 15(6) 18(6) 23(6) 0(5) 0(5) 0(5) 
C61 19(6) 18(6) 18(6) 0(5) 0(5) 2(6) 
C62 18(6) 17(6) 19(6) −4(5) −1(5) −1(5) 
C81 19(6) 15(6) 19(6) 2(5) 0(5) 0(5) 
C91 21(7) 18(7) 16(6) 0(5) 0(5) −2(5) 
O1 25(5) 20(5) 15(4) 1(4) 2(4) −2(4) 
O2 16(5) 19(5) 22(5) 7(4) 0(4) −1(4) 
O3 15(5) 24(5) 17(4) 0(4) −2(4) 0(4) 
O4 16(5) 22(5) 27(5) −4(4) −2(4) −0(4) 
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Table 5: Hydrogen coordinates (× 104) and equivalent isotropic displacement 
parameters (Å2 × 103) for 286-syn. 
 
 x y z U(eq) 
     
H1 1087 4836 3669 18 
H2 8353 6635 4064 19 
H4A 9344 4841 2497 21 
H4B 7831 5472 1987 21 
H5 7703 3424 1929 21 
H7A 9522 3021 3287 21 
H7B 8335 1986 3616 21 
H11A 12224 6484 4246 20 
H11B 10903 6344 4976 20 
H12A 12422 4583 5272 22 
H12B 13819 4819 4575 22 
H13A 14914 6458 5210 36 
H13B 15140 5388 5768 36 
H13C 13483 6258 5899 36 
H31A 5375 6437 3720 23 
H31B 4703 5655 2987 23 
H61 4455 2488 3530 23 
H81 6691 2297 4962 22 
H91 8952 5224 5611 23 
H2A 9476 7333 2964 29 
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Appendix 16: HPLC analysis for compound (±)-325 
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Appendix 17: HPLC analysis for compound (−)-325 
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Appendix 18: HPLC analysis for compound (±)-254 
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Appendix 19: HPLC analysis for compound (+)-254 
 
 
 
